WO1995009843A1 - Hiv protease inhibitors - Google Patents

Hiv protease inhibitors Download PDF

Info

Publication number
WO1995009843A1
WO1995009843A1 PCT/US1994/011307 US9411307W WO9509843A1 WO 1995009843 A1 WO1995009843 A1 WO 1995009843A1 US 9411307 W US9411307 W US 9411307W WO 9509843 A1 WO9509843 A1 WO 9509843A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
substituted
alkyl
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
PCT/US1994/011307
Other languages
French (fr)
Inventor
Bruce A. Dressman
James E. Fritz
Marlys Hammond
William J. Hornback
Stephen W. Kaldor
Vincent J. Kalish
John E. Munroe
Siegfried Heinz Reich
John H. Tatlock
Timothy A. Shepherd
Michael J. Rodriguez
Louis N. Jungheim
Original Assignee
Agouron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to UA96041689A priority Critical patent/UA56984C2/en
Priority to RU96109378A priority patent/RU2139280C1/en
Priority to SI9430421T priority patent/SI0722439T1/en
Priority to HU9600908A priority patent/HU226814B1/en
Priority to AT94930609T priority patent/ATE222240T1/en
Priority to TJ96000281A priority patent/TJ339B/en
Priority to APAP/P/1996/000844A priority patent/AP600A/en
Priority to AU79674/94A priority patent/AU694746B2/en
Priority to BR9407782A priority patent/BR9407782A/en
Priority to JP7511006A priority patent/JP2951724B2/en
Priority to MD96-0141A priority patent/MD1507G2/en
Priority to DK94930609T priority patent/DK0722439T3/en
Priority to HU0900219A priority patent/HU227885B1/en
Priority to SK439-96A priority patent/SK284115B6/en
Application filed by Agouron Pharmaceuticals, Inc. filed Critical Agouron Pharmaceuticals, Inc.
Priority to PL94313871A priority patent/PL185647B1/en
Priority to DE69431193T priority patent/DE69431193T2/en
Priority to RO96-00738A priority patent/RO119363B1/en
Priority to NZ275633A priority patent/NZ275633A/en
Priority to CA002173328A priority patent/CA2173328C/en
Priority to EP94930609A priority patent/EP0722439B1/en
Priority to EE9600091A priority patent/EE05399B1/en
Priority to SK493-2002A priority patent/SK284116B6/en
Publication of WO1995009843A1 publication Critical patent/WO1995009843A1/en
Priority to KR1019960700897A priority patent/KR100190517B1/en
Priority to BG100455A priority patent/BG62567B1/en
Priority to FI961449A priority patent/FI114794B/en
Priority to NO961382A priority patent/NO307050B1/en
Priority to HK98114956A priority patent/HK1013650A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/62—Isoquinoline or hydrogenated isoquinoline ring systems

Definitions

  • This invention relates to a novel series of chemical
  • AIDS Acquired Immune Deficiency Syndrome
  • HTLV-III human T-lymphotropic retrovirus III
  • HIV is a member of the class of viruses known as
  • retroviruses The retroviral genome is composed of RNA which is converted to DNA by reverse transcription. This retroviral DNA is then stably integrated into a host cell's chromosome and,
  • HIV appears to have a particular affinity for the human T-4 lymphocyte cell which plays a vital role in the body's immune system. HIV infection of these white blood cells depletes this white cell population. Eventually, the immune system is rendered inoperative and ineffective against various opportunistic diseases such as, among others, pneumocystic carini pneumonia, Karposis sarcoma, and cancer of the lymph system.
  • the drug azidothymidine has been found effective for inhibiting the reverse transcription of the retroviral genome of the HIV virus, thus giving a measure of control, though not a cure, for patients afflicted with AIDS.
  • the search continues for drugs that can cure or at least provide an improved measure of control of the deadly HIV virus.
  • Retroviral replication routinely features post-translational processing of polyproteins. This processing is accomplished by virally encoded HIV protease enzyme. This yields mature polypeptides that will subsequently aid in the formation and function of infectious virus. If this molecular processing is stifled, then the normal production of HIV is terminated.
  • inhibitors of HIV protease may function as anti-HIV viral agents.
  • HIV protease is one of the translated products from the HIV structural protein pol gene. This retroviral protease
  • HIV protease inhibitors may have the advantages of being more readily available, longer lived in virus, and less toxic than currently available drugs, possibly due to their specificity for the retroviral protease.
  • a novel class of chemical compounds that can inhibit and/or block the activity of the HIV protease, which halts the proliferation of HIV virus, pharmaceutical compositions containing these compounds, and the use of the compounds as inhibitors of the HIV protease.
  • the present invention relates to compounds falling within formula (1) below, and pharmaceutically acceptable salts thereof, that inhibit the protease encoded by human immunodeficiency virus (HIV) type 1 (HIV-1) or type 2 (HIV-2). These compounds are useful in the treatment of infection by HIV and the treatment of the acquired immune deficiency syndrome (AIDS).
  • HIV human immunodeficiency virus
  • the compounds, their pharmaceutically acceptable salts, and the pharmaceutical compositions of the present invention can be used alone or in combination with other antivirals, immunomodulators, antibiotics or vaccines.
  • Compounds of the present invention can also be used as prodrugs. Methods of treating AIDS, methods of treating HIV infection and methods of inhibiting HIV protease are disclosed.
  • the compounds of the present invention are of the formula (1) :
  • Q 1 and Q 2 are independently selected from hydrogen and substituted and unsubstituted alkyl and aryl, and Q 1 and Q 2 may form a ring with G, Q 3 is selected from mercapto and substituted and unsubstituted alkoxyl, aryloxyl, thioether, amino, alkyl,
  • Q 4 -Q 8 are independently selected from hydrogen, hydroxyl, mercapto, nitro, halogen, -O-J, wherein J is a substituted or unsubstituted hydrolyzable group, and substituted and
  • Y and G are independently selected from oxygen, -NH,
  • D is carbon or nitrogen, and wherein D is singly bonded to each of the adjacent ring atoms,
  • E is carbon or nitrogen
  • Q 9 is selected from hydrogen, halogen, hydroxyl, mercapto, and substituted and unsubstituted alkoxyl, aryloxyl, thioether, amino, alkyl, and aryl, wherein Q 9 may form part of a ring,
  • A is a carbocycle or heterocycle, which is optionally further substituted
  • B is a carbocycle or heterocycle, which is optionally further substituted
  • the invention more particularly relates -to preferred
  • Q 1 and Q 2 are substituted or unsubstituted alkyl and the other is as defined above,
  • Q 3 is selected from thioether and aryl
  • Q 4 -Q 8 are independently selected from hydrogen, hydroxyl, halogen, -O-J, wherein J is a substituted or unsubstituted
  • hydrolyzable group and substituted and unsubstituted alkoxyl, amino, alkyl, and L 6 C(O)L 4 , wherein L 6 is a single bond, -O or -N, and further wherein L. is preferably alkyl, hydroxyl, alkoxyl or hydrogen, and further wherein any one or more of Q 4 -Q 8 may form part of a ring,
  • Y and G are each oxygen
  • D is nitrogen, and wherein D is singly bonded to each of the adjacent ring atoms,
  • E is carbon or nitrogen
  • A is a carbocycle or heterocycle that is an aromatic or partially saturated, 5-7 membered mono-ring, which is optionally further substituted
  • B is a heterocycle that is a saturated or partially saturated, 8-12 membered poly-ring, which is optionally further substituted
  • the invention even more particularly relates to compounds of the formula (1) wherein:
  • one of Q 1 and Q 2 is substituted or unsubstituted alkyl, preferably t-butyl, and the other is hydrogen,
  • Q 3 is selected from thioaryl and aryl, preferably thiophenyl and phenyl,
  • Q 4 is alkyl, preferably methyl
  • Q 5 is hydroxyl or -O-J, wherein J is a hydrolyzable group, or substituted or unsubstituted alkoxyl or amino,
  • Q 6 -Q 8 are independently selected from hydrogen, hydroxyl, halogen, -O-J, wherein J is a substituted or unsubstituted
  • hydrolyzable group and substituted and unsubstituted alkoxyl, amino, alkyl, and L 6 C(O)L 4 , wherein L 6 is a single bond, -O or -N, and further wherein L 4 is preferably alkyl, hydroxyl, alkoxyl or hydrogen, and further wherein any one or more of Q 6 - Q 8 may form part of a ring,
  • Y and G are each oxygen
  • D is nitrogen, and wherein D is singly bonded to each of the adjacent ring atoms,
  • Q 9 is hydrogen
  • A is a carbocycle that is an aromatic, 5-6 membered monocyclic ring, preferably phenyl, which is optionally further substituted,
  • B is a heterocycle that is a saturated, 6-14 membered monocyclic or polycyclic ring, which is optionally further
  • M 1 and M 2 are independently selected from hydrogen, mercapto, hydroxyl, and substituted and unsubstituted thioether, alkyl, alkoxyl, aryloxyl, amino, five membered heterocycle and carbocycle, sulfinyl, sulfonyl, and acyl, and wherein M 1 and M 2 optionally form a ring having up to 10 members, wherein preferably M 1 and M 2 independently have from zero to eight non-hydrogen atoms;
  • Preferred compounds of the formula (1) include those wherein: one of Q 1 and Q 2 is tertiary alkyl, preferably t-butyl, and the other is hydrogen, Q 3 is thiophenyl, phenyl, naphthyl, or thionaphthyl,
  • Q 5 is hydroxyl, amino, or -O-J, wherein J is a substituted or unsubstituted hydrolyzable group
  • Q 6 -Q 8 are independently selected from hydrogen, hydroxyl, halogen, -O-J, wherein J is a substituted or unsubstituted
  • hydrolyzable group and substituted and unsubstituted alkoxyl, amino, alkyl, and L 6 C(O)L 4 , wherein L 6 is a single bond, -O or -N, and further wherein L. is preferably alkyl, hydroxyl, alkoxyl or hydrogen, and further wherein any one or more of Q 6 - Q 8 may form part of a ring,
  • Y and G are each oxygen
  • D is nitrogen, and wherein D is singly bonded to each of the adjacent ring atoms,
  • A is phenyl, which is optionally further substituted
  • B is a heterocycle that is a saturated, 9-10 membered bi-ring, preferably decahydroisoquinolinyl or octahydrothieno[3,2-c]pyridinyl,
  • the compounds have the formula 1 (A) :
  • Z is a group having the structure:
  • a is 1, 2, 3, 4, or 5;
  • b is 1, or 2;
  • c is 1, or 2;
  • d is 1, 2, 3, or 4;
  • each R is independently hydrogen, hydroxy, thiol, halo, amino, C 1 -C 4 alkylamino, di(C 1 -C 4 )alkylamino, nitro, carboxy, C 1 -
  • alkoxycarbonyl carbamoyl, N-(C 1 -C 4 )alkylcarbamoyl, C 1 -C 4 alkylsulfonyl, N,N-di(C 1 -C 4 )alkylcarbamoyl, or C 1 -C 4 alkylsulfonylamino;
  • a 1 and A 2 are independently -CH 2 - or -N(R 8 )-;
  • a 3 and A 4 are independently -CH- or -N-;
  • a 5 and A 6 are independently -CH 2 - or -N(R 9 )-;
  • a 7 and A 8 are independently -CH- or -N-;
  • R 8 is hydrogen or C 1 -C 4 alkyl
  • R 9 is hydrogen or C 1 -C 4 alkyl
  • R 1 is aryl, or -S-aryl
  • X is a group having the structure:
  • R is hydrogen, C 1 -C 4 alkyl, or -CH 2 -pyridyl;
  • R 3 is a group having the structure:
  • R 4 at each occurrence is independently hydrogen, C 1 -C 6 alkyl or hydroxy(C 1 -C 4 )alkyl;
  • R 5 and R 6 are independently selected from hydrogen, hydroxy, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, or hydroxy (C 1 -C 4 ) alkyl; with the provisos that :
  • a 5 and A 6 cannot both be -N(R 9 )-;
  • R 1 is aryl, or -S-aryl; X 1 is a group having the formula: , or
  • T 2 is hydrogen, halo, or C 1 -C 4 alkyl
  • R 3 is a group having the structure:
  • p 4 or 5;
  • R 4 at each occurrence is independently hydrogen
  • R and R are independently selected from hydrogen, hydroxy,
  • Z is a group having the structure :
  • a is 1, 2, 3, 4, or 5;
  • b is 1, or 2;
  • c is 1, or 2;
  • d is 1, 2, 3, or 4;
  • each R 7 is independently hydrogen, hydroxy, thiol, halo, amino, C 1 -C 4 alkylamino, di(C 1 -C 4 )alkylamino, nitro, carboxy, C 1 -
  • alkoxycarbonyl carbamoyl, N-(C 1 -C 4 )alkylcarbamoyl, C -C.
  • alkylsulfonyl N,N-di(C 1 -C 4 )alkylcarbamoyl, or C 1 -C 4
  • a 1 and A 2 are independently -CH 2 - or -N(R 8 )-;
  • a 3 and A 4 are independently -CH- or -N-;
  • a 5 and A 6 are independently -CH 2 - or -N(R 9 )-;
  • a 7 and A 8 are independently -CH- or -N-;
  • R 8 is hydrogen or C 1 -C 4 alkyl
  • R 9 is hydrogen or C 1 -C 4 alkyl
  • T 2 is hydrogen, or C 1 -C 4 alkyl
  • a 5 and A 6 cannot both be -N(R 9 )-;
  • Preferred species of the formula (1) are:
  • the present invention further provides pharmaceutical formulations comprising an effective amount of a compound of formula (1) or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier, such as a diluent or excipient.
  • a pharmaceutically acceptable carrier such as a diluent or excipient.
  • the present invention further provides a method of treating AIDS comprising administering to a host or patient, such as a primate, an effective amount of a compound of the present
  • the present invention further provides a method of inhibiting HIV replication comprising administering to an HIV infected cell, a cell susceptible to HIV infection or a host or patient, such as a primate, an effective amount of a compound of the present invention.
  • the present invention provides new compounds falling within formula (1), as described above, that are useful for treating HIV infection and/or AIDS.
  • Compounds of the formula (1) may be prodrugs.
  • compounds wherein at least one of Q 4 -Q 8 is -O-J, as defined above, may be used as prodrugs, which can serve to improve the
  • the preparation of the prodrugs may be carried out by reacting a compound of the formula (1), wherein at least one of
  • Q 4 -Q 8 is -O-H, with, for example, an activated amino acyl, phosphoryl or hemisuccinyl derivative.
  • alkyl refers to straight or branched
  • C 1 -C 8 alkyl represents a
  • C 1 -C 6 alkyl groups include methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl, neo-pentyl, hexyl, isohexyl, and the like.
  • the term "C 1 -C 6 alkyl” includes within its definition the term "C 1 -C 4 alkyl".
  • cycloalkyl represents a saturated or partially saturated, mono- or poly-carbocylic ring, preferably having 5-14 ring carbon atoms.
  • exemplary cycloalkyls include monocyclic rings having from 3-7, preferably 3-6, carbon atoms, such as
  • cyclopropyl cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like.
  • An exemplary cycloalkyl is a C 5 -C 7 cycloalkyl, which is a saturated hydrocarbon ring structure containing from five to seven carbon atoms.
  • alkoxyl represents -O-alkyl.
  • An example of an alkoxyl is a C 1 -C 6 alkoxyl, which represents a straight or
  • C 1 -C 9 alkoxyl groups include methoxyl, ethoxyl, propoxyl, isopropoxyl, butoxyl, sec-butoxyl, t-butoxyl, pentoxyl, hexoxyl, and the like.
  • C 1 -C 6 alkoxyl includes within its definition a C 1 -C 4 alkoxyl.
  • aryl refers to a carbocyclic or heterocyclic, aromatic, 5-14 membered monocyclic or polycyclic ring.
  • exemplary aryls include phenyl, naphthyl, anthryl,
  • beta-carbolinyl phenanthridinyl, acridinyl, perimidinyl
  • phenanthrolinyl phenazinyl, isothiazolyl, phenothiazinyl, and phenoxazinyl.
  • aryloxyl represents -O-aryl
  • hydrolyzable group is a group, which .when bonded to an oxygen, forms an ester, which can be hydrolyzed in vivo to a hydroxyl group.
  • exemplary hydrolyzable groups which are
  • acyl function optionally substituted, include acyl function, sulfonate function and phosphate function.
  • hydrolyzable groups include blocked or unblocked amino acid residue, a hemisuccinate residue, and a nicotinate residue.
  • halogen represents chlorine, fluorine, bromine or iodine.
  • halo represents chloro, fluoro, bromo or iodo.
  • carbocycle represents an aromatic or a saturated or a partially saturated 5-14 membered monocyclic or polycyclic ring, such as a 5- to 7-membered monocyclic or 7- to 10-membered bicyclic ring, wherein all the ring members are carbon atoms.
  • heterocycle represents an aromatic or a saturated or a partially saturated, 5-14 membered, monocylic or polycyclic ring, such as a 5- to 7-membered monocyclic or 7- to 10-membered bicyclic ring, having from one to three heteroatoms selected from nitrogen, oxygen and sulfur, and wherein any nitrogen and sulfur heteroatoms may optionally be oxidized, and any nitrogen
  • heteroatom may optionally be quaternized.
  • the heterocyclic ring may be attached at any suitable heteroatom or carbon atom.
  • heterocycles examples include decahydroisoquinolinyl, octahydro-thieno [3, 2-c] pyridinyl, piperidinyl, piperazinyl, azepinyl, pyrrolyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolyl, isobenzofuranyl, furazanyl, imidazolinyl,
  • quinolinyl chromenyl, xanthenyl, isoquinolinyl, benzimidazolyl, thiadiazolyl, benzopyranyl, benzothiazolyl, benzoazolyl, furyl, tetrahydrofuryl, tetrahydropyranyl, thienyl, benzothienyl, benzo[b]thienyl, naphtho[2,3-b]thienyl, thiamorpholinyl,
  • thiamorpholinylsulfoxide thiamorpholinylsulfone, oxadiazolyl, triazolyl, tetrahydroquinolinyl, tetrahydrisoquinolinyl,
  • phenoxathienyl indolizinyl, isoindolyl, indazolyl, purinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl,
  • quinoxyalinyl quinzolinyl, tetrahydroquinolinyl, cinnolinyl, pteridinyl, carbazolyl, beta-carbolinyl, phenanthridinyl,
  • acridinyl acridinyl, perimidinyl, phenanthrolinyl, phenazinyl, isothiazolyl, phenothiazinyl, and phenoxazinyl.
  • thioether includes S-aryl, such as phenylthio and naphthylthio; S-heterocycle where the heterocycle is saturated or partially saturated; S-(C 5 -C 7 -cycloalkyl; and S-alkyl, such as C 1 -C 6 alkylthio.
  • the -aryl, the -heterocycle, the -cycloalkyl and the -alkyl can optionally be substituted.
  • An example of a thioether is "C 1 -C 6 alkylthio", which represents a straight or branched alkyl chain having from one to six carbon atoms attached to a sulfur atom.
  • Exemplary C 1 -C 6 alkylthio groups include methylthio, ethylthio, propylthio, isopropylthio,
  • mercapto represents -SH.
  • amino represents -NL 1 L 2 , wherein L 1 and L 2 are preferably independently selected from oxygen, carbocycle, heterocycle, alkyl, sulfonyl and hydrogen; or NC(O)L 3 , wherein L 3 is preferably alkyl, alkoxyl, hydrogen or -NL 1 L 2 .
  • the aryl, alkyl and alkoxyl groups can optionally be substituted.
  • An example of an amino is C 1 -C 4 alkylamino, which represents a straight or branched alkyl chain having from one to four carbon atoms attached to an amino group.
  • Exemplary C 1 -C 4 alkylamino groups include methylamino, ethylamino, propylamino, isopropylamino, butylamino, sec-butylamino, and the like.
  • Another example of an amino is di (C 1 -C 4 ) alkylamino, which represents two straight or branched alkyl chains, each having from one to four carbon atoms attached to a common amino group.
  • Exemplary di(C 1 -C 4 )alkylamino groups include dimethylamino, ethylmethylamino, methylpropylamino, ethylisopropylamino, butylmethylamino, sec-butylethylamino, and the like.
  • An example of an amino is C 1 -C 4 alkylsulfonylamino, which has a straight or branched alkyl chain having from one to four carbon atoms attached to a sulfonylammo moiety.
  • Exemplary C 1 -C 4 alkylsulfonylamino groups include methylsulfonylamino, ethylsulfonylamino, propylsulfonylamino, isopropylsulfonylamino, butylsulfonylammo, sec-butylsulfonylamino, t-butylsulfonylamino, and the like.
  • acyl represents L 6 C(O)L 4 , wherein L 6 is a single bond, -O or -N, and further wherein L is preferably alkyl, amino, hydroxyl, alkoxyl or hydrogen.
  • the alkyl and alkoxyl groups can optionally be substituted.
  • An exemplary acyl is a C 1 -C 4
  • alkoxycarbonyl which is a straight or branched alkoxyl chain having from one to four carbon atoms attached to a carbonyl moiety.
  • exemplary C 1 -C 4 alkoxycarbonyl groups include
  • exemplary acyl is a carboxy wherein L 6 is a single bond and L 4 is alkoxyl, hydrogen, or hydroxyl.
  • a further exemplary acyl is N- (C 1 -C 4 )alkylcarbamoyl (L 6 is a single bond and L 4 is an amino), which is a straight or branched alkyl chain having from one to four carbon atoms attached to the nitrogen atom of a carbamoyl moiety.
  • N-(C 1 -C 4 )alkylcarbamoyl groups include N-methylcarbamoyl, N-ethylcarbamoyl, N-propylcarbamoyl, N-isopropylcarbamoyl, N-butylcarbamoyl, and N-t-butylcarbamoyl, and the like.
  • Yet another exemplary acyl is N,N-di(C 1 -C 4 )alkylcarbamoyl, which has two straight or branched alkyl chains, each having from one to four carbon atoms attached to the nitrogen atom of a carbamoyl moiety.
  • N,N-di(C 1 -C 4 )alkylcarbamoyl groups include N,N-dimethylcarbamoyl, N,N- ethylmethylcarbamoyl, N,N-methylpropylcarbamoyl,
  • alkyl preferably alkyl, amino, aryl, cycloalkyl or heterocycle.
  • the alkyl, aryl, cycloalkyl and heterocycle can all optionally be substituted.
  • sulfonyl represents -SO 2 -L 5 , wherein L 5 is preferably alkyl, aryl, cycloalkyl, heterocycle or amino.
  • L 5 is preferably alkyl, aryl, cycloalkyl, heterocycle or amino.
  • the alkyl, aryl, cycloalkyl and heterocycle can all optionally be substituted.
  • An example of a sulfonyl is a C 1 -C 4 alkylsulfonyl, which is a straight or branched alkyl chain having from one to four carbon atoms attached to a sulfonyl moiety.
  • Exemplary C 1 -C 4 alkylsulfonyl groups include methylsulfonyl, ethylsulfonyl, propylsulfonyl, isopropylsulfonyl, butylsulfonyl, sec-butylsulfonyl, t-butylsulfonyl and the like.
  • all chemical groups may be substituted or unsubstituted as long as the valences of such groups allow such substitutions, even if the definitions of the chemical groups do not explicitly state that the groups are substituted or unsubstituted.
  • a group is simply defined as alkyl, it may be substituted or unsubstituted alkyl.
  • substituents for alkyl and aryl include mercapto, thioether, nitro (NO 2 ), amino, aryloxyl, halogen, hydroxyl, alkoxyl, and acyl, as well as aryl, cycloalkyl and saturated and partially saturated heterocycles.
  • substituents for heterocycle and cycloalkyl include those listed above for alkyl and aryl, as well as aryl and alkyl.
  • Exemplary substituted aryls include a phenyl or naphthyl ring substituted with one or more substituents, preferably one to three substituents, independently selected from halo, hydroxy,
  • C 1 -C 4 morpholino (C 1 -C 4 )alkoxy carbonyl, pyridyl (C 1 -C 4 )alkoxycarbonyl, halo (C 1 -C 4 )alkyl, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, carboxy, C 1 -C 4 alkoxycarbonyl, carbamoyl, N-(C 1 -C 4 )alkylcarbamoyl, amino,
  • R 7 is hydroxy, C 1 -C 4 alkoxy, carboxy, C 1 -C 4 alkoxycarbonyl, amino, carbamoyl, C 1 -C 4 alkylamino or di(C 1 -C 4 )alkylamino.
  • Another substituted alkyl is halo(C 1 -C 4 )alkyl, which
  • Exemplary halo(C 1 -C 4 )alkyl groups include chloromethyl, 2-bromoethyl, 1-chloroisopropyl, 3-fluoropropyl, 2,3-dibromobutyl, 3-chloroisobutyl, iodo-t-butyl, trifluoromethyl and the like.
  • hydroxy(C 1 -C 4 )alkyl which represents a straight or branched alkyl chain having from one to four carbon atoms with a hydroxy group attached to it.
  • exemplary hydroxy(C 1 -C 4 )alkyl groups include hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, 2-hydroxyisopropyl, 4-hydroxybutyl and the like.
  • C 1 -C 4 alkylthio(C 1 -C 4 )alkyl is a straight or branched C 1 -C 4 alkyl group with a C 1 -C 4 alkylthio group attached to it.
  • Exemplary C 1 -C 4 alkylthio (C 1 -C 4 )alkyl groups include methylthiomethyl, ethylthiomethyl, propylthiopropyl, sec-butylthiomethyl, and the like.
  • heterocycle (C 1 -C 4 )alkyl which is a straight or branched alkyl chain having from one to four carbon atoms with a heterocycle attached to it.
  • Exemplary heterocycle(C 1 -C 4 )alkyls include pyrrolylmethyl, quinolinylmethyl, 1-indolylethyl, 2-furylethyl, 3-thien-2-ylpropyl, 1-imidazolylisopropyl, 4-thiazolylbutyl and the like.
  • aryl(C 1 -C 4 )alkyl which is a straight or branched alkyl chain having from one to four carbon atoms with an aryl group attached to it.
  • exemplary aryl (C 1 -C 4 )alkyl groups include phenylmethyl, 2-phenylethyl,
  • the heterocycle can, for example, be substituted with 1, 2 or 3 substituents independently selected from halo, halo(C 1 -C 4 )alkyl, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, carboxy, C 1 -C 4
  • alkoxycarbonyl carbamoyl, N-(C 1 -C 4 )alkylcarbamoyl, amino,
  • C 1 -C 4 alkylamino di(C 1 -C 4 )alkylamino or a group having the structure -(CH 2 ) a -R 7 where a is 1, 2, 3 or 4 and R 7 is hydroxy, C 1 -C 4 alkoxy, carboxy, C 1 -C 4 alkoxycarbonyl, amino, carbamoyl, C 1 -C 4 alkylamino or di(C 1 -C 4 )alkylamino.
  • substituted heterocycles include 3-N-t-butyl carboxamide decahydroisoquinolinyl, 6-N-t-butyl carboxamide octahydro-thieno[3,2-c]pyridinyl, 3-methylimidazolyl,
  • 6-methoxybenzimidazolyl 4-hydroxyfuryl, 4-methylisoquinolinyl, 6,8-dibromoquinolinyl, 4,8-dimethylnaphthyl, 2-methyl-1,2,3,4-tetrahydroisoquinolinyl, N-methyl-quinolin-2-yl,
  • Exemplary heterocyclic ring systems represented by A or B include (1) 5-membered monocyclic ring groups such as thienyl, pyrrolyl, imidazolyl, pyrazolyl, furyl, isothiazolyl, furazanyl, isoxazolyl, thiazolyl and the like; (2) 6-membered monocyclic groups such as pyridyl, pyrazinyl, pyrimidinyl, pyridazinly, triazinyl and the like; and (3) polycyclic heterocyclic rings groups, such as decahydroisoquinolinyl, octahydro-thieno [3,2-c] pyridinyl, benzo[b]thienyl, naphtho[2,3-b]thianthrenyl,
  • a cycloalkyl may be optionally substituted with 1, 2 or 3 substituents independently selected from halo, halo (C. -C.) alkyl, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, carboxy, C 1 -C 4 alkoxycarbonyl, carbamoyl, N-(C 1 -C 4 )alkylcarbamoyl, amino, C 1 -C 4 alkylamino, di(C 1 -C 4 )alkylamino or a group having the structure -(CH 2 ) a -R 7 where a is 1, 2, 3 or 4 and R 7 is hydroxy, C 1 -C 4 alkoxy, carboxy, C 1 -C 4 alkoxycarbonyl, amino, carbamoyl, C 1 -C 4 alkylamino or di(C 1 -C 4 )alkylamino.
  • substituents independently selected from halo, halo (C. -C
  • Exemplary substituted hydrolyzable groups include N-benzyl glycyl, N-Cbz-L-valyl, and N-methyl nicotinate.
  • the compounds of the present invention have at least two asymmetric centers denoted by an asterisk in the formula (1) below:
  • the compounds of the present invention can occur in any of the possible
  • stereoisomers which can be optically active or racemic, or can be used alone as essentially pure stereisomers, i.e., at least 95% pure. All asymmetric forms, individual stereoisomers and
  • the individual stereoisomers may be prepared from their respective precursors by the procedures described above, by resolving the racemic mixtures, or by separating the
  • the resolution can be carried out in the presence of a resolving agent, by chromatography or by repeated crystallization or by some combination of these techniques which are known in the art. Further details regarding resolutions can be found in Jacques et al., Enantiomers, Racemates, and
  • the compounds of the present invention are substantially pure, i.e, over 50% pure. More preferably, the compounds are at least 75% pure. Even more preferably, the compounds are more than 90% pure. Even more preferably, the compounds are at least 95% pure, more preferably, at least 97% pure, and most preferably at least 99% pure.
  • the invention includes the
  • a compound of this invention may possess a
  • pharmaceutically acceptable salt refers to salts of the compounds of the above formula which are substantially non-toxic to living organisms.
  • pharmaceutically acceptable salts include those salts prepared by reaction of the compounds of the present invention with a mineral or organic acid or an inorganic base.
  • the reactants are generally combined in a mutual solvent such as diethylether or benzene, for acid addition salts, or water or alcohols for base addition salts.
  • the salts normally precipitate out of solution within about one hour to about ten days and can be isolated by filtration or other conventional methods. Such salts are known as acid addition and base addition salts.
  • Acids that may be employed to form acid addition salts are inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like, and organic acids such as p-toluenesulfonic, methanesulfonic acid, oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like
  • organic acids such as p-toluenesulfonic, methanesulfonic acid, oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like.
  • sulfate pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioate, hexyne-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, sulfonate,
  • xylenesulfonate phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, g-hydroxybutyrate, glycollate, tartrate, methane-sulfonate, propanesulfonate, naphthalene-1-sulfonate, napththalene-2-sulfonate, mandelate and the like.
  • Preferred pharmaceutically acceptable acid addition salts are those formed with mineral acids such as hydrochloric acid and hydrobromic acid, and those formed with organic acids such as maleic acid and methanesulfonic acid.
  • Base addition salts include those derived from inorganic and organic bases, such as ammonium or alkali or alkaline earth metal hydroxides, carbonates, bicarbonates, and the like.
  • bases useful in preparing the salts of this invention thus include sodium hydroxide, potassium hydroxide, ammonium hydroxide, potassium carbonate, sodium carbonate, sodium bicarbonate, potassium bicarbonate, calcium hydroxide, calcium carbonate and the like.
  • the potassium and sodium salt forms are particularly preferred.
  • any salt of this invention is not of a critical nature, so long as the salt as a whole is pharmacologically acceptable and as long as the counterion does not contribute undesired qualities to the salt as a whole.
  • Z is a group having the structure:
  • R 2 is hydrogen, hydroxy, C 1 -C 4 alkyl, halo, amino, nitro, or trifluoromethyl; a is 1, 2, or 3;
  • R 3 is -C(O)NR 4 R 4 ;
  • R 2 is hydrogen, methyl, ethyl, propyl, chloro, fluoro, hydroxy, or amino;
  • X is , or ;
  • R is -CH 2 -pyridyl
  • R 1 is phenyl or -S-phenyl
  • R 3 is -C(O)NH(R 4 );
  • Z is R 2a is methyl, ethyl, or propyl
  • R 2b is hydrogen, hydroxy, or amino
  • R 2c is hydrogen, hydroxy, or amino
  • R is -C(O)NH(t-butyl);
  • X is ;
  • T 2 i.s hydrogen or methyl
  • Z 1 is a group having the structure:
  • R 7 is hydrogen, C 1 -C 4 alkyl, halo, nitro, amino, hydroxy; a is 1, 2, or 3;
  • R 7 is hydrogen, methyl, ethyl, hydroxy, amino, chloro
  • R is -S-phenyl, or -S-naphth-2-yl
  • R 3 is -C(O)NR 4 R 4 ;
  • Z 1 is R 7 a is hydrogen, methyl, ethyl, chloro, bromo, or fluoro; R 7 b is hydrogen, hydroxy, chloro, or ammo;
  • R 7 c is hydrogen, hydroxy, or amino
  • R 3 is -C(O)NH(t-butyl);
  • Preferred compounds are:
  • Each of the above five formulae has five assymetric centers and thus defines a compound selected from the group of 32
  • Preferred stereisomers of these compounds are :
  • the compounds of formula 1 can be prepared according to the following Reaction I.
  • Reaction I is a standard coupling reaction commonly employed in the synthesis of amides or peptides which is carried out by reacting an appropriately substituted amine of formula IA, with an appropriately substituted carboxylic acid reactant of formula IB, in an aprotic solvent or mixture of solvents.
  • the reaction is typically carried out in the presence or absence of a promoting agent, preferably in the presence of a promoting agent, and in the presence of a coupling reagent.
  • Typical aprotic solvents for this reaction are tetrahydrofuran and dimethylformamide, or a mixture of such solvents.
  • the reaction is typically carried out at a temperature from about -30°C to about 25°C.
  • the amine reactant is generally employed in equimolar proportions relative to the carboxylic acid reactant, in the presence of an equimolar quantity to a slight excess of the coupling reagent.
  • Typical coupling reagents include the carbodiimides such as
  • DCC dicyclohexylcarbodiimide
  • N,N'-diethylcarbodiimide the imidazoles such as carbonyldiimidazole
  • reagents such as bis (2-oxo-3-oxazolidinyl)phosphinic chloride (BOP-Cl) or N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) .
  • BOP-Cl bis (2-oxo-3-oxazolidinyl)phosphinic chloride
  • EEDQ N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline
  • a preferred coupling reagent for this reaction is DCC.
  • a promoting agent is preferably included for this reaction; a preferred promoting agent is hydroxybenzotriazole hydrate (HOBT ⁇ H 2 O).
  • the compound may be isolated, if desired, by procedures known in the art, for example, the compound may be crystallized and then collected by filtration, or the reaction solvent may be removed by extraction, evaporation or decantation.
  • the compound may be further purified, if desired, by common techniques such as crystallization or chromatography over solid supports such as silica gel or alumina.
  • the starting compounds of formula IA may be prepared according to the procedures shown in Reaction Scheme A.
  • v is an amino-protecting group
  • ZZ is halo
  • Reaction Scheme A is accomplished by carrying out reactions 1-7 in sequential order. Once a reaction is complete, the intermediate compound may be isolated, if desired, by
  • the compound may be crystallized and then collected by filtration, or the reaction solvent may be removed by extraction, evaporation or decantation.
  • the intermediate compound may be further purified, if desired, by common techniques such as crystallization or chromatography over solid supports such as silica gel or alumina, before carrying out the next step of the reaction scheme.
  • Reaction A.1 is carried out by converting an amino-protected carboxylic acid reactant having the structure:
  • the amino-protected carboxylic acid reactant may be reacted with a C 1 -C 6 alkylchloroformate, such as
  • isobutylchloroformate preferably in the presence of an acid scavenger.
  • Preferred acid scavengers are the trialkylamines, preferably triethylamine.
  • the reaction is typically carried out in an aprotic solvent such as ethyl acetate. Solvent choice is not critical so long as the solvent employed is inert to the ongoing reaction, and the reactants are sufficiently solubilized to effect the desired reaction.
  • the resulting mixed anhydride reactant is preferably used in Reaction A.2 without further isolation or purification.
  • Reaction A.2 is accomplished in two steps. First, a solution of sodium hydroxide, covered with a layer of an ether solvent, preferably diethyl ether, is reacted with a large excess of
  • the sodium hydroxide is preferably used as an aqueous solution having about four to six mol/liter of sodium hydroxide.
  • the organic layer is dried over a dessicant such as potassium hydroxide.
  • This solution is then reacted with the mixed anhydride from Reaction A.1, above, to form the corresponding alpha-diazo carbonyl compound.
  • the diazomethane reactant is preferably used in this reaction without isolation or purification.
  • the reaction is typically carried out at a temperature of from about -50°C to about -10°C, preferably about -20°C.
  • Reaction A.3 the alpha-diazo carbonyl compound prepared in Reaction A.2 is reacted with an acid of the formula H-ZZ where ZZ is halo, typically in an aprotic solvent such as diethylether to form an alpha-halo carbonyl compound.
  • a preferred acid reactant is hydrochloric acid which provides the corresponding alpha-chloro carbonyl compound.
  • the reaction is typically carried out at a temperature from about -30°C to about 0°C. Solvent choice is not critical so long as the solvent employed is inert to the ongoing reaction and the reactants are sufficiently
  • the acid reactant is typically added in the form of an anhydrous gas in small
  • reaction can be monitored by thin layer chromatography.
  • Reaction A.4 the carbonyl moiety on the compound prepared in Reaction A.3 is reduced using standard conditions known in the art to form the corresponding alpha-chloro hydroxy compound.
  • the compound prepared in Reaction A.3 is combined with a reducing agent in a mixture of solvents.
  • Typical reducing agents include sodium borohydride, lithium borohydride, zinc borohydride, diisobutylaluminum hydride, and sodium bis (2-methoxy-ethoxy) aluminum hydride.
  • a preferred reducing agent is sodium
  • borohydride Typical solvent mixtures include a protic and aprotic mixture such as tetrahydrofuran/water. Solvent choice is not critical so long as the solvent employed is inert to the ongoing reaction, and the reactants are sufficiently solubilized to effect the desired reaction.
  • the reaction is typically carried out at a temperature from about -10°C, preferably about 0°C.
  • the alpha-chloro hydroxy compound may be reacted with a potassium hydroxide/ethanol mixture in an alcoholic solvent such as ethanol.
  • the reaction is typically carried out at a
  • reaction is carried out at room temperature from about 0°C to about the reflux temperature of the solvent.
  • the reaction is carried out at room temperature
  • Reaction A.6 the epoxide prepared in Reaction A.5 is reacted with a heterocyclic reactant :
  • solvent choice is not critical so long as the solvent employed is inert to the ongoing reaction, and the reactants are sufficiently solubilized to effect the desired reaction.
  • Typical solvents for this reaction include the alcohols, preferably isopropanol or ethanol. The reaction is preferably carried out at a temperature of about 80°C.
  • Reaction A.7 is a standard amino deprotection reaction using procedures and methods known in the art to afford the
  • This amine which is used in Reaction I, above.
  • This amine may be reacted without purification, but it is preferably purified first.
  • the compounds of formula IA, where Q 3 is -S-aryl are typically prepared by first reacting amino-protected serine with triphenylphosphine and diethylazodicarboxylate (DEAD) in an aprotic solvent at a temperature of from about -80°C to 0°C to form the corresponding beta-lactone.
  • the reaction is typically carried out in an ether, such as tetrahydrofuran at a temperature of from about -80°C to -50°C.
  • the lactone ring is opened to provide a compound having the structure :
  • thioanion compound is preferably formed by reacting the
  • thiol with a strong base, such as sodium hydride or potassium hydride.
  • a strong base such as sodium hydride or potassium hydride.
  • This reaction is typically carried out in an aprotic solvent at a temperature from about 0°C to about 40°C and under an inert atmosphere, such as nitrogen.
  • Typical solvents for this reaction include ethers, preferably tetrahydrofuran.
  • the compounds of formula IA, where Q 3 is -S-aryl may be prepared using the procedures detailed in Photaki .
  • the compounds may be prepared by reacting doubly protected serine (carboxy-protected and amino-protected) with toluenesulfonyl chloride in the presence of dimethylaminopyridine (DMAP) and an acid scavenger such as pyridine in an aprotic solvent such as methylene chloride to form the corresponding toluenesulfonate which may then be reacted with an appropriately substituted thioanion having the structure, -S- aryl.
  • DMAP dimethylaminopyridine
  • an acid scavenger such as pyridine
  • an aprotic solvent such as methylene chloride
  • the thioanion compound is preferably formed by reacting the corresponding thiol with a strong base as described above.
  • the carboxy-protecting group may be removed from the resulting doubly protected arylthioalanine using conditions known in the art.
  • the heterocyclic reactants were typically prepared from the corresponding amino-protected amino acids by acid activation followed by treatment with an alkylamine. This reaction is typically carried out in the presence of an acid scavenger, such as N-methylmorpholine. Removal of the aminoprotecting group using standard chemical deprotecting techniques then provides the desired heterocyclic reactants.
  • the [3S- (3R* , 4aR* , 8aR*) ]-decahydroisoquinoline-3-N-t-butylcarboxamide was prepared using 2S-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid by the following procedure:
  • the piperazine reactants may be prepared by converting an appropriately substituted pyrazine compound to the corresponding piperazine compound using procedures known in the art, preferably using catalytic hydrogenation.
  • the hydrogenation may be accomplished by combining the pyrazine reactant with a catalyst under a hydrogen atmosphere in an aprotic solvent at a temperature from about 0°C to about 60°C.
  • Suitable catalysts include palladium-on-carbon, platinum metal, platinum oxide and the like.
  • a preferred catalyst is platinum oxide.
  • Typical solvents for this reaction include tetrahydrofuran, dimethylformamide or a mixture of tetrahydrofuran and dimethylformamide.
  • the nitrogen atom on the resultant piperazine reactant may be alkylated using procedures known in the art.
  • the piperazine reactant may be reacted with a halo (C 1 -C 4 )alkyl, or halomethylpyridine, such as methyl iodide or chloromethylpyridme.
  • Preferred halo substituents include chloro, bromo and iodo.
  • the reaction is carried out at temperatures of from about 0°C to 60°C in a mutually inert solvent and in the presence of an acid
  • a preferred acid scavenger is potassium carbonate.
  • Typical solvents include a mixture of a protic and aprotic
  • solvents such as acetonitrile and water. Solvent choice is not critical so long as the solvent employed is inert to the ongoing reaction and the reactants are sufficiently solubilized to effect the desired reaction.
  • the alkylated piperazine reactant may be prepared using reductive amination.
  • the piperazine reactant prepared above may be reacted with an aldehyde (for example, 3 -pyridine carboxylic aldehyde, ethanal, propanal) or a ketone in the presence of a reducing agent and an acid.
  • the reaction is typically carried out in an alcoholic solvent such as methanol, ethanol or isopropanol.
  • Typical reducing agents include sodium borohydride, lithium cyanoborohydride, sodium
  • cyanoborohydride and the like.
  • a preferred reducing agent is sodium cyanoborohydride.
  • Typical acids include any protic acid such as hydrochloric acid, sulfuric acid, methanesulfonic acid, or acetic acid.
  • a preferred acid is acetic acid.
  • V 0 and V 1 are independently hydrogen, C 1 -C 8 alkyl, or hydroxy
  • V 2 is hydrogen, an ammo-protecting group, or a group of the formula:
  • V 3 is -(CH 2 ) t -V 3 ';
  • t 0, 1, 2, 3, or 4;
  • V 3' is aryl, -O-aryl, or -S-aryl
  • V 4 is hydrogen or an ammo-protectmg group; f, h and j are each independently 0, 1 or 2; g and i are each independently 0 or
  • V 5 is -CH 2 -, -CHV 5' -, or -CV 5' V 5' -;
  • V 6 is -CH 2 -, -CHV 6' , -CV 6' v 6' -;
  • V 7 is -CH 2 -, -CHV 7' , or -CV 7 ' V 7 ' -;
  • each of V 5' , V 6' , and V 7' is independently selected from halo, hydroxy, C 1 -C 6 alkyl, halo (C 1 -C 6 ) alkyl, hydroxy (C 1 -C 6 ) alkyl, C 1 -C 6 , alkoxy, C 1 -C 6 alkylthio, amino, or cyano;
  • T and W are independently -S-, -S(O)-, -S(O) 2 -, - O-, -NH-, or -(V 9 )-;
  • V 9 is C 1 -C 6 alkyl, aryl (C 1 -C 6 ) alkyl, aryl, or acyl;
  • f, g, h, i and j must be 2, 3, 4, or 5;
  • V 5 is -CV 5' v 5' -
  • V 6 must be -CH 2 - or - CHV 6' -
  • V 7 must be -CH 2 - or -CHV 7' -;
  • V 6 is -CV 6' v 6' -
  • V 5 must be -CH 2 - or - CHV 5' -
  • V 7 must be -CH 2 - or -CHV 7' -;
  • V 7 is -CV 7' v 7' -
  • V 5 must be -CH 2 - or - CHV 5' -
  • V 6 must be -CH 2 - or -CHV 6' -;
  • V 4 , V 3 , V 0 , V 1 , V 5 , T, V 6 , W, V 7 , f, g, h, i, j, are defined as they are above for formula 2, including their
  • V 3' , t, V 5' , V 6' , V 7' , and V 9' definitions of V 3' , t, V 5' , V 6' , V 7' , and V 9' ,
  • V A is an amino-protecting group
  • U in reaction 1-3 above represents the presence of double bonds between, for example, V 5 and V 6 , V 5 and V 5 , or V 7 and V 6 and the like, where g is 0, h is 0 and f is 2, or i is O,
  • Reaction Scheme II is accomplished by carrying out reactions 1-3 (or 1-5) in sequential order.
  • the intermediate compound may be isolated, if desired, by procedures known in the art, for example, the compound may be crystallized and then collected by filtration, or the reaction solvent may be removed by extraction, evaporation or decantation.
  • the intermediate compound may be further purified, if desired, by common techniques such as crystallization or chromatography over solid supports such as silica gel or alumina, before carrying out the next step of the reaction scheme.
  • Reaction II.1 is typically carried out by activating the carboxylic acid moiety using, for example, DCC or a mixed
  • anhydride such as isobutyl
  • reaction followed by reaction with a primary or secondary amine having the formula NV 0 V 1 where V 0 and V 1 are as defined above for formula (2).
  • the reaction is typically carried out in a nonpolar aprotic solvent or mixture of solvents in the presence or absence of an acid scavenger at a temperature of from about -20°C to about 25°C to afford the corresponding amide.
  • Suitable solvents for this reaction include ethers and chlorinated hydrocarbons, preferably diethyl ether, chloroform, or methylene chloride.
  • this reaction is carried out in the presence of an acid scavenger such as a tertiary amine, preferably triethylamine.
  • an acid scavenger such as a tertiary amine, preferably triethylamine.
  • the amide afforded by this reaction may be isolated or further reacted as shown in Reaction II.2.
  • Reaction II.2 is typically carried out by reacting the compound obtained from Reaction II.1 using the procedures detailed in Comprehensive Organic Synthesis, "Heteroatom Manipulation", Barry M. Trost, ed., volume 6, pages 736-746, (1991).
  • an appropriately substituted monocyclic ring is reacted with an aldehyde, such as formaldehyde or trichloroacetaldehyde, in the presence of an acid.
  • the acid may be used as a solvent.
  • Typical acids include hydrochloric acid, hydrobromic acid, sulfuric acid, acetic acid, trifluoroacetic acid, and the like.
  • a co-solvent may optionally be added to the reaction mixture.
  • co-solvent choice is not critical so long as the co-solvent employed is inert to the ongoing reaction, and the reactants are sufficiently solubilized to effect the desired reaction.
  • Typical solvents for this reaction include halogenated solvents such as methylene chloride, trichloroethane, carbontetrachloride, and the like.
  • the aldehyde may be produced in situ using for example, dimethoxymethane and a suitable acid.
  • reaction II.3 the compound isolated from reaction II.2 is reduced to provide a saturated heterocyclic compound as depicted above.
  • Catalytic hydrogenation is a preferred method of
  • Typical catalysts include palladium catalysts, rhodium catalysts (for example rhodium on aluminum) and rhenium catalysts.
  • Preferred catalysts include palladium-on-carbon.
  • solvents for this reaction include the C 1 -C 4 alcohols,
  • the reaction is typically carried out under an atmosphere of hydrogen from about 1000 to about 4000 psi at a temperature of from about 25°C to about 150°C. Preferably, the reaction is carried out under an atmosphere of hydrogen from about 2000 to about 3000 psi at a temperature of from about 50°C to 100°C.
  • the catalyst is generally employed in a amount ranging from about equimolar proportions to about a
  • Reactions II.4 and II.5 may be used to prepare compounds of formula (3) which correspond to compounds of formula (2) where
  • V 3 and V 4 are as defined above for formula (2), including their definitions of V 3' and t.
  • Reaction II.4 is a standard amino deprotection reaction using procedures and methods known in the art to afford the
  • the compound isolated from II.3 may be deprotected using trimethylsilyliodide (TMSI) in an aprotic solvent or mixture of solvents at a
  • Typical solvents include methylene chloride, acetonitrile trichloroethane, and the like.
  • Reaction II.5 the epoxide prepared in Reaction A.5, above, in which Q 3 of Reaction A.5 is replaced by V 3 , is reacted with the compound isolated from Reaction II.4 in an alcoholic solvent at a temperature of from about 20°C to 100°C.
  • Solvent choice is not critical so long as the solvent employed is inert to the ongoing reaction, and the reactants are sufficiently solubilized to effect the desired reaction.
  • Typical solvents for this reaction include the alcohols, preferably isopropanol or ethanol.
  • the reaction is preferably carried out at a temperature of about 80°C.
  • reaction II.5 may optionally be deprotected to provide a compound of formula (3) where V A is hydrogen.
  • the epoxide used in Reaction II.5 may be synthesized using Reaction Scheme A above in which Q 3 of Scheme A is replaced by V 3 .
  • this reactant may be prepared by further
  • carbocyclic or heterocyclic compound for example, carbocyclic or heterocyclic compounds of the formula
  • an oxidizing agent such as selenium dioxide or potassium permanganate at temperatures of from about 0°C to 200°C in a mutually inert solvent, such as water or diphenylether.
  • a second method for preparing compounds of the formula (IB) involves protecting an appropriately substituted carboxylated carbocyclic or heterocyclic group with a carboxy-protecting group, and then further substituting the carbocyclic or heterocyclic group using procedures known in the art.
  • the carboxy-protecting group may then be removed using procedures known in the art to provide the desired carboxylic acid reactant of formula (IB).
  • carboxy-protecting groups include methyl, p-nitrobenzyl, p- methylbenzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, 2,4-dimethoxybenzyl, 2,4,6-trimethoxybenzyl, 2,4,6-trimethylbenzyl, pentamethylbenzyl, 3,4-methylenedioxybenzyl, benzhydryl, 4,4'-dimethoxybenzhydryl, 2,2',4,4'-tetramethoxybenzhydryl, t-butyl, t-amyl, trityl, 4-methoxytrityl, 4,4'-dimethoxy-trityl, 4,4',4'trimethoxytrityl, 2-phenylprop-2-yl, trimethylsilyl, t-butyld
  • a preferred procedure for protecting the carboxy moiety involves the acid activation of the carboxy moiety, followed by the formation of an amide.
  • the carboxy moiety may be converted to an acyl halide, acyl anhydride, acyl imidazole and the like, preferably in the presence of an acid scavenger to form an activated carboxy moiety.
  • an acid scavenger preferably in the presence of an acid scavenger to form an activated carboxy moiety.
  • a commercially available acid chloride is typically employed, obviating the need for further acid activation.
  • Preferred acid scavengers are the
  • trialkylamines preferably triethylamine.
  • the reaction is typically carried out in an aprotic solvent such as diethylether, methylene chloride or the like.
  • a preferred solvent is methylene chloride.
  • Solvent choice is not critical so long as the solvent employed is inert to the ongoing reaction, and the reactants are sufficiently solubilized to effect the desired reaction.
  • the activated carboxy moiety is then reacted with an amine, R 11 -NH 2 , for example aniline, in an aprotic solvent to provide an amide reactant
  • the amide reactant may be further substituted by ortho deprotonation of the group
  • the amide reactant is generally deprotonated twice using two equivalents of a strong base such as n-butyl lithium or sec-butyl lithium relative to the amide reactant, optionally in the presence of a metal coordinating agent such as tetramethylethylenediamine (TMEDA).
  • a metal coordinating agent such as tetramethylethylenediamine (TMEDA).
  • TEDA tetramethylethylenediamine
  • the reaction is typically carried out in an aprotic solvent, preferably an ether such as diethylether, tetrahydrofuran or the like at a temperature from about -78°C to about 25°C.
  • the resultant compound may then be hydrolyzed using
  • a suitable hydrolysis involves exposing the amide reactant to a strong mineral acid, organic acid, or a mineral acid/organic mixture at a temperature from about 100°C to about 160°C.
  • Typical acids which may be used in this reaction include hydrobromic acid, acetic acid, hydrochloric acid and the like.
  • a sealed tube may
  • a third method for preparing the substituted carboxylic acid reactant of formula (IB) involves diazotization of an aniline, followed by a quenching of the resultant diazonium salt.
  • the amino moiety of the aniline reactant is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
  • Nitrous acid may be produced in si tu by treating sodium nitrite with an aqueous solution of a strong acid such as hydrochloric acid, or sulfuric acid. This reaction is typically carried out at or below 5°C.
  • the diazonium salt is then quenched by reaction with suitable reagent to provide the desired substituted aromatic system.
  • suitable quenching reagents include water, cyanide, halide, aqueous sulfuric acid, and the like. Typically, the reaction will be heated to facilitate the desired reaction.
  • carboxylation may be accomplished using a number of different reagents.
  • the carboxylation may be accomplished using a number of different reagents. For example, the
  • carbocyclic or heterocyclic reagent may be reacted with phosgene, oxalyl chloride, urea hydrochloride, or N,N-diethylcarbamoyl chloride in the presence of Friedel-Crafts catalysts.
  • a variation of this method involves reacting the carbocyclic or heterocyclic reagent with an alkyl thiolchloroformate (RSCOCl), or a carbamoyl chloride (H 2 NCOCl) to provide an amide and a thiol ester,
  • RSCOCl alkyl thiolchloroformate
  • H 2 NCOCl carbamoyl chloride
  • the amide and thiol ester may then be hydrolyzed to provide the desired carboxy group. March, at 491.
  • Friedel-Crafts catalysts include the Lewis acids, such as aluminum bromide (AlBr 3 ), aluminum chloride (AlCl 3 ), iron (III) chloride (FeCl 3 ), boron trichloride (BCl 3 ), boron
  • the quinoline carboxylic acid reactants may be prepared by reacting an appropriately substituted aniline with glycerol using the Skraup reaction disclosed in Bradford, L. et al., J. Chem. Soc., 1947, p 437.
  • 3-amino benzoic acid may be reacted with glycerol in the presence of an oxidizing agent such as m-nitro benzene sulfonic acid or sodium m-nitro benzene sulfonate in a 60-75% aqueous solution of sulfuric acid to provide the desired carboxy-substituted quinoline.
  • the reaction is typically carried out at a temperature from about 35°C to reflux temperature for one to six hours, preferably from about 50°C to reflux temperature for two to four hours.
  • the resultant reactants may then be reduced or hydrogenated using procedures known in the art. See e.g., March, at 700.
  • a preferred procedure involves catalytic hydrogenation, for example by combining the quinoline carboxylic acid reactant with hydrogen gas in the presence of a catalyst.
  • a preferred catalyst is palladium-on-carbon.
  • Typical solvents suitable for use in this reaction include any organic solvent such as ethyl acetate.
  • Solvent choice is not critical so long as the solvent employed is inert to the ongoing reaction.
  • the reaction is generally
  • the compounds of formula IA, in which Q 3 is replaced by R 1 can be prepared according to the following Reaction Scheme B.
  • R is an amino-protecting group
  • R 1 , R 3 , and T 2 are as defined above for formula 1(B), including the definition of R 4 , R 5 , R 6 , and p.
  • Reaction Scheme B is accomplished by carrying out reactions 1-6 in sequential order. Once a reaction is complete, the intermediate compound may be isolated, if desired by
  • the compound may be crystallized and then collected by filtration, or the reaction solvent may be removed by extraction, evaporation or decantation.
  • the intermediate compound may be further purified, if desired, by common techniques such as crystallization or chromatography over solid supports such as silica gel or alumina, before carrying out the next step of the reaction scheme.
  • reaction B.1 the reaction is typically carried out by activating, that is, converting, a suitably substituted:
  • Reaction B.2 the acyl chloride or acyl bromide, prepared in Reaction B.1, typically is reacted with ammonia or a primary or secondary amine having the formula
  • R 4 , R 5 , R 6 and p are as defined above for formula 1(B), in a nonpolar aprotic solvent or mixture of solvents in the presence or absence of an acid scavenger to afford the corresponding amide.
  • the reaction is typically carried out at a temperature of from about -20°C to about 25°C.
  • Typical solvents for this reaction include ethers and chlorinated hydrocarbons, preferably
  • this reaction is carried out in the presence of an acid scavenger such as a tertiary amine, preferably triethylamine.
  • an acid scavenger such as a tertiary amine, preferably triethylamine.
  • Reaction B.3 the amide prepared in Reaction B.2, is reacted with a strong base in the presence of a solubilizing agent to afford the corresponding anion which is then reacted in
  • Reaction B.4 with a Weinreb amide to afford a ketone is typically carried out in an aprotic solvent at a temperature of from about -78°C to about 0°C.
  • Typical bases used in Reaction B.3 include lithium amide bases and alkyl lithium bases, preferably C 1 -C 4 alkyl lithium bases and lithium di(C 1 -C 6 ) alkylamide bases.
  • Typical solubilizing agents for Reaction 3 are tetramethyl (C 1 -C 4 )alkylenediamines, preferably tetramethylethylenediamine.
  • Reaction B.4 typically is carried out in an aprotic solvent at a temperature from about -80°C to about -40°C.
  • Typical solvents for Reactions B.3 and B.4 include ethers, preferably tetrahydrofuran.
  • the anion is generally employed in an amount ranging from about equimolar proportions to about a three molar excess of the anion, preferably in about a two molar excess of the anion relative to the Weinreb amide reactant.
  • Reaction B.5 the ketone prepared in Reaction B.3, is reduced to the corresponding alcohol using a suitable reducing agent.
  • the reaction is carried out in a protic solvent at a temperature of from about -25°C to about 25°C.
  • Typical reducing agents for this reaction include sodium borohydride, lithium borohydride, diisobutylaluminum hydride, and sodium bis (2-methoxyethoxy) aluminum hydride.
  • a preferred reducing agent is sodium borohydride.
  • Typical protic solvents for this reaction include alcohols, preferably ethanol.
  • Reaction B.6 is a standard amino deprotection reaction using procedures and methods known in the art to afford the
  • This amine which is used in Reaction I above.
  • This amine may be reacted without purification, but it is preferably purified first.
  • the Weinreb amide used as a reactant in Reaction B.4 is typically prepared by reacting an amino-protected amino acid with N-methoxy-N-methyl-amine in the presence of a promoting agent, an acid scavenger, and a coupling agent.
  • the reaction is typically carried out in an aprotic solvent or mixture of solvents at a temperature of from about -25°C to 25°C.
  • a preferred promoting agent for this reaction is HOBT.H 2 O.
  • Preferred acid scavengers are the tertiary alkylamines, preferably triethylamine or N-methyl-morpholine.
  • a preferred coupling reagent is ethyl
  • the thioanion compound is preferably formed by reacting the corresponding thiol with a strong base, such as sodium hydride or potassium hydride. This reaction is typically carried out in an aprotic solvent at a temperature from about 0°C to about 40°C and under an inert atmosphere, such as nitrogen. Typical solvents for this reaction include ethers, preferably tetrahydrofuran.
  • the desired amide reactant is then formed by reacting the resulting carboxylic acid reactant with N-methoxy-N-methyl-amine in the presence of a promoting agent, an acid scavenger and a coupling agent
  • the compounds of formula (IA), where R 1 replaces Q 3 and where R 1 is -S-aryl may be prepared in Scheme B using the procedures detailed in Photaki, JACS, 85, 1123 (1963), and Sasaki, N.A. et al., Tetrahedron Letters, 28, 6069 (1987).
  • the compounds may be prepared by reacting doubly protected serine (carboxy-protected and amino-protected) with toluenesulfonyl chloride in the presence of dimethylaminopyridine (DMAP) and an acid scavenger such as pyridine in an aprotic solvent such as methylene chloride to form the corresponding toluenesulfonate compound which may then be reacted with an appropriately substituted thioanion having the structure, -S-aryl.
  • DMAP dimethylaminopyridine
  • an acid scavenger such as pyridine
  • an aprotic solvent such as methylene chloride
  • the thioanion compound is preferably formed by reacting the corresponding thiol with a strong base as described above.
  • the carboxy-protecting group may then be removed from the resulting doubly protected arylthioalanine using conditions known in the art.
  • an intermediate for making compounds of the present invention is prepared as follows.
  • the intermediate has the formula 4 :
  • R 1 is aryl, or -S-aryl
  • R 10 is hydrogen or an amino-protecting group
  • R 0 is C 1 -C 4 alkyl or -CH 2 -pyridyl
  • R 3 is a group having the structure
  • p 4 or 5 ;
  • R 4 at each occurrence is independently hydrogen, C 1 -C 6 alkyl or hydroxy(C 1 -C 4 )alkyl;
  • R 5 and R 6 are independently selected from hydrogen, hydroxy, C 1 -C 6 , alkyl, C 1 -C 6 alkoxy, or hydroxy (C 1 -C 4 ) alkyl;
  • the intermediate having the formula 4 is typically made by the process comprising: (a) reducing a compound of the formula
  • R b is an amino protecting group
  • NMR spectra were obtained on a Bruker Corp. 270 MHz instrument or on a General Electric QE-300 300 MHz instrument. The chemical shifts are expressed in delta values (ppm downfield from tetramethylsilane). MS(FD) spectra were taken on a Varian-MAT 731 Spectrometer using carbon dendrite emitters. EIMS spectra were obtained on a CEC 21-110 instrument from Consolidated
  • IR (CHCl 3 ) 3600-3100 (br.), 2929, 2865, 1671, 1515, 1455,
  • IR (CHCD) 3630, 3412, 3011, 1720, 1502, 1236, 1044 cm -1 .
  • IR (CHCI 3 ) 3640, 3022, 2976, 1720, 1502, 1235, 1045 cm -1 .
  • the subtitled compound of Preparation 4E (371 mg, .0.77 mmol) was deprotected substantially as detailed in Preparation 1B, using 110 mg of 10% palladium-on-carbon and hydrogen gas in 20 mL of ethanol to provide 260 mg of a white foam.
  • reaction mixture was reacted for approximately thirty minutes, concentrated under reduced pressure, redissolved in 500 mL of methylene chloride and then washed sequentially with water, hydrochloric acid (pH 2), saturated sodium bicarbonate, water, 1M potassium hydroxide, and brine, dried over sodium sulfate, and concentrated to provide 68.5 g of a white solid.
  • This residue was redissolved in 4 mL of ammonium hydroxide.
  • the resultant solution was extracted four times with 10 mL portions of a 10% solution of isopropanol in chloroform.
  • the combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure to provide a residue.
  • This residue was purified using radial chromatograghy (2 mm plate; gradient eluent of 10-30% methanol in methylene chloride containing 1% ammonium hydroxide) to provide 65 mg of a light yellow foam.
  • a solution was prepared containing 50 mg (0.081 mmol) of the subtitled intermediate of Preparation 7A and 1 mL of a 38% aqueous hydrobromic acid solution. in acetic acid.
  • the resultant reaction mixture was allowed to react at room temperature for approximately 1 hour and then was concentrated under reduced pressure to provide a residue. This residue was slurried with toluene and then concentrated under reduced pressure to provide 61 mg of the desired subtitled intermediate. This compound was used crude without purification in Example 9.
  • the desired subtitled intermediate was prepared substantially in accordance with the procedure detailed in Procedure 2A, using 13.1 mL (127 mmol) of thiophenol, 4.6 g (117 mmol) of a 60% sodium hydride solution and 25.6 g (116 mmol) of L-N (benzyloxycarbonyl)-serine ⁇ -lactone in 450 mL of tetrahydrofuran to provide a residue.
  • This residue was purified using flash chromatography (gradient eluent of 0-2% acetic acid in a 4:1 methylene chloride/ethyl acetate mixture) to provide 27.9 g of a white solid.
  • the desired subtitled compound was prepared substantially in accordance with the procedure detailed in Procedure 2B, using 12.1 g (37 mmol) of the subtitled compound of Preparation 8A, 5.09 mL (37 mmol) of triethylamine, 7.13 mL (55 mmol) isobutyl
  • the desired subtitled compound was prepared substantially in accordance with the procedure detailed in Procedure 2C, using 22.3 g (63 mmol) of the subtitled compound of Preparation 8B and small quantities of hydrochloric acid (gas) in 400 mL of diethylether to provide 21 g of a white solid. This solid was used without further purification.
  • the desired subtitled compound was prepared substantially in accordance with the procedure detailed in Procedure 2D, using 21 g (58 mmol) of the subtitled compound of Preparation 8C, and 2.4 g (63 mmol) of sodium borohydride in 300 mL of tetrahydrofuran to provide a residue. This residue was purified using flash
  • the desired subtitled compound was prepared substantially in accordance with the procedure detailed in Procedure 2E, using 8.3 g (23 mmol) of the subtitled compound of Preparation 8D, 1.4 g (25 mmol) of potassium hydroxide in 400 mL of ethanol to provide a residue. This residue was purified using flash chromatography (gradient eluent of 0-2% ethyl acetate in methylene chloride) to provide 6.4 g of a white solid.
  • the desired subtitled compound was prepared substantially in accordance with the procedure detailed in Procedure 2F, using 6.3 g (19 mmol) of the subtitled compound of Preparation 8E, 5 g (21 mmol) of [3S- (3R* , 4aR*, 8aR*) ]-decahydroisoquinoline-3-N-t-butylcarboxamide in 300 mL of ethanol to provide a residue.
  • This residue was purified using flash chromatography (gradient eluent of 0-20% ethyl acetate in methylene chloride) to provide 4.3 g of a white solid.
  • the desired subtitled compound was prepared substantially in accordance with the procedure detailed in Procedure 2G using 1 g
  • the resulting reaction mixture was reacted for approximately thirty minutes and then diluted with 1N sodium bicarbonate.
  • the resultant layers were separated and the organic layer was washed sequentially with water, IM sodium hydroxide and then brine, dried over sodium sulfate, filtered and then reduced to dryness under reduced pressure to provide 31.6 g of an off-white solid.

Abstract

HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

Description

HIV PROTEASE INHIBITORS
This application is a continuation-in-part of each of United States Patent Application Serial Nos. : (i) 08/133,543 and (ii) 08/133,696; both filed on October 7, 1993.
BACKGROUND OF THE INVENTION
This invention relates to a novel series of chemical
compounds useful as HIV protease inhibitors and to the use of such compounds as antiviral agents.
Acquired Immune Deficiency Syndrome (AIDS) is a relatively newly recognized disease or condition. AIDS causes a gradual breakdown of the body's immune system as well as progressive deterioration of the central and peripheral nervous systems.
Since its initial recognition in the early 1980's, AIDS has spread rapidly and has now reached epidemic proportions within a
relatively limited segment of the population. Intensive research has led to the discovery of the responsible agent, human T-lymphotropic retrovirus III (HTLV-III), now more commonly referred to as the human immunodeficiency virus or HIV.
HIV is a member of the class of viruses known as
retroviruses. The retroviral genome is composed of RNA which is converted to DNA by reverse transcription. This retroviral DNA is then stably integrated into a host cell's chromosome and,
employing the replicative processes of the host cells, produces new retroviral particles and advances the infection to other cells. HIV appears to have a particular affinity for the human T-4 lymphocyte cell which plays a vital role in the body's immune system. HIV infection of these white blood cells depletes this white cell population. Eventually, the immune system is rendered inoperative and ineffective against various opportunistic diseases such as, among others, pneumocystic carini pneumonia, Karposis sarcoma, and cancer of the lymph system.
Although the exact mechanism of the formation and working of the HIV virus is not understood, identification of the virus has led to some progress in controlling the disease. For example, the drug azidothymidine (AZT) has been found effective for inhibiting the reverse transcription of the retroviral genome of the HIV virus, thus giving a measure of control, though not a cure, for patients afflicted with AIDS. The search continues for drugs that can cure or at least provide an improved measure of control of the deadly HIV virus.
Retroviral replication routinely features post-translational processing of polyproteins. This processing is accomplished by virally encoded HIV protease enzyme. This yields mature polypeptides that will subsequently aid in the formation and function of infectious virus. If this molecular processing is stifled, then the normal production of HIV is terminated.
Therefore, inhibitors of HIV protease may function as anti-HIV viral agents.
HIV protease is one of the translated products from the HIV structural protein pol gene. This retroviral protease
specifically cleaves other structural polypeptides at discrete sites to release these newly activated structural proteins and enzymes, thereby rendering the virion replication-competent. As such, inhibition of the HIV protease by potent compounds may prevent proviral integration of infected T-lymphocytes during the early phase of the HIV-1 life cycle, as well as inhibit viral proteolytic processing during its late stage. Additionally, the protease inhibitors may have the advantages of being more readily available, longer lived in virus, and less toxic than currently available drugs, possibly due to their specificity for the retroviral protease.
In accordance with this invention, there is provided a novel class of chemical compounds that can inhibit and/or block the activity of the HIV protease, which halts the proliferation of HIV virus, pharmaceutical compositions containing these compounds, and the use of the compounds as inhibitors of the HIV protease.
Summary of the Invention
The present invention relates to compounds falling within formula (1) below, and pharmaceutically acceptable salts thereof, that inhibit the protease encoded by human immunodeficiency virus (HIV) type 1 (HIV-1) or type 2 (HIV-2). These compounds are useful in the treatment of infection by HIV and the treatment of the acquired immune deficiency syndrome (AIDS). The compounds, their pharmaceutically acceptable salts, and the pharmaceutical compositions of the present invention can be used alone or in combination with other antivirals, immunomodulators, antibiotics or vaccines. Compounds of the present invention can also be used as prodrugs. Methods of treating AIDS, methods of treating HIV infection and methods of inhibiting HIV protease are disclosed.
The compounds of the present invention are of the formula (1) :
Figure imgf000006_0001
wherein:
Q1 and Q2 are independently selected from hydrogen and substituted and unsubstituted alkyl and aryl, and Q1 and Q2 may form a ring with G, Q3 is selected from mercapto and substituted and unsubstituted alkoxyl, aryloxyl, thioether, amino, alkyl,
cycloalkyl, saturated and partially saturated heterocycle, and aryl,
Q4-Q8 are independently selected from hydrogen, hydroxyl, mercapto, nitro, halogen, -O-J, wherein J is a substituted or unsubstituted hydrolyzable group, and substituted and
unsubstituted alkoxyl, aryloxyl, thioether, sulfinyl, sulfonyl, amino, alkyl, cycloalkyl, saturated and partially saturated heterocycle, aryl, and L6C(O)L4, wherein L6 is a single bond, -O or -N, and further wherein L4 is preferably alkyl, hydroxyl, alkoxyl or hydrogen, and further wherein any one of Q4-Q8 may be a member of a spiro ring and any two of Q 4-Q8 may together be members of a ring,
Y and G are independently selected from oxygen, -NH,
-N-alkyl, sulfur, selenium, and two hydrogen atoms,
D is carbon or nitrogen, and wherein D is singly bonded to each of the adjacent ring atoms,
E is carbon or nitrogen,
Q9 is selected from hydrogen, halogen, hydroxyl, mercapto, and substituted and unsubstituted alkoxyl, aryloxyl, thioether, amino, alkyl, and aryl, wherein Q9 may form part of a ring,
A is a carbocycle or heterocycle, which is optionally further substituted, and B is a carbocycle or heterocycle, which is optionally further substituted,
or a pharmaceutically acceptable salt thereof.
The invention more particularly relates -to preferred
compounds of formula (1) wherein:
at least one of Q1 and Q2 is substituted or unsubstituted alkyl and the other is as defined above,
Q3 is selected from thioether and aryl,
Q4-Q8 are independently selected from hydrogen, hydroxyl, halogen, -O-J, wherein J is a substituted or unsubstituted
hydrolyzable group, and substituted and unsubstituted alkoxyl, amino, alkyl, and L6C(O)L4, wherein L6 is a single bond, -O or -N, and further wherein L. is preferably alkyl, hydroxyl, alkoxyl or hydrogen, and further wherein any one or more of Q4-Q8 may form part of a ring,
Y and G are each oxygen,
D is nitrogen, and wherein D is singly bonded to each of the adjacent ring atoms,
E is carbon or nitrogen,
Q9 is hydrogen,
A is a carbocycle or heterocycle that is an aromatic or partially saturated, 5-7 membered mono-ring, which is optionally further substituted, and B is a heterocycle that is a saturated or partially saturated, 8-12 membered poly-ring, which is optionally further substituted,
or a pharmaceutically acceptable salt thereof.
The invention even more particularly relates to compounds of the formula (1) wherein:
one of Q1 and Q2 is substituted or unsubstituted alkyl, preferably t-butyl, and the other is hydrogen,
Q3 is selected from thioaryl and aryl, preferably thiophenyl and phenyl,
Q4 is alkyl, preferably methyl,
Q 5 is hydroxyl or -O-J, wherein J is a hydrolyzable group, or substituted or unsubstituted alkoxyl or amino,
Q6-Q8 are independently selected from hydrogen, hydroxyl, halogen, -O-J, wherein J is a substituted or unsubstituted
hydrolyzable group, and substituted and unsubstituted alkoxyl, amino, alkyl, and L6C(O)L4, wherein L6 is a single bond, -O or -N, and further wherein L4 is preferably alkyl, hydroxyl, alkoxyl or hydrogen, and further wherein any one or more of Q6- Q8 may form part of a ring,
Y and G are each oxygen,
D is nitrogen, and wherein D is singly bonded to each of the adjacent ring atoms,
E is carbon,
Q9 is hydrogen, A is a carbocycle that is an aromatic, 5-6 membered monocyclic ring, preferably phenyl, which is optionally further substituted,
and B is a heterocycle that is a saturated, 6-14 membered monocyclic or polycyclic ring, which is optionally further
substituted, preferably of the formula
Figure imgf000010_0001
wherein M1 and M2 are independently selected from hydrogen, mercapto, hydroxyl, and substituted and unsubstituted thioether, alkyl, alkoxyl, aryloxyl, amino, five membered heterocycle and carbocycle, sulfinyl, sulfonyl, and acyl, and wherein M1 and M2 optionally form a ring having up to 10 members, wherein preferably M1 and M2 independently have from zero to eight non-hydrogen atoms;
or a pharmaceutically acceptable salt thereof.
Preferred compounds of the formula (1) include those wherein: one of Q1 and Q2 is tertiary alkyl, preferably t-butyl, and the other is hydrogen, Q3 is thiophenyl, phenyl, naphthyl, or thionaphthyl,
Q4 is methyl,
Q5 is hydroxyl, amino, or -O-J, wherein J is a substituted or unsubstituted hydrolyzable group,
Q6-Q8 are independently selected from hydrogen, hydroxyl, halogen, -O-J, wherein J is a substituted or unsubstituted
hydrolyzable group, and substituted and unsubstituted alkoxyl, amino, alkyl, and L6C(O)L4, wherein L6 is a single bond, -O or -N, and further wherein L. is preferably alkyl, hydroxyl, alkoxyl or hydrogen, and further wherein any one or more of Q6- Q8 may form part of a ring,
Y and G are each oxygen,
D is nitrogen, and wherein D is singly bonded to each of the adjacent ring atoms,
E is carbon,
Q9 is hydrogen,
A is phenyl, which is optionally further substituted,
and B is a heterocycle that is a saturated, 9-10 membered bi-ring, preferably decahydroisoquinolinyl or octahydrothieno[3,2-c]pyridinyl,
or a pharmaceutically acceptable salt thereof.
According to certain embodiments, the portion of formula (1):
Figure imgf000011_0001
is designated as Z or Z1, and/or the portion of formula (1):
Figure imgf000012_0001
is designated as X or X1.
According to certain of those embodiments, the compounds have the formula 1 (A) :
Figure imgf000012_0002
wherein:
Z is a group having the structure:
Figure imgf000013_0001
where :
a is 1, 2, 3, 4, or 5;
b is 1, or 2;
c is 1, or 2;
d is 1, 2, 3, or 4;
2
each R is independently hydrogen, hydroxy, thiol, halo, amino, C1-C4 alkylamino, di(C1-C4)alkylamino, nitro, carboxy, C1-
C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, halo (C1-C4)alkyl,
,ydroxy(C1-C4)alkyl, C1-C6 alkylthio (C1-C6) alkyl, C1-C4
alkoxycarbonyl, carbamoyl, N-(C1-C4)alkylcarbamoyl, C1-C4 alkylsulfonyl, N,N-di(C1-C4)alkylcarbamoyl, or C1-C4 alkylsulfonylamino;
A 1 and A2 are independently -CH2- or -N(R8)-; A 3 and A4 are independently -CH- or -N-;
A5 and A6 are independently -CH2- or -N(R9)-; A 7 and A8 are independently -CH- or -N-;
R8 is hydrogen or C1-C4 alkyl;
R9 is hydrogen or C1 -C4 alkyl;
R1 is aryl, or -S-aryl;
X is a group having the structure:
Figure imgf000014_0001
where :
R is hydrogen, C1-C4 alkyl, or -CH2-pyridyl; R3 is a group having the structure:
1) -C(O)-NR4R4, 2) , or
Figure imgf000014_0002
3) ;
Figure imgf000014_0003
p is 4 or 5;
R4 at each occurrence is independently hydrogen, C1-C6 alkyl or hydroxy(C1-C4)alkyl; and
R5 and R6 are independently selected from hydrogen, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, or hydroxy (C1-C4) alkyl; with the provisos that :
(1) one of A1 and A2 must be -N(R8)-;
(2) A1 and A2 cannot both be -N(R8)-;
(3) A3 and A4 cannot both be -N-;
(4) one of A5 and A6 must be -N(R9)-;
(5) A5 and A6 cannot both be -N(R9)-;
(6) A7 and A8 cannot both be -N-;
or a pharmaceutically acceptable salt thereof.
Also, according to certain of those embodiments, the
compounds have the formula 1 (B):
Figure imgf000015_0001
wherein:
R1 is aryl, or -S-aryl; X1 is a group having the formula: , or
Figure imgf000016_0001
Figure imgf000016_0002
;
Figure imgf000016_0003
T2 is hydrogen, halo, or C1-C4 alkyl;
R3 is a group having the structure:
1) -C(O)-NR4R4,
2) , or
Figure imgf000016_0004
3) ;
Figure imgf000016_0005
p is 4 or 5;
R4 at each occurrence is independently hydrogen,
C1-C6 alkyl or hydroxy(C1-C4)alkyl; and
R and R are independently selected from hydrogen, hydroxy,
C1-C6 alkyl, C1-C6 alkoxy, or hydroxy(C1-C4)alkyl; Z is a group having the structure :
Figure imgf000017_0001
where :
a is 1, 2, 3, 4, or 5;
b is 1, or 2;
c is 1, or 2;
d is 1, 2, 3, or 4;
each R7 is independently hydrogen, hydroxy, thiol, halo, amino, C1-C4 alkylamino, di(C1-C4)alkylamino, nitro, carboxy, C1-
C6 alkyl, C1-C6 alkoxy, C1-C4 alkylthio, halo(C1-C4)alkyl, hydroxy(C1-C4)alkyl, C1-C4 alkylthio(C1-C4 alkyl, C1-C4
alkoxycarbonyl, carbamoyl, N-(C1-C4)alkylcarbamoyl, C -C.
alkylsulfonyl, N,N-di(C1-C4)alkylcarbamoyl, or C1-C4
alkylsulfonylamino; A1 and A2 are independently -CH2- or -N(R8)-;
A 3 and A4 are independently -CH- or -N-;
A 5 and A6 are independently -CH2- or -N(R9)-;
A 7 and A8 are independently -CH- or -N-;
R8 is hydrogen or C1-C4 alkyl;
R9 is hydrogen or C1-C4 alkyl;
T2 is hydrogen, or C1-C4 alkyl;
with the provisos that:
(1) one of A 1 and A2 must be -N(R8)-;
(2) A1 and A2 cannot both be -N(R8)-;
(3) A3 and A4 cannot both be -N-;
(4) one of A5 and A6 must be -N(R9)-;
(5) A5 and A6 cannot both be -N(R9)-;
(6) A 7 and A8 cannot both be -N-;
or a pharmaceutically acceptable salt thereof.
Preferred species of the formula (1) are:
[3S- (3R*, 4aR*, 8aR*, 2'S*, 3'S*)]-2-[2'-hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''-hydroxyphenyl)pentyl]
decahydroisoquinoline-3-N-t-butylcarboxamide and its
pharmaceutically acceptable salts, especially methanesulfonic acid salt, and its prodrug analogs, wherein the 3'' hydroxy is
converted to -O-J, as defined above, especially the dihydrogen phosphate hydrochloride salt; and [6S- (6R*, 3aS*, 7aR*, 2'S*, 3'S*)]-2-[2'-hydroxy-3'-phenylthiomethyl- 4'aza-5'-oxo-5'-(2''-methyl-3''-hydroxyphenyl)pentyl]-octahydro-thieno[3,2-c]pyridine-6-N-t-butylcarboxamide and its pharmaceutically acceptable salts, especially methanesulfonic acid salt, and its prodrug analogs, wherein the 3'' hydroxy is converted to -O-J, as defined above.
The present invention further provides pharmaceutical formulations comprising an effective amount of a compound of formula (1) or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier, such as a diluent or excipient.
The present invention further provides a method of treating AIDS comprising administering to a host or patient, such as a primate, an effective amount of a compound of the present
invention.
The present invention further provides a method of inhibiting HIV replication comprising administering to an HIV infected cell, a cell susceptible to HIV infection or a host or patient, such as a primate, an effective amount of a compound of the present invention.
Detailed Description of the Invention
The present invention provides new compounds falling within formula (1), as described above, that are useful for treating HIV infection and/or AIDS.
Compounds of the formula (1) may be prodrugs. For example, compounds wherein at least one of Q4-Q8 is -O-J, as defined above, may be used as prodrugs, which can serve to improve the
pharmaceutical properties of the compounds, such as
pharmacokinetic properties, for example, improved bioavailability or solubility. The preparation of the prodrugs may be carried out by reacting a compound of the formula (1), wherein at least one of
Q4-Q8 is -O-H, with, for example, an activated amino acyl, phosphoryl or hemisuccinyl derivative.
All temperatures stated herein are in degrees Celsius (°C). All units of measurement employed herein are in weight units except for liquids which are in volume units.
The term "alkyl" as used herein refers to straight or
branched chain groups, preferably, having one to eight, more preferably having one to six, and most preferably having from one to four carbon atoms. The term "C1-C8 alkyl" represents a
straight or branched alkyl chain having from one to six carbon atoms. Exemplary C1-C6 alkyl groups include methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl, neo-pentyl, hexyl, isohexyl, and the like. The term "C1-C6 alkyl" includes within its definition the term "C1-C4 alkyl".
The term "cycloalkyl" represents a saturated or partially saturated, mono- or poly-carbocylic ring, preferably having 5-14 ring carbon atoms. Exemplary cycloalkyls include monocyclic rings having from 3-7, preferably 3-6, carbon atoms, such as
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like. An exemplary cycloalkyl is a C5-C7 cycloalkyl, which is a saturated hydrocarbon ring structure containing from five to seven carbon atoms.
The term "alkoxyl" represents -O-alkyl. An example of an alkoxyl is a C1-C6 alkoxyl, which represents a straight or
branched alkyl chain having from one to six carbon atoms attached to an oxygen atom. Exemplary C1-C9 alkoxyl groups include methoxyl, ethoxyl, propoxyl, isopropoxyl, butoxyl, sec-butoxyl, t-butoxyl, pentoxyl, hexoxyl, and the like. C1-C6 alkoxyl includes within its definition a C1-C4 alkoxyl.
The term "aryl" as used herein refers to a carbocyclic or heterocyclic, aromatic, 5-14 membered monocyclic or polycyclic ring. Exemplary aryls include phenyl, naphthyl, anthryl,
phenanthryl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, furyl, isothiazolyl, furazanyl, isoxazolyl, thiazolyl, pyridyl,
pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, benzo[b]thienyl, naphtho[2,3-[]thianthrenyl, isobenzofuranyl, chromenyl, xanthenyl, phenoxathienyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinoxyalinyl, quinzolinyl, benzothiazolyl, benzimidazolyl, tetrahydroquinolinyl, cinnolinyl, pteridinyl, carbazolyl,
beta-carbolinyl, phenanthridinyl, acridinyl, perimidinyl,
phenanthrolinyl, phenazinyl, isothiazolyl, phenothiazinyl, and phenoxazinyl.
The term "aryloxyl" represents -O-aryl.
The term "hydrolyzable group" is a group, which .when bonded to an oxygen, forms an ester, which can be hydrolyzed in vivo to a hydroxyl group. Exemplary hydrolyzable groups, which are
optionally substituted, include acyl function, sulfonate function and phosphate function. For example, such hydrolyzable groups include blocked or unblocked amino acid residue, a hemisuccinate residue, and a nicotinate residue.
The term "halogen" represents chlorine, fluorine, bromine or iodine. The term "halo" represents chloro, fluoro, bromo or iodo. The term "carbocycle" represents an aromatic or a saturated or a partially saturated 5-14 membered monocyclic or polycyclic ring, such as a 5- to 7-membered monocyclic or 7- to 10-membered bicyclic ring, wherein all the ring members are carbon atoms.
The term "heterocycle" represents an aromatic or a saturated or a partially saturated, 5-14 membered, monocylic or polycyclic ring, such as a 5- to 7-membered monocyclic or 7- to 10-membered bicyclic ring, having from one to three heteroatoms selected from nitrogen, oxygen and sulfur, and wherein any nitrogen and sulfur heteroatoms may optionally be oxidized, and any nitrogen
heteroatom may optionally be quaternized. The heterocyclic ring may be attached at any suitable heteroatom or carbon atom.
Examples of such heterocycles include decahydroisoquinolinyl, octahydro-thieno [3, 2-c] pyridinyl, piperidinyl, piperazinyl, azepinyl, pyrrolyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolyl, isobenzofuranyl, furazanyl, imidazolinyl,
imidazolidinyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, thianthrenyl, triazinyl, isoxazolidinyl, morpholinyl, thiazolyl, thiazolidinyl,
isothiazolyl, quinuclidinyl, isothiazolidinyl, indolyl,
quinolinyl, chromenyl, xanthenyl, isoquinolinyl, benzimidazolyl, thiadiazolyl, benzopyranyl, benzothiazolyl, benzoazolyl, furyl, tetrahydrofuryl, tetrahydropyranyl, thienyl, benzothienyl, benzo[b]thienyl, naphtho[2,3-b]thienyl, thiamorpholinyl,
thiamorpholinylsulfoxide, thiamorpholinylsulfone, oxadiazolyl, triazolyl, tetrahydroquinolinyl, tetrahydrisoquinolinyl,
phenoxathienyl, indolizinyl, isoindolyl, indazolyl, purinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl,
quinoxyalinyl, quinzolinyl, tetrahydroquinolinyl, cinnolinyl, pteridinyl, carbazolyl, beta-carbolinyl, phenanthridinyl,
acridinyl, perimidinyl, phenanthrolinyl, phenazinyl, isothiazolyl, phenothiazinyl, and phenoxazinyl.
The term "thioether" includes S-aryl, such as phenylthio and naphthylthio; S-heterocycle where the heterocycle is saturated or partially saturated; S-(C5-C7 -cycloalkyl; and S-alkyl, such as C1-C6 alkylthio. In the thioether, the -aryl, the -heterocycle, the -cycloalkyl and the -alkyl can optionally be substituted. An example of a thioether is "C1-C6 alkylthio", which represents a straight or branched alkyl chain having from one to six carbon atoms attached to a sulfur atom. Exemplary C1-C6 alkylthio groups include methylthio, ethylthio, propylthio, isopropylthio,
butylthio, sec-butylthio, t-butylthio, pentylthio, hexylthio, and the like.
The term "mercapto" represents -SH.
The term "amino" represents -NL1L2, wherein L1 and L2 are preferably independently selected from oxygen, carbocycle, heterocycle, alkyl, sulfonyl and hydrogen; or NC(O)L3, wherein L3 is preferably alkyl, alkoxyl, hydrogen or -NL1L2. The aryl, alkyl and alkoxyl groups can optionally be substituted. An example of an amino is C1-C4 alkylamino, which represents a straight or branched alkyl chain having from one to four carbon atoms attached to an amino group. Exemplary C1-C4 alkylamino groups include methylamino, ethylamino, propylamino, isopropylamino, butylamino, sec-butylamino, and the like. Another example of an amino is di (C1-C4) alkylamino, which represents two straight or branched alkyl chains, each having from one to four carbon atoms attached to a common amino group. Exemplary di(C1-C4)alkylamino groups include dimethylamino, ethylmethylamino, methylpropylamino, ethylisopropylamino, butylmethylamino, sec-butylethylamino, and the like. An example of an amino is C1-C4 alkylsulfonylamino, which has a straight or branched alkyl chain having from one to four carbon atoms attached to a sulfonylammo moiety. Exemplary C1-C4 alkylsulfonylamino groups include methylsulfonylamino, ethylsulfonylamino, propylsulfonylamino, isopropylsulfonylamino, butylsulfonylammo, sec-butylsulfonylamino, t-butylsulfonylamino, and the like.
The term "acyl" represents L6C(O)L4, wherein L6 is a single bond, -O or -N, and further wherein L is preferably alkyl, amino, hydroxyl, alkoxyl or hydrogen. The alkyl and alkoxyl groups can optionally be substituted. An exemplary acyl is a C1-C4
alkoxycarbonyl, which is a straight or branched alkoxyl chain having from one to four carbon atoms attached to a carbonyl moiety. Exemplary C1-C4 alkoxycarbonyl groups include
methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl,
isopropoxycarbonyl, butoxycarbonyl, and the like. Another
exemplary acyl is a carboxy wherein L6 is a single bond and L4 is alkoxyl, hydrogen, or hydroxyl. A further exemplary acyl is N- (C1-C4)alkylcarbamoyl (L6 is a single bond and L4 is an amino), which is a straight or branched alkyl chain having from one to four carbon atoms attached to the nitrogen atom of a carbamoyl moiety. Exemplary N-(C1-C4)alkylcarbamoyl groups include N-methylcarbamoyl, N-ethylcarbamoyl, N-propylcarbamoyl, N-isopropylcarbamoyl, N-butylcarbamoyl, and N-t-butylcarbamoyl, and the like. Yet another exemplary acyl is N,N-di(C1-C4)alkylcarbamoyl, which has two straight or branched alkyl chains, each having from one to four carbon atoms attached to the nitrogen atom of a carbamoyl moiety. Exemplary N,N-di(C1-C4)alkylcarbamoyl groups include N,N-dimethylcarbamoyl, N,N- ethylmethylcarbamoyl, N,N-methylpropylcarbamoyl,
N,N-ethylisopropylcarbamoyl, N,N-butylmethylcarbamoyl,
N,N-sec-butylethylcarbamoyl, and the like.
The term "sulfinyl" represents -SO-L5, wherein L5 is
preferably alkyl, amino, aryl, cycloalkyl or heterocycle. The alkyl, aryl, cycloalkyl and heterocycle can all optionally be substituted.
The term "sulfonyl" represents -SO2-L5, wherein L5 is preferably alkyl, aryl, cycloalkyl, heterocycle or amino. The alkyl, aryl, cycloalkyl and heterocycle can all optionally be substituted. An example of a sulfonyl is a C1-C4 alkylsulfonyl, which is a straight or branched alkyl chain having from one to four carbon atoms attached to a sulfonyl moiety. Exemplary C1-C4 alkylsulfonyl groups include methylsulfonyl, ethylsulfonyl, propylsulfonyl, isopropylsulfonyl, butylsulfonyl, sec-butylsulfonyl, t-butylsulfonyl and the like.
As indicated above, many of the groups are optionally substituted. For all formulas herein, all chemical groups may be substituted or unsubstituted as long as the valences of such groups allow such substitutions, even if the definitions of the chemical groups do not explicitly state that the groups are substituted or unsubstituted. For example, if a group is simply defined as alkyl, it may be substituted or unsubstituted alkyl. Examples of substituents for alkyl and aryl include mercapto, thioether, nitro (NO2), amino, aryloxyl, halogen, hydroxyl, alkoxyl, and acyl, as well as aryl, cycloalkyl and saturated and partially saturated heterocycles. Examples of substituents for heterocycle and cycloalkyl include those listed above for alkyl and aryl, as well as aryl and alkyl.
Exemplary substituted aryls include a phenyl or naphthyl ring substituted with one or more substituents, preferably one to three substituents, independently selected from halo, hydroxy,
morpholino (C1-C4)alkoxy carbonyl, pyridyl (C1-C4)alkoxycarbonyl, halo (C1-C4)alkyl, C1-C4 alkyl, C1-C4 alkoxy, carboxy, C1-C4 alkoxycarbonyl, carbamoyl, N-(C1-C4)alkylcarbamoyl, amino,
C1-C4alkylamino, di(C1-C4)alkylamino or a group of the formula
-(CH2)a-R7 where a is 1, 2, 3 or 4; and R7 is hydroxy, C1-C4 alkoxy, carboxy, C1-C4 alkoxycarbonyl, amino, carbamoyl, C1-C4 alkylamino or di(C1-C4)alkylamino.
Another substituted alkyl is halo(C1-C4)alkyl, which
represents a straight or branched alkyl chain having from one to four carbon atoms with 1-3 halogen atoms attached to it.
Exemplary halo(C1-C4)alkyl groups include chloromethyl, 2-bromoethyl, 1-chloroisopropyl, 3-fluoropropyl, 2,3-dibromobutyl, 3-chloroisobutyl, iodo-t-butyl, trifluoromethyl and the like.
Another substituted alkyl is hydroxy(C1-C4)alkyl, which represents a straight or branched alkyl chain having from one to four carbon atoms with a hydroxy group attached to it. Exemplary hydroxy(C1-C4)alkyl groups include hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, 2-hydroxyisopropyl, 4-hydroxybutyl and the like.
Yet another substituted alkyl is C1-C4 alkylthio(C1-C4)alkyl, which is a straight or branched C1-C4 alkyl group with a C1-C4 alkylthio group attached to it. Exemplary C1-C4 alkylthio (C1-C4)alkyl groups include methylthiomethyl, ethylthiomethyl, propylthiopropyl, sec-butylthiomethyl, and the like.
Yet another exemplary substituted alkyl is heterocycle (C1-C4)alkyl, which is a straight or branched alkyl chain having from one to four carbon atoms with a heterocycle attached to it.
Exemplary heterocycle(C1-C4)alkyls include pyrrolylmethyl, quinolinylmethyl, 1-indolylethyl, 2-furylethyl, 3-thien-2-ylpropyl, 1-imidazolylisopropyl, 4-thiazolylbutyl and the like.
Yet another substituted alkyl is aryl(C1-C4)alkyl, which is a straight or branched alkyl chain having from one to four carbon atoms with an aryl group attached to it. Exemplary aryl (C1-C4)alkyl groups include phenylmethyl, 2-phenylethyl,
3-naphthyl-propyl, 1-naphthylisopropyl, 4-phenylbutyl and the like.
The heterocycle can, for example, be substituted with 1, 2 or 3 substituents independently selected from halo, halo(C1-C4)alkyl, C1-C4 alkyl, C1-C4 alkoxy, carboxy, C1-C4
alkoxycarbonyl, carbamoyl, N-(C1-C4)alkylcarbamoyl, amino,
C1-C4alkylamino, di(C1-C4)alkylamino or a group having the structure -(CH2)a-R7 where a is 1, 2, 3 or 4 and R7 is hydroxy, C1-C4 alkoxy, carboxy, C1-C4 alkoxycarbonyl, amino, carbamoyl, C1-C4 alkylamino or di(C1-C4)alkylamino.
Examples of substituted heterocycles include 3-N-t-butyl carboxamide decahydroisoquinolinyl, 6-N-t-butyl carboxamide octahydro-thieno[3,2-c]pyridinyl, 3-methylimidazolyl,
3-methoxypyridyl, 4-chloroquinolinyl, 4-aminothiazolyl,
8-methylquinolinyl, 6-chloroquinoxalinyl, 3-ethylpyridyl,
6-methoxybenzimidazolyl, 4-hydroxyfuryl, 4-methylisoquinolinyl, 6,8-dibromoquinolinyl, 4,8-dimethylnaphthyl, 2-methyl-1,2,3,4-tetrahydroisoquinolinyl, N-methyl-quinolin-2-yl,
2-t-butoxycarbonyl-1,2,3,4-isoquinolin-7-yl and the like.
Exemplary heterocyclic ring systems represented by A or B include (1) 5-membered monocyclic ring groups such as thienyl, pyrrolyl, imidazolyl, pyrazolyl, furyl, isothiazolyl, furazanyl, isoxazolyl, thiazolyl and the like; (2) 6-membered monocyclic groups such as pyridyl, pyrazinyl, pyrimidinyl, pyridazinly, triazinyl and the like; and (3) polycyclic heterocyclic rings groups, such as decahydroisoquinolinyl, octahydro-thieno [3,2-c] pyridinyl, benzo[b]thienyl, naphtho[2,3-b]thianthrenyl,
isobenzofuranyl, chromenyl, xanthenyl, and fully or partially saturated analogs thereof.
A cycloalkyl may be optionally substituted with 1, 2 or 3 substituents independently selected from halo, halo (C. -C.) alkyl, C1-C4 alkyl, C1-C4 alkoxy, carboxy, C1-C4 alkoxycarbonyl, carbamoyl, N-(C1-C4)alkylcarbamoyl, amino, C1-C4 alkylamino, di(C1-C4)alkylamino or a group having the structure -(CH2)a-R7 where a is 1, 2, 3 or 4 and R7 is hydroxy, C1-C4 alkoxy, carboxy, C1-C4 alkoxycarbonyl, amino, carbamoyl, C1-C4 alkylamino or di(C1-C4)alkylamino. Exemplary substituted cycloalkyl groups include 3-methylcyclopentyl, 4-ethoxycyclohexyl,
5-carboxycyclo-heptyl, 6-chlorocyclohexyl and the like.
Exemplary substituted hydrolyzable groups include N-benzyl glycyl, N-Cbz-L-valyl, and N-methyl nicotinate.
The compounds of the present invention have at least two asymmetric centers denoted by an asterisk in the formula (1) below:
Figure imgf000029_0001
As a consequence of these asymmetric centers, the compounds of the present invention can occur in any of the possible
stereoisomeric forms, and can be used in mixtures of
stereoisomers, which can be optically active or racemic, or can be used alone as essentially pure stereisomers, i.e., at least 95% pure. All asymmetric forms, individual stereoisomers and
combinations thereof, are within the scope of the present
invention.
The individual stereoisomers may be prepared from their respective precursors by the procedures described above, by resolving the racemic mixtures, or by separating the
diastereomers. The resolution can be carried out in the presence of a resolving agent, by chromatography or by repeated crystallization or by some combination of these techniques which are known in the art. Further details regarding resolutions can be found in Jacques et al., Enantiomers, Racemates, and
Resolutions, John Wiley & Sons 1981.
Preferably, the compounds of the present invention are substantially pure, i.e, over 50% pure. More preferably, the compounds are at least 75% pure. Even more preferably, the compounds are more than 90% pure. Even more preferably, the compounds are at least 95% pure, more preferably, at least 97% pure, and most preferably at least 99% pure.
As mentioned above, the invention includes the
pharmaceutically acceptable salts of the compounds defined by formula (1). A compound of this invention may possess a
sufficiently acidic, a sufficiently basic, or both functional groups, and accordingly react with any of a number of inorganic or organic bases, and inorganic and organic acids, to form a
pharmaceutically acceptable salt.
The term "pharmaceutically acceptable salt", as used herein, refers to salts of the compounds of the above formula which are substantially non-toxic to living organisms. Exemplary
pharmaceutically acceptable salts include those salts prepared by reaction of the compounds of the present invention with a mineral or organic acid or an inorganic base. The reactants are generally combined in a mutual solvent such as diethylether or benzene, for acid addition salts, or water or alcohols for base addition salts. The salts normally precipitate out of solution within about one hour to about ten days and can be isolated by filtration or other conventional methods. Such salts are known as acid addition and base addition salts.
Acids that may be employed to form acid addition salts are inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like, and organic acids such as p-toluenesulfonic, methanesulfonic acid, oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like.
Examples of pharmaceutically acceptable salts are the
sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioate, hexyne-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, sulfonate,
xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, g-hydroxybutyrate, glycollate, tartrate, methane-sulfonate, propanesulfonate, naphthalene-1-sulfonate, napththalene-2-sulfonate, mandelate and the like.
Preferred pharmaceutically acceptable acid addition salts are those formed with mineral acids such as hydrochloric acid and hydrobromic acid, and those formed with organic acids such as maleic acid and methanesulfonic acid. Base addition salts include those derived from inorganic and organic bases, such as ammonium or alkali or alkaline earth metal hydroxides, carbonates, bicarbonates, and the like. Such bases useful in preparing the salts of this invention thus include sodium hydroxide, potassium hydroxide, ammonium hydroxide, potassium carbonate, sodium carbonate, sodium bicarbonate, potassium bicarbonate, calcium hydroxide, calcium carbonate and the like. The potassium and sodium salt forms are particularly preferred.
It should be recognized that the particular counterion forming a part of any salt of this invention is not of a critical nature, so long as the salt as a whole is pharmacologically acceptable and as long as the counterion does not contribute undesired qualities to the salt as a whole.
Certain compounds are those compounds of formula 1 (A) above wherein :
Z is a group having the structure:
Figure imgf000032_0001
R2 is hydrogen, hydroxy, C1-C4 alkyl, halo, amino, nitro, or trifluoromethyl; a is 1, 2, or 3;
c is 1; and
R3 is -C(O)NR4R4;
or a pharmaceutically acceptable salt thereof.
Of these compounds, more preferred are those compounds where:
Z is ;
Figure imgf000033_0001
R2 is hydrogen, methyl, ethyl, propyl, chloro, fluoro, hydroxy, or amino; X is , or ;
Figure imgf000033_0002
Figure imgf000033_0003
R is -CH2-pyridyl;
R1 is phenyl or -S-phenyl; and
R3 is -C(O)NH(R4);
or a pharmaceutically acceptable salt thereof.
Of these compounds, especially preferred are those compounds where :
;
Z is
Figure imgf000033_0004
R2a is methyl, ethyl, or propyl;
R2b is hydrogen, hydroxy, or amino;
R 2c is hydrogen, hydroxy, or amino;
X is ; and
Figure imgf000034_0001
R is -C(O)NH(t-butyl);
or a pharmaceutically acceptable salt thereof.
Certain other compounds are those compounds of formula 1(B) above wherein:
X is ;
Figure imgf000034_0002
T2 i.s hydrogen or methyl;
Z1 is a group having the structure:
Figure imgf000034_0003
R7 is hydrogen, C1-C4 alkyl, halo, nitro, amino, hydroxy; a is 1, 2, or 3;
c is 1;
or a pharmaceutically acceptable salt thereof.
Of these compounds, more preferred are those compounds where: Z1 is ;
Figure imgf000035_0001
R7 is hydrogen, methyl, ethyl, hydroxy, amino, chloro;
R is -S-phenyl, or -S-naphth-2-yl; and
R3 is -C(O)NR4R4;
or a pharmcaceutically acceptable salt thereof.
Of these compounds, especially preferred are those compounds where : ;
Z1is
Figure imgf000035_0002
R7a is hydrogen, methyl, ethyl, chloro, bromo, or fluoro; R7b is hydrogen, hydroxy, chloro, or ammo;
R7c is hydrogen, hydroxy, or amino;
R3 is -C(O)NH(t-butyl);
or a pharmaceutically acceptable salt thereof. Preferred compounds are:
2-[2'-hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''-hydroxyphenyl)pentyl]decahydroisoquinoline-3-N-t-butylcarboxamide:
Figure imgf000036_0001
2-[2'-hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''-hydroxyphenyl)pentyl]decahydroisoquinoline-3-N-t-butylcarboxamide methanesulfonic acid salt:
Figure imgf000036_0002
2-[2'-hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''-hydroxyphenyl)pentyl]decahydroisoquinoline-3-N-t-butylcarboxamide 3''-dihydrogen phosphate hydrochloride salt
Figure imgf000037_0001
2-[2'-hydroxy-3'-phenylthiomethyl-4'aza-5'-oxo-5'-(2''-methyl-3''-hydroxyphenyl)pentyl]-octahydro-thieno[3,2-c]pyridine-6-N-t-butylcarboxamide:
Figure imgf000037_0002
and
2-[2'-hydroxy-3'-phenylthiomethyl-4'aza-5'-oxo-5'-(2''-methyl-3''-hydroxyphenyl)pentyl]-octahydro-thieno[3,2-c]pyridine-6-N-t-butylcarboxamide methanesulfonic acid salt:
Figure imgf000038_0001
Each of the above five formulae has five assymetric centers and thus defines a compound selected from the group of 32
individual stereoisomers and any mixture of two or more
stereoisomers.
Preferred stereisomers of these compounds are :
[3S-(3R*,4aR*,8aR*,2'S*,3'S*)]-2-[2'-hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''-hydroxyphenyl)pentyl]
decahydroisoquinoline-3-N-t-butylcarboxamide:
Figure imgf000038_0002
[3S-(3R*,4aR*,8aR*,2'S*,3'S*)]-2-[2'-hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''-hydroxyphenyl)pentyl]
decahydroisoquinoline-3-N-t-butylcarboxamide methanesulfonic acid salt :
Figure imgf000039_0001
[3S-(3R*,4aR*,8aR*,2'S*,3'S*)]-2-[2'-hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''-hydroxyphenyl)pentyl]
decahydroisoquinoline-3-N-t-butylcarboxamide 3''-dihydrogen phosphate hydrochloride salt :
Figure imgf000039_0002
[6S-(6R*,3aS*,7aR*,2'S*,3'S )]-2-[2'-hydroxy-3'-phenylthiomethyl-4'aza-5'-oxo-5'-(2''-methyl-3''-hydroxyphenyl)pentyl]-octahydrothieno[3,2-c]pyridine-6-N-t-butylcarboxamide:
Figure imgf000040_0001
and
[6S-(6R*,3aS*,7aR*,2'S ,3'S*)]-2-[2'-hydroxy-3'-phenylthiomethyl-4'aza-5'-oxo-5'-(2''-methyl-3''-hydroxyphenyl)pentyl]-octahydrothieno[3,2-c]pyridine-6-N-t-butylcarboxamide methanesulfonic acid salt:
Figure imgf000040_0002
Other compounds of the present invention include:
[3S- (3R*,4aR*,8aR*,2'S*,3'R*)]-2-[2'-hydroxy-3'-phenylmethyl-4' -aza-5'-oxo-5'-(2''-propyl-3''-hydroxyphenyl)pentyl]
decahydroisoquinoline-3-N-t-butylcarboxamide;
Figure imgf000041_0001
[2S-(2R*,2'S*,3'S*)]-1-[2'-hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(3''-hydroxy-2''-methylphenyl)pentyl]-4-pyrid-3''-ylmethyl piperazine-2-N-t-butylcarboxamide;
Figure imgf000041_0002
[3S- (3R*,4aR*,8aR*,2'S*,3'S*)]-2-[2'-hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(l'',2'',3'',4''-tetrahydroquinolin-5''-yl)pentyl] decahydroisoquinoline-3-N-t-butylcarboxamide;
Figure imgf000042_0001
[3S-(3R*,4aR*,8aR*,2'S*,3'R*)]-2-[2'-hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''-hydroxyphenyl)pentyl]
decahydroisoquinoline-3-N-t-butylcarboxamide;
Figure imgf000042_0002
[3S-(3R*,4aR*,8aR*,2'S*,3'R*)]-2-[2'-hydroxy-3'-phenylmethyl-4'aza-5'-oxo-5'-(2''-ethyl-3''-hydroxyphenyl)pentyl]
decahydroisoquinoline-3-N-t-butylcarboxamide;
Figure imgf000043_0001
[2'R-(2'R*,3'S*)]-N-t-butyl-2-[2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(1'',2'',3'',4''-tetrahydroquinolin-5''-yl)pentyl] benzamide;
[2'R- (2'R*,3'S*)]-N-t-butyl-2-[2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''-hydroxyphenyl)pentyl] benzamide;
[2'R-(2'R*,3'S*)]-N-t-butyl-2-[2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(2''-methyl-3'',5''-diaminophenyl)pentyl] benzamide;
[2'R-(2'R*,3'S*)]-N-t-butyl-2-[2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''-hydroxyphenyl)pentyl]-1-naphthylamide; and [2'R-(2 'R* , 3 'S*) ]-N-t-butyl-2-[2'-hydroxy-3'-naphth-2- ylthiomethyl-4'-aza-5'-oxo-5'-(2''-chloro-3''-aminophenyl)pentyl]- 1-naphthylamide;
or a pharmaceutically acceptable salt of any of the foregoing most preferred compounds.
The compounds of formula 1 can be prepared according to the following Reaction I.
Reaction I
Figure imgf000044_0001
where the variables are as define for formula 1 above.
Reaction I is a standard coupling reaction commonly employed in the synthesis of amides or peptides which is carried out by reacting an appropriately substituted amine of formula IA, with an appropriately substituted carboxylic acid reactant of formula IB, in an aprotic solvent or mixture of solvents. The reaction is typically carried out in the presence or absence of a promoting agent, preferably in the presence of a promoting agent, and in the presence of a coupling reagent. Typical aprotic solvents for this reaction are tetrahydrofuran and dimethylformamide, or a mixture of such solvents. The reaction is typically carried out at a temperature from about -30°C to about 25°C. The amine reactant is generally employed in equimolar proportions relative to the carboxylic acid reactant, in the presence of an equimolar quantity to a slight excess of the coupling reagent. Typical coupling reagents include the carbodiimides such as
dicyclohexylcarbodiimide (DCC) and N,N'-diethylcarbodiimide; the imidazoles such as carbonyldiimidazole; as well as reagents such as bis (2-oxo-3-oxazolidinyl)phosphinic chloride (BOP-Cl) or N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) . A preferred coupling reagent for this reaction is DCC. A promoting agent is preferably included for this reaction; a preferred promoting agent is hydroxybenzotriazole hydrate (HOBT·H2O).
Once the reaction is complete, the compound may be isolated, if desired, by procedures known in the art, for example, the compound may be crystallized and then collected by filtration, or the reaction solvent may be removed by extraction, evaporation or decantation. The compound may be further purified, if desired, by common techniques such as crystallization or chromatography over solid supports such as silica gel or alumina. The starting compounds of formula IA may be prepared according to the procedures shown in Reaction Scheme A.
Reaction Scheme A
Figure imgf000047_0001
where :
v is an amino-protecting group;
B, D, G, Q1, Q2, Q3, and Q9 are defined the same as they are defined above for formula (1); and
ZZ is halo.
Reaction Scheme A, above, is accomplished by carrying out reactions 1-7 in sequential order. Once a reaction is complete, the intermediate compound may be isolated, if desired, by
procedures known in the art, for example, the compound may be crystallized and then collected by filtration, or the reaction solvent may be removed by extraction, evaporation or decantation. The intermediate compound may be further purified, if desired, by common techniques such as crystallization or chromatography over solid supports such as silica gel or alumina, before carrying out the next step of the reaction scheme.
Reaction A.1 is carried out by converting an amino-protected carboxylic acid reactant having the structure:
Figure imgf000048_0001
to the corresponding mixed anhydride under conditions known in the art. For example, the amino-protected carboxylic acid reactant may be reacted with a C1-C6 alkylchloroformate, such as
isobutylchloroformate preferably in the presence of an acid scavenger. Preferred acid scavengers are the trialkylamines, preferably triethylamine. The reaction is typically carried out in an aprotic solvent such as ethyl acetate. Solvent choice is not critical so long as the solvent employed is inert to the ongoing reaction, and the reactants are sufficiently solubilized to effect the desired reaction. The resulting mixed anhydride reactant is preferably used in Reaction A.2 without further isolation or purification.
Reaction A.2 is accomplished in two steps. First, a solution of sodium hydroxide, covered with a layer of an ether solvent, preferably diethyl ether, is reacted with a large excess of
N-methyl-N-nitro-N-nitrosoguanidine to form a diazomethane
reactant. The sodium hydroxide is preferably used as an aqueous solution having about four to six mol/liter of sodium hydroxide. Once this reaction is substantially complete, the organic layer is dried over a dessicant such as potassium hydroxide. This solution is then reacted with the mixed anhydride from Reaction A.1, above, to form the corresponding alpha-diazo carbonyl compound. The diazomethane reactant is preferably used in this reaction without isolation or purification. The reaction is typically carried out at a temperature of from about -50°C to about -10°C, preferably about -20°C.
In Reaction A.3, the alpha-diazo carbonyl compound prepared in Reaction A.2 is reacted with an acid of the formula H-ZZ where ZZ is halo, typically in an aprotic solvent such as diethylether to form an alpha-halo carbonyl compound. A preferred acid reactant is hydrochloric acid which provides the corresponding alpha-chloro carbonyl compound. The reaction is typically carried out at a temperature from about -30°C to about 0°C. Solvent choice is not critical so long as the solvent employed is inert to the ongoing reaction and the reactants are sufficiently
solubilized to effect the desired reaction. The acid reactant is typically added in the form of an anhydrous gas in small
increments until the reaction appears substantially complete. The reaction can be monitored by thin layer chromatography.
In Reaction A.4, the carbonyl moiety on the compound prepared in Reaction A.3 is reduced using standard conditions known in the art to form the corresponding alpha-chloro hydroxy compound. For example, the compound prepared in Reaction A.3 is combined with a reducing agent in a mixture of solvents. Typical reducing agents include sodium borohydride, lithium borohydride, zinc borohydride, diisobutylaluminum hydride, and sodium bis (2-methoxy-ethoxy) aluminum hydride. A preferred reducing agent is sodium
borohydride. Typical solvent mixtures include a protic and aprotic mixture such as tetrahydrofuran/water. Solvent choice is not critical so long as the solvent employed is inert to the ongoing reaction, and the reactants are sufficiently solubilized to effect the desired reaction. The reaction is typically carried out at a temperature from about -10°C, preferably about 0°C.
In Reaction A.5, the alpha-chloro hydroxy compound prepared in Reaction A.4 is treated with a strong base to form the
corresponding epoxide under standard conditions known in the art. For example, the alpha-chloro hydroxy compound may be reacted with a potassium hydroxide/ethanol mixture in an alcoholic solvent such as ethanol. The reaction is typically carried out at a
temperature from about 0°C to about the reflux temperature of the solvent. Preferably the reaction is carried out at room
temperature.
In Reaction A.6, the epoxide prepared in Reaction A.5 is reacted with a heterocyclic reactant :
Figure imgf000051_0001
typically in an alcoholic solvent at a temperature typically ranging from about 20°C to 100°C. Solvent choice is not critical so long as the solvent employed is inert to the ongoing reaction, and the reactants are sufficiently solubilized to effect the desired reaction. Typical solvents for this reaction include the alcohols, preferably isopropanol or ethanol. The reaction is preferably carried out at a temperature of about 80°C.
Reaction A.7 is a standard amino deprotection reaction using procedures and methods known in the art to afford the
corresponding amine which is used in Reaction I, above. This amine may be reacted without purification, but it is preferably purified first.
The compounds of formula IA, where Q3 is -S-aryl, are typically prepared by first reacting amino-protected serine with triphenylphosphine and diethylazodicarboxylate (DEAD) in an aprotic solvent at a temperature of from about -80°C to 0°C to form the corresponding beta-lactone. The reaction is typically carried out in an ether, such as tetrahydrofuran at a temperature of from about -80°C to -50°C. Next, the lactone ring is opened to provide a compound having the structure :
Figure imgf000052_0001
by typically reacting the lactone with an appropriately
substituted thioanion having the structure, -S-aryl. The
thioanion compound is preferably formed by reacting the
corresponding thiol with a strong base, such as sodium hydride or potassium hydride. This reaction is typically carried out in an aprotic solvent at a temperature from about 0°C to about 40°C and under an inert atmosphere, such as nitrogen. Typical solvents for this reaction include ethers, preferably tetrahydrofuran.
Alternatively, the compounds of formula IA, where Q3 is -S-aryl, may be prepared using the procedures detailed in Photaki .
JACS, 85, 1123 (1963), and Sasaki, N.A. et al, Tetrahedron
Letters, 28, 6069 (1987). For example, the compounds may be prepared by reacting doubly protected serine (carboxy-protected and amino-protected) with toluenesulfonyl chloride in the presence of dimethylaminopyridine (DMAP) and an acid scavenger such as pyridine in an aprotic solvent such as methylene chloride to form the corresponding toluenesulfonate which may then be reacted with an appropriately substituted thioanion having the structure, -S- aryl. The thioanion compound is preferably formed by reacting the corresponding thiol with a strong base as described above. The carboxy-protecting group may be removed from the resulting doubly protected arylthioalanine using conditions known in the art. The heterocyclic reactants of the formula
Figure imgf000053_0001
used in Reaction A.6, may be prepared using procedures and methods known in the art. For example, the heterocyclic reactants were typically prepared from the corresponding amino-protected amino acids by acid activation followed by treatment with an alkylamine. This reaction is typically carried out in the presence of an acid scavenger, such as N-methylmorpholine. Removal of the aminoprotecting group using standard chemical deprotecting techniques then provides the desired heterocyclic reactants. Specifically, the [3S- (3R* , 4aR* , 8aR*) ]-decahydroisoquinoline-3-N-t-butylcarboxamide was prepared using 2S-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid by the following procedure:
1) amino-protection (t-Boc);
2) acid activation/reaction with t-butylamine;
3) catalytic hydrogenation;
4) amino-deprotection.
The piperazine reactants may be prepared by converting an appropriately substituted pyrazine compound to the corresponding piperazine compound using procedures known in the art, preferably using catalytic hydrogenation. For example, the hydrogenation may be accomplished by combining the pyrazine reactant with a catalyst under a hydrogen atmosphere in an aprotic solvent at a temperature from about 0°C to about 60°C. Suitable catalysts include palladium-on-carbon, platinum metal, platinum oxide and the like. A preferred catalyst is platinum oxide. Typical solvents for this reaction include tetrahydrofuran, dimethylformamide or a mixture of tetrahydrofuran and dimethylformamide.
The nitrogen atom on the resultant piperazine reactant may be alkylated using procedures known in the art. For example, the piperazine reactant may be reacted with a halo (C1-C4)alkyl, or halomethylpyridine, such as methyl iodide or chloromethylpyridme. Preferred halo substituents include chloro, bromo and iodo. The reaction is carried out at temperatures of from about 0°C to 60°C in a mutually inert solvent and in the presence of an acid
scavenger. A preferred acid scavenger is potassium carbonate. Typical solvents include a mixture of a protic and aprotic
solvents such as acetonitrile and water. Solvent choice is not critical so long as the solvent employed is inert to the ongoing reaction and the reactants are sufficiently solubilized to effect the desired reaction.
Alternatively, the alkylated piperazine reactant may be prepared using reductive amination. For example, the piperazine reactant prepared above may be reacted with an aldehyde (for example, 3 -pyridine carboxylic aldehyde, ethanal, propanal) or a ketone in the presence of a reducing agent and an acid. The reaction is typically carried out in an alcoholic solvent such as methanol, ethanol or isopropanol. Typical reducing agents include sodium borohydride, lithium cyanoborohydride, sodium
cyanoborohydride, and the like. A preferred reducing agent is sodium cyanoborohydride. Typical acids include any protic acid such as hydrochloric acid, sulfuric acid, methanesulfonic acid, or acetic acid. A preferred acid is acetic acid.
The intermediate reactant
Figure imgf000055_0001
can also be prepared that has the formula 2 :
Figure imgf000055_0002
wherein:
V0 and V1 are independently hydrogen, C1-C8 alkyl, or hydroxy
(C1-C8) alkyl;
V 2 is hydrogen, an ammo-protecting group, or a group of the formula:
Figure imgf000055_0003
V3 is -(CH2)t-V3';
t is 0, 1, 2, 3, or 4;
V3' is aryl, -O-aryl, or -S-aryl;
V 4 is hydrogen or an ammo-protectmg group; f, h and j are each independently 0, 1 or 2; g and i are each independently 0 or
1;
V 5 is -CH2-, -CHV5'-, or -CV5' V5'-;
V6 is -CH2-, -CHV6', -CV6'v6'-;
V 7 is -CH2-, -CHV7', or -CV7 'V7 '-;
each of V 5', V 6' , and V 7' is independently selected from halo, hydroxy, C1-C6 alkyl, halo (C1-C6) alkyl, hydroxy (C1-C6) alkyl, C1-C6, alkoxy, C1-C6 alkylthio, amino, or cyano;
T and W are independently -S-, -S(O)-, -S(O)2-, - O-, -NH-, or -(V9)-; and
V9 is C1-C6 alkyl, aryl (C1-C6) alkyl, aryl, or acyl;
with the provisos that :
g and i cannot both be 0;
the sum of f, g, h, i and j must be 2, 3, 4, or 5;
if V5 is -CV5'v5'-, then V6 must be -CH2- or - CHV6'-; and V7 must be -CH2- or -CHV 7'-;
if V6 is -CV6'v6'-, then V5 must be -CH2- or - CHV5'-; and V7 must be -CH2- or -CHV7' -;
if V7 is -CV7'v7'-, then V5 must be -CH2- or - CHV5'-; and V6 must be -CH2- or -CHV6'-;
or a pharmaceutically acceptable salt thereof .
Compounds of formula 3 can be prepared in accordance with the following Reaction Scheme II:
Figure imgf000057_0001
Figure imgf000058_0001
Figure imgf000058_0002
wherein V4, V3, V0, V1, V5, T, V6, W, V7, f, g, h, i, j, are defined as they are above for formula 2, including their
definitions of V3', t, V5', V6', V7', and V9',
VA is an amino-protecting group; and
U in reaction 1-3 above represents the presence of double bonds between, for example, V5 and V6, V5 and V5, or V7 and V6 and the like, where g is 0, h is 0 and f is 2, or i is O,
respectively. Reaction Scheme II, above, is accomplished by carrying out reactions 1-3 (or 1-5) in sequential order. Once a reaction is complete, the intermediate compound may be isolated, if desired, by procedures known in the art, for example, the compound may be crystallized and then collected by filtration, or the reaction solvent may be removed by extraction, evaporation or decantation. The intermediate compound may be further purified, if desired, by common techniques such as crystallization or chromatography over solid supports such as silica gel or alumina, before carrying out the next step of the reaction scheme.
Reaction II.1 is typically carried out by activating the carboxylic acid moiety using, for example, DCC or a mixed
anhydride such as isobutyl, followed by reaction with a primary or secondary amine having the formula NV0V1 where V0 and V1 are as defined above for formula (2). The reaction is typically carried out in a nonpolar aprotic solvent or mixture of solvents in the presence or absence of an acid scavenger at a temperature of from about -20°C to about 25°C to afford the corresponding amide.
Suitable solvents for this reaction include ethers and chlorinated hydrocarbons, preferably diethyl ether, chloroform, or methylene chloride. Preferably, this reaction is carried out in the presence of an acid scavenger such as a tertiary amine, preferably triethylamine. The amide afforded by this reaction may be isolated or further reacted as shown in Reaction II.2.
Reaction II.2 is typically carried out by reacting the compound obtained from Reaction II.1 using the procedures detailed in Comprehensive Organic Synthesis, "Heteroatom Manipulation", Barry M. Trost, ed., volume 6, pages 736-746, (1991). In general, an appropriately substituted monocyclic ring is reacted with an aldehyde, such as formaldehyde or trichloroacetaldehyde, in the presence of an acid. The acid may be used as a solvent. Typical acids include hydrochloric acid, hydrobromic acid, sulfuric acid, acetic acid, trifluoroacetic acid, and the like. A co-solvent may optionally be added to the reaction mixture. The co-solvent choice is not critical so long as the co-solvent employed is inert to the ongoing reaction, and the reactants are sufficiently solubilized to effect the desired reaction. Typical solvents for this reaction include halogenated solvents such as methylene chloride, trichloroethane, carbontetrachloride, and the like.
Alternatively, the aldehyde may be produced in situ using for example, dimethoxymethane and a suitable acid.
In reaction II.3, the compound isolated from reaction II.2 is reduced to provide a saturated heterocyclic compound as depicted above. Catalytic hydrogenation is a preferred method of
reduction. Typical catalysts include palladium catalysts, rhodium catalysts (for example rhodium on aluminum) and rhenium catalysts. Preferred catalysts include palladium-on-carbon. Suitable
solvents for this reaction include the C1-C4 alcohols,
tetrahydrofuran, acetic acid in alcohol, ethyl acetate and the like. A preferred solvent is ethanol. The reaction is typically carried out under an atmosphere of hydrogen from about 1000 to about 4000 psi at a temperature of from about 25°C to about 150°C. Preferably, the reaction is carried out under an atmosphere of hydrogen from about 2000 to about 3000 psi at a temperature of from about 50°C to 100°C. The catalyst is generally employed in a amount ranging from about equimolar proportions to about a
twelve-fold excess (by weight) of the reactant, preferably in about a six- to ten-fold excess (by weight) of the catalyst relative to the substrate.
Reactions II.4 and II.5 may be used to prepare compounds of formula (3) which correspond to compounds of formula (2) where
Figure imgf000061_0001
V3 and V4 are as defined above for formula (2), including their definitions of V3' and t.
Reaction II.4 is a standard amino deprotection reaction using procedures and methods known in the art to afford the
corresponding amine which is then used in Reaction II.5. Chemical deprotection procedures are preferred. For example, the compound isolated from II.3 may be deprotected using trimethylsilyliodide (TMSI) in an aprotic solvent or mixture of solvents at a
temperature of from about 10°C to 60°C, preferably at a
temperature of from about 20°C to 40°C. Typical solvents include methylene chloride, acetonitrile trichloroethane, and the like.
In Reaction II.5, the epoxide prepared in Reaction A.5, above, in which Q3 of Reaction A.5 is replaced by V3, is reacted with the compound isolated from Reaction II.4 in an alcoholic solvent at a temperature of from about 20°C to 100°C. Solvent choice is not critical so long as the solvent employed is inert to the ongoing reaction, and the reactants are sufficiently solubilized to effect the desired reaction. Typical solvents for this reaction include the alcohols, preferably isopropanol or ethanol. The reaction is preferably carried out at a temperature of about 80°C.
The compound isolated from reaction II.5 may optionally be deprotected to provide a compound of formula (3) where VA is hydrogen.
The epoxide used in Reaction II.5 may be synthesized using Reaction Scheme A above in which Q3 of Scheme A is replaced by V3.
The carboxylic acid reactant of formula (IB)
Figure imgf000062_0001
used in Reaction Scheme I, to the extent not commercially
available, can be prepared using known procedures. More
particularly, this reactant may be prepared by further
substitution and/or oxidation of a commercially available
carbocyclic or heterocyclic compound. For example, carbocyclic or heterocyclic compounds of the formula
Figure imgf000062_0002
may be oxidized using procedures known in the art. Specifically, the compound of the formula
Figure imgf000062_0003
may be reacted with an oxidizing agent such as selenium dioxide or potassium permanganate at temperatures of from about 0°C to 200°C in a mutually inert solvent, such as water or diphenylether.
A second method for preparing compounds of the formula (IB) involves protecting an appropriately substituted carboxylated carbocyclic or heterocyclic group with a carboxy-protecting group, and then further substituting the carbocyclic or heterocyclic group using procedures known in the art. The carboxy-protecting group may then be removed using procedures known in the art to provide the desired carboxylic acid reactant of formula (IB).
The term "carboxy-protecting group" as used in the
specification refers to substituents of the carboxy group commonly employed to block or protect the carboxy functionality while reacting other functional groups on the compound. Examples of such carboxy-protecting groups include methyl, p-nitrobenzyl, p- methylbenzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, 2,4-dimethoxybenzyl, 2,4,6-trimethoxybenzyl, 2,4,6-trimethylbenzyl, pentamethylbenzyl, 3,4-methylenedioxybenzyl, benzhydryl, 4,4'-dimethoxybenzhydryl, 2,2',4,4'-tetramethoxybenzhydryl, t-butyl, t-amyl, trityl, 4-methoxytrityl, 4,4'-dimethoxy-trityl, 4,4',4''trimethoxytrityl, 2-phenylprop-2-yl, trimethylsilyl, t-butyldimethylsilyl, phenacyl, 2, 2, 2-trichloroethyl, b- (di{n-butyl)methylsilyl)ethyl, p-toluenesulfonylethyl, 4-nitrobenzylsulfonylethyl, allyl, cinnamyl, 1- (trimethylsilylmethyl)prop-1-en-3-yl and like moieties. A
preferred method of protecting the carboxy group involves
converting the carboxy moiety to an amide moiety and then hydrolyzing the amide back to provide the desired carboxy
substituent. Further examples of these groups are found in E. Haslam, "Protective Groups in Organic Chemistry", J.G.W. McOmie, Ed., Plenum Press, New York, N.Y., 1973, Chapter 5, and T.W.
Greene, "Protective Groups in Organic Synthesis", John Wiley and Sons, New York, N.Y., 1981, Chapter 5.
A preferred procedure for protecting the carboxy moiety involves the acid activation of the carboxy moiety, followed by the formation of an amide. For example, the carboxy moiety may be converted to an acyl halide, acyl anhydride, acyl imidazole and the like, preferably in the presence of an acid scavenger to form an activated carboxy moiety. A commercially available acid chloride is typically employed, obviating the need for further acid activation. Preferred acid scavengers are the
trialkylamines, preferably triethylamine. The reaction is typically carried out in an aprotic solvent such as diethylether, methylene chloride or the like. A preferred solvent is methylene chloride. Solvent choice is not critical so long as the solvent employed is inert to the ongoing reaction, and the reactants are sufficiently solubilized to effect the desired reaction. The activated carboxy moiety is then reacted with an amine, R11-NH2, for example aniline, in an aprotic solvent to provide an amide reactant
Figure imgf000064_0001
which may then be further substituted according to known procedures.
The amide reactant
Figure imgf000065_0001
may be further substituted by ortho deprotonation of the group
Figure imgf000065_0002
to provide the corresponding anion followed by reaction with a variety of reagents such as alkyl halides, or halogenating agents such as bromine. The amide reactant is generally deprotonated twice using two equivalents of a strong base such as n-butyl lithium or sec-butyl lithium relative to the amide reactant, optionally in the presence of a metal coordinating agent such as tetramethylethylenediamine (TMEDA). The reaction is typically carried out in an aprotic solvent, preferably an ether such as diethylether, tetrahydrofuran or the like at a temperature from about -78°C to about 25°C.
The resultant compound may then be hydrolyzed using
procedures known in the art to provide the desired, substituted carboxylic acid reactant of formula (IB). For example, a suitable hydrolysis involves exposing the amide reactant to a strong mineral acid, organic acid, or a mineral acid/organic mixture at a temperature from about 100°C to about 160°C. Typical acids which may be used in this reaction include hydrobromic acid, acetic acid, hydrochloric acid and the like. A sealed tube may
optionally be employed to accelerate the reaction rate.
A third method for preparing the substituted carboxylic acid reactant of formula (IB) involves diazotization of an aniline, followed by a quenching of the resultant diazonium salt.
Specifically, the amino moiety of the aniline reactant is
converted to a diazonium salt by reaction with nitrous acid.
Nitrous acid may be produced in si tu by treating sodium nitrite with an aqueous solution of a strong acid such as hydrochloric acid, or sulfuric acid. This reaction is typically carried out at or below 5°C. The diazonium salt is then quenched by reaction with suitable reagent to provide the desired substituted aromatic system. Representative quenching reagents include water, cyanide, halide, aqueous sulfuric acid, and the like. Typically, the reaction will be heated to facilitate the desired reaction.
There are a variety of reactions that are known in the art which may be used to produce the desired substitutions on the carbocyclic or heterocyclic rings. For example, there are a variety of aromatic electrophilic and nucleophilic substitution reactions outlined in chapters 11 and 13 of March, J. , "Advanced Organic Chemistry," 3rd edition, Wiley, 1985.
In addition, the compounds of the formula (IB) may be
prepared by carboxylating an appropriately substituted carbocyclic or heterocyclic compound. The carboxylation may be accomplished using a number of different reagents. For example, the
carbocyclic or heterocyclic reagent may be reacted with phosgene, oxalyl chloride, urea hydrochloride, or N,N-diethylcarbamoyl chloride in the presence of Friedel-Crafts catalysts. A variation of this method involves reacting the carbocyclic or heterocyclic reagent with an alkyl thiolchloroformate (RSCOCl), or a carbamoyl chloride (H2NCOCl) to provide an amide and a thiol ester,
respectively. The amide and thiol ester may then be hydrolyzed to provide the desired carboxy group. March, at 491.
Examples of Friedel-Crafts catalysts include the Lewis acids, such as aluminum bromide (AlBr3), aluminum chloride (AlCl3), iron (III) chloride (FeCl3), boron trichloride (BCl3), boron
trifluoride (BF3), and the like. See also, March, J., "Advanced Organic Chemistry," 3rd edition, Wiley, 1985; Olah, "Friedel-Crafts and Related Reactions," Interscience, New York, 1963-1965; and Olah, "Friedel-Crafts Chemistry," Wiley, New York, 1973.
Additionally, the quinoline carboxylic acid reactants may be prepared by reacting an appropriately substituted aniline with glycerol using the Skraup reaction disclosed in Bradford, L. et al., J. Chem. Soc., 1947, p 437. For example, 3-amino benzoic acid may be reacted with glycerol in the presence of an oxidizing agent such as m-nitro benzene sulfonic acid or sodium m-nitro benzene sulfonate in a 60-75% aqueous solution of sulfuric acid to provide the desired carboxy-substituted quinoline. The reaction is typically carried out at a temperature from about 35°C to reflux temperature for one to six hours, preferably from about 50°C to reflux temperature for two to four hours.
The resultant reactants may then be reduced or hydrogenated using procedures known in the art. See e.g., March, at 700. A preferred procedure involves catalytic hydrogenation, for example by combining the quinoline carboxylic acid reactant with hydrogen gas in the presence of a catalyst. A preferred catalyst is palladium-on-carbon. Typical solvents suitable for use in this reaction include any organic solvent such as ethyl acetate.
Solvent choice is not critical so long as the solvent employed is inert to the ongoing reaction. The reaction is generally
substantially complete after about 1 to 24 hours when conducted at a temperature in the range of from about 25°C to about 100°C.
According to other embodiments, the compounds of formula IA, in which Q3 is replaced by R1, can be prepared according to the following Reaction Scheme B.
Reaction Scheme B
Figure imgf000069_0001
where :
is a group having the formula:
Figure imgf000069_0002
, or
Figure imgf000069_0003
Figure imgf000069_0004
;
Figure imgf000069_0005
where :
R is an amino-protecting group; and
R 1, R3, and T2 are as defined above for formula 1(B), including the definition of R4, R5 , R6, and p.
Reaction Scheme B, above, is accomplished by carrying out reactions 1-6 in sequential order. Once a reaction is complete, the intermediate compound may be isolated, if desired by
procedures known in the art, for example, the compound may be crystallized and then collected by filtration, or the reaction solvent may be removed by extraction, evaporation or decantation. The intermediate compound may be further purified, if desired, by common techniques such as crystallization or chromatography over solid supports such as silica gel or alumina, before carrying out the next step of the reaction scheme.
In Reaction B.1, the reaction is typically carried out by activating, that is, converting, a suitably substituted:
Figure imgf000070_0001
to the corresponding acyl chloride or acyl bromide by reaction with thionyl chloride, thionyl bromide, phosphorous trichloride, phosphorous tribromide, phosphorous pentabromide or phosphorous pentachloride according to procedures and under conditions known in the art. Suitable compounds :
Figure imgf000070_0002
are commercially available or prepared by standard procedures known in the art. In Reaction B.2, the acyl chloride or acyl bromide, prepared in Reaction B.1, typically is reacted with ammonia or a primary or secondary amine having the formula
H-NR4R4 , , or
Figure imgf000071_0001
;
Figure imgf000071_0002
where R 4, R5, R6 and p are as defined above for formula 1(B), in a nonpolar aprotic solvent or mixture of solvents in the presence or absence of an acid scavenger to afford the corresponding amide.
The reaction is typically carried out at a temperature of from about -20°C to about 25°C. Typical solvents for this reaction include ethers and chlorinated hydrocarbons, preferably
diethylether, chloroform or methylene chloride. Preferably, this reaction is carried out in the presence of an acid scavenger such as a tertiary amine, preferably triethylamine.
In Reaction B.3, the amide prepared in Reaction B.2, is reacted with a strong base in the presence of a solubilizing agent to afford the corresponding anion which is then reacted in
Reaction B.4 with a Weinreb amide to afford a ketone. Reaction B.3 is typically carried out in an aprotic solvent at a temperature of from about -78°C to about 0°C. Typical bases used in Reaction B.3 include lithium amide bases and alkyl lithium bases, preferably C1-C4 alkyl lithium bases and lithium di(C1-C6) alkylamide bases. Typical solubilizing agents for Reaction 3 are tetramethyl (C1-C4)alkylenediamines, preferably tetramethylethylenediamine.
Reaction B.4 typically is carried out in an aprotic solvent at a temperature from about -80°C to about -40°C. Typical solvents for Reactions B.3 and B.4 include ethers, preferably tetrahydrofuran. In Reaction B.4, the anion is generally employed in an amount ranging from about equimolar proportions to about a three molar excess of the anion, preferably in about a two molar excess of the anion relative to the Weinreb amide reactant.
In Reaction B.5, the ketone prepared in Reaction B.3, is reduced to the corresponding alcohol using a suitable reducing agent. The reaction is carried out in a protic solvent at a temperature of from about -25°C to about 25°C. Typical reducing agents for this reaction include sodium borohydride, lithium borohydride, diisobutylaluminum hydride, and sodium bis (2-methoxyethoxy) aluminum hydride. A preferred reducing agent is sodium borohydride. Typical protic solvents for this reaction include alcohols, preferably ethanol.
Reaction B.6 is a standard amino deprotection reaction using procedures and methods known in the art to afford the
corresponding amine which is used in Reaction I above. This amine may be reacted without purification, but it is preferably purified first.
The Weinreb amide used as a reactant in Reaction B.4 is typically prepared by reacting an amino-protected amino acid with N-methoxy-N-methyl-amine in the presence of a promoting agent, an acid scavenger, and a coupling agent. The reaction is typically carried out in an aprotic solvent or mixture of solvents at a temperature of from about -25°C to 25°C. A preferred promoting agent for this reaction is HOBT.H2O. Preferred acid scavengers are the tertiary alkylamines, preferably triethylamine or N-methyl-morpholine. A preferred coupling reagent is ethyl
dimethylaminopropylcarbodiimide hydrochloride. The Weinreb amide afforded by this reaction is preferably isolated prior to its use in Reaction B.4.
The compounds of formula IA, where R replaces Q3 and where R is -S-aryl, are prepared in Scheme B by first reacting amino-protected serine with triphenylphosphine and
diethylazodicarboxylate (DEAD) in an aprotic solvent at a
temperature of from about -80°C to 0°C to form the corresponding beta-lactone. The reaction is typically carried out in an ether, such as tetrahydrofuran at a temperature of from about -80°C to -50°C. Next, the lactone ring is opened to provide a compound having the structure:
Figure imgf000073_0001
by reacting the lactone with an appropriately substituted thioanion having the structure, -S-aryl. The thioanion compound is preferably formed by reacting the corresponding thiol with a strong base, such as sodium hydride or potassium hydride. This reaction is typically carried out in an aprotic solvent at a temperature from about 0°C to about 40°C and under an inert atmosphere, such as nitrogen. Typical solvents for this reaction include ethers, preferably tetrahydrofuran. The desired amide reactant is then formed by reacting the resulting carboxylic acid reactant with N-methoxy-N-methyl-amine in the presence of a promoting agent, an acid scavenger and a coupling agent
substantially as described above.
Alternatively, the compounds of formula (IA), where R1 replaces Q3 and where R1 is -S-aryl, may be prepared in Scheme B using the procedures detailed in Photaki, JACS, 85, 1123 (1963), and Sasaki, N.A. et al., Tetrahedron Letters, 28, 6069 (1987). For example, the compounds may be prepared by reacting doubly protected serine (carboxy-protected and amino-protected) with toluenesulfonyl chloride in the presence of dimethylaminopyridine (DMAP) and an acid scavenger such as pyridine in an aprotic solvent such as methylene chloride to form the corresponding toluenesulfonate compound which may then be reacted with an appropriately substituted thioanion having the structure, -S-aryl. The thioanion compound is preferably formed by reacting the corresponding thiol with a strong base as described above. The carboxy-protecting group may then be removed from the resulting doubly protected arylthioalanine using conditions known in the art.
According to certain embodiments, an intermediate for making compounds of the present invention is prepared as follows. The intermediate has the formula 4 :
Figure imgf000075_0001
wherein :
R1 is aryl, or -S-aryl;
R10 is hydrogen or an amino-protecting group;
R0 is C1-C4 alkyl or -CH2-pyridyl;
R3 is a group having the structure
1) -C(O) -NR4R4,
2) , or
Figure imgf000075_0002
3)
;
Figure imgf000075_0003
p is 4 or 5 ;
R4 at each occurrence is independently hydrogen, C1-C6 alkyl or hydroxy(C1-C4)alkyl; and
R5 and R6 are independently selected from hydrogen, hydroxy, C1-C6, alkyl, C1-C6 alkoxy, or hydroxy (C1-C4) alkyl;
or a pharmaceutically acceptable salt thereof. The intermediate having the formula 4 is typically made by the process comprising: (a) reducing a compound of the formula
Figure imgf000076_0001
to provide a piperazine compound;
(b) alkylating the piperazine compound to provide a compound of the formula ; and then
Figure imgf000076_0002
(c) reacting the piperazine compound of step (b) with an epoxide of the formula
where Rb is an amino protecting group;
in an alcoholic solvent at a temperature of from about 20°C to
100°C to form a compound of formula 4 wherein R10 is an amino-protecting group; and
d) optionally removing the amino-protecting group to form a compound of formula 4 wherein R10 is hydrogen.
The following Preparations and Examples illustrate aspects of the invention. These examples are for illustrative purposes and are not intended to limit the scope of the invention.
Abbreviations for the terms melting point, nuclear magnetic resonance spectra, electron impact mass spectra, field desorption mass spectra, fast atom bombardment mass spectra, infrared spectra, ultraviolet spectra, elemental analysis, high performance liquid chromatography, and thin layer chromatography are,
respectively, m.p., NMR, EIMS, MS(FD), MS(FAB), IR, UV, Analysis, HPLC, and TLC. In addition, the absorption maxima listed for the IR spectra are those of interest, not all maxima observed.
In conjunction with the NMR spectra, the following
abbreviations are used: singlet (s), doublet (d), doublet of doublets (dd), triplet (t), quartet (q), multiplet (m), doublet of multiplets (dm), broad singlet (br.s), broad doublet (br.s), broad triplet (br.t), and broad multiplet (br.m). J indicates the coupling constant in Hertz (Hz). Unless otherwise noted, NMR data refer to the free base of the subject compound.
The NMR spectra were obtained on a Bruker Corp. 270 MHz instrument or on a General Electric QE-300 300 MHz instrument. The chemical shifts are expressed in delta values (ppm downfield from tetramethylsilane). MS(FD) spectra were taken on a Varian-MAT 731 Spectrometer using carbon dendrite emitters. EIMS spectra were obtained on a CEC 21-110 instrument from Consolidated
Electrodynamics Corporation. MS (FAB) spectra were obtained on a VG ZAB-3 Spectrometer. IR spectra were obtained on a Perkin-Elmer 281 instrument. UV spectra were obtained on a Cary 118
instrument. TLC was carried out on E. Merck silica gel plates. Melting points are uncorrected. Preparation 1
A. [3S-( 3R* , 4aR* , 8aR* , 2 ' S* , 3 ' R*) ] - 2 -[3'-N- (Benzyloxycarbonyl)amino-2'-hydroxy-4'- phenyl]butyl decahydroisoquinoline-3-N- t-butylcarboxamide
A solution of [1'S- (1 'R*, 1R*) ]-1-[1'-N-(benzyloxycarbonyl)amino-2'-(phenyl)ethyl]oxirane and [3S- (3R*, 4aR* , 8aR*) ]-decahydroisoquinoline-3-N-t-butylcarboxamide in absolute ethanol was heated at 80°C overnight. The reaction mixture was reduced to dryness under reduced pressure to provide a residue. This residue was purified using flash chromatography (gradient eluent of 10-50% ethyl acetate in methylene chloride) to provide 6.47 g of an off-white foam.
Yield: 75%.
1H NMR (CDCl3) : δ 1.29 (s, 9H), 1.25-2.05 (m, 2H),
2.20-2.35 (m, 2H), 2.55-2.70 (m, 11H),
2.85-3.10 (m, 3H), 3.24 (br.s, 1H),
3.82 (br.s, 1H), 3.98 (br.s, 1H),
4.99 (br.s, 2H), 5.16-5.18 (m, 1H),
5.80 (br.s, 1H), 7.05-7.38 (m, 10H).
IR (CHCl3) : 3600-3100 (br.), 3031, 2929, 1714, 1673, 1512,
1455, 1368, 1232, 1199, 1047 cm-1.
MS(FD) : m/e 536 (M+).
B. [3S- ( 3R* , 4aR* , 8aR* , 2 ' S* , 3 ' R*)]-2-[3'- Amino-2'-hydroxy-4'-phenyl]butyl
decahydroisoquinoline-3-N-t-butylcarboxamide
A rapidly stirring suspension of 6.37 g (11.91 mmol) of the subtitled compound of Preparation IA and 1.2 g of 10% palladium-on-carbon in 200 mL of absolute ethanol was placed under an atmosphere of hydrogen. After approximately 48 hours, the reaction mixture was filtered through celite and reduced to dryness under reduced pressure to provide 5.09 g of the desired subtitled compound. This compound was used without further purification.
1H NMR (CDCl3) : δ 1.33 (s, 9H), 1.40-1.95 (m, 10H),
2.25-2.48 (m, 2H), 2.59-2.75 (m, 3H),
2.80-3.40 (m, 7H), 3.75-3.90 (m, 1H),
6.19 (br.s, 1H), 7.18-7.35 (m, 5H).
IR (CHCl3) : 3600-3100 (br.), 2929, 2865, 1671, 1515, 1455,
1367, 1245, 1047 cm-1.
MS(FD): m/e 402 (M+, 100).
Preparation 2
A. 2R-N(Benzyloxycarbonyl)amino-3- naohth-2-ylthio propanoic acid
To a solution of 1.28 g (8.00 mmol) of naphthalene-2-thiol in
30 mL of tetrahydrofuran, was slowly added 1.77 g (8.16 g) of 60% sodium hydride, under nitrogen. After stirring for approximately
15 minutes, a solution of N(benzyloxycarbonyl) serine-β-lactone in
20 mL of tetrahydrofuran was slowly added. The reaction mixture was allowed to react at room temperature for approximately one hour, and then was concentrated under reduced pressure to provide a residue. This residue was dissolved in ethyl acetate and washed sequentially with 0.5N sodium bisulfate and a saturated brine solution. The resulting layers were separated and the organic layer was dried over sodium sulfate, filtered, and then
concentrated under reduced pressure to provide a residue. This residue was purified using flash chromatography to provide 2.08 g of a pale yellow solid.
Yield: 68%.
1H NMR (CDCl3) : δ 3.42-3.61 (br.m, 2H),
5.53-5.76 (br.s, 1H), 4.85-5.08 (br.m,
2H), 5.54-5.76 (br.s, 1H), 7.06-7.97 (m, 12H).
[α]D -55.72° (c 1.0, MeOH) .
IR (KBr) : 3348, 3048, 1746, 1715, 1674, 1560, 1550, 1269,
1200, 1060 cm-1.
MS(FD): m/e 381 (M+), 381 (100).
Analysis for C20H19NO4S:
Calcd: C, 66.12; H, 5.02; N, 3.67;
Found: C, 66.22; H, 5.04; N, 3.86.
B. 3R-1-Diazo-2-oxo-3-N-(benzyloxycarbonyl)amino-4-(naphth-2-ylthio) butane
To a cold (-30°C) solution of 15.38 g (40.3 mmol) of the subtitled compound of Preparation 2A in 230 mL of ethyl acetate, was slowly added 5.62 mL (40.3 mmol) of triethylamine, under nitrogen via syringe. To the resulting solution was then added
7.84 mL (60.5 mmol) of isobutyl chloroformate, via syringe. In a separate flask, 10 g of N (methyl)-N(nitro)-N(nitroso)-guanidine was carefully added to a bilayer mixture of 170 mL of diethylether and 170 mL of a 5N sodium hydroxide solution, resulting in a large evolution of gas. When this reaction was substantially complete, the organic layer was decanted from the aqueous layer onto
potassium hydroxide and dried. This diazomethane formation and addition was repeated using identical quantities of diethylether and sodium hydroxide and 30 g of N(methyl)-N(nitro)-N(nitroso)guanidine. The resultant diazomethane reactant was then added to the mixed anhydride solution prepared above and the reaction mixture was allowed to react cold (-30°C) for approximately 20 minutes. When the reaction was substantially complete, as
indicated by TLC, nitrogen was bubbled through the solution using a fire polished Pasteur pipet to remove any excess diazomethane and then the solution was concentrated under reduced pressure to provide a residue. This residue was purified using flash
chromatography (eluent of 10% ethyl acetate in methylene chloride) to provide 13.62 g of a yellow oil.
Yield: 83%.
1H NMR (CDCl3) : δ 3.32-3.46 (m, 2H), 4.40-4.67 (m, 1H),
5.00-5.09 (m, 2H), 5.44 (s, 1H), 5.76
(d, J=7.8 Hz, 1H), 7.25-7.86 (m, 12H).
C. 3R-1-Chloro-2-oxo-3-N-(benzyloxycarbonyl)amino-4-(naphth-2-ylthio) butane
A short burst (about 2 seconds) of anhydrous hydrochloric acid (gas) was passed through a cold (-20°C) solution of 13.62 g
(33.59 mmol) of the subtitled compound of Preparation 2B in 230 mL of diethylether, resulting in the evolution of a gas. This procedure was repeated taking care not to add excess hydrochloric acid. When the reaction was substantially complete, as indicated by TLC, the solution was concentrated under reduced pressure to provide a residue. This residue was purified using flash
chromatography (eluent of 10% ethyl acetate in methylene chloride) to provide 12.05 g of a pale tan solid. Yield: 87%.
1H NMR (CDCl3) : δ 3.41 (dd, J=12,6 Hz, 1H), 3.53 (dd,
J=12,6 Hz, 1H), 4.18 (AB q, J=41.9 Hz,
J=15.9 Hz, 2H), 4.77 (dd, J=9, 3 Hz, 1H),
5.04 (AB q, J=12 Hz, J=10.4 Hz, 2H),
5.59 (d, J=7 Hz, 1H), 7.24-7.85 (m, 12H).
[α] -80.00° (c 1.0, MeOH) .
IR (CHCl3) : 3426, 3031, 3012, 1717, 1502, 1340, 1230,
1228, 1045 cm-1.
MS(FD): m/e 413 (M+), 413 (100).
Analysis for C22H20NO3SCl:
Calcd: C, 63.84; H, 4.87; N, 3.38;
Found: C, 64.12; H, 4.95; N, 3.54.
D. [3R-(3R*,4S*)]-1-Chloro-2-hydroxy-3-N- (benzyloxycarbonyl)amino-4-(naphth-2- ylthio) butane
To a cold (0°C) solution of 530 mg (1.28 mmol) of the
subtitled compound of Preparation 2C, in 10 mL of tetrahydrofuran and 1 mL of water, was added 73 mg (1.92 mmol) of sodium
borohydride. When the reaction was substantially complete as indicated by TLC, the solution was adjusted to pH 3 using 10 mL of an aqueous saturated ammonium chloride solution and 500 μL of a
5N hydrochloric acid solution. The resultant solution was
extracted twice with methylene chloride and the combined organic layers were washed with water, dried over sodium sulfate, filtered and then concentrated under reduced pressure to provide a residue.
This residue was purified using radial chromatography (eluent of methylene chloride) to provide 212 mg of a tan solid. Yield: 40%.
1H NMR (CDCl3) : δ 3.40 (s, 2H), 3.61-3.71 (m, 2H),
3.97-3.99 (m, 2H), 4.99 (s, 2H),
5.16 (br.s, 1H), 7.21-7.83 (complex, 12H).
MS(FD): m/e 415 (M+) , 415 (100).
[α]D -47.67° (c 0.86, MeOH).
IR (CHCD) : 3630, 3412, 3011, 1720, 1502, 1236, 1044 cm-1.
Analysis for C22H22NO3ClS :
Calcd: C, 63.53; H, 5.33; N, 3.37;
Found: C, 63.72; H, 5.60; N, 3.64.
E. [1'R-( 1 'R* , 1S*) ]-1-[(1'-N-(Benzyloxycarbonyl)
amino-2'-(naphth-2-ylthio)ethyl] oxirane
A solution of 31 mg (0.55 mmol) of potassium hydroxide in 1 mL of ethanol was added to a solution of 190 mg (0.46 mmol) of the subtitled compound of Preparation 2D, in 6 mL of a 1 : 2 ethanol/ethyl acetate solution. When the reaction was substantially complete, as indicated by TLC, the reaction mixture was poured into a water/methylene chloride mixture. The resulting layers were separated, and the organic layer was washed with water, dried over sodium sulfate, filtered and then concentrated under reduced pressure to provide a residue. This residue was purified using radial chromatography (eluent of 10% ethyl acetate in methylene chloride) to provide 172 mg of a light tan solid.
Yield: 99%.
1H NMR (CDCl3) : δ 2.76 (br.s, 2H) 3.01 (br.s, 1H),
3.31 (d, J=5 Hz, 2H), 3.77 (br.s, 1H), 5.05 (s, 2H), 5.22 (d, J=6 Hz, 1H),
7.25-7.85 (complex, 12H).
[α]D -125.42° (c 0.59, MeOH) .
MS(FD): m/e 379 (M+), 379 (100).
IR (CHCI3) : 3640, 3022, 2976, 1720, 1502, 1235, 1045 cm-1.
Analysis for C22H21NO3S:
Calcd: C, 69.63; H, 5.58; N, 3.69;
Found: C, 69.41; H, 5.53; N, 3.64.
F. [2S-(2R*, 2 'R*, 3 'S*)]-1-[2'-Hydroxy-3'-(N- benzyloxycarbonyl)amino-4'-(naphth-2- ylthio)butyl] piperidine-2-N-(t-butyl)carboxamide
A solution of 0.51 g (1.34 mmol) of the subtitled compound of Preparation 2E and 0.26 g (1.41 mmol) of the subtitled compound of Preparation 4C in 25 mL of isopropanol was heated to 55°C for approximately forty eight hours. The resultant reaction mixture was cooled and then concentrated under reduced pressure to provide a crude material. This material was purified using radial
chromatography (4mm plate; eluent of 10% acetone in methylene chloride) to provide 104 mg of a white foam.
Yield: 14%.
1H NMR (CDCl3) : δ 1.29 (s, 9H), 1.44-1.82 (m, 6H),
2.19 (m, 1H), 2.40 (m, 1H), 2.68 (m, 2H),
3.09 (m, 1H), 3.46 (m, 2H), 4.00 (m, 2H),
5.01 (s, 2H), 5.73 (d, 1H), 6.01 (br.s, 1H),
7.23-7.34 (m, 5H), 7.45 (m, 3H),
7.72-7.83 (m, 4H).
MS(FD): m/e 563 (M+, 100). G. [2S-(2R*,2'S*,3'S*)]-1-[2'-Hydroxy-3'- amino-4'-(naphth-2-ylthio)butyl] piperidine- 2-N-(t-butyl) carboxamide
A solution containing 1.05 g (0.18 mmol) of the subtitled compound of Preparation 2F in 10 mL of 30% hydrobromic acid in acetic acid was reacted for approximately one hour. The resultant reaction mixture was concentrated, azeotroped three times with toluene, redissolved in methanol containing 4.5 mL each of
diethylamine and ammonium hydroxide and then concentrated under reduced pressure to provide a residue. This residue was purified using radial chromatography (1mm plate; eluent of 3% methanol in methylene chloride containing 1% acetic acid) to provide 64 mg of a white foam.
Yield: 80%.
1H NMR (CDCl3) : δ 1.29 (s, 9H), 1.52-1.73 (m, 6H),
1.84 (m, 1H), 2.31-2.43 (m, 2H),
2.75-3.04 (m, 5H), 3.17 (m, 1H),
3.41 (m, 1H), 3.71 (m, 1H), 6.22 (br.s,
1H), 7.47 (m, 3H), 7.73-7.82 (m, 4H).
MS(FD): m/e 430 (M+, 100).
Preparation 3
A. 2S-N-(Benzyloxycarbonyl)-2-pyrrolidinecarboxylate
pentafluorophenyl ester
To a cold (0°C) solution of 30 g (0.12 mol) of 2S- N(benzyloxycarbonyl)-2-pyrrolidinecarboxylic acid and 25.8 g (0.14 mol) of pentafluorophenol in 450 mL of tetrahydrofuran, was added
27.7 g (0.14 mol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide
(EDC) in one portion, followed by 150 mL of methylene chloride. The resultant reaction mixture was warmed to room temperature and reacted for approximately four hours. When the reaction was substantially complete, as indicated by TLC, the reaction mixture was concentrated under reduced pressure to provide a residue.
This residue was dissolved in 500 mL of ethyl acetate and washed sequentially with water, potassium carbonate, 1N hydrochloric acid and brine, dried over sodium sulfate, filtered and then reduced to dryness under reduced pressure to provide a solid. This solid was redissolved in hexane and washed with potassium carbonate, dried over sodium sulfate, filtered and reduced to dryness under reduced pressure to provide 45.95 g of the desired subtitled compound. Yield: 92%.
1H NMR (CDCl3) : δ 1.95-2.15 (m, 2H), 2.20-2.35 (m, 1H),
2.35-2.50 (m, 1H), 3.50-3.75 (m, 2H),
4.65-4.75 (m, 1H), 5.02-5.30 (m, 2H),
7.20-7.45 (m, 5H).
B. 2S-N-(Benzyloxycarbonyl)pyrrolidine-2-N(t- butyl)carboxamide
To a cold (0°C) solution of 45.90 g (0.111 mmol) of the subtitled compound of Preparation 3A in 100 mL of anhydrous methylene chloride, was slowly added 100 mL (0.952 mmol) of t-butylamine. The reaction mixture was warmed to room temperature and reacted for approximately one hour and then diluted with 1000 mL of methylene chloride and then washed sequentially with 1N potassium carbonate, 1N hydrochloric acid, 1N potassium carbonate, and brine, dried over sodium sulfate, and then plug filtered using 50% ethyl acetate in hexane to provide 37.74 g of the desired compound which was used without further purification.
1H NMR (CDCl3) : δ 0.95-1.50 (m, 9H), 1.70-2.40 (m, 4H),
3.30-3.60 (m, 2H), 4.10-4.30 (m, 1H),
4.95-5.35 (m, 2H), 5.65 (br.s, 0.5H),
6.55 (br.s, 1H), 7.20-7.50 (m, 5.5H).
C. 2S-Pyrrolidine-2-N-(t-Butyl)carboxamide
The subtitled compound of Preparation 3B (2.71 g, 8.9 mmol) was deprotected substantially as detailed in Preparation IB, using 500 mg of 10% palladium-on-carbon and hydrogen gas (1 atmosphere) in 200 mL of ethanol.
Yield: 1.53 g (100%).
1H NMR (CDCl3) : δ 1.35 (s, 9H), 1.60-1.75 (m, 2H),
1.76-1.90 (m, 1H), 2.00-2.15 (m, 1H),
2.58 (br.s, 1H), 2.80-3.05 (m, 2H),
3.55-3.65 (m, 1H), 7.45 (br.s, 1H).
D. [2S-(2R* , 2 'S* , 3 'R* ) ]-1-[3'-N(Benzyloxycarbonyl)- amino-2'-hydroxy-4'-phenylbutyl] pyrrolidine- 2-N-(t-butyl)carboxamide
A solution containing 122 mg (0.72 mmol) of the subtitled compound of Preparation 3C and 200 mg (0.68 mmol) of [1S- (1R*, 1 'R*) ]-1-[(1'-N-(benzyloxycarbonyl)amino-2'-phenyl)ethyl] oxirane in 10 mL of methanol was stirred overnight. When the reaction was substantially complete, as indicated by TLC, the reaction mixture was concentrated under reduced pressure. The desired compound was purified using column chromatography
(gradient eluent of 2-4% methanol in methylene chloride) to provide 232.2 mg of a clear amorphous solid. Yield: 55%.
[α] D -56.97° (c=0.27, MeOH).
1H NMR (CDCl3) : δ 1.33 (s, 9H), 1.55-1.95 (m, 4H),
2.05-2.25 (m, 1H), 2.40-2.55 (m, 1H),
2.65-2.75 (m, 2H), 2.80-3.00 (m, 3H),
3.15-3.30 (m, 1H), 3.65-3.75 (m, 1H),
3.85-3.95 (m, 1H), 4.86 (br.d, J=1.1 Hz,
1H), 5.03 (s, 2H), 6.95 (m, 1H),
7.15-7.40 (m, 10H).
IR (CHCl3) : 3700-3100 (br.), 3434, 3031, 2976, 1720, 1664,
1604, 1512, 1455, 1394, 1367, 1343, 1233,
1156, 1107, 1063, 1028, 911 cm-1.
MS(FD): m/e 468 (M+, 100)
E. [2S-(2R*, 2 'S*, 3 'R*)]-1-[3'-Amino-2'-hydroxy-4'- phenylbutyl] pyrrolidine-2-N-t-butylcarboxamide
The subtitled compound of Preparation 3D (222 mg, 0.47 mmol) was deprotected substantially as detailed in Preparation 1B, using
67 mg of 10% palladium-on-carbon and hydrogen gas (1 atmosphere) in 15 mL of ethanol. The desired compound was purified using column chromatography (eluent of 10% isopropanol in methylene chloride containing 0.75% ammonium hydroxide) to provide 80 mg of an off-white solid.
Yield: 51%.
[α]D -55.26° (c=0.23, MeOH).
1H NMR (CDCl3) : δ 0.80-3.70 (m, 25H), 6.90-7.40 (m, 6H). IR (CHCl3) : 3692, 3600-3200 (br.), 2975, 1657, 1603, 1522,
1497, 1479, 1455, 1393, 1366, 1232, 1198,
1137, 1049, 882 cm-1.
MS(FD) : m/e 334 (M+, 100).
Preparation 4
A. 2S-N-(t-Butoxycarbonyl) piperidine-2-carboxylic acid
A solution of 1.64 g of sodium carbonate in 15 ml of water was added to a cold (0°C) solution of 2.0 g (15.5 mol) of 2S-piperidinecarboxylic acid in 50 mL of dioxane. After
approximately ten minutes, 3.7 g (17.0 mol) of di-t-butyl
dicarbonate was added to the mixture. The resultant reaction mixture was reacted for approximately six hours, concentrated to one fourth of the original volume and then acidified to pH 2 using 1M sodiumhydrogen sulfate and ethyl acetate. The resulting layers were separated, and the organic layers were washed with a
saturated brine solution, dried over sodium sulfate, filtered and then reduced to dryness under reduced pressure to provide 2.67 g of a white crystalline solid.
Yield: 75%.
[a]D -55.26° (c=0.23, MeOH).
1H NMR (CDCl3) : δ 1.20-1.80 (m, 15H), 2.15-2.30 (m, 1H),
2.85-3.10 (m, 1H), 3.90-4.10 (m, 2H),
4.70-5.00 (m, 1H).
IR (CHCl3) : 3700-1800 (br.), 3025, 3018, 3011, 2980, 2947,
2865, 1716, 1685, 1449, 1394, 1368, 1280,
1252, 1162, 1147, 1129 cm-1. MS(FD) : m/e 229 (M+, 100).
Analysis for C27H37N3O4 :
Calcd: C, 57.63; H, 8.35; N, 6.11;
Found: C, 57.90; H, 8.35; N, 6.19.
B. 2S-N-(t-Butoxycarbonyl) piperidine-2- carboxylate, pentafluorophenylester
To a cold (0°C) solution of 2.53 g (11.03 mol) of the subtitled compound of Preparation 4A and 2.34 g (12.7 mol) of pentafluorobenzoic acid in 50 mL of tetrahydrofuran, was added 2.42 g (12.7 mol) of EDC. The resultant reaction mixture was warmed to room temperature and reacted for approximately two hours. The mixture was then concentrated under reduced pressure to provide a solid. This solid was redissolved in methylene chloride and washed sequentially with potassium carbonate and brine, dried over sodium sulfate, filtered and then reduced to dryness under reduced pressure to provide 3.85 g of a clear oil which solidified on standing.
Yield: 88%.
1Ή NMR (CDCl3) : δ 1.20-1.90 (m, 15H), 2.30-2.40 (m, 1H),
2.90-3.15 (m, 1H), 3.90-4.15 (m, 1H),
5.05-5.35 (m, 1H).
C. 2S-N-(t-Butoxycarbonyl) piperidine-2-N-t- butylcarboxamide
b To a cold (0°C) solution of 3.8 g (9.6 mmol) of the subtitled compound of Preparation 4B in 200 mL of methylene chloride, was slowly added 2.53 mL (24.0 mmol) of t-butylamine. The reaction mixture was reacted for approximately four hours and then
concentrated under reduced pressure to provide a residue. This residue was redissolved in methylene chloride and then washed sequentially with 1M potassium carbonate and brine, dried over sodium sulfate, filtered and then purified using column
chromatography (gradient eluent of 10-20% ethyl acetate in hexane) to provide 2.52 g of a white solid.
Yield: 92%.
[α]D -41.47° (c=0.506, MeOH).
1H NMR (CDCl3) : δ 1.10-1.70 (m, 15H), 2.20-2.35 (m, 1H),
2.65-2.82 (m, 1H), 3.90-4.10 (m, 1H),
4.62 (br.s, 1H).
IR (CHCl3) : 3600-3300 (br.), 2978, 2945, 2869, 1677, 1512,
1455, 1413, 1394, 1367, 1317, 1280, 1255,
1162, 1144, 1127, 1078, 1042, 868 cm-1.
MS(FD): m/e 284 (M+, 100).
Analysis for C15H28N2O3:
Calcd: C, 63.35; H, 9.92; N, 9.85;
Found: C, 63.10; H, 9.66; N, 9.92.
D. 2S-Piperidine-2-N-t-butylcarboxamide
A solution containing 1.0 g (3.5 mol) of the subtitled compound of Preparation 4C and 3.5 mL of trifluoroacetic acid in 25 mL of methylene chloride was stirred at room temperature for approximately two hours. The reaction mixture was concentrated and azeotroped once with toluene. The resultant reaction mixture was then partitioned between methylene chloride and sodium
bicarbonate. The resulting layers were separated and the organic layer was dried over sodium sulfate, filtered and reduced to dryness under reduced pressure to provide 641 mg of the subtitled compound .
Yield: 99%.
[α]D -22.45° (c=0.95, MeOH).
1H NMR (CDCl3) : δ 1.20-1.50 (m, 12H), 1.51-1.62 (m, 1H),
1.64 (s, 1H), 1.75-1.88 (m, 1H),
1.90-2.00 (m, 1H), 2.60-2.72 (m, 1H),
2.98-3.10 (m, 2H), 6.63 (br.s, 1H).
IR (CHCl3) : 3363, 3002, 2969, 2940, 2860, 1738, 1660,
1522, 1480, 1455, 1398, 1367, 1324, 1295,
1230, 1129, 1110, 852 cm-1.
MS(FD): m/e 184 (M+, 100).
E. [2S-(2R* , 2 'S*, 3 'R*)]-N-[3'-(N-Benzyloxycarbonyl)amino-2'- hydroxy-4'-phenyl]butyl piperidine-2-N-t-butylcarboxamide
A solution containing 195 mg (1.06 mmol) of the subtitled compound of Preparation 4D and 300 mg (1.01 mmol) of [1S- (1R* , 1 'R*) ]-1-[(1'-N(benzyloxycarbonyl)amino-2'- phenyl) ethyl] oxirane in 10 mL of isopropanol was stirred at 55°C for approximately forty eight hours. When the reaction was substantially complete, as indicated by TLC, the reaction mixture was concentrated under reduced pressure. The desired compound was purified using column chromatography (gradient eluent of 1-5% isopropanol in methylene chloride).
Yield: 395 mg (81%).
[α]D -55.64° (c=0.22, MeOH).
1H NMR (CDCl3) : δ l.32 (s, 9H), 1.45-1.90 (m, 6H),
2.25-2.50 (m, 2H), 2.70-3.20 (m, 5H), 3.30-3.40 (m, 1H), 3.75-4.05 (m, 2H),
4.95-5.10 (m, 3H) , 6.15 (br.s, 1H),
7.18-7.40 (m, 10H) .
IR (CHCl3) : 3700-3100 (br.), 3623, 3021, 2976, 1668, 1603,
1511, 1456, 1313, 1047, 878 cm-1.
MS(FD): m/e 482 (M+, 100).
F. [2S-(2R*,2'S*,3'R*)]-N-[3'-Amino-2'-hydroxy-4'- phenyl]butyl piperidine-2-N-t-butylcarboxamide
The subtitled compound of Preparation 4E (371 mg, .0.77 mmol) was deprotected substantially as detailed in Preparation 1B, using 110 mg of 10% palladium-on-carbon and hydrogen gas in 20 mL of ethanol to provide 260 mg of a white foam.
Yield: 97%.
[αlD -64.92° (c=0.39, MeOH).
1H NMR (CDCl3) : δ 1.35 (s, 9H), 1.45-1.90 (m, 6H),
2.25-2.35 (m, 1H), 2.50-2.90 (m, 5H),
3.00-3.40 (m, 3H), 3.85-3.98 (m, 1H),
6.29 (s, 1H), 7.15-7.38 (m, 5H).
IR (CHCl3) : 3693, 3650-3100 (br.), 2943, 2862, 1671, 1603,
1517, 1497, 1455, 1394, 1367, 1233, 1185,
1049, 887 cm-1.
MS(FD): m/e 348 (M+, 100).
Preparation 5
A. Pyrazine-2-N-(t-butyl)carboxamide
To a slurry of 50 g (0.403 mol) pyrazine-2-carboxylic acid in 600 mL of tetrahydrofuran and 100 mL of dimethylformamide, was added 65.9 g (0.407 mol) of carbonyldiimidazole. The resultant reaction mixture was reacted at 50°C until gas evolution ceased. After the reaction mixture cooled, 73.5 g (1.00 mol) of t-butylamine was slowly added. The reaction mixture was reacted for approximately thirty minutes, concentrated under reduced pressure, redissolved in 500 mL of methylene chloride and then washed sequentially with water, hydrochloric acid (pH 2), saturated sodium bicarbonate, water, 1M potassium hydroxide, and brine, dried over sodium sulfate, and concentrated to provide 68.5 g of a white solid.
Yield: 95%.
1H NMR (CDCl3) : δ 1.51 (s, 9H), 7.73 (br.s, 1H),
8.49 (m, 1H), 8.72 (m, 1H), 9.38 (s, 1H).
B. (+/-)-Piperazine-2-N-(t-butyl)carboxamide
A mixture of 68.5 g (0.382 mol) of the subtitled compound of Preparation 5A, 70 g (0.308mol) of platinum oxide in 186 mL of ethanol was heated overnight at 40°C under a hydrogen atmosphere (60 psi). The resultant crude material was filtered and the filtrate was concentrated to provide 65 g of white solid.
Yield: 95%.
MS(FD): m/e 185 (M+, 100).
C. (+/-)-4-(Pyrid-3'-ylmethyl)piperazine-2-N-(t- butyl) carboxamide
To a solution of 5.0 g (0.027 mol) of the subtitled compound of Preparation 5B in 160 mL of a 1:1 mixture of water and
acetonitrile, was added 18.65 g (0.135 mol) of potassium
carbonate. The resultant mixture was vigorously stirred during the addition of 4.43 g (0.027 mol) of 3-chloromethylpyridme hydrochloride and then allowed to react overnight. The resultant reaction mixture was concentrated under reduced pressure, slurried in a solution of 20% isopropanol in chloroform and washed
sequentially with water and brine, dried over sodium sulfate, filtered and then concentrated to provide a residue. This residue was purified using flash chromatography (eluent of 5% methanol in methylene chloride containing 1% ammonium hydroxide) to provide 1.34 g of a clear yellow oil.
Yield: 18%.
1H NMR (CDCl3): δ l.10 (s, 9H), 1.89-2.01 (m, 2H),
2.35 (m, 1H), 2.57-2.74 (m, 4H),
3.09 (m, 1H), 3.27 (s, 2H),
6.71 (br.s, 1H), 7.03 (m, 1H),
7.44 (m, 1H) 8.26 (m, 2H).
IR (KBr) : 3691, 3611, 3366, 2974, 1666, 1602, 1521,
1479, 1456, 1427, 1393, 1366, 1324, 1139,
1047, 839 cm-1.
MS(FD): m/e 276 (M+, 100).
D. [2S-{ 2R*, 2 'S*, 3 'R*)]-1-[2'-Hydroxy-3'-(N- benzyloxycarbonyl)amino-4'-phenylbutyl]-4-(pyrid- 3''-ylmethyl) piperazine-2-N-(t-butyl) carboxamide
A solution containing 0.377 g (1.27 mmol) of [1S- (1R* , 1 'R*) ] - 1-[(1'-N-Benzyloxycarbonyl)amino-2'-phenyl)ethyl]oxirane and 0.350 g (1.27 mmol) of the subtitled compound of Preparation 5C in 12 mL of isopropanol was reacted at 45°C for approximately forty eight hours. The reaction mixture was cooled and then concentrated under reduced pressure to provide a crude material. This material was purified using radial chromatography (6mm plate; gradient eluent of 5-10% isopropanol in methylene chloride) to provide 120 mg of isomer A and 68 mg of isomer B.
Yield: 26% overall.
Isomer A:
1H NMR (CDCl3) : δ 1.33 (s, 9H), 2.26-2.89 (m, 13H),
3.29 (m, 1H), 3.45 (s, 2H),
3.79-3.95 (m, 3H), 4.73 (br.s, 1H),
4.97 (br.s, 2H), 5.20 (m, 1H),
7.14-7.29 (m, 6H) 7.57 (m, 1H),
7.82 (br.s, 1H), 8.53 (m, 2H).
IR (KBr) : 3692, 3434, 2970, 2829, 1714, 1661, 1604,
1579, 1512, 1455, 1427, 1393, 1365, 1231,
1149, 1029, 909 cm-1.
MS(FD): m/e 573 (M+, 100).
E. [2S-( 2R* , 2 'S*, 3 'R*)]-1-[2'-Hydroxy-3'-amino-4'- phenyl]butyl-4-(pyrid-3''-ylmethyl) piperazine- 2-N-(t-butyl)carboxamide
A solution containing 0.062 g (0.11 mmol) of the subtitled compound of Preparation 5D (isomer A) was stirred for
approximately ninety minutes in 1.5 mL of a solution of 30% hydrobromic acid in acetic acid. The resultant mixture was concentrated, azeotroped three times with toluene, redissolved in methanol containing 1 mL each of diethylamine and ammonium hydroxide and then concentrated under reduced pressure to provide a residue. This residue was purified using radial chromatography
(2mm plate; gradient eluent of 15-25% methanol in methylene chloride containing 1% ammonium hydroxide) to provide 13 mg of a white solid. Yield: 28%.
1H NMR (CDCl3) : δ 1.33 (s, 9H), 2.36-3.21 (m, 15H),
3.47 (d, 2H), 3.75 (m, 1H), 7.19-7.30
(m, 6H) 7.57 (m, 2H), 8.52 (m, 2H).
MS(FD): m/e 440 (M+, 100).
Preparation 6
A. [2S-( 2R* , 2 'S*, 3 'S*)]-1-[3'-N-(Benzyloxycarbonyl)amino- 2'-hydroxy-4'-phenylthiobutyl]-4-[pyrid-3''-ylmethyl] piperazine-2-N-t-butylcarboxamide [isomer B]
A solution of 596 mg (1.81 mmol) of [1S-(1R*,1'S*)]-1-[1'-N- (benzyloxycarbonyl) amino-2'-(phenylthio)ethyl] oxirane and 500 mg (1.81 mmol) of the subtitled compound of Preparation 5C in 15 mL of isopropanol were heated at 43 °C for approximately forty-eight hours. The reaction was monitored using TLC (10% isopropanol in methylene chloride containing 1% ammonium hydroxide; Isomer A Rf = 0.7; Isomer B Rf = 0.6). When the reaction was substantially complete, the reaction mixture was concentrated under reduced pressure to provide a residue. This residue was purified using radial chromatography (6 mm plate; gradient eluent of 5-15% isopropanol in methylene chloride containing 1% ammonium
hydroxide) to provide 200 mg of isomer A as a light tan foam and 119 mg of an off-white foam (isomer B).
Isomer A:
Yield: 18%.
1H NMR (CDCl3) : δ 1.31 (s, 9H), 2.25-2.62 (m, 7H),
2.78-2.95 (m, 2H), 2.98-3.08 (m, 1H), 3.10-3.25 (m, 2H), 3.40-3.55 (m, 2H),
3.72-3.85 (m, 1H), 3.90-4.00 (m, 1H),
5.05 (s, 2H), 7.01 (br.s, 1H), 7.10-7.40
(m, 11H), 7.62 (d, J=7.8 Hz, 1H), 8.49 (s, 2H).
MS(FD): m/e 606 (M+, 100).
Analysis for C33H43N5O4S:
Calcd: C, 65.42; H, 7.15; N, 11.56;
Found: C, 65.38; H, 7.27; N, 11.36.
Isomer B:
Yield: 11%.
1H NMR (CDCl3) : δ 1.33 (s, 9H), 2.25-2.85 (m, 8H),
3.20-3.32 (m, 3H), 3.47 (s, 2H),
3.78-3.95 (m, 2H), 5.06 (s, 2H),
5.30-5.38 (m, 1H), 7.10-7.42 (m, 12H),
7.55-7.85 (m, 2H), 8.50-8.60 (m, 2H).
MS (FD) : m/e 606 (M), 497 (100).
HR MS (FAB) for C33H44N5O4S:
Calcd: 606.3114;
Found: 606.3141.
B. [2S-(2R*,2'S*,3'S*)]-1-[2'-Hydroxy-3'-amino- 4'-phenylthiobutyl]-4-[pyrid-3''-ylmethyl]
piperazine-2-N-t-butylcarboxamide
A solution of 110 mg (0.18 mmol) of isomer B from Preparation
6A in 5 mL of 30% hydrobromic acid in acetic acid was stirred at room temperature for approximately 1 hour. The reaction mixture was concentrated under reduced pressure to provide a residue.
This residue was redissolved in 4 mL of ammonium hydroxide. The resultant solution was extracted four times with 10 mL portions of a 10% solution of isopropanol in chloroform. The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure to provide a residue. This residue was purified using radial chromatograghy (2 mm plate; gradient eluent of 10-30% methanol in methylene chloride containing 1% ammonium hydroxide) to provide 65 mg of a light yellow foam.
Yield: 72%.
1H NMR (CDCl3) : δ 1.25 (s, 9H), 2.25-2.78 (m, 7H),
3.00-3.32 (m, 4H), 3.47 (s, 2H),
3.60-3.75 (m, 1H), 4.18-4.35 (m, 1H),
6.90-7.65 (m, 9H), 8.40-8.60 (m, 2H).
MS(FD): m/e 473 (M+, 100).
Preparation 7
A. [3S-( 3R* , 4aR* , 8aR* , 2 ' S* , 3 ' S*) ]-2-[3'-N- (Benzyloxycarbonyl)amino-2'-hydroxy-4'- (naphth-2-ylthio)]butyl decahydroisoquinoline-3-N-(t-butyl) carboxamide
A solution was prepared containing 165 mg (0.40 mmol) of the subtitled intermediate of Preparation 2E and 94 mg (0.43 mmol) of 3-(1-N(t-butyl)amino-1-oxomethyl) octahydro-(2H)-isoquinoline in 5 mL of ethanol. The resulting reaction mixture was allowed to react at 80°C for approximately 19 hours. The solution was then cooled to room temperature and concentrated under reduced pressure to provide a residue. This residue was purified using radial chromatography (eluent of 10% ethyl acetate in methylene chloride) to provide 103 mg of an off-white foam.
Yield: 42%. 1H NMR (CDCl3) : δ 1.10-1.73 (m, 20H), 2.13-2.31 (m, 2H),
2.44-2.53 (m, 1H), 2.56-2.68 (m, 1H),
2.86-2.97 (m, 1H), 3.52 (br.s, 2H),
4.02 (br.s, 2H), 4.98 (s, 2H),
5.65 (s, 1H), 5.94 (s, 1H),
7.25-7.83 (complex, 13H).
MS (FD) : m/e 629 (M+), 138 (100).
[α]D -92.45° (c 1.06, MeOH).
IR (CHCl3) : 3429, 3010, 2929, 1713, 1670, 1514, 1455,
1047 cm-1.
Analysis for C35H47N3O4S:
Calcd: C, 69.98; H, 7.67; N, 6.80;
Found: C, 69.86; H, 7.78; N, 6.58.
B. [3S-( 3R* , 4aR* , 8aR* , 2 'S* , 3 ' S*) ]-2-[3'-amino-2'- hydroxy-4'-(naphth-2-ylthio)]butyl decahydroisoquinoline-3-N-(t-butyl) carboxamide
A solution was prepared containing 50 mg (0.081 mmol) of the subtitled intermediate of Preparation 7A and 1 mL of a 38% aqueous hydrobromic acid solution. in acetic acid. The resultant reaction mixture was allowed to react at room temperature for approximately 1 hour and then was concentrated under reduced pressure to provide a residue. This residue was slurried with toluene and then concentrated under reduced pressure to provide 61 mg of the desired subtitled intermediate. This compound was used crude without purification in Example 9.
1H NMR (CDCl3) : δ 1.14 (s, 1H), 1.17-2.07 (complex, 15H),
2.66-2.87 (m, 2H), 3.21-3.25 (m, 2H), 3.75 (d, J=12 Hz, 1H),
3.85 (d, J=6 Hz, 1H), 4.36-4.47 (m, 1H),
6.73 (s, 1H), 7.39-7.90 (complex, 7H) .
MS (FD) : 483 (M+), 483 (100) .
Preparation 8
A. 2R-2-N (Benzyloxycarbonyl)amino-3- phenylthio propanoic acid
The desired subtitled intermediate was prepared substantially in accordance with the procedure detailed in Procedure 2A, using 13.1 mL (127 mmol) of thiophenol, 4.6 g (117 mmol) of a 60% sodium hydride solution and 25.6 g (116 mmol) of L-N (benzyloxycarbonyl)-serine β-lactone in 450 mL of tetrahydrofuran to provide a residue. This residue was purified using flash chromatography (gradient eluent of 0-2% acetic acid in a 4:1 methylene chloride/ethyl acetate mixture) to provide 27.9 g of a white solid.
Yield: 72%.
1H NMR (CDCl3) : δ 7.55-7.18 (m, 10H),
5.55 (d, J=7 Hz, 1H), 5.08 (s, 2H),
4.73-4.60 (m, 1H), 3.55-3.30 (m, 2H).
IR (KBr) : 3304, 3035, 1687, 1532, 736 cm-1.
MS(FD): m/e 332, 288, 271, 181.
Analysis for C-7H17NO4S:
Calcd: C, 61.61; H, 5.17; N, 4.23;
Found: C, 61.69; H, 5.22; N, 4.47. B. 3S-1-Diazo-2-oxo-3-N-(benzyloxycarbonyl)amino-4- phenylthio butane
The desired subtitled compound was prepared substantially in accordance with the procedure detailed in Procedure 2B, using 12.1 g (37 mmol) of the subtitled compound of Preparation 8A, 5.09 mL (37 mmol) of triethylamine, 7.13 mL (55 mmol) isobutyl
chloroformate, 146 mmol of a diazomethane solution to provide a residue. The diazomethane solution was prepared using 100 mL of diethylether, 150 mL of a 5N sodium hydroxide solution and 21 g (146 mmol) of N(methyl)-N(nitro)-N(nitroso)-guanidine as described in Preparation 2B. This residue was purified using flash
chromatography (gradient eluent of 0-5% ethyl acetate in methylene chloride) to provide a yellow oil.
Yield: 73%
1Η NMR (CDCl3) : δ 7.50-7.19 (m, 10H),
5.62 (d, J=7 Hz, 1H), 5.47 (br.s, 1H),
5.11 (s, 2H), 4.50-4.32 (m, 1H),
3.33 (d, J=6 Hz, 1H).
IR (KBr) : 3012, 2115, 1720, 1501, 1367, 1228 cm-1.
MS (FD) : m/e 356, 328, 242.
C. 3R-1-Chloro-2-oxo-3-N-(benzyloxycarbonyl)amino-4- phenylthio butane
The desired subtitled compound was prepared substantially in accordance with the procedure detailed in Procedure 2C, using 22.3 g (63 mmol) of the subtitled compound of Preparation 8B and small quantities of hydrochloric acid (gas) in 400 mL of diethylether to provide 21 g of a white solid. This solid was used without further purification. 1H NMR (CDCl3) : δ 7.50-7.15 (m, 10H), 5.56 (dd, J=2,6.7 Hz, 1H), 5.11 (s, 2H), 4.78-4.67 (m, 1H),
4.20 (d, J=15.9 Hz, 1H), 4.12 (d, J=15.9
Hz, 1H), 3.48-3.23 (m, 2H).
IR (KBr) : 3349, 1732, 1684, 1515, 1266 cm-1.
MS (FD) : m/e 363 (M+).
Analysis for C18H18NO3SCl:
Calcd: C, 59.42; H, 4.99; N, 3.85;
Found: C, 59.57; H, 5.09; N, 4.13.
D. [2S-(2R*,3S*)]-1-Chloro-2-hydroxy-3-N- (benzyoxycarbonyl)amino-4-phenylthio butane
The desired subtitled compound was prepared substantially in accordance with the procedure detailed in Procedure 2D, using 21 g (58 mmol) of the subtitled compound of Preparation 8C, and 2.4 g (63 mmol) of sodium borohydride in 300 mL of tetrahydrofuran to provide a residue. This residue was purified using flash
chromatography (gradient eluent of 0-2% methanol in methylene chloride) followed by flash chromatography (gradient eluent of 0-2% ethyl acetate in chloroform) and then recrystallized from methylene chloride at -78-C to provide 8.3 g of the subtitled compound.
Yield: 39%.
1H NMR (CDCl3) : d 7.47-7.19 (m, 10H), 5.22-5.03 (m, 1H),
5.09 (s, 2H), 4.01-3.89 (m, 2H),
3.75-3.58 (m, 2H), 3.32 (d, J=4 Hz, 2H).
IR (KBr): 3321, 2951, 1688, 1542, 1246, 738 cm-1.
MS (FD) : m/e 366 (M+), 119. Analysis for C18H20NO3SCl :
Calcd: C, 59.09; H, 5.51; N, 3.83;
Found: C, 59.03; H, 5.50; N, 3.96.
E. [1'R-( 1 'R*, 1S*)]-1-[(1'-N-(benzyoxy- carbonyl)amino-2'-phenylthio)ethyl oxirane
The desired subtitled compound was prepared substantially in accordance with the procedure detailed in Procedure 2E, using 8.3 g (23 mmol) of the subtitled compound of Preparation 8D, 1.4 g (25 mmol) of potassium hydroxide in 400 mL of ethanol to provide a residue. This residue was purified using flash chromatography (gradient eluent of 0-2% ethyl acetate in methylene chloride) to provide 6.4 g of a white solid.
Yield: 85%.
1H NMR (CDCl3) : δ 7.45-7.15 (m, 10 H), 5.12 (s, 1H),
5.08 (s, 2H), 3.77-3.62 (m, 1H),
3.21 (d, J=6 Hz, 2H), 2.99 (m, 1H),
2.77 (m, 2H).
IR (KBr): 3303, 3067, 1694, 1538, 1257, 741 cm-1.
MS (FD) m/e 329.
Analysis for C32H45N3O4S:
Calcd: C, 65.63; H , 5.81; N, 4.25;
Found: C, 65.48; H, 5.82; N, 4.29.
F. [3S-( 3R*, 4aR* , 8aR* , 2 ' S*, 3 ' S*)]-2-[3'-N- (benzyloxycarbonyl)amino-2'-hydroxy-4'- (phenyl)thio]butyl decahydroisoquinoline- 3-N-t-butyl carboxamide
The desired subtitled compound was prepared substantially in accordance with the procedure detailed in Procedure 2F, using 6.3 g (19 mmol) of the subtitled compound of Preparation 8E, 5 g (21 mmol) of [3S- (3R* , 4aR*, 8aR*) ]-decahydroisoquinoline-3-N-t-butylcarboxamide in 300 mL of ethanol to provide a residue. This residue was purified using flash chromatography (gradient eluent of 0-20% ethyl acetate in methylene chloride) to provide 4.3 g of a white solid.
Yield: 40%.
1H NMR (CDCl 3): δ 7.41-7.11 (m, 10H), 5.90 (d, J=5 Hz,
1H), 5.64 (s, 1H), 5.05 (d, J=4 Hz, 2H),
4.08-3.90 (m, 2H), 3.40 (d, J= 6, 2H),
3.05 (s, 1H), 2.95-2.85 (m, 1H), 2.62-2.45
(m, 2H), 2.28-2.15 (m, 2H), 2.05-1.88 (m,
2H), 1.78-1.10 (m, 7H), 1.29 (s, 9H).
IR(KBr) : 3330, 2925, 2862, 1706, 1661, 1520, 1454, 1246,
738, 694 cm-1.
MS (FD) : m/e 568 (M+), 467.
Analysis for C32H45N3O4S:
Calcd: C, 67.69; H, 7.99; N, 7.40;
Found: C, 67.64; H, 8.20; N, 7.45.
G. [3S-( 3R*, 4aR*, 8aR*, 2 'S*, 3 'S*) ] - 2 -[3'-amino-2'- hydroxy-4'-(phenyl)thio]butyl
decahvdroisoσuinoline-3-N-t-butyl carboxamide
The desired subtitled compound was prepared substantially in accordance with the procedure detailed in Procedure 2G using 1 g
(1.8 mmol) of the subtitled compound of Preparation 8F and 40 mL of a 30% hydrobromic acid in acetic acid solution, with the exception that the crude material was dissolved in 30 mL of methanol. To the resulting solution, was added 2 mL of
diethylamine and 2 mL of concentrated ammonium hydroxide and then the mixture was concentrated under reduced pressure to provide a residue. This residue was redissolved in water and ethyl acetate. The resulting layers were separated and the organic layer was washed sequentially with an aqueous sodium bicarbonate solution and brine, dried over sodium sulfate, filtered and then reduced to dryness under reduced pressure to provide a residue. This residue was purified using flash chromatography (gradient eluent of 0-10% methanol in chloroform (containing 3 drops of ammonium hydroxide per 1000 mL of chloroform) to provide 0.54 g of a white foam.
Yield: 71%. separate
1H NMR (CDCl3) : δ 7.41-7.16 (m, 5H), 6.07 (s, 1H),
3.78-3.70 (m, 1H), 3.45-3.38 (m, 1H),
3.03-2.84 (m, 3H), 2.38-2.20 (m, 3H),
2.00-1.05 (m, 12H), 1.33 (s, 9H).
IR (KBr): 2924, 2862, 1660, 1517, 1454, 1439, 737,
691 cm-1.
MS (FD) : m/e 434 (M+), 293.
Preparation 9
A. 3 -Methoxy-N-phenylbenzamide
A solution of 13.4 mL (147 mmol) of aniline in 30.7 mL of triethylamine was slowly added to a solution containing 25.1 g (147 mmol) of 3-methoxybenzoyl chloride in methylene chloride.
The resulting reaction mixture was reacted for approximately thirty minutes and then diluted with 1N sodium bicarbonate. The resultant layers were separated and the organic layer was washed sequentially with water, IM sodium hydroxide and then brine, dried over sodium sulfate, filtered and then reduced to dryness under reduced pressure to provide 31.6 g of an off-white solid.
Yield: 95%.
B. 3-Methoxy-2-methyl-N-phenylbenzamide
To a cold (-70°C) solution of 4.54 g (20 mmol) of the
subtitled compound of Preparation 9A and 5.11 g (44 mmol) of TMEDA in 70 mL of anhydrous tetrahydrofuran, was added 26.9 mL of a 1.56M solution of n-butyl lithium in hexane. The resultant reaction mixture was warmed to -15°C and stirred for approximately 45 minutes to provide a yellow slurry. The slurry was then recooled to -70°C and 2.89 g (20 mmol) of methyl iodide was added, resulting in the formation of a white precipitate. The reaction mixture was stirred overnight at room temperature, quenched with saturated ammonium chloride and diluted with diethylether. The resulting layers were separated and the organic phase washed sequentially with saturated ammonium chloride, water, saturated sodium bicarbonate and brine solutions. The organic extracts were then dried over sodium sulfate and concentrated to provide a white solid which was purified by recrystallization from a 2:1 ethyl acetate/hexane solution to provide 4.00 g of needles.
Yield: 99%.
1H NMR (CDCl3) : δ 2.36 (s, 3H), 3.88 (s, 3H),
3.89 (s, 1H), 6.90-7.70 (m, 8H).
IR (CHCl3) : 3424, 3013, 2963, 2943, 2840, 1678, 1597,
1585, 1519, 1463, 1438, 1383, 1321, 1264,
1240, 1178, 1083, 1069 cm-1.
MS(FD): m/e 241 (M+, 100). Analysis for C15H15NO2 :
Calcd: C, 74.67; H, 6.27; N, 5.80;
Found: C, 74.65; H, 6.29; N, 5.82.
C. 3-Hydroxy-2-methylbenzoic acid
A mixture of 1.21 g (5.00 mmol) of the subtitled compound of Preparation 9B, 35 mL of 5N hydrochloric acid and 20 mL of a 30% solution of hydrobromic acid in acetic acid were heated at reflux for 24 hours. After cooling, the reaction mixture was diluted with 100 mL of ethyl acetate and 100 mL of water. The resulting layers were separated and the organic layer was washed once with water and then basified to pH 11 using 0.5N sodium hydroxide The resulting layers were separated and the aqueous layer reacidified to pH 1 using 5N hydrochloric acid. The desired compound was then extracted from this aqueous layer using ethyl acetate. The ethyl acetate extracts were then washed with brine, dried over sodium sulfate, filtered, and then concentrated to provide a residue which after two concentrations from hexane yielded 750 mg of a white solid.
Yield: 98%.
1H NMR (DMSO-d6) : δ 2.26 (s, 3H), 6.98 (d, J=8.03 Hz, 1H),
7.02 (t, J=7.69 Hz, 1H), 7.15 (d, J=7.37
Hz, 1H), 9.55 (br.s, 1H).
IR (CHCI3) : 3600-2100 (br.), 3602, 2983, 1696, 1588,
1462, 1406, 1338, 1279, 1174, 1154, 1075,
1038, 920, 892, 854, 816 cm-1.
MS(FD): m/e 152 (M+, 100). Analysis for C8H8O3 :
Calcd: C, 63.15; H, 5.30;
Found: C, 63.18; H, 5.21.
Alternatively, the desired subtitled compound was prepared by adding 22.6 g (0.33 mol) of sodium nitrite in small portions to a cooled (-10°C) solution of 45 g (0.30 mol) of 3-amino-2-methylbenzoic acid and 106 g (58 mL; 1.08 mol) of concentrated sulfuric acid in 400 mL of water, while maintaining the
temperature below 7°C. The resultant reaction mixture was stirred for approximately 30 minutes at -10°C, poured into a solution of 240 mL of concentrated sulfuric acid in 1.2 L water, and then slowly heated to 80°C (heavy gas evolution occurs between the temperatures of 40-60°C). When the gas evolution stopped, the reaction mixture was cooled to room temperature and the subtitled compound was extracted five times with ethyl acetate (600 mL). The combined organic phases were combined with 500 mL of an aqueous saturated sodium carbonate soluton. The resultant layers were separated and the aqueous layer was acidified to pH 2 with concentrated hydrochloric acid. The titled compound was then extracted using ethyl acetate (500 mL) and the combined organic phases were washed with brine, dried over sodium sulfate, filtered and then concentrated under reduced pressure to provide a crude material. This material was purified using two recrystallizations from a ethyl acetate/chloroform mixture to provide 23.2 g of a light orange powder.
Yield: 52%. Preparation 10
A. 2-Ethyl-3-methoxy-N-phenylbenzamide
The subtitled compound was prepared substantially in
accordance with the procedure detailed in Preparation 9B, using 13.5 mL (21 mmol) of 1.56M n-butyl lithium, 2.27 g (10.0 mmol) of the subtitled compound of Preparation 9A, 2.56 g (22.0 mmol) of TMEDA and 1.56 g (10.0 mmol) of ethyl iodide in 50 mL of anhydrous tetrahydrofuran. The resultant crude material was purified by recrystallization from a 3:1 solution of ethyl acetate/hexane to provide 1.57 g of needles.
Yield: 62%.
1H NMR (CDCl3) : δ 1.22 (t, J=7.4 Hz, 3H), 2.81 (q, J=7.4
Hz, 2H), 3.88 (s, 3H), 6.96 (d, J=8.2 Hz,
1H), 7.05 (d, J=7.6 Hz, 1H), 7.10-7.45 (m,
4H), 7.50 (s, 1H), 7.62 (d, J=7.95 Hz,
1H).
MS(FD): m/e 255 (M+, 100).
Analysis for C16H17NO2:
Calcd: C, 75.27; H, 6.71; N, 5.49;
Found: C, 75.39; H, 6.72; N, 5.43.
B. 2-Ethyl-3-hydroxybenzoic Acid
A solution containing 180 mg (0.71 mmol) of the subtitled compound of Preparation 10A, 3 mL of 5N hydrochloric acid and 3 mL of a 30% solution of hydrobromic acid/acetic acid were heated for 20 hours in a sealed tube at 155°C. After cooling, the reaction mixture was diluted with ethyl acetate and water. The resulting layers were separated and the organic layer was extracted once with water and then basified to pH 11 using 0.5N sodium hydroxide. The resulting layers were separated and the aqueous layer
reacidified to pH 1 using 5N hydrochloric acid. The desired compound was then extracted from this aqueous layer using ethyl acetate. The ethyl acetate extracts were washed with brine, dried over sodium sulfate, filtered and then concentrated to provide 103 mg of a pale red solid.
Yield: 88%.
1H NMR (acetone-d6) : δ 1.16 (t, J=7.4 Hz, 3H), 2.98 (q,
J=7.4 Hz, 2H), 7.00-7.15 (m, 2H),
7.32-7.36 (m, 1H), 8.48 (br.s, 1H).
MS(FD): m/e 166 (M+, 100).
Preparation 11
A. 2-Fluoro-3-methoxy-N-phenylbenzamide
The desired subtitled compound was prepared substantially in accordance with the procedure detailed in Preparation 9B, by adding a solution of 3.15 g (10.0 mmol) of N-fluorobenzenesulfonimide in 5 mL of tetrahydrofuran to a solution containing 13.5 mL (21.0 mmol) of 1.56M n-butyl lithium, 2.27 g (10.0 mmol) of the subtitled compound of Preparation 9A and 2.56 g (22.0 mmol) of TMEDA in 50 mL of anhydrous tetrahydrofuran. The resultant crude material was recrystallized twice from a 2:1 solution of ethyl acetate/hexane and then further purified using radial chromatography (6 mm, 0.5% ethyl acetate in methylene chloride) to provide 540 mg of an off-white solid. Yield: 22%.
1H NMR (CDCl3) : δ 3.94 (s, 3H), 7.05-7.80 (m, 8H),
8.35-8.50 (m, 1H).
MS(FD): m/e 245 (M+, 100).
B. 2-Fluoro-3-hydroxybenzoic Acid
The subtitled compound was prepared substantially in
accordance with the procedure detailed in Preparation 9C, using a solution of 255 mg (1.02 mmol) of the subtitled compound of
Preparation 11A, 3 mL of 5N hydrochloric acid and 5 mL of a 30% solution of hydrobromic acid in acetic acid to provide 134 mg of a white solid.
Yield: 86%.
1H NMR (acetone-d6 ) : δ 7.05-7.50 (m, 5H).
MS (FD) : m/e 156 (M+, 100).
Preparation 12
A. 4-N-(Phenyl)carbamoyl pyridine
A solution of 22.8 mL (250 mmol) of aniline in 104.5 mL (750 mmol) of triethylamine was slowly added to a solution of 44.5 g (250 mmol) of 4-chloroformyl pyridinium hydrochloride in 500 mL of chloroform. The resulting reaction mixture was stirred overnight and then refluxed for 2 hours. After cooling, the reaction mixture was diluted with 600 mL of water which resulted in the formation of a precipitate. After adding 200 mL of isopropanol to the mixture, the resultant layers were separated and the organic layer was washed sequentially with 0.1N sodium hydroxide, water and then brine, dried over sodium sulfate, filtered and then concentrated under reduced pressure at 70°C to provide a white solid with a brown tinge. This solid was washed with 200 mL of ethyl acetate to provide 38.9 g of the desired subtitled compound. Yield: 78%.
B. 4-N-(Phenyl)carbamoyl pyridine N-oxide
To a hot (85-90°C) solution of 19.8 g (100 mmol) of the subtitled compound of Preparation 12A in 60 mL of glacial acetic acid, was slowly added 51 mL of hydrogen peroxide behind a blast shield. The resultant reaction mixture was reacted for
approximately four hours at 90°C, cooled to room temperature, diluted in about 60 mL of a mixture of isopropanol and chloroform and then basified to pH 12. The resultant layers were separated and the combined organic extracts were dried over sodium sulfate, filtered and concentrated under reduced pressure to provide a pale yellow solid. This solid was triturated with 250 mL of methylene chloride and reduced to dryness to provide 15.95 g of an off-white solid.
Yield: 75%.
C. 2-Chloro-4-N-(phenyl)carbamoyl pyridine
To a solution of 20.2 g (97.0 mmol) of phosphorus
pentachloride in 27 mL (289 mmol) of phosphorous oxychloride, was added 14.4 g (67.2 mmol) of the subtitled compound of Preparation 12B. The resultant reaction mixture was slowly heated to 130°C and reacted for approximately 40 minutes. The reaction mixture was cooled to room temperature and then concentrated under reduced pressure to provide a residue. This residue was redissolved in 80 mL of water and then diluted with 80 mL of aqueous potassium carbonate resulting in the formation of a yellow precipitate. The precipitate was isolated by filtration, dissolved in 250 mL of hot ethanol and then hot filtered to provide a dark yellow solution. This solution was concentrated under reduced pressure to
approximately 160 mL and then hot filtered again before the addition of about 50-60 mL of water. The resultant solution was cooled and the desired compound was isolated by recrystallization to provide 8.0 g of pale yellow and white needles.
Yield: 51%.
D. 2-Methoxy-4-N-(phenyl)carbamoyl pyridine
To a slurry of 4.09 g (18.0 mmol) of the subtitled compound of Preparation 12C in 30 mL of methanol, was added 2.92 g (42.0 mmol) of sodium methoxide. The resultant reaction mixture was refluxed for approximately eighteen hours, cooled and concentrated under reduced pressure to provide a solid. This solid was washed with water and triturated with cold benzene to provide 1.8 g of a solid. Analysis of this solid indicated that the reaction was not complete, so an additional 10.01 g (144 mmol) of sodium methoxide was added to the solid in methanol. The resultant reaction mixture was refluxed in methanol for fifteen hours and worked up identically to provide 300 mg of a solid. This solid was purified using column chromatography (2 mm plate; eluent of 40% ethyl acetate in hexane) followed by recrystallization from hot hexane to provide 140 mg of the desired compound.
Yield: 3%. E. 2-Methoxy-3-methyl-4-N-(phenyl)carbamoyl pyridine
The subtitled compound was prepared substantially in
accordance with the procedure detailed in Preparation 9B, using 260 mg (1.17 mmol) of the subtitled compound of Preparation 12D, 404 mL (2.68 mmol) of TMEDA, 1.78 mL (2.68 mmol) of n-butyl lithium, and 329 mL (5.61 mmol) of methyl iodide in 2 mL of tetrahydrofuran. The crude material was purified using radial chromatography (2 mm plate; eluent of 40% ethyl acetate in hexane) followed by recyrstallization from hot hexane to provide 140 mg of the desired subtitled compound.
F. 3-methyl-2-pyridone-4-carboxylic acid
A slurry of 150 mg (0.598 mmol) of the subtitled compound of Preparation 12E in 4 mL of 5N hydrochloric acid (aqueous) was refluxed for approximately five hours. After cooling, the
reaction mixture was concentrated under reduced pressure to provide a yellow oil. This oil was dissolved in 15 mL of water and the resultant solution was adjusted to pH 8 using potassium hydroxide and then diluted with 10 mL of toluene. The resulting layers were separated and the aqueous layer was acidified to pH 3.5 using a 5N hydrochloric acid solution and then concentrated under reduced pressure to provide a yellow solid. This solid was slurried in 2 mL of hot ethanol and filtered through a cotton plug. The filtrate was then reduced to dryness under reduced pressure to provide 130 mg of a solid. This solid was washed with 5 mL of hot 10% acetic acid in ethyl acetate to provide 17 mg of a solid which was then crystallized in ethanol to provide 6.8 mg of the desired subtitled compound.
Yield: 6%.
Preparation 13
2,6-Dichloro-3-hydroxy benzoic acid
Chlorine gas (20 g; 282 mmol) was slowly bubbled through a cold (-70°C) solution of 20 g (145 mmol) of 3-hydroxy benzoic acid in 100 mL of methanol, under nitrogen, resulting in a temperature increase to about -5°C. The reaction mixture was recooled and after approximately thirty minutes, the chlorine gas was flushed out with nitrogen. The reaction mixture was then warmed to room temperature and diluted with 100 mL of water. The desired titled compound was isolated by recrystallization to provide a white solid. This solid was purified by recyrstallization from 90 mL of water followed by recrystallization from 250 mL of benzene
containing 10 mL of acetone to provide 4.8 g of the desired titled compound.
Yield: 16%.
Preparation 14
2-Chloro-3-hydroxy benzoic acid
Chlorine gas (10.3 g; 147 mmol) was slowly bubbled through a cold solution of 20 g (145 mmol) of 3-hydroxy benzoic acid in 100 mL of methanol, under nitrogen, while maintaining the temperature below -60°C. After approximately thirty minutes, the chlorine gas was flushed out with nitrogen and the reaction mixture was allowed to warm to room temperature and diluted with 100 mL of water. The desired titled compound was isolated by recrystallization to provide a white solid. This solid was purified by
recyrstallization from 50 mL of water followed by
recrystallization from 130 mL of benzene containing 10 mL of acetone to provide the desired titled compound.
Preparation 15
A. 2-Methyl-3-methoxy benzoate methyl ester
A slurry of 306 mg (2.00 mmol) of the subtitled compound of Preparation 9C, 1.06 mL (20.0 mmol) of methyl iodide and 1.38 g (10.0 mmol) of potassium carbonate in 8 mL of acetone was refluxed for approximately 3 hours. Since the reaction was not complete, an additional 2 mL (37.7 mmol) of methyl iodide, 2 g (14.5 mmol) of potassium carbonate and 10 mL of acetone were added to the reaction mixture. After refluxing the mixture for approximately sixteen hours, the mixture was filtered. The filtrate was then concentrated under reduced pressure to provide a residue. This residue was dissolved in ethyl acetate and washed with water and then reduced to dryness under reduced pressure to provide 188 mg of material which was 88% desired product.
B. 2-Methyl-3-methoxy benzoic acid
A solution of 116 mg (4.86 mmol) of lithium hydroxide in 1 mL of water was added to a solution of 175 mg (0.97 mmol) of the subtitled compound of Preparation 15A in 3 mL of tetrahydrofuran. The resultant reaction mixture was stirred rapidly. When the reaction was substantially complete, as indicated by TLC, the reaction mixture was concentrated under reduced pressure to provide a residue. This residue was redissolved with 10 mL of hexane, 25 mL of water and 3 mL of 1N sodium hydroxide. The resulting layers were separated and the aqueous layer was diluted with ethyl acetate and then acidifed to pH 1 using 1M hydrochloric acid. The resulting layers were separated and the ethyl acetate layer was washed with brine, dried over sodium sulfate, filtered and reduced to dryness under reduced pressure to provide 73 mg of the desired subtitled compound.
Preparation 16
A. 2-Butyl-3-methoxy-N-phenylbenzamide
The desired subtitled compound was prepared substantially in accordance with the procedure detailed in Preparation 9B, using 11.95 mL of 1.51M of n-butyl lithium in hexanes (18.04 mmol), 1.95 g (8.95 mmol) of the subtitled compound of Preparation 9A, 2.19 g (18.89 mmol) of TMEDA and 1.60 g (9.45 mmol) butyl iodide in 30 mL of anhydrous tetrahydrofuran. The resultant crude material was purified using radial chromatography (4mm plate; eluent of 15% ethyl acetate in hexane) to provide 83 mg of a clear, colorless oil.
Yield: 3.5%.
1H NMR (CDCl3) : δ 0.89 (t, J=7 . 27 Hz, 3H), 1.36 (m, 2H),
1.56 (m, 2H), 2.78 (m, 2H), 3.84 (s, 3H),
6.92 (d, J=7.98 Hz, 1H), 7.00 (d, J=7.36 Hz , 1H), 7 . 11 - 7 . 22 (m, 2H) , 7 . 35 (t , 2H),
7.59 (m, 2H).
IR (CHCl3) : 3691, 3619, 3424, 3024, 3010, 2963, 2874, 1679,
1602, 1580, 1517, 1459, 1437, 1315, 1265,
1177, 1055, 877 cm-1.
MS(FD): m/e 283 (M+, 100).
B. 2-Butyl-3-hydroxybenzoic Acid
The desired subtitled compound was prepared substantially in accordance with the procedure detailed in Preparation 10B, using 80 mg (0.28 mmol) of the subtitled compound of Preparation 16A in 2 mL of 5N hydrochloric acid, and 2 mL of 30% hydrobromic acid in acetic acid to provide 44 mg of crude material which was used without further purification.
Yield: 60% (by 1H NMR).
1H NMR (CDCl3) : δ 0.96 (t, J=8.09 Hz, 3H), 1.44 (m, 2H),
1.59 (m, 2H), 3.03 (m, 2H), 6.99 (d,
J=8.03 Hz, 1H), 7.15 (t, J=7.77 Hz, 1H),
7.59 (d, J=6.85 Hz, 1H).
Preparation 17
A. 3-Methoxy-2-propyl-N-phenylbenzamide
The desired subtitled compound was prepared substantially in accordance with the procedure detailed in Preparation 9B, using 2.5 g (11.0 mmol) of the subtitled compound of Preparation 9A, 2.81 g (24.2 mmol) of TMEDA, 15.23 mL (23.13 mmol) of n-buttl lithium and 1.33 g (11.0 mmol) of allyl bromide in 30 mL of tetrahydrofuran to provide 2.5 g of crude material. This material was dissolved in 30 mL of absolute ethanol in the presence of 0.5 g of 10% palladium-on-carbon and the resulting mixture was reacted under a hydrogen atmosphere for approximately twelve hours. The mixture was then filtered over celite and the filtrate was
concentrated under reduced pressure to provide an orange oil.
This oil was purified using radial chromatography (6mm plate;
eluent of 10% ethyl acetate in hexane) to provide 438 mg of a white foam.
Yield: 15%.
1H NMR (CDCl3) : δ 0.94 (t, J=7.35 Hz, 3H), 1.62 (m, 2H),
2.75 (m, 2H), 3.84 (s, 3H),
6.92 (d, J=8.06 Hz, 1H),
7.00 (d, J=7.39 Hz, 1H), 7.16 (m, 2H),
7.34 (t, 2H), 7.59 (d, 2H),
7.69 (br.s, 1H).
B. 3-Hydroxy-2-propylbenzoic Acid
The desired subtitled compound was prepared substantially in accordance with the procedure detailed in Preparation 10B, using 438 mg (1.62 mmol) of the subtitled compound of Preparation 17A in 7 mL of 5N hydrochloric acid and 7 mL of 30% hydrobromic acid in acetic acid to provide a tan solid. This solid was purified by recrystallization from hot toluene to provide 84 mg of a tan solid.
Yield: 29%.
1H NMR (CDCl3) : δ 1.01 (t, J=7.33 Hz, 3H), 1.63 (m, 2H),
2.98 (m, 2H), 6.98 (d, J=7.97 Hz, 1H), 7 . 14 (t , J=7 . 86 Hz , 1H), 7 . 57 (d, J=7 . 28
Hz, 1H).
IR (KBr): 3383, 3047, 2962, 2872, 2641, 1698, 1458, 1412,
1341, 1296, 1278, 1223, 1174, 1086, 929, 815,
752 cm-1.
MS(FD): m/e 180 (M+, 100).
Preparation 18
A. 2-Isopropyl-3-methoxybenzonitrile
To a mixture of 2.76 g (0.115 mol) of magnesium in 75 mL of diethylether, was slowly added 24.31 g (0.143 mol) isopropyl iodide. The resulting reaction mixture was allowed to react until all of the magnesium was consumed. Then, a solution of 15.0 g (0.92 mol) of 2, 3-dimethoxy benzonitrile in 75 mL of diethylether was added over ninety minutes. The resulting reaction mixture was reacted overnight at room temperature and then refluxed for four hours. The resultant reaction mixture was then cooled to 0°C, and the top layer was decanted into saturated ammonium chloride and ice. The resultant layers were separated and the organic layer was washed sequentially with a dilute sodium hydroxide solution, water, and a dilute hydrochloric acid solution, dried over sodium sulfate, filtered and then concentrated to provide an orange oil. This oil was distilled under reduced pressure (5 inch vigreux column; 0.2mm Hg) to provide 6.25 g of an orange oil.
Yield: 39%. 1H NMR ( CDCl3 ) : δ 1 . 37 (d , J=6 . 47 Hz , 6H), 3 . 55 (m, 1H),
3 . 83 ( s , 3H), 7 . 04 (d, J=7 . 79 Hz , 1H) ,
7.18 (m, 2H).
IR (CHCl3) : 3690, 3617, 3019, 2968, 2939, 2841, 2228,
1577, 1470, 1457, 1440, 1387, 1363, 1265,
1100, 1070, 1045, 878 cm-1.
MS(FD): m/e 175 (M+, 100).
B. 3-Hydroxy-2-isopropyl benzoic acid
The desired subtitled compound was prepared substantially in accordance with the procedure detailed in Preparation 10B, using 330 mg (1.88 mmol) of the subtitled compound of Preparation 18A in 2 mL of 5N hydrochloric acid and 30% hydrobromic acid in acetic acid. The crude product was purified using radial chromatography (2mm plate; eluent of 3% methanol in methylene chloride containing 1% acetic acid) to provide 125 mg of a rose colored solid.
Yield: 37%.
1H NMR (CDCl3) : δ 1.40 (d, J=6.92 Hz, 6H), 3.62 (m, 1H),
6.83 (d, J=7.86 Hz, 1H), 7.06 (t, J=7.89
Hz, 1H), 7.24 (d, J=7.55 Hz, 1H).
IR (CHCl3) : 3599, 3025, 2965, 2876, 1695, 1603, 1584,
1466, 1454, 1404, 1360, 1275, 1234, 1166,
1148, 1086, 1057, 926 cm-1.
MS(FD): m/e 180 (M+, 100).
Analysis for C10H12O3:
Calcd: C, 66.65; H, 6.71;
Found: C, 66.53; H, 6.84. Preparation 19
3-methylisonicotinic acid
To a hot (155°C) solution of 10.7 g (0.1 mol) of 3,4-lutidine in 100 mL diphenylether, was added 18 g (0.16 mol) selenium dioxide in portions. After about 20 minutes, the reaction was heated to 185°C and allowed to react for approximately thirty minutes. After cooling, the reaction mixture was diluted with water and filtered. The filtrate was extracted with chloroform and the chloroform extracts were then concentrated under reduced pressure to provide 6.0 g of a pale brown solid.
Yield: 44%.
1H NMR (CDCl3) : δ 2.43 (s, 3H), 7.61 (d, J=4.98 Hz, 1H),
8.49 (d, J=4.99 Hz, 1H), 8.53 (s, 1H).
13C NMR (CDCl3) : δ 17.91, 123.21, 132.81, 138.15, 148.12,
152.71, 167.89 ppm.
IR (KBr): 3425, 2418, 1724, 1606, 1445, 1387, 1303, 1278,
1235, 1100, 1072, 850 cm-1.
MS(FD): m/e 138 (M+,100).
Preparation 20
5-quinolinecarboxylic acid
To a solution containing 15 g (0.1 mol) of
m-aminobenzoic acid, 27 g (0.13 mol) of m-nitrobenzene sulfonate and 25 g (0.4 mol) of glycerol, was added 125 g of 70% sulfuric acid. The resultant reaction mixture was refluxed for about 2.5 hours, diluted with 125 mL of water, basified to pH 9 using ammonium hydroxide, stirred overnight with 5 g of charcoal, and then filtered. The filtrate was then boiled with 5 g charcoal, filtered, and then cooled to 50°C, acidified to pH 5 with glacial acetic acid (15 mL), and filtered to provide a brown solid. This solid was boiled in 300 mL of water containing 10 mL of acetic acid and hot filtered to provide crude material. This material was purified using recrystallization from boiling acetic acid to provide 6.1 g of a pale brown solid.
Yield: 32%.
1H NMR (CDCl3) : δ 7.62 (m, 1H), 7.81 (t, J=7.82 Hz, 1H),
8.20 (m, 2H), 8.93 (d, J=3.79 Hz, 1H),
9.24 (d, J=8.58 Hz, 1H).
IR (KBr) : 2772, 2431, 1906, 1708, 1610, 1589, 1507, 1363,
1323, 1269, 1235, 1211, 1141, 1076, 1034, 999,
866, 807 cm-1.
MS(FD): m/e 173 (M+,100).
Preparation 21
1,2,3,4-tetrahydro-5-quinolinecarboxylic acid
A solution containing 1.03 g (5.95 mmol) of the titled compound of Preparation 20, 1.87 g (29.77 mmol) of ammonium formate in 100 mL of ethanol was purged with nitrogen for 10 minutes. To this solution was added 0.5 g of palladium black and the resultant reaction mixture was heated to 65°C. After
approximately three hours, the reaction mixture was filtered; the resultant filtrate was concentrated under reduced pressure to provide a residue. This residue was partitioned between water (pH 4) and a solution of 10% isopropanol in chloroform. The resulting layers were separated, and the organic layer was washed with water (pH=4), dried over sodium sulfate, filtered, and concentrated to provide crude material. This material was purified using radial chromatography (2mm plate; gradient eluent of 5-10% methanol in methylene chloride containing 1% acetic acid) to provide 87 mg of a tan solid.
Yield: 8%.
1H NMR (CDCl3) : δ 1.04 (m, 2H), 2.16 (t, 2H), 2.40 (m,
2H), 5.81 (d, J=8.05 Hz, 1H), 6.09 (t,
J=7.78 Hz, 1H), 6.23 (d, J=7.96 Hz, 1H).
IR(KBr) : 3296, 2965, 2929, 1691, 1597, 1474, 1461, 1443,
1350, 1305, 1279, 1236, 1184, 1159, 1106, 1073,
1022, 827 cm-1.
MS(FD): m/e 177 (M+,100).
Analysis for C10H11NO2:
Calcd: C, 67.78; H, 6.26; N, 7.90;
Found: C, 67.96; H, 6.10; N, 7.88.
Preparation 22
A. 3-Amino-2-methyl benzoate methyl ester
A solution of 10 g (66.2 mmol) of 3-amino-2-methyl benzoic acid and 20 g of p-toluenesulfonic acid monohydrate in 400 mL of methanol was refluxed overnight and then diluted with a mixture of ethyl acetate and 1M potassium carbonate. The resulting layers were cooled and then separated. The organic layer was then washed sequentially with 1M potassium carbonate, and brine, dried over sodium sulfate, filtered and then concentrated to provide 9.23 g of an orange oil.
Yield: 85%.
1H NMR (CDCl3) : δ 2.34 (s, 3H), 3.73 (br.s, 2H),
3.88 (s, 3H), 6.81 (d, J=7.96 Hz, 1H),
7.05 (t, J=7.78 Hz, 1H),
7.19-7.30 (m, 1H).
IR (CHCl3) : 3406, 3027, 3012, 2978, 2953, 1718, 1621,
1467, 1435, 1315, 1301, 1265, 1196, 1159,
1108, 1066, 1045, 810 cm-1.
MS(FD): m/e 165 (M+, 100).
B. 3-N-(Methylsulfonyl)amino-2-methyl benzoate methyl ester
To a cold (0°C) solution of 1.07 g (6.48 mmol) of the
subtitled compound of Preparation 22A in 50 mL of anhydrous methylene chloride, was added 1.18 g (6.80 mmol) of methylsulfonic anhydride. The resultant reaction mixture was reacted overnight at room temperature and then diluted with 100 mL of methylene chloride, washed twice with a sodium bicarbonate solution, dried over sodium sulfate, filtered, concentrated, redissolved in hexane and then concentrated again to provide a residue. This residue was then triturated three times in hexane and then reduced to dryness under reduced pressure to provide 1.46 g of a pink solid. This solid was then recrystallized using 20 mL of a 30% hexane/50% ethyl acetate/20% methanol mixture.
Yield: 57%. 1H NMR (DMSO-d6) : δ 2.25-2.45 (m, 4.5H), 2.97 (s, 1.5H) ,
3.80 (s, 3H), 7.23-7.63 (m, 3H),
9.24 (s, 1H).
IR (KBr): 3900-2400 (br.), 3298, 1713, 1466, 1320, 1290,
1265, 1248, 1210, 1183, 1156, 1047, 971, 964,
752, 563, 519 cm-1.
MS(FD): m/e 243 (M+, 100).
Analysis for C10H13NO4S:
Calcd: C, 49.37; H, 5.39; N, 5.76;
Found: C, 49.15; H, 5.54; N, 5.80.
C. 3-N-(Methylsulfonyl)amino-2-methyl benzoic acid
The desired subtitled compound was prepared substantially in accordance with the procedure detailed in Preparation 15B, using
400 mg (1.64 mmol) of the subtitled compound of Preparation 22B, and 118 mg (4.93 mmol) of lithium hydroxide in 20 mL of
tetrahydrofuran and 8 mL of water, to provide 206 mg of a white solid.
Yield: 55%.
1H NMR (DMSO-d6) : δ 2.43 (s, 3H), 2.97 (s, 3H),
7.26 (t, J=7.87 Hz, 1H),
7.43 (d, J=7.79 Hz, 1H),
7.60 (d, J=7.17 Hz, 1H).
IR (KBr): 3800-2200 (br.), 3252, 1685, 1404, 1334, 1309,
1277, 1149, 982, 965, 914, 780, 763, 748, 632,
518, 498 cm-1.
MS(FD): m/e 243 (M+, 100). Preparation 23
A. 3-methoxy-N-phenylbenzamide
A solution of 13.4 mL (147 mmol) of aniline in 30.7 mL of triethylamine was slowly added to a solution containing 25.1 g (147 mmol) of 3-methoxybenzoyl chloride in methylene chloride. The resulting reaction mixture was reacted for approximately thirty minutes and then diluted with 1N sodium bicarbonate. The resultant layers were separated and the organic layer was washed sequentially with water, 1M sodium hydroxide and then brine, dried over sodium sulfate, filtered and then reduced to dryness under reduced pressure to provide 31.6 g of an off-white solid.
Yield: 95%.
B. 3-Methoxy-2-methyl-N-phenylbenzamide
To a cold (-70°C) solution of 4.54 g (20 mmol) of the
subtitled compound of Preparation 23A and 5.11 g (44 mmol) of TMEDA in 70 mL of anhydrous tetrahydrofuran, was added 26.9 mL of a 1.56M solution of n-butyl lithium in hexane. The resultant reaction mixture was warmed to -15°C and stirred for approximately 45 minutes to provide a yellow slurry. The slurry was then recooled to -70°C and 2.89 g (20 mmol) of methyl iodide was added, resulting in the formation of a white precipitate. The reaction mixture was stirred overnight at room temperature, quenched with saturated ammonium chloride and diluted with diethylether. The resulting layers were separated and the organic phase washed sequentially with saturated ammonium chloride, water, saturated sodium bicarbonate and brine solutions. The organic extracts were then dried over sodium sulfate and concentrated to provide a white solid which was purified by recrystallization from a 2:1 ethyl acetate/hexane solution to provide 4.00 g of needles.
Yield: 99%.
1H NMR (CDCl3) : δ 2.36 (s, 3H), 3.88 (s, 3H),
3.89 (s, 1H), 6.90-7.70 (m, 8H).
IR (CHCl3) : 3424, 3013, 2963, 2943, 2840, 1678, 1597,
1585, 1519, 1463, 1438, 1383, 1321, 1264,
1240, 1178, 1083, 1069 cm-1.
MS(FD): m/e 241 (M+, 100).
Analysis for C15H15NO2 :
Calcd: C, 74.67; H, 6.27; N, 5.80;
Found: C, 74.65; H, 6.29; N, 5.82.
C. 2-Methyl-3-hydroxybenzoic acid
A mixture of 1.21 g (5.00 mmol) of the subtitled compound of Preparation 23B, 35 mL of 5N hydrochloric acid and 20 mL of a 30% solution of hydrobromic acid in acetic acid were heated at reflux for 24 hours. After cooling, the reaction mixture was diluted with 100 mL of ethyl acetate and 100 mL of water. The resulting layers were separated and the organic layer was washed once with water and then basified to pH 11 using 0.5N sodium hydroxide The resulting layers were separated and the aqueous layer reacidified to pH 1 using 5N hydrochloric acid. The desired compound was then extracted from this aqueous layer using ethyl acetate. The ethyl acetate extracts were then washed with brine, dried over sodium sulfate, filtered, and then concentrated to provide a residue which after two concentrations from hexane yielded 750 mg of a white solid. Yield: 98%.
1H NMR (DMSO-d6) : δ 2.26 (s, 3H), 6.98 (d, J=8.03 Hz, 1H),
7.02 (t, J=7.69 Hz, 1H),
7.15 (d, J=7.37 Hz, 1H),
9.55 (br.s, 1H).
IR (CHCl3) : 3600-2100 (br.), 3602, 2983, 1696, 1588,
1462, 1406, 1338, 1279, 1174, 1154, 1075,
1038, 920, 892, 854, 816 cm-1.
MS(FD): m/e 152 (M+, 100).
Analysis for C8H8O3 :
Calcd: C, 63.15; H, 5.30;
Found: C, 63.18; H, 5.21.
Alternative Preparation for
2-Methyl-3-hydroxybenzoic acid
To a cold (0°C) suspension of 0.54 g (3.3 mmol) of 2-methyl-3-aminobenzoic acid in 5 mL of water containing 0.65 mL of
concentrated sulfuric acid, was added 0.25 g (3.6 mmol) of solid sodium nitrite. After approximately 15 minutes the reaction mixture was poured into 20 mL of warm water containing 4 mL of concentrated sulfuric acid. The resultant reaction mixture was heated slowly to 90°C, resulting in gas evolution. After the gas evolution ceased, the solution was cooled to room temperature and extracted with ethyl acetate. The organic layers were combined, washed with 0.5N hydrochloric acid, dried and concentrated under reduced pressure. The crude residue was purified by rapid filtration through silica gel (eluent of 5% methanol in methylene chloride) to yield 350 mg of a white solid (m.p. 137-138°C).
Yield: 69%.
1H NMR (CDCl3) : δ 8.18 (br.s, 1H), 7.42 (d, J=7.7 Hz, 1H),
7.13 (t, J=7.9 Hz, 1H),
6.93 (d, J=7.9 Hz, 1H), 2.46 (s, 3H).
Analysis for C8H8O3 :
Calcd: C, 63.15; H, 5.29;
Found: C, 63.32; H, 5.36.
Preparation 24
A. N-(t-Butyl)-2-methylbenzamide
To a cold (0°C) solution of 139.2 g (0.9 mol) of o-toluoyl chloride in 1200 mL of methylene chloride at 25°C, under nitrogen, was slowly added 180.0 g (1.8 mol) of triethylamine followed by the dropwise addition of a solution containing 73.14 g (1.0 mol) of t-butylamine in 200 mL of methylene chloride. The resulting reaction mixture was warmed to room temperature and allowed to react for 2.5 hours. The reaction mixture was then diluted with 1800 mL of water. The resulting organic and aqueous layers were separated, and the organic layer was washed sequentially with 2N sodium hydroxide, 1.0N hydrochloric acid and brine, dried over magnesium sulfate, filtered and then reduced to dryness under reduced pressure to provide 167.6 g of the desired subtitled compound as an off-white solid (mp 77-78°C).
Yield: 97%. 1H NMR (CDCl3) : δ 1.41 (s, 9H), 2.41 (s, 3H),
5.54 (br.s, 1H), 7.13-7.30 (m, 4H).
IR (CHCI3) : 3430, 3011, 2971, 2932, 1661, 1510, 1484,
1452, 1393, 1366, 1304, 1216, 876 cm-1.
MS(FD): m/e 191 (M+), 191 (100).
Analysis for C12H17NO:
Calcd: C, 75.35; H, 8.76; N, 7.32;
Found: C, 75.10; H, 9.11; N, 7.20.
B. S-N-t-Butyl-2-(3-(N-benzyloxycarbonyl)amino-2- oxo-4-phenylbutyl)benzamide
To a solution of 7.0 g (36.5 mmol) of the subtitled compound of Preparation 24A in 200 mL of anhydrous tetrahydrofuran, was added 12.1 mL (80.3 mmol) of N,N,N',N'-tetramethylethylenediamine (TMEDA) was added via syringe. The resulting solution was cooled to -78°C and then 55.9 mL of sec-butyllithium was added dropwise via syringe while maintaining the temperature of the reaction under -60°C. The resulting reaction solution was then allowed to stir for approximately 1 hour at -78°C before the addition of a solution containing 5.00 g (14.6 mmol) of S-N-methoxy-N-methyl-2- (N-benzyloxycarbonyl) amino-3-phenylpropanamide in 50 mL of
anhydrous tetrahydrofuran was added via cannula while maintaining the reaction temperature below -65°C. The resulting reaction mixture was warmed to -20°C, quenched using 20 mL of saturated ammonium chloride and then diluted with 200 mL of diethylether. The organic and aqeous layers were separated and the organic layer was washed sequentially with water, 0.2N sodiumhydrogensulfate and brine, dried over sodium sulfate, filtered and then reduced to dryness under reduced pressure to provide a colorless oil. This oil was purified using flash chromatography (eluent of 25% ethyl acetate in methylene chloride) to provide 6.08 g of a colorless foam.
Yield: 88%.
[α]D -289.26° (c 0.12, MeOH).
1H NMR (CDCl3) δ 1.38 (s, 9H), 2.99 (dd, J=15; 6 Hz, 1H),
3.24 (dd, J=15; 6 Hz, 1H),
3.89 (d, J=18 Hz, 1H),
4.16 (d, J=18 Hz, 1H),
4.72 (dd, J=15, 6 Hz, 1H),
5.00-5.09 (m, 2H), 5.56 (d, J=6 Hz, 1H),
5.93 (br.s, 1H), 7.03-7.40 (m, 14H).
IR (CHCl3) : 3431, 3027, 3012, 2973, 1713, 1658, 1511,
1454, 1383, 1366, 1307, 1231, 1046 cm-1.
MS(FD) m/e 472 (M+), 218 (100).
Analysis for C29H32N2O4:
Calcd: C, 73.70; H, 6.82; N, 5.93;
Found: C, 73.41; H, 6.98; N, 5.83.
C. [2R- (2R*, 3S*) ]-N-t-Butyl-2-(3-(N- benzyloxycarbonyl)amino-2-hydroxy-4- phenylbutyl)benzamide
To a solution of 6.96 g (14.7 mmol) of the subtitled compound of Preparation 24B in 200 mL of absolute ethanol, under nitrogen, was added 2.78 g (73.5 mmol) of sodium borohydride. When the reaction was substantially complete, as indicated by thin layer chromatography (TLC), the reaction mixture was diluted with 200 mL of ethyl acetate and quenched by the dropwise addition of 20 mL of saturated ammonium chloride. The organic and aqueous layers were then separated and the organic layer was washed sequentially with 1N hydrochloric acid, saturated sodium bicarbonate solution and brine, dried over sodium sulfate, filtered and then reduced to dryness under reduced pressure to provide 6.4 g of a colorless oil. This oil was purified using flash chromatography (gradient eluent of 2-10% methylene chloride in ethyl acetate) to provide 5.12 g of the subtitled compound.
Yield: 74%.
[α]D +10.38° (c 0.10, MeOH).
1H NMR (CDCl3) : δ 1.40 (s, 9H), 2.79 (dd, J=12; 3 Hz, 1H),
2.90-2.98 (m, 2H), 3.04 (44, J=12, 3 Hz,
1H), 3.70-3.81 (m, 1H), 3.97 (m, 1H),
4.96-5.08 (m, 2H), 5.10 (d, J=9 Hz, 1H),
5.88 (d, J=6 Hz, 1H), 5.93 (s, 1H),
7.13-7.42 (m, 14H).
IR (CHCl3) : 3431, 3028, 3012, 2971, 1773, 1643, 1515,
1454, 1367, 1229, 1028 cm-1.
MS(FD): m/e 475 (M+), 475 (100).
Analysis for C29H34N2O4 :
Calcd: C, 73.39; H, 7.22; N, 5.99;
Found: C, 73.12; H, 7.48; N, 5.62.
D. [2R- (2R*, 3S*) ]-N-t-Butyl-2-(3-ammo-2-hydroxy- 4-phenylbutyl) benzamide
A suspension was prepared containing 41.0 g (120 mmol) of the subtitled compound of Preparation 24C and 500 mg of 10% palladium-on-carbon in 150 mL of absolute ethanol. This suspension was shaken under 60 psi hydrogen in a Parr shaker apparatus. The 10% palladium-on-carbon catalyst was then removed by filtration. The resultant filtrate was reduced to dryness under reduced pressure to provide 31.1 g of a light yellow foam. This compound was used without further purification.
Yield: 96%.
[α] +34.68° (c 1.0, MeOH).
1H NMR (CDCl3) : δ 1.46 (s, 9H),
2.71 (dd, J=13.7; 9.5 Hz, 1H),
2.84 (dd, J=13.3; 2.51 Hz, 1H),
2.95-3.06 (m, 2H), 3.23-3.29 (m, 1H),
3.84-3.90 (m, 1H), 6.23 (s, 1H),
7.19-7.37 (m, 12H).
IR (CHCl3) : 3440, 3382, 3007, 2970, 2934, 1643, 1516, 1454,
1367, 1213 cm-1.
MS(FD): m/e 341 (M+), 341 (100).
Preparation 25
A. 2R-2-N(t-Butoxycarbonyl)amino-3-naphth-2- ylthio propanoic acid
To a solution of 2.14 g (13.4 mmol) 2 -naphthalene thiol in 40 mL of anhydrous tetrahydrofuran at room temperature, was added a suspension of 0.54 g (13.5 mmol) of sodium hydride in mineral oil. After approximately 15 minutes, a solution of 2.5 g (13.4 mmol) of S-N(t-butoxycarbonyl)-serine-b-lactone in 30 mL of tetrahydrofuran was added dropwise. The resultant reaction mixture was allowed to react for approximately one hour and then was concentrated under reduced pressure to provide a gummy solid. This solid was purified using flash chromatagraphy (eluent of 1% methanol in ethyl acetate) to provide 4.35 g of a white solid.
Yield: 94%.
1H NMR (CDCl3) : δ 10.25 (s, 1H), 7.89 (s, 1H),
7.78 (m, 3H), 7.46 (m, 3H), 5.39 (d, 1H),
4.61 (m, 1H), 3.49 (m, 2H), 1.37 (s, 9H).
B. 2R-N(Methoxy)-N(methyl) [2-N(t- butoxycarbonyl)amino-3-naphth-2- ylthiol propanamide
To a cold (0°C) solution containing 4.3 g (12.4 mmol) of the subtitled intermediate of Preparation 25A, 1.58 g (16.15 mmol) of N,O-dimethylhydroxylamine hydrochloride, 2.18 g (16.15 mmol) of 1-hydroxybenzotriazole hydrate (HOBT·H2O), 2.24 mL (16.15 mmol) of triethylamine and 2.73 mL (24.86 mmol) N-methylmorpholine in 100 mL of methylene chloride, was added 2.62 g (13.67 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC). The resulting reaction mixture was allowed to react at room
temperature overnight. The reaction mixture was diluted with 100 mL of hexane, washed sequentially with 200 mL of a saturated sodium bicarbonate solution and 200 mL of brine. The resulting layers were separated and the organic layer was dried over sodium sulfate, filtered and then concentrated under reduced pressure to provide a clear yellow oil.
1H NMR (CDCl3) : δ 7.90 (s, 1H), 7.80 (m, 3H),
7.49 (m, 3H), 5.41 (d, 1H), 4.92 (m, 1H),
3.59 (s, 3H), 3.18-3.46 (m, 2H),
3.05 (s, 3H), 1.42 (s, 9H).
MS (FD) : m/e 391 (M+), 390 (100). C. 3R-N(t-Butyl)-2-[2'-oxo-3'-N(t- butoxycarbonyl)amino-4'-naphth-2-ylthio]butyl
benzamide
To a cold (-78°C) solution containing 8.60 g (45 mmol) of the subtitled compound of Preparation 24A, and 14.2 mL (95 mmol) of TMEDA in 100 mL of anhydrous tetrahydrofuran and under an inert atmosphere, was slowly added 111 mL (95 mmol) of a 0.85M solution of sec-butyllithium in hexanes, via syringe. The internal
temperature of the reaction vessel was monitored during the addition of the sec-butyllithium to ensure that the temperature did not exceed -57°C. After allowing the resultant reaction mixture to react for approximately one hour at -78°C, a solution of 7.90 g (20 mmol) of the subtitled intermediate of Preparation 2B in 80 mL of tetrahydrofuran was added dropwise. When the addition was complete, the reaction was warmed to -20°C and then was quenched by the addition of a saturated ammonium chloride solution. The resulting mixture was then diluted with 600 mL of diethylether. The resulting layers were separated and the organic layer was washed sequentially with a IM sodium bisulfate solution and a brine solution, dried over sodium sulfate, filtered and then concentrated under reduced pressure to provide a yellow oil. This oil was purified using flash chromatography (gradient eluent of 10-50% ethyl acetate in hexane) to provide 8.5 g of the desired subtitled intermediate.
Yield: (82%).
1H NMR (CDCl3) : δ 7.90 (s, 1H), 7.79 (t, 3H),
7.48 (m, 3H), 7.40 (d, 1H), 7.29 (m, 2H), 7.05 (d, 1H), 5.94 (br.s, 1H),
5.65 (m, 1H), 4.65 (d, 1H),
4.24 (d, J=17 Hz, 1H),
3.86 (d, J=17 Hz, 1H), 3.66 (m, 1H),
3.40 (m, 1H), 1.42 (s, 9H), 1.39 (s, 9H) .
MS (FD) : m/e 521 (M+) , 521(100) .
D. [(2R- (2R*,3R*)]-N(t-Butyl)-2-[2'-hydroxy-3'- N(t-butoxycarbonyl)amino-4'-naphth-2- ylthio] butyl benzamide
To a solution of 3.49 g (6.7 mmol) of the subtitled
intermediate of Preparation 25C in 150 mL of absolute ethanol, was added 0.51 g (13 mmol) of sodium borohydride and the resulting reaction mixture was allowed to react overnight at room
temperature. The reaction was then cooled to 0°C, quenched with a saturated ammonium chloride solution and diluted with 550 mL of methylene chloride. The resulting layers were separated and the organic layer was washed sequentially with 1NN hydrochloric acid,
2N sodium hydroxide and brine, dried over sodium sulfate, filtered and then concentrated under reduced pressure to provide a
colorless foam. This foam was purified using flash chromatography
(gradient eluent of 10-25% hexane in ethyl acetate) to provide
2.78 g of the desired subtitled intermediate.
Yield: 78%.
1H NMR (CDCl3) : δ 7.84 (s, 1H), 7.73 (m, 3H),
7.41 (m, 3H), 7.29 (t, 2H), 7.16 (t, 2H), 6 . 53 (s , 1H), 5 . 32 (d , 1H), 3 . 86 (m, 2H),
3.33 (m, 2H), 2.83 (m, 2H), 1.40 (s, 9H).
MS (FD) : m/e 523 (M+), 522 (100).
Analysis for C30H38N2O4S :
Calcd: C, 68.94; H, 7.33; N, 5.36;
Found: C, 68.65; H, 7.34; N, 5.15.
E. [(2R- (2R*, 3R*) ]-N(t-Butyl)-2-[2'-hydroxy-3'- amino-4'-naphth-2-ylthiol butyl benzamide
To a cold (0°C) solution of 2.89 g (5.53 mmol) of the subtitled intermediate of Preparation 25D in 100 mL of methylene chloride, was added 18 mL of trifluoroacetic acid. The resulting reaction mixture was allowed to react for approximately one hour.
The reaction mixture was then concentrated under reduced pressure to provide a foam. This foam was slurried in toluene and then concentrated under reduced pressure to provide a foam which was purified using flash chromatography (eluent of 5% methanol in methylene chloride) to provide 1.71 g of a white foam.
Yield: 74%.
1H NMR (CDCl3) : δ 7.75-7.85 (m, 4H), 7.24-7.51 (m, 7H),
6.06 (s, 1H), 3.75 (m, 1H), 3.61 (m, 1H),
3.07 (m, 2H), 2.95 (m, 2H), 1.47 (s, 9H).
MS(FD): m/e 423 (M+), 422(10.0).
Preparation 26
A. N-t-Butyl-2-methyl-1-naphthylamide
The desired subtitled compound was prepared substantially in accordance with the procedure detailed in Preparation 24A. The crude material was purified by recrystallization from a hexane/ ethyl acetate mixture to provide 20.99 g of colorless needles (mp
124-126°C).
Yield: 68%.
1H NMR (CDCl3) : δ 1.54 (s, 9H), 2.50 (s, 3H),
5.50-5.65 (br.s, 1H), 7.23-7.54 (m, 3H),
7.74 (d, J=10 Hz, 1H),
7.78 (d, J=10 Hz, 1H),
7.87 (d, J=10 Hz, 1H).
IR (CHCl3): 3424, 3010, 2969, 1660, 1512, 1503, 1454,
1366, 1291, 1263, 1221 cm-1.
MS(FD): m/e 241 (M+), 241(100).
Analysis for C16H19NO:
Calcd: C, 79.63; H, 7.94; N, 5.80;
Found: C, 79.90; H, 8.11; N, 5.76.
B. S-N-t-Butyl-2-(3-(N-benzyloxycarbonyl)amino-4- phenyl-2-oxobutyl)-1-naphthylamide
The desired subtitled compound was prepared substantially in accordance with the procedure detailed in Preparation 24A. The resultant residue was purified using flash chromatography
(gradient eluent of 10-30% ethyl acetate in hexane) to provide 7.43 g of a colorless foam.
Yield: 86%.
[α]D -6.86° (c 0.10, MeOH).
1H NMR (CDCl3) : δ 1.45 (s, 9H), 3.03 (dd, J=15, 8 Hz, 1H),
3.18 (dd, J=15, 5 Hz, 1H),
3.91 (d, J=16 Hz, 1H), 4.04 (d, J=16 Hz, 1H), 4.70-4.80 (m, 1H),
4.94-5.06 (m, 2H), 5.41 (d, J=8 Hz, 1H),
6.12-6.20 (br.s, 1H), 7.10-7.38 (m, 11H),
7.42-7.58 (m, 2H), 7.76-7.85 (m, 2H),
7.93 (s, J=9 Hz, 1H).
IR (CHCl3) : 3420, 3029, 3012, 2970, 1713, 1658, 1505,
1455, 1367, 1232, 1045 cm-1.
MS(FD): m/e 522 (M+), 522(100).
Analysis for C33H34N2O4 :
Calcd: C, 75.84; H, 6.56; N, 5.36;
Found: C, 75.56; H, 6.74; N, 5.17.
C. [2R- (2R*,3S*)]-N-t-Butyl-2-(3-(N- benzyloxycarbonyl)amino-3-phenylmethyl-2- hydroxypropyl)-1-naphthylamide
The desired subtitled compound was prepared substantially in accordance with the procedure detailed in Preparation 24C. The resultant material was purified using flash chromatography
(gradient eluent of 2-10% ethyl acetate in methylene chloride) to provide 5.50 g of a colorless foam.
Yield: 74%.
[α]D +11.85° (c 0.20, MeOH).
1H NMR (CDCl3) : δ 1.54 (s, 9H), 2.85-3.15 (m, 4H),
3.85-3.95 (m, 1H), 4.00-4.13 (m, 2H),
4.90-5.34 (m, 3H), 5.85-5.95 (m, 1H),
7.05-7.60 (m, 15H), 7.81 (d, J=9 Hz, 2H),
7.91 (d, 9 Hz, 2H).
IR (CHCl3) : 3420, 3012, 2970, 1713, 1643, 1515, 1454,
1367, 1219, 1209, 1028 cm-1. MS(FD): m/e 524 (M+), 524(100).
Analysis for C33H36N2O4:
Calcd: C, 75.55; H, 6.92; N, 5.34;
Found: C, 75.41; H, 7.16; N, 5.14.
D. [2R- (2R* , 3S* )]-N-t-Butyl-2-(3-amino-2- hydroxypropyl)-1-naphthylamide
The desired subtitled compound was prepared substantially in accordance with the procedure detailed in Preparation 24D. The crude filtrate was concentrated to provide 1.30 g of a colorless foam which was used without any further purification.
Yield: 92%.
Preparation 27
A. 2-Iodo-4-hydroxymethyl toluene
To a solution of 5.0 g (19.1 mmol) of 2-iodo-3-methyl benzoic acid in 50 mL of anhydrous tetrahydrofuran, was slowly added 22 mL of a 1M borane solution in tetrahydrofuran. The resultant
reaction mixture was reacted for approximately ninety minutes and then was quenched with ethanol resulting in the evolution of hydrogen gas. The mixture was diluted with ethyl acetate. The resulting layers were separated and the organic layer was washed sequentially with sodium bicarbonate and brine, dried over sodium sulfate, filtered and crystallized from a hexane/ethyl acetate mixture to provide 120 mg of the desired subtitled compound.
B. 2-Methyl-5-hydroxymethyl benzoic acid
A mixture of 142 mg (5.92 mmol) of lithium hydroxide and 249 mg (1.48 mmol) of the subtitled compound of Preparation 27A in a 3:1 tetrahydrofuran/water mixture were reacted for approximately twenty four hours. When the reaction was complete, as indicated by TLC, the reaction mixture was concentrated under reduced pressure and acidifed by the addition of 1N hydrochloric acid. The mixture was diluted with ethyl acetate and the resulting layers were separated. The organic layer was washed with brine, dried over sodium sulfate, filtered and reduced to dryness to provide 70 mg of the desired subtitled compound.
Preparation 28
2-Methyl-3-methylamino benzoic acid
To a solution of 500 mg (2.5 mmol) of 2-methyl-3-amino benzoate methyl ester in 5 mL of dimethylformamide, was added 387 mg (2.7 mmol) of methyl iodide and 700 mg (5.4 mmol) of
diisopropylethylamine. The resultant reaction mixture was heated to 70°C for approximately two hours and then poured into 10 mL of IN potassium hydroxide. After about sixteen hours, the mixture was acidified to pH 6 by the addition of 2N hydrochloric acid. The desired titled compound was extracted into ethyl acetate, dried and reduced to dryness under reduced pressure to provide 343 mg of a white solid (m.p. 165-167°C).
Yield: 84%.
1H NMR (CDCl3) : δ 12.52 (br.s, 1H),
7.38 (d, J=7.8 Hz, 1H),
7.25 (t, J=7.9 Hz, 1H),
6.93 (d, J=7.8 Hz, 1H), 2.92 (s, 3H),
2.21 (s, 3H). Analysis for C9H11NO2 :
Calcd: C, 65.44; H, 6.71; N, 8.48;
Found: C, 65.62; H, 6.84; N, 8.26.
Preparation 29
A. 2-Methyl-5-amino benzoic acid
The desired titled compound was prepared by reducing 2-methyl-5-nitrobenzoic acid using a tin/hydrochloric acid mixture (m.p. 142-144°C).
Yield: 75%
1H NMR (DMSO-d6) : δ 12.67 (br.s, 1H), 7.23 (s, 1H),
7.04 (d, J=8.2 Hz, 1H),
6.82 (d, J=7.9 Hz, 1H), 3.25 (s, 2H),
2.40 (s, 3H).
Analysis for C8H9NO2 :
Calcd: C, 63.57; H, 6.00; N, 9.27;
Found: C, 63.81; H, 6.24; N, 9.06.
B. 2-Methyl-5-hydroxybenzoic acid
The desired subtitled compound was prepared substantially in accordance with the procedure detailed in Alternate Preparation 23C, using the subtitled compound of Preparation 29A.
Yield: 65% (m.p. 136-139°C).
1H NMR (DMSO) : δ 12.77 (br.s, 1H), 9.46 (br. s, 1H),
7.26 (s, 1H), 7.12 (d, J=8.3 Hz, 1H),
6.85 (d, J=8.1 Hz, 1H), 2.41 (s, 3H). Analysis for C8H8O3 :
Calcd: C, 63.15; H, 5.29;
Found: C, 63.27; H, 5.22.
Preparation 30
A. 5-Cyanoisoquinoline
To a cold (0°C) solution of 10.0 g (61.4 mmol) of 5-aminoisoquinoline in 288 mL of 1.5N hydrochloric acid, was added 15 mL of 5.2M sodium nitrite in water. After approximately 5 minutes, a cool saturated solution of sodium bicarbonate was added to the reaction mixture until the reaction solution tested
negative using the iodide and starch paper test. The resultant solution was poured into a cold (0-5°C) biphasic mixture
containing 300 ml of toluene and 150 mL of an aqueous solution containing 8.4 g (177 mmol) of sodium cyanide and 7.6 g (85 mmol) of copper cyanide. The resultant reaction mixture was warmed to room temperature, reacted for approximately 1 hour, and then diluted with a mixture of ethyl acetate and water. The resulting layers were separated, and the organic phase was dried over sodium sulfate, filtered, and then reduced to dryness under reduced pressure to provide 5.9 g of a yellow solid.
Yield: 56%.
1H NMR (CDCl3) : δ 9.38 (s, 1H), 8.76 (d, J=5.89 Hz, 1H),
8.25 (d, J=8.29 Hz, 1H),
8.13 (d, J=8.30 Hz, 1H), 8 . 03 (d, J=8 . 59 Hz , 1H),
7.71 (t, J=7.78 Hz, 1H);
IR (KBr): 3433, 3090, 3026, 2924, 2226, 1618, 1574, 1495,
1433, 1373, 1277, 1225, 1034, 829, 766, 714.
B. 5-Carboxyisoquinoline
A solution of 6.5 g (42 mmol) of the subtitled compound of Preparation 30A in 55 mL of concentrated hydrochloric acid was heated to 155°C in a sealed tube for 5.5 hours and then was cooled to room temperature, and then reduced to dryness to provide a solid. This solid was redissolved in 300 mL of water, and the resultant solution was adjusted to pH 6 using a dilute ammonium hydroxide solution, resulting in the precipitation of a brown solid. This solid was isolated using filtration, azeotroped with benzene, and then dried at 130°C under reduced pressure for approximately 3 hours to provide 5.7 g of a fine dark tan powder (m.p. 270-272°C).
Yield: 78%.
1H NMR (DMSO) : δ 13.4 (br.s, 1H),
8.69 (d, 1H, J=6.00 Hz),
8.58 (d, 1H, J=4.6 Hz),
8.40 (d, 1H, J=7.37 Hz),
8.36 (d, 1H, J=8.12 Hz),
7.74 (t, 1H, J=7.76);
IR (KBr) : 3460, 3014, 2930, 2851, 2777, 2405, 1912, 1711,
1622, 1574, 1493, 1427, 1375, 1264, 1211, 1152,
1044. C. 5-Carboxyisoquinoline pentafluorophenylester
To a cold (0°C) solution of 1.53 g (7.39 mmol) of 1,3-dicyclohexylcarbodiimide (DCC) in 60 mL of ethyl acetate, was added 1.28 g (7.39 mmol) of the subtitled compound of Preparation 30B, and 4.08 g (22.17 mmol) of pentafluorophenol in 30 mL of ethyl acetate. The resultant reaction mixture was reacted for approximately 6 hours at 0°C and then filtered through celite. The resultant filtrate was washed sequentially with 1N sodium hydroxide, water, and brine, and then concentrated under reduced pressure to provide a white solid. This solid was purified using column chromatography (silica; eluent of 33% ethyl acetate in hexanes) to provide 1.80 g of the desired subtitled compound, (m.p. 142-144°C).
Yield 72%.
1H NMR (CDCl3) : δ 9.38 (s, 1H), 8.74 (m, 3H),
8.34 (d, J=8.1 Hz, 1H),
7.78 (t, J=7.7 Hz, 1H);
IR (KBr): 3422, 3021, 2089, 1752, 1622, 1522, 1215, 758.
Analysis for C16H6NO2F5·0.3CH2Cl2:
Calcd: C, 57.30; H, 2.17; N, 4.03.
Found: C, 57.40; H, 2.10; N, 4.33.
Preparation 31
5-Carboxyquinoline pentafluorophenylester
The desired subtitled compound was prepared substantially in accordance with the procedure detailed in Preparation 30C, using 0.236 g (1.36 mmol) of 5-carboxyquinoline, 0.746 g (4.05 mmol) of pentafluorophenol, and 0.571 g (2.76 mmol) of DCC in 25 mL of ethyl acetate, with the exception that the reaction mixture was allowed to react for 48 hours. The resultant crude material was purified using column chromatography to provide 0.40 g of a white solid.
Yield 87%.
1H NMR (CDCl3) : δ 9.33 (d, J=8.54 Hz, 1H),
9.03 (dd, J=4.16, 1.28 Hz, 1H),
8.63 (d, J=7.25 Hz, 1H),
8.47 (d, J=8.53 Hz, 1H);
7.87 (t, J=7.96 Hz, 1H),
7.61 (dd, J=8.76, 4.18 Hz, 1H);
IR (KBr) : 3472, 2667, 2461, 1749, 1520, 1319, 1259, 1182,
1145, 1105, 1005, 947, 812.
Preparation 32
1H-indoline-4-carboxylic acid
To a cold (10°C) solution containing 100 mg (0.62 mmol) of indole-4-carboxylic acid in 5 mL of acetic acid, was added 390 mg (6.2 mmol) of solid sodium cyanoborohydride. The resultant mixture was reacted at room temperature for approximately 16 hours and then diluted with water. The desired compound was extracted from this solution using methylene chloride and the organic extracts were then dried over sodium sulfate and filtered. The crude material was purified using column chromatography (silica; eluent of 1% methanol in methylene chloride) to provide 12 mg of the titled compound. (m.p. 97-98°C). Yield : 12% .
1H NMR ( CDCl3 ) : δ 7 . 48 (d , J=8 . 8 Hz , 1H) ,
7 . 34 ( t , J=8 . 6 Hz , 1H),
6.88 (d, J=8.8 Hz, 1H), 3.59 (m, 4H).
Analysis for C9H9NO2 :
Calcd: C, 66.25; H, 5.56; N, 8.58.
Found: C, 66.36; H, 5.82; N, 8.42.
Preparation 33
A. 2,3-Dimethoxy-6-chlorotoluene
To a mixture of 25 g (0.16 mmol) of 1-methyl-2,3-dimethoxybenzene in 25 mL of acetic acid, was slowly added 26.4 g (0.33 mmol) of 1-chloromethylmethylether. The resultant reaction mixture was reacted overnight at 30°C and then diluted with cold water, resulting in the formation of a precipitate. This
precipitate was purified by recrystallization from hot hexanes and then reduced to dryness under reduced pressure to provide 20.3 g of a white solid (m.p. 69-70°C).
Yield: 62%.
1H NMR (CDCl3) : δ 7.01 (d, J=6.1 Hz, 1H),
6.75 (d, 4.62 (s, 2H), 3.85 (s, 3H),
3.76 (s, 3H), 2.37 (s, 3H).
Analysis for C10H13O2Cl:
Calcd: C, 59.93; H, 6.54;
Found: C, 59.87; H, 6.43. B. 2-Methyl-3,4-dimethoxybenzoic acid
To a mixture of 3.0 g (15 mmol) of the subtitled compound of Preparation 33A in 150 mL of water, was added 3.2 g (20 mmol) of solid potassium permangenate and 3.0 g (36 mmol) of sodium
carbonate. The resultant reaction mixture was then heated to 80°C and allowed to react for approximately 24 hours. After cooling, the reaction mixture was filtered and diluted with ethyl acetate. The resultant layers were then separated and the aqueous layer was acidifed using 2N hydrochloric acid which resulted in the
formation of a precipitate. This precipitate was isolated using filtration and washed with cold hexane to provide 1.7 g of a white solid (m.p. 179-180°C).
Yield: 58%.
1H NMR (DMSO-d6) : δ 12.49 (br.s, 1H), 7.71 (br.s, 1H),
6.99 (br.s, 1H), 3.89 (s, 3H),
3.77 (s, 3H), 2.45 (s, 3H).
Analysis for C10H12O4:
Calcd: C, 61.28; H, 6.17;
Found: C, 61.36; H, 6.24.
C. 2-Methyl-3,4-dihydroxybenzoic acid
To a cold (0°C) mixture of 250 mL (1.3 mmol) of the subtitled compound of Preparation 33B in 5 mL of methylene chloride, was added 6.4 mL of a 6.4 mmol/1.0 m solution of boron tribromide in methylene chloride. The resultant reaction mixture was reacted for approximately 90 minutes and then diluted with 25 mL of 2N hydrochloric acid. The desired compound was extracted using ethyl acetate, and the organic extracts were dried over sodium sulfate, filtered, and concentrated to provide 197 mg of a tan solid (m.p.
200-201°C).
Yield: 92%.
1H NMR (DMSO) : δ 12.14 (br.s, 1H), 9.96 (br.s, 1H,),
8.34 (br.s, 1H), 7.27 (d, J=7.0 Hz, 1H),
6.67 (d, J=6.7 Hz, 1H), 2.37 (s, 3H).
Analysis for C8H8O4 :
Calcd: C, 57.14; H, 4.80;
Found: C, 57.34; H, 4.76.
Example 1
[3S-( 3R* , 4aR* , 8aR* , 2 ' S* , 3 'R*)]-2-[2'-Hydroxy-3'- phenylmethyl-4'-aza-5'-oxo-5'-(2''-fluoro-3''- hydroxyphenyl)pentyl] decahydroisoquinoline-3-N-t- butylcarboxamide
To a cold (-10°C) solution containing 80 mg (0.20 mmol) of the subtitled compound of Preparation 1B, 31 mg (0.20 mmol) of
Preparation 11B and 27 mg (0.20 mmol) of 1-hydroxybenzotriazole hydrate (HOBT·H2O) in 3 mL of anhydrous tetrahydrofuran, was added
41 mg (0.20 mmol) of 1,3-dicyclohexylcarbodiimide (DCC). The reaction mixture was stirred for 36 hours at room temperature and then concentrated under reduced pressure. The resultant residue was redissolved in ethyl acetate, filtered through celite, washed sequentially with saturated sodium bicarbonate and brine, dried over sodium sulfate, filtered and concentrated. The crude product was purifed using radial chromatography (1mm plate; gradient eluent of 2-5% methanol in methylene chloride) to provide 79 mg of a white foam.
Yield: 73%. [α]D -90.80° (c=0.333, MeOH) .
1H NMR (CDCl3) : δ 1.24 (s, 9H), 1.16-2.05 (m, 14H),
2.20-2.40 (m, 2H), 2.55-2.70 (m, 2H),
2.90-3.04 (m, 2H), 3.10-3.25 (m, 1H),
4.03 (br.s, 1H), 4.51 (br.s, 1H),
6.01 (s, 1H), 6.90-7.35 (m, 9H).
IR (CHCl3): 3580, 3550-3100 (br.), 2929, 2865, 1662, 1596,
1521, 1472, 1455, 1394, 1368, 1293, 1157,
1047, 879, 839 cm-1.
MS(FD): m/e 540 (M+, 100).
HR MS (FAB): m/e for C31H43N3O4F:
Calcd: 540. 3238;
Found: 540.3228.
Example 2
[3S-(3R*, 4aR*, 8aR*, 2'S*, 3'R*)]-2-[2'-Hydroxy-3'- phenylmethyl-4'-aza-5'-oxo-5'-(2''-chloro-pyrid-3''- yl)pentyl] decahydroisoquinoline-3-N-t-butylcarboxamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 1, using 80 mg (0.20 mmol) of the subtitled compound of Preparation IB, 31 mg (0.20 mmol) of
2-chloronicotinic acid, 41 mg (0.20 mmol) of DCC and 27 mg (0.20 mmol) of HOBT·H2O in 3 mL of anhydrous tetrahydrofuran. The crude product was purified using radial chromatography (1 mm plate;
gradient eluent of 0-5% methanol in methylene chloride) to provide
58 mg of an off-white foam.
Yield: 54%. [a] -70.64° (c = 0.224, MeOH) .
1H NMR (CDCl3) : δ l.16 (s, 9H), 1.17-2.10 (m, 12H),
2.25-2.37 (m, 2H), 2.52-2.70 (m, 2H),
2.97-3.06 (m, 2H), 3.44-3.53 (m, 2H),
4.05 (br.s, 1H), 4.60-4.70 (m, 1H),
5.64 (s, 1H), 7.18-7.38 (m, 7H),
7.60-7.63 (m, 1H), 8.38-8.40 (m, 1H).
IR (CHCl3) : 3618, 3428, 3650-3100 (br.), 2929, 1667, 1583, 1515, 1455, 1401, 1368, 1247, 1071, 1046,
877 cm-1.
MS(FD): m/e 541 (M+), 440 (100).
Analysis for C30H41N4O3Cl :
Calcd: C, 66.59; H, 7.64; N, 10.35; Cl, 6.55;
Found: C, 66.60; H, 7.58; N, 10.17; Cl, 6.84.
Example 3
[3S-(3R*,4aR*,8aR*,2'S*,3'R*)]-2-[2'-Hydroxy-3'- phenylmethyl-4'-aza-5'-oxo-5'-(2''-ethyl-3''- hydroxyphenyl)pentyl] decahydroisoquinoline-3-N-t- butylcarboxamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 1, using 80 mg (0.20 mmol) of the subtitled compound of Preparation IB, 35 mg (0.21 mmol) of the subtitled compound of Preparation 10B, 41 mg (0.20 mmol) of
DCC and 27 mg (0.20 mmol) of HOBT·H2O in 3 mL of anhydrous tetrahydrofuran. The crude product was purified using radial chromatography (1 mm plate; gradient eluent of 3-5% methanol in methylene chloride) to provide 71 mg of an off-white foam.
Yield: 65%. [α] : -76.29° (c=0.291, MeOH) .
1H NMR (CDCl3) : δ 1.03 (t, J=7.42 Hz, 3H), 1.21 (s, 9H),
1.22-2.10 (m, 11H), 2.24-2.35 (m, 2H),
2.44-2.70 (m, 4H), 2.96-3.05 (m, 2H),
3.26-3.40 (m, 1H), 3.96-4.23 (m, 2H),
4.53 (br.s, 1H), 5.80 (s, 1H),
6.30-6.56 (m, 3H), 6.77 (d, J=7.77 Hz,
1H), 6.88 (t, J=7.75 Hz, 1H), 7.19-7.39
(m, 5H) .
IR (CHCl3) : 3700-3100 (br.), 3429, 3327, 3011, 2971, 2930,
2867, 1662, 1604, 1585, 1514, 1455, 1394,
1368, 1278, 1155, 1087, 1046, 910 cm-1.
MS(FD): m/e 550 (M+, 100).
HR MS (FAB) : m/e for C33H48N3O4:
Calcd: 550.3645;
Found: 550.3664.
Example 4
[2S-(2R*,2'S*,3'R*)]-1-[2'-Hydroxy-3'-phenylmethyl-4'- aza-5'-oxo-5'-(2''-methyl-3''-hydroxyphenyl)pentyl]
pyrrolidine-2-N-t-butylcarboxamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 1, using 55 mg (0.16 mmol) of the subtitled compound of Preparation 3E, 25 mg (0.16 mmol) of the subtitled compound of Preparation 9B, 33 mg (0.16 mmol) of DCC and 22 mg (0.16 mmol) of HOBT·H2O in 2 mL of anhydrous
tetrahydrofuran. The crude product was purified using radial chromatography (1 mm plate; gradient eluent of 4-8% methanol in methylene chloride) to provide 52 mg of a white solid.
Yield: 69%.
[α]D: -72.15° (c=0.211, MeOH).
1H NMR (CD3OD) : δ 1.33 (s, 9H), 1.70-1.90 (m, 4H),
2.06-2.20 (m, 1H), 2.45-3.30 (m, 8H),
3.60-3.70 (m, 1H), 4.25-4.38 (m, 1H),
6.48 (d, J=8.8 Hz, 1H),
6.74 (d, J=7.7 Hz, 1H),
6.93 (t, J=7.7 Hz, 1H),
7.15-7.32 (m, 5H).
IR (CHCl3) : 3600-2700 (br.), 3450, 3255, 2968, 2928, 1653,
1632, 1588, 1513, 1454, 1364, 1291, 1233,
1064, 884, 836 cm-1.
MS(FD): m/e 468 (M+, 100).
Analysis for C27H37N3O4:
Calcd: C, 69.35; H, 7.98; N, 8.99.
Found: C, 69.54; H, 8.10; N, 9.19.
Example 5
[3S-( 3R* , 4aR* , 8aR* , 2 'S* , 3 'R*) ] - 2 -[2'-Hydroxy-3'- phenylmethyl-4'-aza-5'-oxo-5'-(pyrid-3''-yl-N- oxidyl)pentyl] decahvdroisoquinoline-3-N-t-butylcarboxamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 1, using 80 mg (0.20 mmol) of the subtitled compound of Preparation 1B, 28 mg (0.20 mmol) of nicotinic acid N-oxide, 41 mg (0.20 mmol) of DCC and 27 mg (0.20 mmol) of HOBT·H2O in 3 mL of anhydrous tetrahydrofuran. The crude product was purified using radial chromatography (1 mm plate;
gradient eluent of 5-10% methanol in methylene chloride) to provide 81 mg of a white foam.
Yield: 76%.
[α] : -104.39° (c=0.213, MeOH).
1H NMR (DMSO-d6) : δ 1.19 (s, 9H), 1.19-2.10 (m, 14H),
2.50-2.60 (m, 1H), 2.65-2.79 (m, 1H),
2.95-3.10 (m, 2H), 3.83 (br.s, 1H),
4.22-4.32 (m, 1H), 4.87 (d, J=5.5 Hz,
1H), 7.06-7.11 (m, 1H), 7.17-7.22 (m,
2H), 7.33-7.44 (m, 3H), 7.57 (d, J=8.0
Hz, 1H), 8.26 (d, J=6.4 Hz, 1H),
8.44-8.48 (m, 2H).
IR (CHCl3) : 3600-3100 (br.), 3428, 2930, 2864, 1669, 1603,
1515, 1479, 1455, 1432, 1394, 1368, 1300, 1279,
1245, 1135, 1083, 1046, 1017 cm-1.
MS(FD): m/e 522 (M+, 100).
Example 6
[2S-(2R*, 2 'S*, 3 'R*) ]-1-[2'-Hydroxy-3'- phenylmethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''- hydroxyphenyl)pentyl]piperidine-2-N-t-butylcarboxamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 1, using 100 mg (0.29 mmol) of the subtitled compound of Preparation 4F, 44 mg (0.29 mmol) of the subtitled compound of Preparation 9B, 59 mg (0.29 mmol) of DCC and 39 mg (0.29 mmol) of HOBT·H2O in 5 mL of anhydrous
tetrahydrofuran. The crude product was purified using radial chromatography (1 mm plate; gradient eluent of 1.5-7% methanol in methylene chloride) to provide 57 mg of an off-white foam.
Yield: 41%.
[α] : -58.90° (c=0.163, MeOH).
1H NMR (CD3OD) : δ 1.29 (s, 9H), 1.50-2.20 (m, 10H),
2.60-2.75 (m, 4H), 3.10-3.35 (m, 4H),
3.85-4.02 (m, 2H), 4.10-4.35 (m, 2H),
4.85 (s, 1H), 3.85-4.02 (m, 2H), 4.10-4.35
(m, 2H), 4.85 (s, 1H), 6.55 (d, J=7.29 Hz,
1H), 6.75 (d, J=7.83 Hz, 1H), 6.90-6.96
(m, 1H), 7.15-7.35 (m, 5H).
IR (CDCl3) : 3601, 3600-3100 (br), 3428, 3340, 3008, 2941,
2861, 1661, 1601, 1587, 1514, 1455, 1394,
1367, 1284, 1156, 1086, 1047, 832 cm-1.
MS(FD): m/e 482 (M+, 100).
Analysis for C28H39N3O4:
Calcd: C, 69.83; H, 8.16; N, 8.72.
Found: C, 69.84; H, 8.46; N, 8.50.
Example 7
[3S-( 3R* , 4aR* , 8aR* , 2 ' S* , 3 ' R*) ] - 2 -[2'-Hydroxy-3'- phenylmethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''- fluorophenyl)pentyl] decahydroisoquinoline-3-N-t- butylcarboxamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 1, using 80 mg (0.20 mmol) of the subtitled compound of Preparation 1B, 31 mg (0.20 mmol) of
3-fluoro-2-methylbenzoic acid, 41 mg (0.20 mmol) of DCC and 27 mg
(0.20 mmol) of HOBT·H2O in 3 mL of anhydrous tetrahydrofuran. The crude product was purified using radial chromatography (l mm plate; gradient eluent of 1.5-3% methanol in methylene chloride) to provide 40 mg of a white foam.
Yield: 37%.
[α] : -80.10° (c=0.132, MeOH).
1H NMR (CDCl3) : δ 1.13 (s, 9H), 1.13-2.10 (m, 16H),
2.20-2.35 (m, 2H), 2.50-2.70 (m, 2H),
2.95-3.05 (m, 2H), 3.53-3.58 (m, 1H),
3.98 (s, 1H), 4.03-4.10 (m, 1H), 5.68 (s,
1H), 6.83-7.07 (m, 3H), 7.10-7.40 (m, 5H).
IR (CHCl3) : 3650-3150 (br), 3429, 3030, 3008, 2930, 2863,
1672, 1608, 1514, 1455, 1394, 1368, 1277,
1046, 910, 830 cm-1.
MS(FD): m/e 538 (M+, 100).
HR MS (FAB) : m/e for C32H45N3O3F:
Calcd: 538.3445;
Found: 538.3469.
Example 8
[3S - .( 3R* , 4aR* , 8aR* , 2 ' S* , 3 'R*) ]-2-[2'-Hydroxy-3'-phenylmethyl- 4'-aza-5'-oxo-5'-(2''-chloro-3'',5''-dihydroxyphenyl)pentyl] decahydroisoquinoline-3-N-t-butylcarboxamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 1, using 100 mg (0.25 mmol) of the subtitled compound of Preparation 1B, 47 mg (0.25 mmol) of
2-chloro-3,5-dihydroxy benzoic acid, 51 mg (0.25 mmol) of DCC and
34 mg (0.25 mmol) of HOBT·H2O in 2 mL of anhydrous
tetrahydrofuran. The crude product was purified using radial chromatography (2 mm plate; gradient eluent of 2-10% methanol in methylene chloride) to provide 47 mg of a white solid.
Yield: 33%.
[α]D: -53.79° (c=0.097, MeOH).
1H NMR (CDCl3) : δ 0.5-3.10 (m, 32H), 3.70-4.60 (m, 2H),
6.00-7.50 (m, 8H).
IR (CHCl3) : 3700-3100 (br.), 2930, 2865, 1658, 1604, 1521,
1455, 1368, 1246, 1156, 1047, 1014, 856 cm-1.
MS(FD) : 572 (M+, 100).
Analysis for C31H42N3O5Cl :
Calcd: C, 65.08; H, 7.40; N, 7.34.
Found: C, 65.30; H, 7.35; N, 7.43.
Example 9
[3S-( 3R* , 4aR* , 8aR* , 2 ' S* , 3 'R*) ] - 2 - [2 '-Hydroxy-3'-phenylmethyl- 4'-aza-5'-oxo-5'-(2''-methyl-3'',5''-diaminophenyl)pentyl] decahydroisoquinoline-3-N-t-butylcarboxamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 1, using 100 mg (0.25 mmol) of the subtitled compound of Preparation 1B, 41 mg (0.25 mmol) of
3,5-diamino-2-methyl benzoic acid, 51 mg (0.25 mmol) of DCC and 34 mg (0.25 mmol) of HOBT·H2O in 2 mL of anhydrous tetrahydrofuran and 0.5 mL of dimethylformamide. The crude product was purified using radial chromatography (1 mm plate; gradient eluent of 1-10% methanol in methylene chloride) to provide 30 mg of a light orange foam.
Yield: 22% [α] -89.27° (c=0.137, MeOH) .
1H NMR (CDCl3) : δ 1.21 (s, 9H), 1.30-2.02 (m, 16H),
2.19-2.35 (m, 2H), 2.48-2.70 (m, 2H),
2.90-3.07 (m, 2H), 3.10-3.23 (m, 1H),
3.50 (br.s, 4H), 3.94 (br.s, 1H), 4.40-4.50 (m, 1H), 5.70 (s, 1H), 5.89-5.95 (m,
2H), 6.30 (d, J=8.4 Hz, 1H), 7.15-7.33 (m,
5H) .
IR (CHCl3) : 3600-3100 (br), 3029, 3005, 2928, 2865, 1664,
1621, 1513, 1455, 1392, 1367, 1276, 1244,
1171, 1047, 841 cm-1.
MS(FD): m/e 550 (M+, 100).
HR MS (FAB): m/e for C32H4gN5O3:
Calcd: 550.3757;
Found: 550.3762.
Example 10
[3S-(3R*,4aR*,8aR*,2'S*,3'R*)]-2-[2'-Hydroxy-3'-phenylmethyl- 4'-aza-5'-oxo-5'-(2''-methyl-3'',5''-dinitrophenyl)pentyl] decahydroisoquinoline-3-N-t-butylcarboxamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 1, using 100 mg (0.25 mmol) of the subtitled compound of Preparation 1B, 56 mg (0.25 mmol) of
3,5-dinitro-2-methyl benzoic acid, 51 mg (0.25 mmol) of DCC and 34 mg (0.25 mmol) of HOBT·H2O in 3 mL of anhydrous tetrahydrofuran.
The crude product was purified using radial chromatography (1 mm plate; gradient eluent of 0-3% methanol in methylene chloride) to provide 61 mg of an off-white foam. Yield: 41%.
[α] -105.96° (c=0.302, MeOH) .
1H NMR (CDCl3) : δ 1.02 (s, 9H), 1.02-2.60 (m, 20H),
2.90-3.06 (m, 2H), 3.21 (br.s, 1H),
3.60-3.75 (m, 1H), 4.05-4.20 (m, 1H),
4.65-4.80 (m, 1H), 5.47 (s, 1H),
7.20-7.50 (m, 5H), 8.00-8.20 (m, 2H),
8.56 (s, 1H).
IR (CHCl3) : 3621, 3500-3100 (br), 3428, 3024, 2977, 2931,
1665, 1615, 1539, 1455, 1347, 1278, 1245,
1047, 878 cm-1.
MS(FD): m/e 610 (M+, 100).
HR MS(FAB): m/e for C32H44N5O7:
Calcd: 610.3241;
Found: 610.3240.
Example 11
[3S-(3R*,4aR*,8aR*,2'S*,3'R*)]-2-[2'-Hydroxy-3'- phenylmethyl-4'-aza-5'-oxo-5'-(2''-chloro-3''- hydroxyphenyl)pentyl] decahydroisoquinoline-3-N-t- butylcarboxamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 1, using 116 mg (0.29 mmol) of the subtitled compound of Preparation 1B, 50 mg (0.29 mmol) of the titled compound of Preparation 14, 60 mg (0.29 mmol) of DCC and 39 mg (0.29 mmol) of HOBT·H2O in 4 mL of anhydrous
tetrahydrofuran. The crude product was purified using radial chromatography (1 mm plate; gradient eluent of 2.5-5% methanol in methylene chloride) to provide 83 mg of a white solid. Yield: 51%.
[α] -74.29° (c=0.140, MeOH) .
1H NMR (CDCl3) : δ 1.19 (s, 9H), 1.19-2.80 (m, 16H),
2.90-3.15 (m, 2H), 3.35 (br.s, 1H),
4.06 (br.s, 1H), 4.56 (br.s, 1H),
5.85 (br.s, 1H), 6.60-6.70 (m, 1H),
6.90-7.35 (m, 8H).
IR (CHCl3) : 3621, 3600-3100 (br), 3429, 2977, 2929, 1671,
1584, 1515, 1445, 1394, 1368, 1292, 1182,
1046, 878, 823 cm-1.
MS(FD): m/e 556 (M+, 100).
Analysis for C31H42N3O4Cl:
Calcd: C, 66.95; H, 7.61; N, 7.56.
Found: C, 66.76; H, 7.72; N, 7.69.
Example 12
[3S-{3R*,4aR*,8aR*,2'S*,3'R*)]-2-[2'-Hydroxy-3'-phenylmethyl- 4'-aza-5'-oxo-5'-(2''-methyl-3''-hydroxyphenyl)pentyl] decahydroisoquinoline-3-N-t-butylcarboxamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 1, using 261 mg (0.65 mmol) of the subtitled compound of Preparation 1B, 100 mg (0.65 mmol) of the subtitled compound of Preparation 9B, 134 mg (0.65 mmol) of
DCC and 88 mg (0.65 mmol) of HOBT·H2O in 6 mL of anhydrous
tetrahydrofuran and 0.2 mL of anhydrous dimethylformamide. The crude product was purified using radial chromatography (2 mm plate; gradient eluent of 1-5% methanol in methylene chloride) to provide 304 mg of a white solid. Yield: 87%.
[α] -75.00° (c=0.200, MeOH).
1H NMR (CDCl3) : δ 1.18 (s, 9H), 1.19-2.05 (m, 18H),
2.20-2.35 (m, 2H), 2.50-2.70 (tn, 2H),
2.90-3.05 (m, 2H), 3.22-3.35 (m, 1H),
3.96-4.05 (m, 1H), 4.45-4.55 (m, 1H),
5.77 (s, 1H), 6.53 (d, J=7.4 Hz, 2H),
6.75 (d, J=7.8 Hz, 1H), 6.85-6.90 (m, 1H),
7.15-7.35 (m, 6H).
IR (CHCl3) : 3606, 3600-3100 (br.), 3429, 3011, 2929, 2865,
1663, 1604, 1587, 1514, 1455, 1367, 1277,
1200, 1156, 1046, 910 cm-1.
MS(FD): m/e 537 (M+, 100).
HR MS (FAB) : m/e for C32H46N3O4:
Calcd: 536.3488;
Found: 536.3488.
Example 13
[3S-(3R*, 4aR* , 8aR*, 2 'S*, 3 'R*) ]-2-[2'-Hydroxy-3'-phenylmethyl- 4'-aza-5'-oxo-5'-(2''-methyl-3''-methoxyphenyl)pentyl] decahydroisoquinoline-3-N-t-butylcarboxamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 1, using 80 rag (0.20 mmol) of the subtitled compound of Preparation IB, 33 mg (0.20 mmol) of the subtitled compound of Preparation 15B, 41 mg (0.20 mmol) of
DCC and 27 mg (0.20 mmol) of HOBT·H2O in 2 mL of anhydrous
tetrahydrofuran. The crude product was purified using radial chromatography (2 mm plate; eluent of 2.5% methanol in methylene chloride) to provide 93 mg of a white foam.
Yield: 84%.
1H NMR (CDCl3) : δ 1.17 (s, 9H), 1.17-2.05 (m, 12H),
2.05 (S, 3H), 2.25-2.38 (m, 2H),
2.50-2.75 (m, 2H), 2.95-3.10 (m, 2H),
3.35-3.50 (m, 1H), 3.79 (s, 3H),
3.98-4.15 (m, 2H), 4.59-4.65 (m, 1H),
5.72 (s, 1H), 6.47 (br.d, J=8.21 Hz, 1H),
6.63 (d, J=7.7 Hz, 1H), 6.82 (d, J=8.12
Hz, 1H), 7.08 (t, J=7.0 Hz, 1H), 7.15-7.45
(m, 5H).
Analysis for C33H47N3O4:
Calcd: C, 72.10; H, 8.62; N, 7.64.
Found: C, 71.84; H, 8.49: N, 7.67.
Example 14
[3S-{ 3R* , 4aR* , 8aR* , 2 'S* , 3 'R*) ]-2-[2'-Hydroxy-3'- phenylmethyl-4'-aza-5'-oxo-5'-(2'',3''-dichlorophenyl)pentyl] decahydroisoquinoline-3-N-t-butylcarboxamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 1, using 80 mg (0.20 mmol) of the subtitled compound of Preparation 1B, 38 mg (0.20 mmol) of
2,3-dichloro benzoic acid, 41 mg (0.20 mmol) of DCC and 27 mg
(0.20 mmol) of HOBT·H2O in 3 mL of anhydrous tetrahydrofuran. The crude product was purified using radial chromatography (2 mm plate; gradient eluent of 2.5-5% methanol in methylene chloride) to provide 95 mg of a white foam. Yield: 84%.
1H NMR (CDCl3) : δ 1.16 (s, 9H), 1.17-2.05 (m, 12H),
2.20-2.38 (m, 2H), 2.50-2.75 (m, 2H),
2.95-3.10 (m, 2H), 3.40-3.55 (m, 1H),
3.69 (s, 1H), 4.00-4.10 (m, 1H),
4.58-4.72 (m, 1H), 5.77 (s, 1H),
6.98-7.47 (m, 9H).
MS(FD): m/e 574 (M+), 473(100).
Example 15
[3S-( 3R*, 4aR* , 8aR* , 2 'S* , 3 'R*) ]-2-[2'-Hydroxy-3'- phenylmethyl-4'-aza-5'-oxo-5'-(2''- trifluoromethylphenyl)pentyl] decahydroisoquinoline-3-N-t- butylcarboxamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 1, using 80 mg (0.20 mmol) of the subtitled compound of Preparation 1B, 38 mg (0.20 mmol) of 2-trifluoromethyl benzoic acid, 41 mg (0.20 mmol) of DCC and 27 mg (0.20 mmol) of HOBT·H2O in 3 mL of anhydrous tetrahydrofuran. The crude product was purified using radial chromatography (2 mm plate; gradient eluent of 2.5-5% methanol in methylene chloride) to provide 72 mg of a white foam.
Yield: 63%.
1H NMR (CDCl3) : δ 1.10 (s, 9H), 1.16-2.05 (m, 14H),
2.15-2.35 (m, 2H), 2.45-2.70 (m, 2H),
2.92-3.05 (m, 2H), 3.38-3.55 (m, 1H),
3.70 (br.s, 1H), 3.98-4.10 (m, 1H), 4.58-4.70 (m, 1H), 5.90 (s, 1H),
7.00-7.65 (m, 10H) .
MS(FD) : m/e 573 (M+, 100) .
/Analysis for C32H42N3O3F3 :
Calcd: C, 67.00; H, 7.38; N, 7.32.
Found: C, 67.11; H, 7.09; N, 7.10.
Example 16
[3S-{3R*,4aR*,8aR*,2'S*,3'R*)]-2-[2'-Hydroxy-3'- phenylmethyl-4'-aza-5'-oxo-5'-(2''-oxo-3''- methyl-pyrid-4''-yl)pentyl] decahydroisoquinoline-3-N-t-butylcarboxamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 1, using 14.7 mg (0.037 mmol) of the subtitled compound of Preparation IB, 5.6 mg (0.037 mmol) of the subtitled compound of Preparation 12F, 7.6 mg (0.037 mmol) of DCC and 4.9 mg (0.037 mmol) of HOBT·H2O in 1.3 mL of anhydrous dimethylformamide. The crude product was purified using radial chromatography (1 mm plate; eluent of 10% methanol in methylene chloride) to provide 6.5 mg of a white solid.
Yield: 34%.
1H NMR (CDCl3) : δ 1.00-3.40 (m, 32H), 4.00-4.70 (m, 3H),
5.90-6.10 (m, 1H), 6.90-7.40 (m, 8H).
MS(FD): m/e 537 (M+, 100). Example 17
[3S-( 3R* , 4aR* , 8aR* , 2 ' S* , 3 'R*) ] - 2 - [2'-Hydroxy-3'-phenylmethyl- 4'-aza-5'-oxo-5'-(2'',6''-dichloro-3''-hydroxyphenyl)pentyl] decahydroisoquinoline-3-N-t-butylcarboxamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 1, using 48 mg (0.12 mmol) of the subtitled compound of Preparation 1B, 25 mg (0.12 mmol) of the subtitled compound of Preparation 13, 2.5 mg (0.12 mmol) of DCC and 16 mg (0.12 mmol) of HOBT·H2O in 2 mL of anhydrous
tetrahydrofuran. The crude product was purified using radial chromatography (1 mm plate; gradient eluent of 2-5% methanol in methylene chloride) to provide 14 mg of the desired titled
compound.
1H NMR (CDCl3) : δ 0.9-2.15 (m, 23H), 2.22-2.85 (m, 4H),
2.95-3.10 (m, 2H), 3.30-3.58 (m, 1H),
3.98-4.12 (m, 1H), 4.56-4.75 (m, 1H),
5.60-5.82 (m, 1H), 6.60-6.79 (m, 1H),
6.90-7.40 (m, 6H).
IR (CHCl3) : 3010, 2937, 1644, 1606, 1605, 1497, 1474,
1454, 1433, 1417, 1341, 1313, 1274, 1252,
1161, 1093, 1074, 1027, 991 cm-1.
MS(FD): m/e 590 (M+, 100).
Example 18
[3S-( 3R* , 4aR* , 8aR* , 2 'S* , 3 'R*)]-2-[2'-Hydroxy-3'- phenylmethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''- aminophenyl)pentyl] decahydroisoquinoline-3-N-t- butylcarboxamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 1, using 100 mg (0.25 mmol) of the subtitled compound of Preparation 1B, 38 mg (0.25 mmol) of 3-amino-2-methyl benzoic acid, 34 mg (0.25 mmol) of HOBT·H2O, 52 mg (0.25 mmol) of DCC in 3 mL of anhydrous tetrahydrofuran, with the exception that the reaction was conducted in the presence of 76 mg (0.75 mmol) of triethylamine. The resultant material was purified using radial chromatography (2 mm plate; gradient eluent of 2-5% methanol in methylene chloride) to provide 78 mg of an off-white foam.
Yield: 58%.
1H NMR (CDCl3) : δ 1.19 (s, 9H), 1.20-2.08 (m, 15H),
2.20-2.35 (m, 2H), 2.50-2.70 (m, 2H),
2.92-3.05 (m, 2H), 3.28-3.38 (m, 1H),
3.61 (br.s, 1H), 3.93-4.20 (m, 2H),
4.45-4.58 (m, 1H), 5.80 (s, 1H), 6.44 (d,
J=7.5 Hz, 2H), 6.63 (d, J=7.9 Hz, 1H),
6.90 (t, J=7.7 Hz, 1H), 7.17-7.36 (m,
6H).
MS(FD): m/e 535 (M+, 100).
Example 19
[2S-(2R* , 2 'S*, 3 'S*) ]-1-[2'-Hydroxy-3'-phenylthiomethyl-4'- aza-5'-oxo-5'-(3''-hydroxy-2''-methylphenyl)pentyl]-4-pyrid- 3''-ylmethyl piperazine-2-N-t-butylcarboxamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 1, using 50 mg (0.11 mmol) of the subtitled compound of Preparation 6B, 16 mg (0.11 mmol) of the subtitled compound of Preparation 9C, 14 mg (0.11 mmol) of
HOBT·H2O and 22 mg (0.11 mmol) of DCC in 2 mL of anhydrous tetrahydrofuran. The resultant material was purified using radial chromatography (1 mm plate; gradient eluent of 5-10% methanol in methylene chloride) to provide 35 mg of an off-white foam.
Yield: 55%.
1HNMR (CDCl3) : δ 1.29 (s, 9H), 2.18 (s, 3H),
2.23-2.33 (m, 1H), 2.45-2.85 (m, 7H),
3.20-3.35 (m, 3H), 3.45 (s, 1H),
4.00-4.10 (m, 1H), 4.25-4.35 (m, 1H),
5.00-5.40 (br.s, 1H), 6.61 (d, J=7.6 Hz,
1H), 6.76-6.80 (m, 2H), 6.92 (t, J=7.7 Hz,
1H), 7.12-7.43 (m, 7H), 7.57-7.62 ( m,
1H), 7.78 (br.s, 1H), 8.48-8.58 (m, 2H).
MS (FD) : m/e 606 (M+, 100).
Example 20
[3S-( 3R*, 4aR* , 8aR* , 2 'S*, 3 'R*)]-2-[2'-Hydroxy-3'-phenylmethyl- 4'-aza-5'-oxo-5'-(2''-isopropyl-3''-hydroxyphenyl)pentyl] decahydroisoquinoline-3-N-t-butylcarboxamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 1, using 55 mg (0.137 mmol) of the subtitled compound of Preparation IB, 24.7 mg (0.137 mmol) of the subtitled compound of Preparation 18B, 28.25 mg (0.137 mmol) of DCC, and 18.5 mg (0.137 mmol) of HOBT·H2O in 8 mL of tetrahydrofuran. The resultant crude material was purified using radial chromatography (1mm plate; eluent of 3% methanol in
methylene chloride) to provide 46 mg of a white foam.
Yield: 60%. [α]D -84.61 (c=2.60, MeOH) .
1H NMR (CDCl3) : δ 1.19 (d, J=3.7 Hz, 3H),
1.21 (d, J=3.75 Hz, 3H), 1.23 (s, 9H),
1.27-1.51 (m, 7H), 1.61-2.00 (m, 6H),
2.26-2.35 (m, 2H) , 2.56-2.65 (m, 2H),
2.91-3.03 (m, 3H), 3.19-3.27 (m, 1H),
3.96 (m, 1H), 4.51 (m, 1H), 5.82 (br.s,
1H), 5.93 (br.s, 1H), 6.23 (d, J=8.53 Hz,
1H), 6.46 (d, J=7.15 Hz, 1H), 6.66 (d,
J=7.17 Hz, 1H), 6.86 (t, J=7.74 Hz, 1H),
7.21-7.31 (m, 5H).
IR (CDCl3) : 3427, 3322, 3028, 3008, 2930, 2868, 1660,
1603, 1582, 1513, 1455, 1393, 1366, 1304,
1278, 1245, 1088, 1059 cm-1.
MS(FD): m/e 564 (M+, 100).
Analysis for C34H49N3O4:
Calcd: C, 72.43; H, 8.76; N, 7.45;
Found: C, 72.13; H, 8.85; N, 7.30.
Example 21
[3S-(3R*,4aR*,8aR*,2'S*,3'R*)]-2-[2'-Hydroxy-3'-phenylmethyl- 4'-aza-5'-oxo-5'-(2''-butyl-3''-hydroxyphenyl)pentyl]
decahydroisoquinoline-3-N-t-butylcarboxamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 1, using 91 mg (0.227 mmol) of the subtitled compound of Preparation IB, 44 mg (0.227 mmol) of the subtitled compound of Preparation 16B, 46.7 mg (0.227 mmol)
DCC, and 30.6 mg (0.227 mmol) of HOBT·H2O in 10 mL of tetrahydrofuran. The resultant crude material was purified using radial chromatography (1mm plate; gradient eluent of 4-7% methanol in methylene chloride) to provide 72 mg of a white foam.
Yield: 55%.
[α]D -77.36 (c=0.36, MeOH).
1H NMR (CDCl3) : δ 0.84 (t, J=7.2 Hz, 3H), 1.20 (s, 9H),
1.29-2.00 (m, 18H), 2.27 (m, 2H),
2.48-2.69 (m, 4H), 2.99 (m, 2H),
3.29 (m, 1H), 3.99 (m, 1H), 4.49 (m, 1H),
5.85 (s, 1H), 6.45 (m, 2H), 6.75 (d,
J=7.19 Hz, 1H), 6.86 (t, J=7.67 Hz, 1H),
7.21-7.31 (m, 5H).
IR (KBr): 3303 (br.), 3087, 3029, 2927, 2862, 1647,
1583, 1520, 1455, 1366, 1281, 1209, 1108, 735,
698 cm-1.
MS(FD): m/e 578 (M+, 100).
HR MS (FAB): m/e for C35H51N3O4:
Calcd: 578.3958;
Found: 578.3962.
Example 22
[3S-(3R*, 4aR*, 8aR*, 2 ' S*, 3 ' R*)]-2-[2'-Hydroxy-3'-phenylmethyl- 4'-aza-5'-oxo-5'-(2''-propyl-3''-hydroxyphenyl)pentyl] decahydroisoαuinoline-3-N-t-butylcarboxamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 1, using 67 mg (0.167 mmol) of the subtitled compound of Preparation 1B, 30 mg (0.167 mmol) of the subtitled compound of Preparation 17B, 34 mg (0.167 mmol) of DCC, and 23 mg (0.167 mmol) of HOBT·H2O in 4 mL of
tetrahydrofuran. The resultant crude material was purified using radial chromatography (1mm plate; eluent of 3% methanol in methylene chloride) to provide 75 mg of a white foam.
Yield: 80%.
[α]D -43.75 (c=0.160, MeOH).
1H NMR (CDCl3) : δ 0.87 (t, 3H), 1.18 (s, 9H), 1.21-2.04
(m, 15H), 2.24-2.33 (m, 2H), 2.49-2.58 (m,
3H), 2.66 (m, 1H), 2.98 (m, 2H), 3.37 (m,
1H), 3.99 (m, 1H), 4.52 (m, 1H), 5.07 (m,
1H), 5.70 (s, 1H), 6.43 (d, J = 8.32 Hz,
1H), 6.56 (d, J=7.32 Hz, 1H), 6.76 (d,
J=7.12 Hz, 1H), 6.95 (t, J=7.78 Hz, 1H),
7.20-7.33 (m, 5H).
IR (KBr): 3287 (br.), 3086, 2932, 2868, 1681, 1558, 1456,
1368, 1334, 1291, 1261, 1218, 1169, 1101, 1042,
776, 734, 552 cm-1.
MS(FD): m/e 564 (M+, 100).
HR MS (FAB) : m/e for C34H50N3O4:
Calcd: 564.3801;
Found: 564.3789.
Example 23
[3S-( 3R* , 4aR* , 8aR* , 2 ' S* , 3 ' S*)]-2-[2'-Hydroxy-3'- phenylthiomethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''- hydroxyphenyl)pentyl] decahydroisoquinoline-3-N-t- butylcarboxamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 1, using 70 mg (0.16 mmol) of the subtitled compound of Preparation 8G, 24.6 mg (0.16 mmol) of the subtitled compound of Preparation 9C, 33 mg (0.16 mmol) of DCC, and 22 mg (0.16 mmol) of HOBT·H2O in 4 mL of tetrahydrofuran. The resultant crude material was purified using radial
chromatography (1mm plate; eluent of 3% methanol in methylene chloride) to provide 54 mg of a white foam.
Yield: 60%.
[α]D -119.23 (c=0.26, MeOH).
1H NMR (CDCl3) : δ 1.09 (s, 9H), 1.12-1.79 (m, 12H),
1.93-2.02 (m, 2H), 2.17-2.30 (m, 2H),
2.31 (s, 3H), 2.43-2.61 (m, 2H), 2.91 (m,
1H), 3.42 (m, 1H), 3.78 (m, 1H), 4.07 (m,
1H), 4.47 (m, 1H), 5.37 (m, 1H), 5.51
(br.s, 1H), 6.84 (m, 1H), 7.06 (m, 2H),
7.17-7.32 (m, 4H), 7.45 (m, 2H).
IR (KBr) : 3297, 2925, 2862, 1627, 1586, 1530, 1482, 1466,
1439, 1366, 1287, 1221, 1156, 1119, 1026, 801,
735, 689 cm-1.
MS(FD): m/e 568 (M+, 100).
HR MS (FAB) for C 32H46N3O4S :
Calcd: 568.3209;
Found: 568.3182. Example 24
[3S-( 3R* , 4aR* , 8aR* , 2 ' S* , 3 ' S*) ] - 2 -[2'-Hydroxy-3'-(naphth-2- ylthiomethyl)-4'-aza-5'-oxo-5'-(2''-methyl-3''- hydroxyphenyDpentyl] decahydroisoquinoline-3-N-t- butylcarboxamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 1, using 70 mg (0.145 mmol) of the subtitled compound of Preparation 7B, 22 mg (0.145 mmol) of the subtitled compound of Preparation 9C, 29 mg (0.145 mmol) of DCC, and 19 mg (0.145 mmol) of HOBT·H2O in 4 mL of
tetrahydrofuran. The resultant crude material was purified using flash chromatography (gradient eluent of 5-15% acetone in
methylene chloride) to provide 65 mg of a white solid.
Yield: 73%.
[α]D -112.00 (c=0.25, MeOH).
1H NMR (CDCl3) : δ 1.10 (s, 9H), 1.15-1.80 (m, 12H),
1.93- 2.06 (m, 1H), 2.17-2.28 (m, 2H),
2.29 (s, 3H), 2.42-2.61 (m, 2H), 2.94 (d,
1H), 3.51 (m, 1H), 3.83-3.92 (m, 1H), 4.10
(m, 1H), 5.36 (br.s, 1H), 5.53 (br.s, 1H),
6.79 (m, 1H), 6.93 (m, 2H), 7.21 (d,
J=8.83 Hz, 1H), 7.40-7.53 (m, 3H), 7.73
(m, 3H), 7.90 (s, 1H).
IR (KBr): 3427, 3311 (br), 2929, 2864, 1703, 1661, 1587,
1514, 1456, 1393, 1366, 1276, 1200, 1177, 1146,
1119, 1070, 1042 cm-1.
MS(FD) : m/e 618 (M+, 100). Analysis for C34H49N3O4:
Calcd: C, 69.98; H, 7.67; N, 6.80.
Found: C, 69.92; H, 7.72; N, 6.75.
Example 25
[2S-(2R*, 2 'S*, 3 'S*) ]-1-[2'-Hydroxy-3'-(naphth-2- ylthiomethyl)-4'-aza-5'-oxo-5'-(2''-methyl-3''- hydroxyphenyl)pentyl] piperidine-2-N-t-butylcarboxamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 1, using 28 mg (0.065 mmol) of the subtitled compound of Preparation 2G, 10 mg (0.065 mmol) of the subtitled compound of Preparation 9C, 13.5 mg (0.065 mmol) of DCC, and 9 mg (0.065 mmol) HOBT·H2O in 2 mL of tetrahydrofuran. The resultant crude material was purified using radial
chromatography (1mm plate; eluent of 2% methanol in methylene chloride) to provide 23 mg of a white foam.
Yield: 63%.
[αlD -233.33 (c=0.09, MeOH).
1H NMR (CDCl3) : δ 1.17 (s, 9H), 1.26 (m, 1H), 1.56-1.73
(m, 6H), 2.19-2.23 (m, 2H), 2.25 (s, 3H),
2.42 (m, 1H), 2.62-2.73 (m, 2H), 3.11-3.19
(m, 1H), 3.50-3.72 (m, 2H), 4.10 (m, 1H),
4.45 (m, 1H), 5.89 (s, 1H), 6.77-6.87 (m,
3H), 7.00 (d, J=8.65 Hz, 1H), 7.43-7.51
(m, 3H), 7.72-7.80 (m, 3H), 7.88 (s, 1H).
IR (KBr): 3329, 2934, 2857, 1646, 1586, 1522, 1457, 1364,
1284, 1223, 1133, 1072, 944, 835, 811, 744,
474 cm-1. MS(FD): m/e 564 (M+, 100).
HR MS (FAB) for C32H42N304S:
Calcd: 564.2896;
Found: 564.2916.
Example 26
[2S-(2R*, 2 'S* , 3 'R*) ]-1-[2'-Hydroxy-3'-phenylmethyl-4'-aza-5'- oxo-5'-(2''-methyl-3''-hydroxyphenyl)pentyl]-4-(pyrid-3'''- ylmethyl) piperazine-2-N-t-butylcarboxamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 1, using 65 mg (0.148 mmol) of the subtitled compound of Preparation 5E, 22.5 mg (0.148 mmol) of the subtitled compound of Preparation 9C, 30.5 mg (0.148 mmol) of DCC, and 20 mg (0.148 mmol) of HOBT·H2O in 5 mL of
tetrahydrofuran. The resultant crude material was purified using radial chromatography (1mm plate; eluent of 3% methanol in
methylene chloride) to provide 64 mg of a white foam.
Yield: 75%.
1H NMR (CDCl3) : δ 1.33 (s, 9H), 1.86 (s, 3H), 2.30 (m,
1H), 2.49-2.98 (m, 11H), 3.33 (m, 1H),
3.46 (m, 1H), 4.02 (m, 1H), 4.46 (m, 1H),
6.29 (d, J=9.16 Hz, 1H), 6.46 (d, J=7.23
Hz, 1H), 6.73 (d, J=7.79 Hz, 1H), 6.83 (t,
J=7.84 Hz, 1H), 7.17-7.31 (m, 7H), 7.60
(m, 1H), 7.95 (br.s, 1H), 8.50-8.55 (m,
2H).
MS(FD): m/e 574 (M+, 100). HR MS (FAB) : m/e for C33H44N5O4:
Calcd: 574.3393;
Found: 574.3373.
Example 27
[3S-( 3R* , 4aR* , 8aR* , 2 'S* , 3 'R*) ]-2-[2'-Hydroxy-3'- phenylmethyl-4'-aza-5'-oxo-5'-(2''-ethyl-3''- hydroxyphenyl)pentyl] decahydroisoquinoline-3-N-t- butylcarboxamide monomesylate salt
To a cold (0°C) solution of 35.1 mg (0.064 mmol) of the titled compound of Example 3 in 2 μL of anhydrous methylene chloride, was added dropwise 134 mL (0.067 mmol) of a 0.5M solution of methanesulfonic acid in methylene chloride. The resulting reaction was reduced to dryness under reduced pressure (0.2-0.1 Torr) to provide 38 mg (crude) of a light yellow foam. Yield: 90%.
1H NMR (CD3OD) : δ 0.91 (t, J=7.39, 3H), 1.29 (s, 9H),
1.30-3.20 (m, 21H), 4.00-4.40 (m, 2H),
6.47 (d, J=7.30 Hz, 1H), 6.73 (d, J=7.78
Hz, 1H), 6.91 (t, J=7.78 Hz, 1H),
7.15-7.32 (m, 5H).
Example 28
[3S-( 3R* , 4aR* , 8aR* , 2 'S* , 3 'R*) ]-2-[2'-Hydroxy-3'- phenylmethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''- hydroxyphenyl)pentyl] decahydroisoquinoline-3-N-t- butylcarboxamide monomesylate salt
The titled compound was prepared substantially in accordance with the procedure detailed in Example 27, using 125 mg (0.23 mmol) of the titled compound of Example 13 in 5 mL of anhydrous methylene chloride, and 240 μL (0.24 mmol) of a 1.0M solution of methanesulfonic acid in methylene chloride to provide 136 mg
(crude) of an off-white foam.
Yield: 95%
1H NMR (CD3OD) : δ 1.12 (s, 9H), 1.10-2.20 (m, 16H),
2.60-2.75 (m, 4H), 3.10-3.50 (m, 6H),
3.60-3.70 (m, 1H), 3.90-4.30 (m, 3H),
6.53 (d, J=7.35 Hz, 1H), 6.55 (t, J=7.87
Hz, 1H), 6.89 (t, J=7.82 Hz, 1H).
Example 29
[3S-( 3R* , 4aR* , 8aR* , 2 ' S* , 3 'S*) ]-2-[2'-Hydroxy-3'- phenylthiomethyl-4'-aza-5'-oxo-5'-(2''-methyl- phenyl)pentyl] decahydroisoquinoline-3-N-t-butylcarboxamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 1, using 15 mg (0.034 mmol) of the subtitled compound of Preparation 8G, 4.7 mg (0.034 mmol) of o-toluic acid, 7.13 mg (0.034 mmol) of DCC, and 4.7 mg (0.034 mmol) of HOBT·H2O in 2.5 mL of tetrahydrofuran. The resultant material was purified using radial chromatography (1mm plate;
eluent 10% acetone in methylene chloride) to provide 16 mg of a white foam.
Yield: 84%.
[α]D -80.00 (c=0.15).
1H NMR (CDCl 3) : δ 1.04 (s, 9H), 1.08-1.80 (m, 11H),
1.93 (m, 3H), 2.22 (m, 4H), 2.44 (m, 1H),
2.49 (s, 3H), 2.58 (m, 1H), 2.94 (m, 1H), 3.47 (m, 1H), 3.84 (m, 1H), 4.03 (m, 1H),
4.50 (m, 1H), 5.45 (br.s, 1H), 7.12-7.32
(m, 7H), 7.45 (m, 2H), 7.51 (d, J=7.51 Hz,
1H) .
IR (KBr): 3327, 2928, 2852, 1627, 1574, 1535, 1481, 1364,
1311, 1275, 1225, 1088, 737 cm-1.
HR MS (FAB) for C32H46N3O3S:
Calcd: 552.3260;
Found: 552.3272.
Example 30
[3S-(3R*, 4aR*, 8aR*, 2'S*, 3'S*)]-2-[2'-Hydroxy-3'- phenylthiomethyl-4'-aza-5'-oxo-5'-[3''-methyl-pyrid-4''- yl)]pentyl] decahydroisoquinoline-3-N-t-butylcarboxamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 1, using 15 mg (0.034 mmol) of the subtitled compound of Preparation 8G, 6.69 mg (0.048 mmol) of the titled compound of Preparation 19, 7.13 mg (0.034 mmol) of
DCC, and 4.7 mg (0.034 mmol) of HOBT·H2O in 1.5 mL of
tetrahydrofuran and 1 mL of dimethylformamide. The resultant material was purified using radial chromatography (1mm plate;
gradient eluent of 3-5% methanol in methylene chloride) to provide
10 mg of a white foam.
Yield: 52%.
[α]D -95.65 (c=0.115).
1H NMR (CDCl3) : δ 1.00 (s, 9H), 1.20-1.77 (m, 12H),
1.99 (m, 1H), 2.17 (m, 2H), 2.44 (m, 5H), 2.92 (m, 1H), 3.41 (m, 1H), 3.84 (m, 1H),
4.13 (m, 1H), 4.56 (m, 1H), 5.39 (s, 1H),
7.20-7.46 (m, 6H),
7.75 (d, J=8.94 Hz, 1H), 8.46 (m, 2H).
IR (KBr): 3307, 2925, 2860, 1653, 1542, 1481, 1439, 1391,
1365, 1281, 1224, 1058, 1041, 738, 691, 669 cm-1.
HR MS (FAB) for C31H45N4O3S:
Calcd: 553.3212;
Found: 553.3222.
Example 31
[3S-( 3R* , 4aR* , 8aR* , 2 'S* , 3 'S*) ] -2 -[2'-Hydroxy-3'- phenylthiomethyl-4'-aza-5'-oxo-5'-(quinolin-5''- yl)pentyl] decahydroisoquinoline-3-N-t-butylcarboxamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 1, using 15 mg (0.034 mmol) of the subtitled compound of Preparation 8G, 6.0 mg (0.034 mmol) of the titled compound of Preparation 20, 7.13 mg (0.034 mmol) of DCC, and 4.7 mg (0.034 mmol) HOBT·H2O in 2 mL of tetrahydrofuran. The resultant material was purified using radial chromatography (lmm plate; gradient eluent of 3-5% methanol in methylene
chloride) to provide 15 mg of a white foam.
Yield: 74%.
[α]D -99.50 (c=0.201).
1H NMR (CDCl3) : δ 0.74 (s, 9H), 1.15-1.79 (m, 12H),
1.97 (m, 1H), 2.17 (m, 2H), 2.36 (m, 1H),
2.54 (m, 1H), 2.90 (m, 1H), 3.45 (m, 1H), 3.99 (m, 1H), 4.16 (m, 1H), 4.62 (m, 1H),
5.29 (s, 1H), 7.18-7.32 (m, 3H),
7.40-7.50 (m, 3H), 7.70 (tn, 1H),
7.89 (m, 2H), 8.17 (m,
1H), 8.91 (m, 2H).
IR (KBr) : 3299, 2923, 2862, 1644, 1546, 1481, 1439, 1390,
1327, 1279, 1222, 1207, 1037, 810, 735, 689 cm-1.
HR MS (FAB) for C34H45N4O3S:
Calcd: 589.3212;
Found: 589.3237.
Example 32
[3S-( 3R* , 4aR* , 8aR* , 2 ' S* , 3 ' S*) ]-2-[2'-Hydroxy-3'- phenylthiomethyl-4'-aza-5'-oxo-5'-(1",2",3",4"- tetrahydroquinolin-5''-yl)pentyl] decahydroisoquinoline-3-N-t-butylcarboxaraide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 1, using 18 mg (0.04 mmol) of the subtitled compound of Preparation 8G, 7.38 mg (0.04 mmol) of the titled compound of Preparation 21, 8.56 mg (0.04 mmol) of DCC, and 5.61 mg (0.04 mmol) of HOBT·H2O in 2 mL of
tetrahydrofuran. The resultant material was purified using radial chromatography (1mm plate; gradient eluent of 3-5% methanol in methylene chloride) to provide 12 mg of a white foam.
Yield: 50%.
[α]D -98.59 (c=0.142).
1H NMR (CDCl3) : δ 1.13 (s, 9H), 1.14-2.04 (m, 15H),
2.19 (m, 2H), 2.45 (m, 1H), 2.57 (m, 1H), 2.75 (m, 1H), 2.90-3.09 (m, 2H),
3.26 (m, 2H), 3.44 (m, 2H), 3.75 (m, 1H),
4.01-4.14 (m, 2H), 4.42 (m, 1H),
5.56 (s, 1H), 6.49 (d, J=7.96 Hz, 1H),
6.80 (d, J=7.40 Hz, 1H),
6.93 (t, J=7.72 Hz, 1H),
7.08 (d, J=8.39 Hz, 1H), 7.18 (m, 1H),
7.27 (m, 2H), 7.42 (d, 2H) .
IR (KBr) : 3327, 2928, 2852, 1629, 1590, 1519, 1481, 1449,
1364, 1310, 1275, 1229, 1087, 738, 690 cm-1.
HR MS (FAB) for C34H49N4O3S:
Calcd: 593.3525;
Found: 593.3552.
Example 33
[2S-(2R*, 2'S*, 3'S*)]-1-[2'-Hydroxy-3'-phenylthiomethyl- 4'-aza-5'-oxo-5'-(1'',2'',3'',4''-tetrahydroquinolin-5''- yl)pentyl]-4-(pyrid-3'''-ylmethyl)piperazine-2-N-t- butylcarboxamide
To a cooled (-10°C) solution containing 45 mg (0.10 mmol) of the subtitled compound of Preparation 6B, 18 mg (0.10 mmol) of
1,2,3,4-tetrahydroguinoline-5-carboxylic acid, 30 mg (0.30 mmol) of triethylamine, and 14 mg (0.10 mmol) of HOBT·H2O in 2 mL of anhydrous tetrahydrofuran, was added 22 mg (0.11 mmol) of DCC.
The resultant reaction mixture was stirred for approximately 24 hours at room temperature and then concentrated under reduced pressure to provide a residue. This residue was redissolved in ethyl acetate, and filtered through celite. The filtrate was then extracted sequentially with saturated sodium bicarbonate (twice), brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude material was purified using radial chromatography (1 mm plate; gradient eluent of 2.5-5% methanol in methylene chloride) to provide 33 mg of an off-white foam.
Yield: 62%.
1H NMR (CDCl3) : δ 1.29 (s, 9H), 1.79-1.97 (m, 2H),
2.26-3.00 (m, 11H), 3.20-3.50 (tn, 9H),
3.95-4.05 (m, 1H), 4.23-4.35 (m, 1H),
6.43-6.62 (m, 2H), 6.89 (t, J=7.8 Hz, 1H),
7.12-7.35 (m, 6H), 7.41 (d, J=7.7 Hz, 2H),
7.57-7.70 (m, 2H), 8.50-8.58 (m, 2H).
MS(FD): m/e 631 (M+, 100).
Example 34
[2S-( 2R*, 2 'S* , 3 'S*) ]-1-[2'-Hydroxy-3'-phenylthiomethyl-4'- aza-5'-oxo-5'-(quinolin-5''-yl)pentyl]-4-(pyrid-3'''- ylmethyl)piperazine-2-N-t-butylcarboxaraide
The titled compound was isolated from Example 33 Yield: 13 mg of an off-white foam.
1H NMR (CDCl3) : δ 1.18 (s, 9H), 2.27-2.90 (m, 9H),
3.17-3.60 (m, 5H), 4.07-4.19 (m, 1H),
4.40-4.55 (m, 1H), 4.75-4.95 (m, 1H),
6.90-7.68 (m, 11H), 8.16 (d, J=8.1 Hz,
1H), 8.48-8.60 (m, 2H), 8.80 (d, J=8.4 Hz,
1H), 8.89-8.97 (m, 1H).
MS(FD): m/e 527 (M+, 100). Example 35
[2S-(2R*, 2 'S* , 3 'S*)]-1-[2'-Hydroxy-3'-phenylthiomethyl-4'- aza-5'-oxo-5'-[3''-methyl-pyrid-4''-yl)]pentyl]-4-(pyrid- 3'''-ylmethyl)piperazine-2-N-t-butylcarboxamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 1, using 20.3 mg (0.148 mmol) of the titled compound of Preparation 19, 70 mg (0.148 mmol) of the subtitled compound of Preparation 19, 31 mg (0.148 mmol) of DCC, and 20 mg (0.148 mmol) of HOBT·H2O in tetrahydrofuran
containing 62 mL of triethylamine. The resultant material was purified using radial chromatography (2mm plate; gradient eluent of 2.5-15% methanol in methylene chloride) to provide 48 mg of a white foam.
Yield: 55%.
1H NMR (CDCl3) : δ 1.23 (s, 9H), 2.30-2.90 (m, 12H),
3.16-3.50 (m, 5H), 4.02-4.10 (m, 1H),
4.30-4.42.41 (m, 1H), 4.85 (br.s, 1H),
6.90-7.60 (m, 10H),
8.38-8.57 (m, 3H).
MS(FAB): m/e 591.4 (M+, 100).
Example 36
[3S-( 3R*, 4aR*, 8aR* , 2 'S* , 3 'S*) ] -2 -[2'-Hydroxy-3'-phenylmethyl- 4'-aza-5'-oxo-5'-[2''-methyl-3''-N-(methylsulfonyl)aminophenyl)]pentyl] decahydroisoquinoline-3-N-t-butylcarboxamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 1, using 70 mg (0.17 mmol) of the subtitled compound of Preparation IB, 40 mg (0.17 mmol) of the titled compound of Preparation 22, 35 mg (0.17 mmol) of DCC, and 23 mg (0.17 ramol) of HOBT·H2O in 2 mL of anhydrous
tetrahydrofuran. The resultant material was purified using radial chromatography (2mm plate; gradient eluent of 1-5% methanol in methylene chloride) to provide 72 mg of an off-white solid.
Yield: 69%.
1H NMR (CDCl3) : δ 1.14 (s, 9H), 1.19-2.38 (m, 19H),
2.50-2.70 (m, 2H), 2.92-3.06 (m, 4H),
3.43-3.55 (m, 1H), 4.01-4.10 (m, 1H),
4.58-4.70 (m, 1H), 5.66 (s, 1H),
6.37 (br.s, 1H), 6.82-6.93 (m, 2H),
7.10-7.39 (m, 6H),
7.48 (d, J=8.16 Hz, 1H).
IR (KBr): 3691, 3600-3300 (br.), 2929, 2866, 1672, 1603,
1513, 1455, 1393, 1368, 1327, 1277, 1154, 1047,
972, 909, 877 cm-1.
MS(FD) : m/e (M+, 100).
Example 37
[3S-( 3R* , 4aR* , 8aR* , 2 'S*, 3 'S*) ]-2-[2'-Hydroxy-3'-phenylmethyl- 4'-aza-5'-oxo-5'-[(1'',2'',3'',4''-tetrahydroquinolin-5''- yl)]pentyl] decahydroisoquinoline-3-N-t-butylcarboxaraide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 1, using 18.5 mg (0.046 mmol) of the subtitled compound of Preparation 1B, 8.14 mg (0.046 mmol) of the titled compound of Preparation 20, 9.48 mg (0.046 mmol) of DCC, and 6.21 mg (0.046 mmol) of HOBT·H2O in 2 mL of anhydrous tetrahydrofuran. The resultant material was purified using radial chromatography (1mm plate; gradient eluent of 2-5% methanol in methylene chloride) to provide 11 mg of a foam.
Yield: 43%.
1H NMR (CDCl3) : δ 1.20 (s, 9H), 1.25-2.02 (m, 15H),
2.28 (m, 2H), 2.46-2.70 (m, 4H),
2.99 (m, 2H), 3.21 (m, 1H), 3.35 (m, 1H),
3.98 (m, 1H), 4.49 (m, 1H),
5.75 (br.s, 1H), 6.38 (m, 3H),
6.83 (t, 1H), 7.21-7.33 (m, 5H).
Example 38
[3S-( 3R* , 4aR* , 8aR* , 2 ' S* , 3 ' S* ) ] - 2 -[2'-Hydroxy-3'- phenylthiomethyl-4'-aza-5'-oxo-5'-[6''-methyl- (1'',2'',3'',4''-tetrahydroquinolin-5''-yl)]pentyl]
decahydroisoquinoline-3-N-t-butylcarboxamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 1, using 15 mg (0.035 mmol) of the subtitled compound of Preparation 8G, 6.5 mg (0.035 mmol) of 6-methyl-1,2,3,4-tetrahydro-5-quinoline carboxylic acid, 7.15 mg (0.035 mmol) of DCC, and 4.7 mg (0.035 mmol) of HOBT·H2O in 2 mL of tetrahydrofuran and 1 mL of dimethylformamide. The
resultant material was purified using radial chromatography (1mm plate; gradient eluent of 3-5% methanol in methylene chloride) to provide 12.5 mg of a white solid.
Yield: 60%.
HR MS (FAB) for C35H47N4O3S:
Calcd: 603.3369;
Found: 603.3384. Example 39
[3S-( 3R* , 4aR* , 8aR* , 2 'S* , 3 ' S*)]-2-[2'-Hydroxy-3'- phenylthiomethyl-4'-aza-5'-oxo-5'-[2'',6''-dimethyl- 3''-hydroxyphenyl]pentyl] decahydroisoquinoline-3-N-t- butylcarboxamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 1, using 20 mg (0.046 mmol) of the subtitled compound of Preparation 8G, 11.53 mg (0.0694 mmol) of 2,6-dimethyl-3-hydroxy benzoic acid, 9.54 mg (0.046 mmol) of DCC, and 6.25 mg (0.046 mmol) of HOBT·H2O in 3 mL of
tetrahydrofuran. The resultant material was purified using radial chromatography (1mm plate; eluent of 4% methanol in methylene chloride) to provide 14 mg of a white solid.
Yield: 52%.
HR MS (FAB) for C33H48N3O4S:
Calcd: 582.3375;
Found: 582.3373.
Example 40
[2R'- (2R ' *, 3 'S*) ]-N-t-Butyl-2-[2'-hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''-hydroxyphenyl)pentyl]benzamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 40, using 100 mg (0.29 mmol) of the subtitled compound from Preparation 24D, 44 mg (0.29 mmol) of the subtitled compound of Preparation 23C, 60 mg (0.29 mmol) of DCC and 39 mg (0.29 mmol) of 1-hydroxybenzotriazole hydrate (HOBT·H2O) in 4 mL of anhydrous tetrahydrofuran. The crude product was purifed using radial chromatography (2 mm plate; gradient eluent of 2-5% methanol in methylene chloride) to provide 58 mg of a white powder.
Yield: 42%.
[α]D 2.34° (c=3.4, MeOH).
1H NMR (CD3OD) : δ 1.47 (s, 9H), 1.88 (s, 3H),
2.70-2.80 (m, 1H), 2.95-3.10 (m, 3H),
3.25-3.30 (m, 1H), 3.85-3.95 (m, 1H),
4.35-4.45 (m, 1H), 4.84 (s, 1H),
6.55-6.58 (m, 1H), 6.74 (d, J=8.0 Hz, 1H),
6.94 (t, J=7.8 Hz, 1H),
7.15-7.45 (m, 11H).
IR (CHCl 3) : 3580, 3550-3100 (br), 2929, 2865, 1662, 1596,
1521, 1472, 1455, 1394, 1368, 1293, 1157,
1047, 879, 839 cm-1.
MS(FD) : 475 (M+, 100).
HR MS (FAB): m/e for C29H35N2O4:
Calcd: 475.2597;
Found: 475.2610.
Example 41
[2'R- (2 'R*, 3 'S*) ]-N-t-Butyl-2-[2'-hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2''-raethyl-5''-hydroxymethylphenyl)pentyl] benzamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 40, using 95 mg (0.28 mmol) of the subtitled compound of Preparation 24D, 65 mg (0.28 mmol) of the subtitled compound of Preparation 27B, 58 mg (0.28 mmol) of DCC and 38 mg (0.28 mmol) of HOBT·H2O in 2 mL of tetrahydrofuran containing 0.2 mL of dimethylformamide. The crude product was purified using radial chromatography (2 mm plate; eluent of 4% methanol in methylene chloride) to provide 64.6 mg of the desired titled compound.
Yield: 47%.
[α]D -0.003 (c=1.02, MeOH).
1H NMR (CDCl3) : δ 1.44 (s, 9H), 1.98 (s, 3H),
2.70-2.85 (m, 1H), 3.00-3.12 (m, 2H),
3.25-3.35 (m, 1H), 3.85-3.97 (m, 1H),
4.00-4.10 (m, 2H), 4.35-4.46 (m, 1H),
4.50 (s, 2H), 6.98-7.43 (m, 11H),
8.06-8.18 (m, 1H)
MS(FD): m/e (M+ +1, 490).
Analysis for C30H36N2O4:
Calcd: C, 73.74; H, 7.43; N, 5.52;
Found: C, 74.00; H, 7.49; N, 5.68.
Example 42
[2'R- (2 'R*, 3 'S*) ]-N-t-Butyl-2-[2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''-aminophenyl)pentyl] benzamide
To a cold (0°C) solution of 50 mg (0.12 mmol) of the
subtitled compound of Preparation 25E in 2.0 mL of
dimethylformamide, was added 22 mg (0.14 mmol) of 2-methyl-3-aminobenzoic acid, 16 mg (0.12 mmol) of HOBT, 22 mg (0.12 mmol) of
EDC and 0.081 mL (0.58 mmol) of triethylamine. The resulting reaction mixture was stirred at 0°C for approximately one hour and then sixteen hours at room temperature. The mixture was then quenched with water and extracted with ethyl acetate. The resulting layers were separated and the organic layer was dried, filtered and concentrated under reduced pressure to provide a crude residue. This residue was purified using flash
chromatography (eluent of 3% methanol in methylene chloride) to provide 52 mg of a white solid (mp 105-106°C).
Yield: 80%.
1H NMR (CDCl3) : δ 7.89 (s, 1H), 7.75 (tn, 3H), 7.40 (m, 7H),
6.86 (t, J=9.0 Hz, 1H), 6.12 (s, 1H),
5.93 (s, 1H), 4.51 (m, 1H), 4.02 (m, 1H),
3.68 (br.s, 2H), 3.51 (m, 3H), 3.12 (s, 2H),
3.04 (dd, J=13.4, 10.1 Hz, 1H),
2.92 (dd, J=13.4, 3.3 Hz, 1H), 2.23 (s, 3H),
1.50 (s, 9H).
IR (KBr): 3304, 3068, 1633, 1516, 1321, 1221, 1076, 746 cm-1. Analysis for C33H37N3O3S:
Calcd: C, 71.32; H, 6.71; N, 7.56;
Found: C, 71.54; H, 6.83; N, 7.32.
Example 43
[2'R- (2 'R*, 3 'S*) ]-N-t-Butyl-2-[2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''-N(methyl)arainophenyl)pentyl] benzamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 42, using 100 mg (0.23 mmol) of the subtitled compound of Preparation 25E in 2.0 mL of dimethylformamide, 42 mg (0.26 mmol) of the titled compound of
Preparation 28, 32 mg (0.23 mmol) of HOBT, 45 mg (0.23 mmol) of EDC and 0.16 mL (1.20 mmol) of triethylamine. The crude residue was purified using flash chromatography (eluent of 2% methanol in methylene chloride) to provide 102 mg of a white solid (mp 111- 113°C).
Yield: 76%.
1H NMR (CDCl3) : δ 7.89 (s, 1H), 7.75 (m, 2H),
7.52-7.21 (m, 9H), 7.00 (t, J=7.9 Hz, 1H),
6.62 (t, J=7.4 Hz, 1H),
6.41 (d, J=9.1 Hz, 1H),
6.09 (d, J=5.8 Hz, 1H), 5.91 (s, 1H),
4.48 (m, 1H), 4.01 (m, 1H), 3.69 (s, 1H),
3.50 (m, 2H), 3.01 (m, 2H), 2.85 (s, 3H),
2.15 (s, 3H), 1.45 (s, 9H).
Analysis for C34H39N3O3S:
Calcd: C, 71.67; H, 6.89; N, 7.37;
Found: C, 71.92; H, 6.74; N, 7.42.
Example 44
[2'R- (2 'R* , 3 'S*) ]-N-t-Butyl-2-[2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(2''-chloro-3''-aminophenyl)pentyl]benzamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 42, using 100 mg (0.23 mmol) of the subtitled compound of Preparation 25E in 2.0 mL of dimethylformamide, 48 mg (0.28 mmol) of 2-chloro-3-aminobenzoic acid, 32 mg (0.23 mmol) of HOBT, 45 mg (0.23 mmol) of EDC and 0.16 mL (1.20 mmol) of triethylamine. The crude residue was purified using flash chromatography (eluent of 2% methanol in methylene chloride) to provide 97 mg of a white solid (mp 107-108°C).
Yield: 72%.
1H NMR (CDCl3) : δ 7.89 (s, 1H), 7.78 (in, 2H),
7.61-7.23 (m, 9H), 6.95 (t, J=7.8 Hz, 1H),
6.78 (m, 1H), 6.52 (d, J=7.9 Hz, 1H),
6.05 (d, J=6.0 Hz, 1H), 5.92 (s, 1H),
4.51 (m, 1H), 4.21 (s, 2H), 4.16 (tn, 1H),
3.51 (m, 2H), 3.01 (m, 3H), 1.49 (s, 9H).
Analysis for C32H34ClN3O3S:
Calcd: C, 66.71; H, 5.95; N, 7.29;
Found: C, 66.85; H, 6.06; N, 7.42.
Example 45
[2'R- (2 'R* , 3 ' S*) ]-N-t-Butyl-2-[2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(2''-bromo-3''-aminophenyl)pentyl] benzamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 42, using 100 mg (0.23 mmol) of subtitled compound of Preparation 25E in 2.0 mL of dimethylformamide, 61 mg (0.28 mmol) of 2-bromo-3-aminobenzoic acid, 32 mg (0.23 mmol) of HOBT, 45 mg (0.23 mmol) of EDC and 0.16 mL (1.20 mmol) of triethylamine. The crude residue was purified using flash chromatography (eluent of 2% methanol in methylene chloride) to provide 102 mg of a white solid (mp 110-112°C).
Yield: 71%. 1H NMR (CDCl3) : δ 7.88 (s, 1H), 7.78 (m, 2H),
7.60-7.25 (m, 9H), 6.95 (t, J=7.8 Hz, 1H),
6.78 (m, 1H), 6.52 (d, J=7.9 Hz, 1H),
6.1 (d, J=6.1 Hz, 1H), 5.90 (s, 1H),
4.52 (m, 1H), 4.21 (s, 2H), 4.15 (tn, 1H),
3.50 (m, 2H), 3.00 (m, 3H), 1.49 (s, 9H) .
Analysis for C32H34BrN3O3S:
Calcd: C, 61.93; H, 5.52; N, 6.77;
Found: C, 61.82; H, 5.83; N, 6.63.
Exaraple 46
[2'R- (2'R*, 3'S*)]-N-t-Butyl-2-[2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''-hydroxyphenyl)pentyl] benzamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 42, using 75 mg (0.18 mmol) of subtitled compound of Preparation 25E in 2.0 mL of
dimethylformamide, 32 mg (0.21 mmol) of the subtitled compound of
Preparation 23C, 24 mg (0.18 mmol) of HOBT, 34 mg (0.18 mmol) of
EDC and 0.12 mL (0.88 mmol) of triethylamine. The crude residue was purified using flash chromatography (eluent of 1% methanol in methylene chloride) to provide 52 mg of a white solid (mp 119- 120°C)
Yield: 53%.
IR (KBr): 3297, 1636, 1518, 1284, 1221, 1073, 746 cm-1.
1H NMR (CDCl3) : δ 7.90 (s, 1H), 7.76 (m, 3H), 7.48 (m, 6H),
6.79 (m, 4H), 6.52 (d, J=9.2 Hz, 1H), 6.23 (s, 1H), 5.92 (s, 1H), 4.50 (m, 1H),
4.02 (m, 1H), 3.49 (m, 3H),
3.03 (dd, J=13.4, 10.2 Hz, 1H),
2.97 (dd, J=13.4, 3.4 Hz, 1H), 2.25 (s, 3H),
1.49 (s, 9H).
Analysis for C33H36N2O4S:
Calcd: C, 71.19; H, 6.52; N, 5.03;
Found: C, 70.95; H, 6.59; N, 4.87.
Example 47
[2'R- (2'R*, 3'S*)]-N-t-Butyl-2-[2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(2''-methyl-5''-aminophenyl)pentyl] benzamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 42, using 100 mg (0.23 mmol) of subtitled compound of Preparation 25E in 2.0 mL of dimethylformamide, 44 mg (0.28 mmol) of the titled compound of Preparation 29, 32 mg (0.23 mmol) of HOBT, 45 mg (0.23 mmol) of EDC and 0.16 mL (1.20 mmol) of triethylamine. The crude residue was purified using flash chromatography (eluent of 2% methanol in methylene chloride) to provide 101 mg of a white solid (mp 106-107°C).
Yield: 79%.
1H NMR (CDCl3) : δ 7.89 (s, 1H), 7.76 (m, 3H),
7.40-7.25 (m, 7H), 6.85 (t, J=9.0 Hz, 1H),
6.62 (d, J=7.7 Hz, 1H),
6.43 (d, J=9.0 Hz, 1H), 6.08 (d, J=5.8 Hz, 1H), 5.89 (s, 1H),
4.51 (m, 1H), 4.02 (m, 1H), 3.70 (br.s, 2H),
3.50 (tn, 3H), 3.04 (dd, J=13.3, 10.1 Hz, 1H),
2.92 (dd, J=13.3, 3.2 Hz, 1H), 2.21 (s, 3H),
1.50 (s, 9H).
Analysis for C33H37N3O3S:
Calcd: C, 71.32; H, 6.71; N, 7.56;
Found: C, 71.64; H, 6.93; N, 7.45.
Example 48
[2'R- (2'R*, 3'S*)]-N-t-Butyl-2-[2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''-hydroxyphenyl)pentyl]-1-naphthylamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 42, using 100 mg (0.21 mraol) of subtitled compound of Preparation 26D in 2.0 mL of dimethylformamide, 35 mg (0.23 mmol) of the subtitled compound of Preparation 23C, 29 mg (0.21 mmol) of HOBT, 40 mg (0.21 mmol) of EDC and 0.15 mL (1.10 mmol) of triethylamine. The crude residue was purified using flash chromatography (eluent of 1.5% methanol in methylene chloride) to provide 106 mg of a white solid (mp 115-117°C).
Yield: 82%.
1H NMR (CDCl3) : δ 7.90 (s, 1H), 7.76 (m, 2H),
7.53-7.24 (m, 11H), 6.B5 (t, J=7.6 Hz, 1H),
6.73 (m, 1H), 6.63 (d, J=5.7 Hz, 1H),
6.51 (d, J=9.2 Hz, 1H), 6.10 (s, 1H), 5.90 (s, 1H), 4.50 (m, 1H), 4.09 (m, 1H),
3.48 (tn, 2H), 3.10 (dd, J=12.9, 9.7 Hz, 1H),
2.88 (dd, J=12.9, 3.2 Hz, 1H), 2.13 (s, 3H),
1.46 (s, 9H).
Analysis for C37H38N2O4S:
Calcd: C, 73.24; H, 6.31; N, 4.62;
Found: C, 73.46; H, 6.70; N, 4.35.
Exaraple 49
[2'R- (2 'R* , 3 'S*) ]-N-t-Butyl-2-[2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(2''-chloro-3''-aminophenyl)pentyl] -1-naphthylamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 42, using 100 mg (0.21 mmol) of subtitled compound of Preparation 26D in 2.0 mL of dimethylformamide, 39 mg (0.23 mmol) of 2-chloro-3-aminobenzoic acid, (29 mg (0.21 mmol) of HOBT, 40 mg (0.21 mmol) of EDC, and 0.15 mL (1.10 mmol) of triethylamine. The crude residue was purified using flash chromatography (eluent of 1.5% methanol in methylene chloride) to provide 97 mg of a white solid (mp 110-112°C).
Yield: 74%.
1H NMR (CDCl3) : δ 7.90 (s, 1H), 7.81 (m, 4H),
7.75-7.21 (m, 9H), 6.95 (t, J=7.8 Hz, 1H),
6.75 (m, 1H), 6.51 (d, J=*8.2 Hz, 1H),
6.12 (d, J=5.9 Hz, 1H), 5.95 (s, 1H), 4.50 (m, 1H), 4.21 (s, 2H), 4.15 (m, 1H),
3.51 (m, 2H), 3.00 (m, 3H), 1.49 (s, 9H).
Analysis for C36H36ClN3O3S :
Calcd: C, 69.05; H, 5.79; N, 6.71;
Found: C, 69.21; H, 5.85; N, 6.54.
Example 50
[2'R-(2 'R*, 3 'S*) ]-N-t-Butyl-2-[2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(3''-aminophenyl)pentyl] benzamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 42, using 100 mg (0.23 mmol) of subtitled compound of Preparation 25E in 2.0 mL of dimethylformamide, 38 mg (0.28 mmol) of 3-aminobenzoic acid, 32 mg (0.23 mmol) of HOBT, 45 mg (0.23 mmol) of EDC, and 0.16 mL (1.20 mmol) of triethylamine. The crude residue was purified using flash chromatography (eluent of 2% methanol in methylene chloride) to provide 90 mg of a white solid (mp 101-102°C) .
Yield: 72%.
1H NMR (CDCl3) : δ 7.87 (s, 1H), 7.78 (m, 2H),
7.61-7.22 (m, 10H), 6.96 (t, J=7.7 Hz, 1H),
6.76 (m, 1H), 6.52 (d, J=7.8 Hz, 1H),
6.04 (d, J=6.1 Hz, 1H), 5.91 (s, 1H),
4.5 (m, 1H), 4.20 (s, 2H), 4.15 (m, 1H),
3.50 (m, 2H), 3.01 (m, 3H), 1.49 (s, 9H).
Analysis for C32H35N3O3S:
Calcd: C, 70.95; H, 6.51; N, 7.76;
Found: C, 71.21; H, 6.72; N, 7.72. Example 51
[2'R-(2 'R*, 3 'S*) ]-N-t-Butyl-2-[2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(3''-hydroxyphenyl)pentyl] benzamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 42, using 50 mg (0.12 mmol) of subtitled compound of Preparation 25E in 2.0 mL of
dimethylformamide, 20 mg (0.14 mmol) of 3-hydroxybenzoic acid, 16 mg (0.12 mmol) of HOBT, 22 mg (0.12 mmol) of EDC, and 0.081 mL (0.58 mmol) of triethylamine. The crude residue was purified using flash chromatography (eluent of 50% ethyl acetate in hexane) to provide 36 mg of a white solid (mp 125-128°C).
Yield: 57%.
1H NMR (CDCl3) : δ 7.87 (s, 1H), 7.73 (m, 3H),
7.20-7.50 (m, 7H), 6.95-7.15 (m, 4H),
6.80 (m, 1H), 6.80 (m, 1H), 6.50 (s, 1H),
6.30 (m, 1H), 5.95 (s, 1H), 4.53 (m, 1H),
4.10 (m, 1H), 3.45 (m, 2H), 3.03 (dd, J=13.4,
10.5 Hz, 1H), 2.90 (dd, J=13.4, 3.5 Hz , 1H),
1.46 (s, 9H).
HR MS for C32H34N2O4S:
Calcd: m/e 675.1294;
Found: m/e 675.1311.
Example 52
[2'R-(2 'R* , 3 'S*) ]-N-t-Butyl-2-[2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(2''-methylphenyl)pentyl] benzamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 42, using 50 mg (0.12 mmol) of subtitled compound of Preparation 25E in 2.0 mL of
dimethylformamide, 19 mg (0.14 mmol) of 2-methylbenzoic acid, 16 mg (0.12 mmol) of HOBT, 22 mg (0.12 mmol) of EDC, and 0.081 mL (0.58 mmol) of triethylamine. The crude residue was purified using flash chromatography (eluent of 40% ethyl acetate in hexane) to provide 33 mg of a white solid (m.p. 85-87°C).
Yield: 52%.
1H NMR (CDCl3) : δ 7.89 (d, J=1.0 Hz, 1H), 7.76 (m, 3H),
7.15-7.52 (m, 11H), 7.02 (t, J=7.4 Hz, 1H),
6.48 (d, J=9.0 Hz, 1H), 6.08 (d, J=6.1 Hz,
1H), 5.89 (s, 1H), 4.53 (m, 1H), 4.02 (m,
1H), 3.48 (d, J=6.8 Hz, 2H), 3.00 (dd,
J=13.4, 10.2 Hz, 1H), 2.92 (dd, J=13.4, 3.6
Hz, 1H), 2.46 (s, 3H), 1.45(s, 9H).
HR MS for C33H36N2O3S:
Calcd: m/e 673.1501;
Found: m/e 673.1504.
Example 53
[2'R- (2 'R*, 3 'S*) ]-N-t-Butyl-2-[2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(2''-methyl-3'',5''-diarainophenyl)pentyl] benzamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 42, using 50 mg (0.12 mmol) of subtitled compound of Preparation 25E in 2.0 mL of
dimethylformamide, 23 mg (0.14 mmol) of 2-methyl-3,5-diaminobenzoic acid, 16 mg (0.12 mmol) of HOBT, 22 mg (0.12 mmol) of EDC, and 0.081 mL (0.58 mmol) of triethylamine. The crude oil was purified by flash chromatography (eluent of 5% methanol in methylene chloride) to provide 28 mg of an off-white powder (m.p.
125-128°C).
Yield: 42%.
1H NMR (CDCl3) : δ 7.90 (d, J=1.2 Hz, 1H), 7.77 (m, 3H),
7.20-7.53 (m, 10H), 6.35 (d, J= 9.3 Hz, 1H),
6.15 (br.m, 1H), 6.01 (d, J=2.1 Hz, 1H),
5.92 (S, 1H), 5.83 (d, J=2.1 Hz, 1H),
4.50 (m, 1H), 3.96 (m, 1H), 3.50 (m, 4H),
3.03 (dd, J=13.4, 10.2 Hz, 1H),
2.91 (dd, J=13.4, 3.5 Hz, 1H), 2.10 (s, 3H),
1.47 (s, 9H).
HR MS for C33H3gN4O3S:
Calcd: m/e 703.1719;
Found: m/e 703.1733.
Example 54
[2'R- (2 'R*, 3 'S*) ]-N-t-Butyl-2-[2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(2'',2''-dichlorophenyl)pentyl] benzamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 42, using 75 mg (0.18 mmol) of subtitled compound of Preparation 25E in 1.0 mL of
dimethylformamide, 40 mg (0.21 mmol) of 2, 3-dichlorobenzoic acid,
24 mg (0.18 mmol) of HOBT, 34 mg (0.18 mmol) of EDC, and 0.12 mL
(0.88 mmol) of triethylamine. The crude oil was purified using flash chromatography (gradient eluent of 25-50% ethyl acetate in hexane) to provide 75 mg of a white solid (m.p. 116-119°C). Yield: 74%.
1H NMR (CDCl3) : δ 7.90 (s, 1H), 7.75 (m, 3H),
7.20-7.52 (m, 9H),
7.13 (dd, J=7.9, 1.2 Hz, 1H),
7.00 (t, J=7.8 Hz, 1H),
6.64 (d, J=9.9 Hz, 1H), 5.88 (br.s, 1H),
4.52 (m, 1H), 4.03 (m, 1H),
3.50 (d, J=6.0 Hz, 2H), 3.00 (m, 2H),
1.44 (s, 9H).
Analysis for C32H32Cl2N2O3S :
Calcd: C, 64.53; H, 5.42; N, 4.70;
Found: C, 64.54; H, 5.50; N, 4.73.
Example 55
[2'R- (2'R*, 3'S*)]-N-t-Butyl-2-[2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(2''-chloro-5''-aminophenyl)pentyl] benzamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 42, using 75 mg (0.18 mmol] of subtitled compound of Preparation 25E in 1.0 mL of
dimethylformamide, 36 mg (0.21 mmol) of the titled compound of
Preparation 29, 24 mg (0.18 mmol) of HOBT, 34 mg (0.18 mmol) of
EDC and 0.12 mL (0.88 mmol) of triethylamine. The crude oil was purified using flash chromatography (eluent of 50% ethyl acetate in hexane) to provide 90 mg of a white solid (m.p. 109-110°C).
Yield: 90%. 1H NMR (CDCl3) : δ 7.89 (s, 1H), 7.75 (m, 3H),
7.21-7.52 (m, 10H), 7.04 (d, J=8.3 Hz, 1H),
6.73 (m, 1H), 6.55 (m, 2H), 5.92 (br.s, 1H) ,
4.50 (m, 1H), 3.99 (m, 1H),
3.52 (d, J=5.6 Hz, 2H), 3.02 (m, 2H),
1.45 (s, 9H).
Analysis for C32H34ClN3O3S :
Calcd: C, 66.71; H, 5.95; N, 7.29;
Found: C, 66.94; H, 6.34; N, 6.92.
Example 56
[2'R- (2'R*, 3'S*)]-N-t-Butyl-2-[2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(2''-chloro-3''-hydroxyphenyl)pentyl] benzamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 42, using 75 mg (0.18 mmol) of subtitled compound of Preparation 25E in 1.0 mL of
dimethylformamide, 36 mg (0.21 mmol) of the titled compound of Preparation 14, 24 mg (0.18 mmol) of HOBT, 34 mg (0.18 mmol) of EDC, and 0.12 mL (0.88 mmol) of triethylamine. The crude oil was purified using flash chromatography (gradient eluent of 25-50% ethyl acetate in hexane) to provide 71 mg of a white solid (m.p. 104-105°C)
Yield: 71%
1H NMR (CDCl3) : δ 7.90 (d, J=1.0 Hz, 1H), 7.7 (m, 3H),
7.19-7.52 (m, 8H), 7.00 (m, 2H),
6.87 (m, 1H), 6.64 (d, J=9.1 Hz, 1H), 5.89 (s, 1H), 4.52 (tn, 1H), 4.04 (tn, 1H),
3.50 (d, J=6.1 Hz, 1H),
3.05 (dd, J=13.4, 10.2 Hz, 2H),
2.94 (dd, J=13.4, 3.6 Hz, 1H), 1.45 (s, 9H).
Analysis for C32H33ClN2O4S:
Calcd: C, 66.59; H, 5.76; N, 4.85;
Found: C, 66.64; H, 5.90; N, 4.93.
Example 57
[2'R-(2 'R*, 3 'S*) ]-N-t-Butyl-2-[2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(isoquinolin-5''-yl)pentyl]
benzamide
To a solution of 0.40 g (0.95 mmol) of the subtitled compound of Preparation 25E and 134 μL (1.22 mmol) of N-methyl morpholine in 15 mL of tetrahydrofuran, was added 0.45 g (1.33 mmol) of the subtitled compound of Preparation 30C. The resultant reaction mixture was reacted for approximately 8 hours and then diluted with ethyl acetate. The resultant layers were separated and the organic layer was washed sequentially with water, and brine, and then concentrated to provide a crude material. This crude material was purified using flash chromatography (silica; eluent of 4% methanol in methylene chloride) to provide
0.53 g of a white solid (m.p. 109-112°C).
Yield: 97%.
1H NM1 (CDCl ) : δ 9.19 (s, 1H), 8.50 (d, J=4.6 Hz, 1H),
8.23 (d, J=5.9 Hz, 1H), 7.92 (m, 2H),
7.76 (m, 3H), 7.56 (tn, 3H), 7.43 (m, 3H), 7.32 (m, 2H), 7.24 (m, 1H),
6.88 (d, J=9.0 Hz, 1H), 6.05 (br.s, 1H),
5.93 (s, 1H), 4.64 (m, 1H), 4.12 (m, 1H),
3.51 (d, J=6.3 Hz, 2H), 3.01 (m, 2H),
1.40 (s, 9H).
IR (neat film) :
3428, 3019, 2978, 1647, 1514, 1215, 758 cm-1.
HR MS for C35H36N3O3S (MH+):
Calcd: 578.2477;
Found: 578.2468.
Analysis for C35H35N3O3S· 0.17 CH2Cl2 :
Calcd: C, 71.33; H, 6.02; N, 7.10; S, 5.41;
Found: C, 71.35; H, 6.00; N, 7.09; S, 5.44.
Exaraple 58
[2'R- (2 'R* , 3 'S*) ]-N-t-Butyl-2-[2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(1",2",3",4"-tetrahydroisoquinolin-5''-yl)pentyl] benzamide
To a solution of 0.15 g (0.26 mmol) of the titled compound of
Example 57 in 6 mL of acetic acid, was added 0.08 g (1.27 mmol) of sodium cyanoborohydride. The resultant reaction mixture was reacted for approximately 1 hour, and then was quenched by the addition of a saturated solution of sodium bicarbonate. The desired compound was then extracted using ethyl acetate and the organic extracts were washed sequentially with water, and brine, and then concentrated under reduced pressure to provide a foam.
This foam was purified using flash chromatography (silica; eluent of 4% methanol in methylene chloride) to provide 0.10 g of a white amorphous solid (m.p. 197-199°C).
Yield: 66%.
1H NMR (CDCl3) : δ 7.85 (s, 1H), 7.75 (m, 3H),
7.50-7.20 (m, 7H), 7.06 (m, 1H),
6.95 (m, 2H), 6.59 (d, J=9.1 Hz, 1H),
6.02 (s, 1H), 4.48 (br.s, 1H),
4.00 (br.s, 1H), 3.98 (s, 2H), 3.45 (m, 2H),
3.01 (s, 1H), 2.98 (d, J=6.0 Hz, 3H),
2.89 (m, 3H), 1.44 (s, 9H), OH not observed.
IR (neat film) :
3418, 3281, 3019, 1632, 1516, 1215, 756;
HR MS for C35H40N3O3S:
Calcd: 582.2790;
Found: 582.2792.
Analysis for C35H35N3O3S·0.17 CH2Cl2 :
Calcd: C, 70.85; H, 6.65; N, 7.05; S, 5.38;
Found: C, 70.85; H, 6.74; N, 7.16; S, 5.42.
Example 59
[2'R-(2 'R* , 3 'S*) ]-N-t-Butyl-2-[2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-[2-N(methyl)-1'',2'',3'',4''-tetrahydroisoquinolin-5''-yl)pentyl] benzamide
To a hot (60°C) solution of 0.11 g (0.19 mmol) of the titled compound of Example 57 in 3 mL of tetrahydrofuran, was added 53 mg
(1.40 mmol) of sodium borohydride and 75 μL of formic acid.
After approximately 1 hour, the reaction mixture was quenched by the addition of a saturated sodium bicarbonate solution. The desired compound was then extracted using ethyl acetate and the organic extracts were washed sequentially with water, and brine, and then concentrated to provide a foam. This foam was purified using flash chromatography (silica; eluent of 5% methanol in methylene chloride) to provide 0.05 g of a white amorphous solid (m.p. 110-113°C).
Yield: 44%.
1H NMR (CDCl3) : δ 7.86 (s, 1H), 7.75 (m, 3H),
7.50-7.20 (tn, 7H), 7.00 (m, 3H),
6.46 (d, J=9.0 Hz, 1H),
6.13 (d, J=5.0 Hz, 1H), 5.96 (s, 1H),
4.45 (m, 1H), 3.97 (m, 1H), 3.54 (s, 2H),
3.46 (m, 2H), 3.20-2.90 (m, 4H),
2.60 (t, J=5.9 Hz, 2H), 2.40 (s, 3H),
1.44 (s, 9H).
IR (n at film) :
3432, 3019, 2976, 1645, 1516, 1215, 756 cm-1.
HRMS for C36H42N3O3S (MH+) :
Calcd: 596.2947;
Found: 596.2939.
Analysis for C36H41N3O3S· 0.32 CH2Cl2 :
Calcd: C, 70.02; H, 6.74; N, 6.75; S, 5.15;
Found: C, 70.03; H, 6.74; N, 6.81; S, 5.24. Example 60
[2'R- (2 'R*, 3 'S*) ]-N-t-Butyl-2-[2'-hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(1'',2'',3'',4''-tetrahydroisoquinolin-5''-yl)pentyl] benzamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 58.
1H NMR (CDCl3) : δ 7.42 (m, 10H), 7.00 (m, 3H),
6.28 (d, J=9.4 Hz, 1H), 5.95 (s, 1H),
4.60 (m, 1H), 3.95 (bs, 3H),
2.80-3.20 (m, 7H), 2.62 (m, 1H),
1.47 (s, 9H).
Analysis for C3 1H3 7N3O3 ·MeOH:
Calcd: C, 72.29; H, 7.77; N, 7.90;
Found: C, 72.61; H, 7.58; N, 7.61.
Example 61
[2'R- (2 'R* , 3 'S*) ]-N-t-Butyl-2-[2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(naphth-1''-yl)pentyl] benzamide
To a cold (0°C) solution of 100 mg (0.23 mmol) of the subtitled compound of Preparation 25E in 2.0 mL of
dimethylformamide, was added 45 mg (0.26 mmol) of naphthalene-1-carboxylic acid, 32 mg (0.23 mmol) of HOBT, 45 mg (0.23 mmol) of
EDC and 0.16 mL (1.20 mmol) of triethylamine. The resultant reaction mixture was reacted for approximately 1 hour at 0°C and
16 hours at room temperature, then diluted with 10 mL of ethyl acetate. The resultant mixture was washed with water, dried over sodium sulfate, filtered and then concentrated under reduced pressure to provide a residue. This residue was purified using flash chromatography (eluent of 1% methanol in methylene chloride) to provide 82 mg of a white solid (m.p. 92-95°C).
Yield: 63%.
1H NMR (CDCl3) : δ 8.35 (br.s, 1H), 7.95-7.68 (m, 7H),
7.62-7.30 (m, 10H), 6.71 (d, J=8.9 Hz, 1H),
6.10 (d, 6.2 Hz, 1H), 5.89 (s, 1H), 4.61 (m, 1H), 4.26 (m,
1H),
3.51 (d, J=8.9 Hz, 2H), 3.0 (m, 2H),
1.51 (s, 9H).
Analysis for C36H36N2O3S:
Calcd: C, 74.97; H, 6.29; N, 4.86;
Found: C, 75.13; H, 6.45; N, 4.49.
Exaraple 62
[2'R- (2 'R* , 3 'S*) ]-N-t-Butyl-2-[2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(indol-4''-yl)pentyl] benzamide
The titled compound was prepared and substantially in
accordance with the procedure detailed in Example 61, using 100 mg
(0.23 mmol) of the subtitled compound of Preparation 25E, 42 mg
(0.26 mmol) of the titled compound of Preparation 32, 32 mg (0.23 mmol) of HOBT, 45 mg (0.23 mmol) of EDC, and 0.16 mL (1.20 mmol) of triethylamine in 2.0 mL of dimethylformamide. The crude residue was purified using flash chromatography (eluent of 1% methanol in methylene chloride) to provide 43 mg of a white solid
(m.p. 109-110°C).
Yield: 35%. 1H NMR (CDCl3) : δ 8.45 (br.s, 1H), 7.90 (s, 1H),
7.76 (m, 3H), 7.57-7.23 (m, 10H),
7.19-6.89 (m, 3H), 6.24 (d, J=6.2 Hz, 1H),
5.97 (s, 1H), 4.63 (m, 1H), 4.13 (m, 1H),
3.51 (m, 2H), 3.01 (m, 2H), 1.49 (s, 9H),
Analysis for C H36N3O3S:
Calcd: C, 72.18; H, 6.24; N, 7.43;
Found: C, 72.31; H, 6.37; N, 7.22.
Example 63
[2'R-(2 'R*, 3 'S*) ]-N-t-Butyl-2-[2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(quinolin-5''-yl)pentyl] benzamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 57, using 0.060 g (0.15 mmol) of the subtitled corapound of Preparation 25E, 42 μL(0.38 mmol) of N-methylmorpholine, and 0.074 g (0.38 mmol) of the titled compound of Preparation 31 in 2 mL of tetrahydrofuran to provide 0.045 g of the white solid.
Yield: 54%.
1H NMR (CDCl3) : δ 8.85 (tn, 1H), 8.75 (m, 1H),
8.75 (d, J=8.21 Hz, 1H), 8.07 (m, 2H),
7.95 (s, 1H), 7.76 (m, 3H), 7.64 (m, 2H),
7.54 (m, 2H), 7.44 (m, 2H), 7.38 (m, 3H),
7.25 (m, 1H), 4.88 (s, 2H), 4.45 (m, 1H),
4.05 (m, 1H), 3.69 (dd, J=14 , 3.09 Hz, 1H)
3.23 (m, 1H), 3.05 (m, 2H), 1.32 (s, 9H). IR (KBr) : 3485, 3429, 3279, 3061, 2964, 1638, 1543, 1454, 1364, 1319, 1219, 1072, 806, 746 cm-1.
HR MS for C35H36N3O3S (MH+) :
Calcd: 578.2477;
Found: 578.2491.
Analysis for C35H35N3O3S· 0.6H2O:
Calcd: C, 71.42; H, 6.20; N, 7.14; S, 5.45;
Found: C, 71.44; H, 6.16; N, 7.19; S, 5.41.
Exaraple 64
[2'R- (2 'R* , 3 'S*) ]-N-t-Butyl-2-[2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(1'',2'',3'',4''-tetrahydroquinolin-5''-yl)pentyl] benzamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 58, using 0.023 g (0.36 mmol) of sodium cyanoborohydride, 0.041 g (0.07 mmol) of the titled compound of Example 63, and 2 mL of acetic acid to provide 0.024 g of a white amorphous solid.
Yield: 60%.
1H NMR (CDCl3) : δ 7.88 (s, 1H), 7.75 (m, 3H), 7.42 (m, 6H),
6.79 (t, J=7.73 Hz, 1H),
6.54 (d, J=7.28 Hz, 1H),
6.44 (d, J=8.15 Hz, 2H), 6.10 (br. 1H),
5.91 (br.s, 1H), 4.45 (m, 1H), 4.05 (m, 1H),
3.48 (m, 2H), 3.24 (t, J=5.50 Hz, 2H),
2.89 (tn, 4H) 1.85 (m, 2H), 1.46 (s, 9H). IR (KBr): 3450, 2972, 1638, 1618, 1591, 1512, 1454, 1309, 1119, 1134, 1086, 814, 698, 621cm-1.
HR MS for C35H40N3O3S (MH+) :
Calcd: 582.2790;
Found: 582.2792.
Example 65
[2'R-(2 'R* , 3 'S*) ]-N-t-Butyl-2-[2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(indolin-4''-yl)pentyl] benzamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 61, using 100 mg (0.23 mmol) of the subtitled compound of Preparation 25E, 42 mg (0.26 mmol) of the titled compound of Preparation 32, 32 mg (0.23 mmol) of HOBT, 45 mg (0.23 mmol) of EDC, and 0.16 mL (1.20 mmol) of triethylamine in 2.0 mL of dimethylformamide. The crude residue was purified using flash chromatography (eluent of 1.5% methanol in methylene chloride) to provide 12 mg of a white solid (m.p. 83- 04°C).
Yield: 9%.
1H NMR (CDCl3) : δ 7.99 (s, 1H), 7.76 (m, 3H),
7.69-7.23 (m, 10H), 7.10 (d, J=8.8 Hz, 1H),
6.60 (d, J=8.9 Hz, 1H),
5.99 (d, J=6.2 Hz, 1H), 5.89 (s, 1H),
4.53 (m, 1H), 4.11 (m, 1H), 3.44 (m, 6H),
3.01 (m, 2H), 1.49 (s, 9H).
Analysis for C34H37N3O3S:
Calcd: C, 71.92; H, 6.57; N, 7.40;
Found: C, 72.21; H, 6.72; N, 7.26. Example 66
[2'R- (2 'R*, 3 'S*) ]-N-t-Butyl-2-[2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(quinolin-4''-yl)pentyl] benzamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 61, using 100 mg (0.23 mmol) of the subtitled compound of Preparation 25E, 45 mg (0.26 mmol) of quinoline-4-carboxylic acid, 32 mg (0.23 mmol) of HOBT, 45 mg (0.23 mmol) of EDC, and 0.16 mL (1.20 mmol) of triethylamine in 2.0 mL of dimethylformamide. The crude residue was purified using flash chromatography (eluent of 1.5% methanol in methylene chloride) to provide 42 mg of a white solid (m.p. 89-92°C).
Yield: 32%.
1H NMR (CDCl3) : δ 8.59 (s, 1H), 8.33 (d, J=7.9 Hz, 1H),
8.09 (d, J=8.4 Hz, 1H), 7.93 (s, 1H),
7.80-7.71 (m, 4H), 7.69-7.25 (m, 8H),
7.15 (s, 1H), 6.88 (d, J=8.4 Hz, 1H),
5.99 (s, 1H), 5.85 (s, 1H), 4.63 (m, 1H),
4.21 (m, 1H), 3.51 (d, 6.2 Hz, 2H),
3.02 (m, 2H), 1.39 (s, 9H).
Analysis for C35H35N3O3S:
Calcd: C, 72.76; H, 6.11; N, 7.27;
Found: C, 72.91; H, 6.33; N, 7.36. Example 67
[2'R-(2 'R*, 3 'S*) ]-N-t-Butyl-2-[2'-hydroxy-3'-naphth-2-hiomethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''-nitrophenyl)pentyl] benzamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 61, using 100 mg (0.23 mmol) of the subtitled compound of Preparation 25E, 47 mg (0.26 mmol) of 2-methyl-3-nitrobenzoic acid, 32 mg (0.23 mmol) of HOBT, 45 mg (0.23 mmol) of EDC, and 0.16 mL (1.20 mmol) of triethylamine in 2.0 mL of dimethylformamide. The crude residue was purified using flash chromatography (eluent of 1% methanol in methylene chloride) to provide 100 mg of a white solid (m.p. 80-81°C).
Yield: 74%.
1H NMR (CDCl3) : δ 7.89 (s, 1H), 7.75 (m, 3H),
7.65-7.25 (tn, 9H), 7.10 (d, J=7.9 Hz, 1H),
6.63 (d, J=8.9 Hz, 1H),
5.97 (d, J=6.0 Hz, 1H), 5.87 (s, 1H),
4.53 (m, 1H), 4.11 (m, 1H),
3.44 (m, J=6.3 Hz, 2H),
3.03 (dd, J=13.3, 10.2 Hz, 1H),
2.28 (dd, J=13.5, 2.8 Hz, 1H),
2.53 (s, 3H), 1.47 (s, 9H).
Analysis for C33H35N3O5S:
Calcd: C, 67.67; H, 6.02; N, 7.17;
Found: C, 67.83; H, 5.93; N, 7.05. Example 68
[2'R-(2 'R*, 3 'S*) ]-N-t-Butyl-2-[2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(3''-nitro-6''-methylphenyl)pentyl] benzamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 61, using 100 mg (0.23 mmol) of the subtitled compound of Preparation 25E, 47 mg (0.26 mmol) of 2-methyl-5-nitrobenzoic acid, 32 mg (0.23 mmol) of HOBT, 45 mg (0.23 mmol) of EDC, and 0.16 mL (1.20 mmol) of triethylamine in 2.0 mL of dimethylformamide. The crude residue was purified using flash chromatography (eluent of 1% methanol in methylene chloride) to provide 102 mg of a white solid (m.p. 85-88°C).
Yield: 75%.
1H NMR (CDCl3) : δ 8.17 (s, 1H), 8.07 (d, J=8.4 Hz, 1H),
7.78 (m, 2H), 7.59-7.22 (m, 10H),
6.71 (d, J=8.9 Hz, 1H),
6.03 (d, J=6.1 Hz, 1H), 5.9 (s, 1H),
4.52 (m, 1H), 4.13 (m, 1H),
3.45 (d, J=6.2 Hz, 2H),
3.03 (dd, J=13.3, 9.61 Hz, 1H),
2.9 (dd, J=13.3, 3.72 Hz, 1H),
2.55 (s, 3H), 1.43 (s, 9H).
Analysis for C33H35N3O5S:
Calcd: C, 67.67; H, 6.02; N, 7.17;
Found: C, 67.92; H, 6.22; N, 7.02. Example 69
[2'R-(2 'R*, 3 'S*) ]-N-t-Butyl-2-[2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(1''-N(methyl)indol-4''-yl)pentyl] benzamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 61, using 100 mg (0.23 mmol) of the subtitled compound of Preparation 25E, 46 mg (0.26 mmol) of 1-N-methyl-4-carboxylic acid indoline, 32 mg (0.23 mmol) of HOBT, 45 mg (0.23 mmol) of EDC, and 0.16 mL (1.20 mmol) of triethylamine in 2.0 mL of dimethylformamide. The crude residue was purified using flash chromatography (eluent of 1% methanol in methylene chloride) to provide 42 mg of a white solid (m.p. 86-89°C).
Yield: 31%.
1H NMR (CDCl3) : δ 7.88 (s, 1H), 7.79-7.65 (m, 3H),
7.53-6.95 (m, 13H), 6.22 (d, J=6.3 Hz, 1H),
5.99 (s, 1H), 4.67 (m, 1H), 4.13 (m, 1H),
3.75 (s, 3H), 3.51 (m, 2H), 3.03 (m, 2H),
1.49 (s, 9H).
Analysis for C35H35N3O3S:
Calcd: C, 72.51; H, 6.43; N, 7.25;
Found: C, 72.83; H, 6.51; N, 7.15.
Exaraple 70
[2'R- (2 'R*, 3 'S*) ]-N-t-Butyl-2-[2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(2''-methyl-3'',4''-dihydroxyphenyl)pentyl] benzamide
The titled compound was prepared substantially in accordance with the procedure detailed in Example 61, using 100 mg (0.23 mmol) of the subtitled compound of Preparation 25E, 44 mg (0.26 mmol) of the subtitled compound of Preparation 33C, 32 mg (0.23 mmol) of HOBT, 45 mg (0.23 mmol) of EDC, and 0.16 mL (1.20 mmol) of triethylamine in 2.0 mL of dimethylformamide. The crude residue was purified using flash chromatography (eluent of 2.5% methanol in methylene chloride) to provide 76 mg of a white solid (m.p. 121-123°C).
Yield: 58%.
1H NMR (CDCl3) : δ 7.89 (s, 1H), 7.75 (m, 2H),
7.55-7.22 (m, 10H), 6.85 (t, J=7.9 Hz, 1H),
6.72 (m, 2H), 6.61 (d, J=5.7 Hz, 1H),
6.50 (d, J=9.4 Hz, 1H), 6.13 (s, 1H),
5.92 (s, 1H), 4.51 (m, 1H), 4.09 (m, 1H),
3.51 (m, 2H), 3.12 (dd, J=13.1, 10 Hz, 1H),
2.87 (dd, J=13.1, 3.1 Hz, 1H), 2.13 (s, 3H),
1.46 (s, 9H).
Analysis for C33H36N2O5S:
Calcd: C, 69.21; H, 6.34; N, 4.89;
Found: C, 69.43; H, 6.72; N, 4.72.
Example 71
[2'R-(2 'R* , 3 'S*) ]-N-t-Butyl-2-[2'-hydroxy-3'-naphth-2-ylthiomethγl-4'-aza-5'-oxo-5'-(3''-hydroxyphenyl)pentyl] benzamide
The desired titled compound was prepared substantially in accordance with the procedure detailed in Example 61, using 100 mg
(0.23 mmol) of the subtitled compound of Preparation 25E, 45 mg
(0.26 mmol) of 2-chloro-4-aminobenzoic acid, 32 mg (0.23 mmol) of
HOBT, 45 mg (0.23 mmol) of EDC, and 0.16 mL (1.20 mmol) of triethylamine in 2.0 mL of dimethylformamide. The crude residue was purified using flash chromatography (eluent of 2% methanol in methylene chloride) to provide 92 mg of a white solid (m.p. 102- 104°C).
Yield: 69%.
1H NMR (CDCl3) : δ 7.88 (s, 1H), 7.77 (m, 2H),
7.61-7.23 (m, 9H), 6.95 (t, J=7.7 Hz, 1H),
6.75 (m, 1H), 6.51 (d, J=7.8 Hz, 1H),
6.06 (d, J=6.1 Hz, 1H). 5.90 (s, 1H),
4.51 (m, 1H), 4.20 (s, 2H), 4.12 (m, 1H),
3.50 (m, 2H), 3.01 (tn, 3H), 1.48 (s, 9H).
Analysis for C32H34ClN3O3S:
Calcd: C, 66.71; H, 5.95; N, 7.29;
Found: C, 66.92; H, 5.97; N, 7.16.
Exaraple 72
[2'R- (2 'R* , 3 'S*) ]-N-t-Butyl-2-[2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(2''-methyl-5''- hydroxyphenyl)pentyl] benzamide
The desired titled compound was prepared substantially in accordance with the procedure detailed in Example 61, using 100 mg
(0.23 mmol) of the subtitled compound of Preparation 25E, 47 mg
(0.26 mmol) of the subtitled compound of Preparation 29B, 32 mg
(0.23 mraol) of HOBT, 40 mg (0.23 mmol) of EDC, and 0.16 mL (1.20 mmol) of triethylamine in 2.0 mL of dimethylformamide. The crude residue was purified using flash chromatography (eluent of 3% methanol in methylene chloride) to provide 86 mg of a white solid
(m.p. 104-106°C). Yield: 67%.
1H NMR (CDCl3) : δ 7.85 (s, 1H), 7.72 (tn, 3H),
7.60-7.22 (m, 9H) ,
6.92 (t, J=7.5 Hz, 1H) ,6.72 (m, 1H),
6.50 (d, J=7.6 Hz, 1H), 5.96 (s, 1H),
5.90 (s, 1H), 4.50 (m, 1H),
4.15 (m, 1H) . 4.02 (m, 1H), 2.51 (m, 2H),
3.01 (m, 3H), 2.36 (s, 3H), 1.45 (s, 9H).
Analysis for C33H37N3O3S:
Calcd: C, 71.32; H, 6.71; N, 7.56;
Found: C, 71.56; H, 6.76; N, 7.52.
Exaraple 73
[2'R- (2'R*, 3'S*)]-N-t-Butyl-2-[2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(3''-hydroxy-4''-aminophenyl)pentyl] benzamide
The desired titled compound was prepared substantially in accordance with the procedure detailed in Example 61, using 100 mg
(0.23 mmol) of the subtitled compound of Preparation 25E, 40 mg
(0.26 mmol) of 3-hydroxy-4-aminobenzoic acid, 32 mg (0.23 mmol) of
HOBT, 45 mg (0.23 mmol) of EDC, and 0.16 mL (1.20 mmol) of
triethylamine in 2.0 mL of dimethylformamide. The crude residue was purified using flash chromatography (eluent of 3% methanol in methylene chloride) to provide 43 mg of a white solid (m.p. 119- 122°C).
Yield: 34%. 1H NMR (CDCl3) : δ 7.91 (s, 1H), 7.75 (m, 2H),
7.60-7.20 (m, 10H), 6.96 (t, J=7.9 Hz, 1H),
6.75 (m, 1H), 6.55 (d, J=7.8 Hz, 1H),
6.1 (s, 1H), 5.95 (s, 1H), 4.51 (m, 1H),
4.23 (s, 2H), 4.12 (ra, 1H) . 3.52 (tn, 2H),
3.00 (m, 3H), 1.48 (s, 9H) .
Analysis for C32H35N2O4S:
Calcd: C, 68.92; H, 6.33; N, 7.53;
Found: C, 69.12; H, 6.57; N, 7.32.
Reaction Scheme III shows the structures of compounds in Examples 74 A through L below.
Figure imgf000220_0001
Figure imgf000221_0001
Example 74
Example A
N-(Benzyloxycarbonyl)-3-(2-thienyl)-D,L-alanine
Into a 500 ml flask was placed 3.0 g of 3-(2-Thienyl)-D,L-alanine (optically active material in the L-form is available from Aldrich or SIGMA and could be used to obtain an optically active product) in 75 ml H2O/60 ml dioxane, and 5.6 g K2CO3 was added, followed by 2.85 ml of carbobenzyloxy chloride. The mixture was stirred rapidly for 1 hour. TLC (21/7/7/9, EtOAc/AcOH/CH3CN/H 0) showed that the starting material was gone. A new higher Rf product was seen. The dioxane was concentrated off and the aqueous layer was washed with Et2O (75 ml). The aqueous layer was mixed with CH2Cl2 (150 ml) and acidified to pH = 2.0 with 5 N HCl. The desired N-(Benzyloxycarbonyl)-3-(2-thienyl)-D,L-alanine was extracted with CH2Cl2. The organic layer was separated and dried with Na2SO4, filtered, and concentrated to give 5.05 g of desired
N-(Benzyloxycarbonyl)-3-(2-thienyl)-D,L-alanine (98% yield).
1 H NMR (300 MHz, CDCl3): δ 7.37 (m, 5H);
7.18 (d, J=4Hz, 1H); 6.95 (m, 1H); 6.83 (m, 1H);
5.35 (d, J=8Hz, 1M); 5.15 (s, 2H); 4.7 (m, 1H);
and 3.4 (m, 2H).
Example B
N-(Benzyloxycarbonyl)-3-(2-thienyl)-L-alanine
tert-butyl amide
Into a 500 ml flask was placed 8.06 g of the subtitled compound of Example A, N-(Benzyloxycarbonyl)-3-(2-thienyl)-L-alanine, in 130 ml of THF. The compound was cooled to 0°C. N- Methylmorpholine (4.23 ml) was added, followed by
isobutylchloroformate (4.04 ml) over two minutes. The mixture was stirred for 15-20 minutes, and 3.74 ml of t-butylamine was added. The bath was removed, and the mixture was stirred at room
temperature for two hours . The mixture was concentrated on rotovap, and the residue was taken up in ethyl acetate. The residue was washed successively with H2O, HCl, and saturated
NaHCO3 solution. The organics were separated and dried with
Na2SO4, filtered, and concentrated to an oil. The oil was
dissolved in 100 ml hot hexane and cooled in a refrigerator overnight to give a solid. The hexane was decanted, followed by drying to yield a solid of 9.25 g N-(carbobenzyloxy)-3-(2-thienyl)-L-alanine-tert-butylamide (97% yield).
1H NMR (300 MHz, CDCl3): δ 7.37 (s, 5H);
7.2 (d, J-4HZ, 1H); 6.95 (dd, J=4Hz, 8Hz, 1H);
6.87 (d, J=4Hz, 1H); 5.52 (m, 2H); 5.12 (s, 2H);
4.27 (m, 1H); 3.27 (m, 2H), and 1.23 (s, 9H).
Example C
N-t-butyl-5-benzyloxycarbonyl-(4, 5, 6, 7)-tetrahydrothieno[3,2- c]pyridine-6S-N-t-butyl carboxamide
Into a 50 ml flask was placed 500 mg of the subtitled
compound of Example B, N-(Benzyloxycarbonyl)-3-(2-thienyl)-L-alanine tert-butyl amide, in 12 ml of 1,1,2 trichloroethane. 2 ml of TFA was added, followed by 2 ml dimethoxymethane. The mixture was heated to reflux, followed by TLC every five minutes. After 15 minutes, TLC showed that the starting material was gone. Mostly, the desired product was obtained, removed from heat, and poured into 30 ml of H2O containing 3.5 g K2CO3 and 40 ml CH2Cl2. The desired product was transferred to a separatory funnel, and the organics were separated and dried with Na2SO4, filtered, and concentrated to oil. The product was purified by flash
chromotography through 25 g (SiO2) with 3% EtOAc/CH2Cl2. 357 mg of N-t-butyl-5-benzyloxycarbonyl-(4, 5, 6, 7)-tetrahydrothieno[3,2-c]pyridine-6S-N-t-butyl carboxamide (69% yield) was obtained.
A period of fifteen minutes from time of reflux to removal of heating source and immediate work-up are very important to avoid side reactions.
1 H NMR (300 MHz, d6 DMSO) : δ 7.35 (m, 7H); 6.83 (m, 1H);
5.15 (m, 2H); 4.98 (m, 1H) ; 4.35 (m, 2H);
3.10 (tn, 2H); and 1.10 (s, 9H).
MS: m/e 372 (M+)
Exaraple D
[6S- ( 6R*, 3aS*, 7aR*) ]-N-(Benzyloxycarbonyl)- octahydrothieno[3,2-c]pyridine-6-N-t-butyl carboxamide
Into a high pressure hydrogenation vessel was placed the subtitled compound of Example C, N-t-butyl-5-benzyloxycarbonyl- (4, 5, 6, 7)-tetrahydro-thieno [3,2-c] pyridine-6S-N-t-butyl
carboxamide, (10.5 g) and 105 g of 5% Pd on carbon in 1100 ml of
THF and 525 ml of ETOH. The mixture was placed under H2 (3000 psi) at 80°C for 24 hours. The reaction mixture was cooled and the catalyst was filtered and washed with 20% MeOH/CHCl3. The organic filtrate was combined and concentrated to a crude oil. The oil was taken up in CH2Cl2 and flash chroraatographed on 250 g of (Si02) eluted with 2% MeOH/CH2Cl2. The desired cis isomer (major) came through contaminated with a small amount of a minor isomer. This mixture was recrystallized by dissolving in 1.5 ml of MeOH, adding 20 ml of Et2O, followed by adding 120 ml of hexane, and the mixture was placed in a refrigerator overnight. The crystals obtained were filtered, washed with cold hexane and dried under vacuum to give 2.54 g of the cis isomer [6S-(6R*,3aS* , 7aR*) ]-N-(benzyloxycarbonyl)octahydrothieno[3,2-c]pyridine-6-N-t-butyl carboxamide (24% yield).
H NMR (300 MHz, CDCl3): δ 7.37 (s, 5H);
6.0 and 5.5 (br.s, 1H); 5.18 (br.s, 2H);
4.22 (m, 2H); 3.40 (m, 1H); 2.87 (m, 3H);
2.48 (m, 1H); 2.15 (m, 2H); 1.70 (m, 1H); and
1.15 (br.s, 9H).
MS: m/e 377 (M+ +1).
Example E
[ 6S - ( 6R* , 3aS* , 7aR*) ]-Octahydrothieno
[3 , 2 -c]pyridine-6-N-t-butyl carboxamide
Into a 100 ml flask was placed 2.41 g of the subtitled compound of Example D, [6S- ( 6R*, 3aS* , 7aR*)]-N- (Benzyloxycarbonyl)-octahydrothieno[3,2-c]pyridine-6-N-t-butyl carboxamide, in 12 ml of 1:1 CH3CN/CH2Cl2. The first portion of trimethylsilyl iodide (TMSI) (1.9 ml) was added and stirred for 10 minutes. A second portion of TMSI (0.94 ml) was added and stirred for 10 minutes. A third portion of TMSI (0.48 ml) was added and stirred for 30 minutes. The TLC (5% EtOAc/CH2Cl2) showed that the starting material was gone. The reaction mixture was diluted with 30 ml of diethylether and 40 ml of H2O and 6 ml of 1 N HCl. The ether layer was separated and washed with 15 ml of 0.1 N HCl. The combined ether layers were discarded, and aqueous washes were combined. Saturated NaHCO3 was added to adjust the pH of the aqueous layer to 8. The aqueous layer was extracted twice with 200 ml CH2Cl2, and the organic layers were combined and dried over Na2SO4. The solution was filtered and concentrated to give 1.3 g (84% yield) of desired [6S- ( 6R*, 3aS*,
7aR*) ]-octahydrothieno[3,2-c]pyridine-6-N-t-butyl carboxamide.1H NMR (300 MHz, CDCl3): δ 6.43 (s, 1H); 3.22 (m, 2H);
2.95 (m, 4H); 2.17 (m, 3H); 2.0 (m, 1H);
1.55 (m, 2H); and 1.32 (s, 9H).
[α]D (EtOH) = -179.1° (at 25°C).
Example F
[6S- ( 6R* , 3aS* , 7aR* , 2 'S* , 3 'S*)]-5-[2-Hydroxy-4- phenylthio-3- (benzoxycarbonyl)-aminobutyl]
-octahydrothieno[3,2-c]pyridine-6-N-t-butyl
carboxamide
Into a 100 ml flask was placed 1.45 g of [1'R-(1'R* , IS*)]-1- [(1'-N-(Benzyloxycarbonyl)amino-2'-(phenylthio)ethyl] oxirane (obtained following Preparation 8E ( [1'R-(1'R*,1S*)]-1-[(1'-N- (Benzyloxycarbonyl)amino-2'-(phenylthio)ethyl] oxirane may also be obtained as set forth in Example M below)) and 1.07 g of the subtitled compound of Example 75, [6S- ( 6R*, 3aS*, 7aR*) ] -Octahydrothieno[3,2-c]pyridine-6-N-t-butyl carboxamide, in 30 ml of EtOH, and the mixture was heated to 65°C for 60 hours. The reaction mixture was concentrated to a foam and purified on chromatotron (4000 micron plate), eluted with 1% MeOH/CH2Cl2. The desired fractions were concentrated to give 1.8 g of desired
[6S-(6R*, 3aS*, 7aR*, 2'S*, 3'S*)]-5-[2-Hydroxy-4-phenylthio-3-(benzoxycarbonyl)-aminobuty l]-octahydrothieno [3,2-c]pyridine-6-N-t-butyl carboxamide. Some mixed fractions at the beginning were combined to give 326 mg of a mixture, which was again submitted to the same chromatographic conditions on a 2000 micron plate. An additional 228 mg of desired [6S-(6R*, 3aS*, 7aR*, 2'S*,
3'S*)]-5-[2-Hydroxy-4-phenylthio-3-(benzoxycarbonyl)-arainobutyl]-octahydrothieno[3,2-c]pyridine-6-N-t-butyl carboxamide was
obtained. The total yield of [6S-{6R*, 3aS*, 7aR*, 2'S*,
3'S*)]-5-[2-Hydroxy-4-phenylthio-3-(benzoxycarbonyl)-aminobutyl]-octahydrothieno[3,2-c]pyridine-6-N-t-butyl carboxamide obtained was (80.5% yield).
1 H NMR (300 MHz, CDCl3): δ 7.30 (m, 10H) ; 5.80 (m, 2H);
5.08 (AB, 2H); 3.95 (m, 2H); 3.42 (m, 2H);
3.17 (m, 3H); 2.90 (m, 2H); 2.67 (m, 1H);
2.58 (m, 1H); 2.48 (m, 1H); 2.35 (m, 2H);
1.98 (m, 4H); and 1.30 (s, 9H).
Exaraple G
[6S-(6R*, 3aS*, 7aR*, 2'S*, 3'S*)]-5-[2-Hydroxy-4- phenylthio-3-aminobutyl]-octahydrothieno[3,2-c]
pyridine-6-N-t-butyl carboxaraide
Into a 100 ml flask was placed 1.8 g of the subtitled compound of Example F, [6S-{6R*, 3aS*, 7aR*, 2'S*, 3'S*)]-5-[2- Hydroxy-4-phenylthio-3-(benzoxycarbonyl)-aminobutyl]-octahydrothieno[3,2-c]pyridine-6-N-t-butyl carboxamide, in 10 ml each of CH2Cl2 and CH3CN. A first portion of TMSI (1.14 ml) was added and stirred for 10 minutes. A second portion of TMSI (0.72 ml) was added and stirred for 10 minutes. A third portion of TMSI (0.24 ml) was added and stirred for 15 minutes. The reaction mixture was diluted with 40 ml of Et2O and poured into 30 ml of 0.1 N HCl and 60 ml of Et2O. The Et2O layer was separated and the organics were discarded. The aqueous layer was made basic with saturated NaHCO3 solution and extracted with CH2Cl2 (2 × 100 ml). The organics were separated, dried with Na2SO4, filtered, and concentrated to afford 1.18 g of [6S- ( 6R*, 3aS* , 7aR* , 2 'S* ,3 'S*) ]-5-[2-Hydroxy-4-phenylthio-3-aminobutyl]-octahydrothieno[3,2-c]pyridine-6-N-t-butyl carboxamide (86% yield) as a white solid.
1 H NMR (300 MHz, CDCl3): δ 7.38 (m, 2H); 7.28 (m, 2H);
7.20 (m, 1H); 6.23 (s, 2H); 3.65 (s, 1H)
3.28 (m, 3H); 2.90 (m, 4H); 2.70 (m, 2H)
2.58 (m, 1H); 2.43 (m, 1H); 2.34 (m, 1H)
2.05 (m, 4H); 1.80 (m, 3H); and 1.32 (s, 9H).
IR (CHCl3): 3430; 3005; 2973; 1670; 1514; 1456; 1366;
and 1090 cm-1.
MS: m/e 437 (M+). Example H
[6S-(6R*, 3aS*, 7aR*, 2'S*, 3'S*)]-2-[2'- Hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'- (2''-methyl-3''-hydroxyphenyl)pentyl]-octahydrothieno[3,2-c] pyridine-6-N-t-butyl carboxaraide
Into a 25 ml flask was placed 40 mg of the subtitled compound of Example G, [6S-(6R*, 3aS*, 7aR*, 2'S*, 3'S*)]-5-[2-Hydroxy-4-phenylthio-3-aminobutyl]-octahydrothieno[3,2-c]pyridine-6-N-t-butyl carboxamide, 14 mg of 3-hydroxy-2-methyl benzoic acid, and 12.6 mg of HOBT in 2 ml of THF, and the reaction mixture was cooled to -10°C. DCC (18.7 mg) was added, and the mixture was warmed to room temperature and stirred for 85 hours. The reaction mixture was diluted with 2 ml of Et2O and filtered through a cotton plug, the filtrate was concentrated, and the residue was eluted on chromatotron (2000 micron plate) with 3% MeOH/CHCl3. The desired fractions were concentrated to give 44 mg of [6S-(6R*, 3aS*, 7aR*, 2'S*, 3'S*)]-2-[2'-Hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''-hydroxyphenyl)pentyl]-octahydrothieno[3,2-c]pyridine-6-N-t-butyl carboxamide (85% yield).
Example I
[6S-(6R*, 3aS*, 7aR*, 2'S*, 3'S*)]-2-[2'- Hydroxy-3'- phenylthiomethyl-4'-aza-5'-oxo-5'-(2''- methyl-3''- hydroxyphenyl)pentyl]-octahydrothieno[3,2-c] pyridine-6-N-t-butyl carboxamide methanesulfonic acid salt
Into a 50 ml flask was placed 330 mg of the subtitled
compound of Example H, [6S-{6R*, 3aS*, 7aR*, 2'S*, 3'S*)]-2-[2'-Hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''- hydroxyphenyl)pentyl]-octahydrothieno[3,2-c]pyridine-6-N-t-butyl carboxamide, in CH2Cl2/CH3CN (4 ml/2 ml), and 37.5 ml of MeSo3H was added via a microliter-syringe. The mixture became cloudy. The reaction mixture was diluted with 1 ml of CH2Cl2, and Et2O and hexane were added and concentrated. The residue was sonicated with hexane and concentrated two times to obtain 385 mg of desired [6S-{6R*, 3aS*, 7aR*, 2'S*, 3'S*)]-2-[2'-Hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''-hydroxyphenyl)pentyl]-octahydrothieno[3,2-c]pyridine-6-N-t-butyl carboxamide methanesulfonic acid salt (100% yield).
Exaraple J
[6S-(6R*, 3aS*, 7aR*, 2'S*, 3'R*)]-5-[2- Hydroxy-4-phenyl-3- (benzoxycarbonyl)-aminobutyl]- octahydrothieno[3,2-c]pyridine-6-N- t-butyl carboxamide
Into a 50 ml flask was placed 145 mg of [1'S-(1'R*,1R*)]-1- [(1'-N-(Benzyloxycarbonyl)amino-2'-(phenyl)ethyl] oxirane
(obtainable as in Reaction Scheme A (steps 1 through 5) below, and 118 mg of the subtitled compound of Example E, [6S-(6R*, 3aS*,7aR*)]-Octahydrothieno[3,2-c]pyridine- 6-N-t-butyl carboxamide, as a mixture of enantiomers in 3 ml of EtOH. The mixture was heated to 65°C and was maintained at this temperature for 20 hours. The reaction mixture was concentrated, and the crude residue was purified by chromatatron on a 2000 micron plate, eluted with 1% MeOH/CHCl3 to afford 98 mg of [6S- (6R*, 3aS*, 7aR*, 2'S*,
3'R*)]-5-[2-Hydroxy-4-phenyl-3(benzoxycarbonyl)-aminobutyl]-octahydrothieno[3,2-c]pyridine-6-N- t-butyl carboxamide (37% yield) and 109 mg of a diasteromer of [6S-(6R*, 3aS*, 7aR*, 2'S*, 3'R*)]-5-[2-Hydroxy-4-phenyl-3-(benzoxycarbonyl)-aminobutyl]-octahydrothieno[3,2-c]pyridine-6-N- t-butyl carboxamide.
If substantially enantiomerically pure [6S-(6R*, 3aS*,
7aR*)]-Octahydrothieno[3,2-c]pyridine-6-N-t-butyl carboxamide is used instead of [6S-(6R*, 3aS*, 7aR*)]-Octahydrothieno[3,2-c]pyridine-6-N-t-butyl carboxamide as a mixture of enantiomers, a higher yield of [6S-(6R*, 3aS*, 7aR*, 2'S*, 3'R*)]-5-[2-Hydroxy¬4-phenyl-3-(benzoxycarbonyl)-aminobutyl]-octahydrothieno[3,2-c]pyridine-6-N-t-butyl carboxamide should result. (See, e.g., Example F above.)
Exaraple K
[6S-{6R*, 3aS*, 7aR*, 2'S*, 3'R*)]-5-[2-Hydroxy-4- phenyl-3- aminobutyl]-octahydrothieno[3,2-c]
pyridine-6-N-t-butyl carboxaraide
Into a 25 ml flask was placed 85 mg of the subtitled compound of Example J, [6S-(6R*, 3aS*, 7aR*, 2'S*, 3'22*)]-5-[2-Hydroxy-4-phenyl-3-(benzoxycarbonyl)-aminobutyl]-octahydrothieno[3,2-c]pyridine-6-N-t-butyl carboxamide, in CH3CN/CH2Cl2. TMSI was added in portions of 56 microliters, 34
microliters and 11 microliters, respectively, every ten minutes and stirred for 1 1/2 hours. The mixture was diluted with Et2O (5 ml) and poured into 15 ml of 1 N HCl and Et2O (20ml). The
organics were separated and discarded. The aqueous layer was treated with 30 ml of saturated NaHCO3 solution and extracted with CH2Cl2 (2 × 50 ml). The organics were dried with Na2SO4,
filtered, and concentrated to an oil that crystallized to give 64 mg [6S-(6R*, 3aS*, 7aR*, 2'S*, 3'R*)]-5-[2-Hydroxy-4-phenyl-3-aminobutyl]-octahydrothieno[3,2-c]pyridine-6-N-t-butyl carboxamide (100% yield).
1H NMR (300 MHz, CDCl3): δ 7.28 (m, 5H); 6.38 (s, 1H);
3.75 (m, 1H); 3.32 (m, 2H); 3.12 (m, 1H)
2.93 (m, 2H); 2.78 (m, 2H); 2.58 (m, 3H)
2.38 (m, 1H); 2.12 (m, 5H); 1.83 (m, 2H)
and 1.35 (s, 9H).
Exaraple L
[6S-(6R*, 3aS*, 7aR*, 2'S*, 3'R*)]-2-[2'-Hydroxy-3'- phenylmethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''- hydroxyphenyl)pentyl]- octahydrothieno[3,2-c]pyridine- 6-N-t-butyl carboxamide
Into a 25 ml flask was placed 64 mg of the subtitled compound of Example K, [6S-(6R*, 3aS*, 7aR*, 2'S*, 3'R*)]-5-[2¬Hydroxy-4-phenyl-3-aminobutyl]-octahydrothieno[3,2-c]pyridine-6-N-t-butyl carboxamide, 24 mg of 3 -hydroxy-2 -methyl benzoic acid (obtained by the method disclosed in Preparation 23C), and 22 mg of HOBT.H2O in 2 ml of THF, and the mixture was cooled to -10°C. DCC (32 mg) was added, and the mixture was warmed to room
temperature and stirred for 60 hours. The reaction mixture was diluted with 2 ml of Et2O, filtered through a cotton plug, and the filtrate was concentrated, and the residue was eluted on
chromatotron (2000 micron plate) with 1.5% MeOH/CHCl to 4% MeOH/ CHCl- gradient . The desired fractions were concentrated to give 72 mg of [6S-(6R*, 3aS*, 7aR*, 2'S*, 3'R*)]-2-[2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''- hydroxyphenyl)pentyl]-octahydrothieno[3,2-c]pyridine-6-N-t-butyl carboxamide (85% yield).
Example 75
[3S-{ 3R*, 4aR*, 8aR* , 2 'S*, 3 'S*)]-2-[2'- Hydroxy-3'- phenylthiomethyl-4'-aza-5'-oxo-5'-(2''- methyl-3''- hydroxyphenyl)pentyl]-decahydroisoquinoline- 3-N-t-butyl carboxamide methanesulfonic acid salt
This compound was prepared as in Example 23, with the
exception that Preparation Steps 8A and 8D were changed as set forth in step (1) below, and the salt formation step (2) below was added.
(1)
To a 2 L flask was added Ph3P (109.6 g) in 500 ml of CH2Cl2, and the mixture was cooled to -70°C. To the mixture was added a solution of diethylazidodicarboxylate (66 ml) in 60 ml of THF dropwise over 25 minutes. After 25 minutes, a solution of N-carbobenzyloxy-L-serine (100 g) in 400 ml of THF was added
dropwise over 45 minutes and allowed to warm to room temperature in a water bath over two hours. 150 ml of THF was added to the mixture. In another flask, a solution of thiophenol (46 g) in 1 L of THF was cooled in an ice bath to 0°C and treated portionwise with an NaH dispersion (10 g) to give a thick solution. After one hour, the crude lactone solution was added to the thiolate
solution dropwise via an addition funnel over 30 minutes. After 12 hours, a white precipitate was filtered off, and the filter cake washed with THF. The solid was taken up in 0.4 N NaHSO4 and EtOAc, separated, and the organic layer was washed with brine, dried, and evaporated to afford 85 g of 2R-2-N- (benzyloxycarbonyl)amino-3-phenylthio propanoic acid as a viscous oil.
The original solid is believed to be the sodium salt of the desired product. Thus, the yield and ease of isolation may be improved by isolation of the sodium salt directly.
The crude chloroketone 3R-l-Chloro-2-oxo-3-N(benzyloxycarbonyl) amino-4 -phenylthio butane (16.87 g, 46.4 mmol) was added to 1 L absolute EtOH and 200 mL THF, and the solution was cooled in a CO2-acetone bath (-78°Tint), and NaBH (2.63 g, 69.5 mmol) in 200 ml absolute EtOH was added dropwise over 1 h (Tint < -75°C). TLC analysis after the addition showed that the reaction was complete. The reaction was diluted with 300 mL ether and was quenched by the slow addition of 0.4 N NaHSO3 with
stirring, which produced the evolution of gas. This mixture was concentrated under reduced pressure to remove most of the EtOH and additional water was added. The mixture was extracted with ether, and the combined organic layers were washed with saturated aqueous NaHCO3 and brine, dried (Na2SO4), and concentrated to afford 15.7 g of an off white solid. This material was triturated with boiling hexane (300 mL), and the hexane was carefully decanted while hot. This was repeated 10 times (300 mL each) to provide 10.35 g of an off white solid (one pure isomer by TLC). The hexane filtrate was concentrated to give 6 g of white solid which was set aside. The triturated solid was heated with 50 raL CH2Cl and about 6 mL hexane and filtered hot. The clear solution was allowed to cool to 25°C and was then placed in the freezer. The resulting solid was filtered and washed with hexanes to give 7.157 g of a white solid. The filtrate was combined with the hexane filtrate from above and with crude reaction product from two small scale experiments (500 mg starting ketone each), and the combined material was chromatographed on SiO2 (2 : 1 hexanes-ether -- - >1 : 1 hexanes-ether, loaded with CH2Cl2) to afford 2.62 g of additional product. A total of 10.31 g pure isomer of [2S-( 2R* , 3S*) ] ~ 1-Chloro-2-hydroxy-3-N-(benzyloxycarbonyl)amino-4-phenylthio butane (50% yield from acid) was obtained.
alphaD = -63.6° (c=1, MeOH).
(2)
Salt Formation
[3S-(3R*,4aR*,8aR*,2'S*,3'S*)1-2-[2'Hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''-hydroxyphenyl)pentyl] decahydroisoquinoline-3-N-t-butylcarboxamide (3.34 g) was dissolved in 30 ml of MeOH and 30 ml of CH2Cl2, and a solution of methanesulfonic acid (596 mg) in 10 ml of CH2Cl2 was added dropwise. After 10 minutes , the reaction mixture was concentrated to foam. The crude salt was taken up in 5 ml of THF and added slowly to a mixture of 175 ml of ethyl ether and 25 ml of hexanes with stirring until a fine suspension
resulted. This was cooled in a freezer, filtered cold and washed several times with ethyl ether, followed by drying in a vacuum oven to afford 3.75 g (96%) of [3S-{ 3R*, 4aR*, 8aR*, 2 'S*,
3 'S*) ]-2-[2'-Hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'- (2''-methyl-3''-hydroxyphenyDpentyl]-decahydroisoquinoline-3-N-t-butyl carboxamide methanesulfonic acid salt as a white powder. Example 76
3-(Bisbenzoxyphosphinyl)oxy-2-methyl Benzoic Acid
Figure imgf000236_0001
To a cooled (0ºC), stirred solution of 706 mg (4.67 mmol) of 3-hydroxy-2-methylbenzoic Acid in 30 mL of pyridine was added dropwise 10.3 mL (10.21 mmol) of a 1.0 M solution of lithium hexamethyldisilazide over 5 minutes. After stirring for 5 minutes, 3.0 g (5.57 mmol) of tetrabenzylpyrophosphate was added in one portion, and the reaction mixture was warmed to room temperature over 30 minutes. The reaction mixture was
concentrated, and the residue was partitioned between 2.5 N HCL (200 mL) and a 50/50 mixture of ethyl acetate/ hexane (200 mL). The layers were separated, and the aqueous layer was extracted twice with a 50/50 solution of ethyl acetate/ hexane. The organic layers were combined, washed with brine and dried over sodium sulfate. Purification of the crude product by flash
chromatography (gradient eluent of 50-70% ethyl acetate/ hexane/ 2% Acetic acid) gave 910 mg of a light yellow oil, which is 3- (bisbenzoxyphosphinyl)oxy-2-methyl benzoic acid.
Yield: 47%
1Η NMR (CDCl3): d 2.49 (s, 3H), 5.14 (d, J = 8.60 Hz, 4H), 7.10-7.40 (m, 11H), 7.48 (d, J = 8.09 Hz, 1H), 7.81 (d, J = 7.80 Hz, 1H). IR (CHCl3): 3700-2350 (br), 1700, 1457, 1382, 1273, 1240, 1179, 1082, 1034, 1023, 1001, 966, 881, 851 cm-1.
MS (FD): m/e 413 (M+, 100).
Example 77
[3S-(3R*, 4aR*, 8aR*, 2'S*,3'R*)]-2-[2'-Hydroxyphenylmethyl-4'-aza-5'-oxa-5'-(2"-methyl-3"- (bisbenzoxyphosphinyl)oxyphenyl)pentyl]
decahydroisoquinoline-3-N-t-butyl carboxamide
Figure imgf000237_0001
To a cooled (-10°C) solution of 95 mg (0.23 mmol) of the subtitled compound of Example 76, 3-(Bisbenzoxyphosphinyl)oxy-2-methyl benzoic acid, 92 mg (0.23 mmol) of [3S-(3R* , 4aR*, 8aR*,2 'S*, 3 'R*) ]-2-[3'-Amino-2'-hydroxy-4'-phenyl]butyl
decahydroisoquinoline-3-N-t-butyl carboxamide (see for example Preparation 1B), and 31 mg (0.23 mmol) of HOBt in 5 mL of anhydrous THF, was added 48 mg (0.23 mmol) of DCC in one portion. After stirring for 3 days at room temperature, the reaction mixture was diluted with ethyl acetate and filtered through a plug of cotton. The resulting filtrate was extracted twice with saturated sodium carbonate, washed with brine, and dried over sodium sulfate. Purification of the crude product by radial chromatography (2 mm plate; gradient eluent of 2.5-5% methanol/ methylene chloride) gave 100 mg of a white foam, which is [3S-(3R*, 4aR*, 8aR*, 2'S*, 3'R*)]-2-[2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'- (2''-methyl-3''- (Bisbenzoxyphosphinyl)oxyphenyl)pentyl]- decahydroisoquinoline-3-N-t-butyl carboxamide.
Yield: 52%
1Η NMR (CDCl3): d 1.13 (s, 9H), 1.14-2.10 (m, 15H), 2.23-2.36 (m, 2H), 2.50-2.70 (m, 2H), 2.92-3.05 (m, 2H), 3.39-3.50 (m, 1H), 3.80-4.10 (m, 2H), 4.52-4.62 (m, 1H), 5.03-5.13 (m, 4H) , 5.65 (s, 1H) , 6.62 (d, J = 8.51 Hz, 1H) , 6.83 (d, J = 7.60 Hz, 1H), 7.02
(t, J = 8.10 Hz, 1H).
IR (CHCl3): 3690, 3600-3100 (br), 3009, 2929, 2866, 1672, 1603,
1513, 1456, 1368, 1277, 1239, 1182, 1037, 1023, 1001, 967,
880 cm- 1.
MS (FD): m/e 796 (M+, 100).
Analysis for C46H58N3O7P1:
Calcd: C, 69.41; H, 7.34; N, 5.28.
Found: C, 69.57; H, 7.33; N, 5.20.
Example 78
[3S-(3R*, 4aR*, 8aR*, 2'S*, 3'R*)]-2-[2'-Hydroxy-3'- phenylmethyl-4'-aza-5'-oxa-5'-(2"-methyl-3"- Hydroxyphenyl)pentyl]decahydroisoquinoline-3- N-t-butyl carboxamide 3"-dihydrogen phosphate
Figure imgf000238_0001
A mixture of 86 rag (0.108 mmol) of the subtitled compound of Example 77, [3S-(3R*, 4aR*, 8aR*, 2 'S*, 3 'R*) ]-2-[2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''- (bisbenzoxyphosphinyl)oxyphenyl)pentyl]-decahydroisoquinoline-3-N-t-butyl carboxamide, and 23 mg of 10% Palladium on carbon in 16 mL of methanol was stirred under one atmosphere of hydrogen for 1 hour. The reaction mixture was filtered through celite and concentrated to give 61 mg of a white solid, which is [3S-{3R*,4aR*, 8aR*, 2 'S* , 3 'R*)]-2-[2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''-hydroxyphenyl)pentyl]-decahydroisoquinoline-3-N-t-butyl carboxamide 3''-dihydrogen phosphate.
Yield: 96%
1H NMR (Methanol-d4): d 1.32 (s, 9H), 1.33-2.21 (m, 14H), 2.602.75 (m, 1H), 3.18-3.49 (m, 5H), 3.56-3.70 (m, 1H), 3.95-4.35 (m, 3H), 5.47 (s, 1H), 6.71 (d, J = 7.26 Hz, 1H), 7.02 (t, J = 8.24 Hz, 1H), 7.15-7.35 (m, 5H), 7.40 (d, J = 8.18 Hz, 1H).
IR (KBr): 3800-2400 (br), 1673, 1545, 1456, 1395, 1368, 1222, 1185, 1077, 942, 857, 792 cm-1.
MS (FAB): m/e 616.3 (M+, 100).
Example 79
[3S-(3R*, 4aR*, 8aR*, 2'S*, 3'S*)]-2-[2'-Hydroxy-3'- phenylthiomethyl-4'-aza-5'-oxa-5'-(2"-methyl-3"- (bisbenzoxyphosphinyl)oxyphenyl)pentyl]
decahydroisoquinoline-3-N-t-butyl carboxamide
Figure imgf000240_0001
To a cooled (0°C), stirred solution of 478 mg (1.16 mmol) of the subtitled compound of Example 76, 3-(bisbenzoxyphosphinyl)oxy-2-methyl benzoic acid, 500 mg (1.16 mmol) of (3S-( 3R*, 4aR*, 8aR*,2 'S*, 3 'S*) ] -2 -[3'-amino-2'-hydroxy-4'(phenyl)thio]butyl
decahydroisoquinoline-3-N-t-butyl carboxamide (see, for example, Preparation 8G or Preparation 8G with the modifications of
Preparations 8A and 8D as in Example 75), 352 mg (3.48 mmol) of triethyl amine, and 166 mg (1.23 mmol) of HOBt in 8 mL of
anhydrous THF was added 254 mg (1.23 mmol) of DCC in one portion. After stirring overnight at room temperature, the reaction mixture was concentrated, the residue was taken up in ethyl acetate and filtered through a plug of cotton. The resulting filtrate was extracted twice with saturated sodium carbonate, washed with brine, and dried over sodium sulfate. Purification of the crude product by radial chromatography (6 mm plate; gradient eluent of 30% ethyl acetate/ hexane) gave 644 mg of a white foam, which is [3S-(3R*, 4aR* , 8aR*, 2 'S*, 3 'S*) ] -2 -[2'-Hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''- (Bisbenzoxyphosphinyl)oxyphenyl)pentyl]-decahydroisoquinoline-3-N-t-butyl carboxamide.
Yield: 67%
1H NMR (CDCl3): d 1.04 (s, 9H), 1.15-2.61 (m, 19H), 2.89-3.00 (m, 1H), 3.39-3.50 (m, 1H), 3.67 (s, 1H), 3.75-3.85 (m, 1H), 4.03-4.15 (m, 1H), 4.43-4.58 (m, 1H), 5.00-5.20 (m, 4H), 5.47 (s, 1H), 7.10-7.55 (m, 19H).
IR (CHCl 3): 3600-3150 (br), 3010, 2975, 2929, 2867, 1670, 1517, 1457, 1440, 1368, 1277, 1239, 1082, 1035, 1025, 1001, 968,
879 cm-1.
MS (FAB): 828.4 (M+, 100).
Analysis for C46H58N3O7S1P1:
Calcd: C, 66.73; H, 7.06; N, 5.07; S, 3.87.
Found: C, 66.56; H, 7.29; N, 4.82; S, 3.62.
Example 80
[3S-(3R*, 4aR*, 8aR*, 2'S*, 3'S*)]-2-[2'-Hydroxy-3'- phenylthiomethyl-4'-aza-5'-oxa-5'-2"-methyl- 3''-Hydroxyphenyl)pentyl]decahydroisoquinoline-3- N-t-butyl carboxaraide 3"-Dihydroqen Phosphate Hydrochloride
Figure imgf000241_0001
A mixture of 505 mg (0.61 mmol) of the subtitled compound of Example 79, [3S-( 3R*, 4aR* , 8aR*, 2 'S*, 3 'S*)]-2-[2'-Hydroxy-3'- phenylthiomethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''- (Bisbenzoxyphosphinyl)oxyphenyl)pentyl]-decahydroisoquinoline-3-N-t-butyl carboxamide, and 500 mg of 10% Palladium on carbon in 20 mL of methanol was stirred under one atmosphere of hydrogen for 24 hours. The reaction mixture was filtered through celite and concentrated to give 380 mg of the crude product which was
purified by HPLC (Waters Nova Pack Cl8 RCM Column (40x10 cm);
Flow rate of 40 mL/minute; Eluent of 45% (1% HCl) water, 15% acetonitrile, 40% methanol) , to give 230 mg of a white foam, which is [3S-{ 3R* , 4aR* , 8aR* , 2 ' S* , 3 ' S*) ] - 2 - [2 '-Hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''-hydroxyphenyl)pentyl]-decahydroisoquinoline-3--N-t-butyl
carboxamide 3''-dihydrogen phosphate.
Yield: 58%
1Η NMR (Methanol-d4): d 1.10-2.30 (m, 25H), 2.39 (s, 3H), 2.95-3.65 (m, 4H), 3.90-4.25 (m, 3H), 7.15-7.50 (m, 8H), 7.99 (s, 1H). IR (KBr): 3700-2100 (br), 1674, 1547, 1458, 1440, 1395, 1368, 1241, 1182, 1074, 1025, 966, 867 cm-1.
MS (FAB): m/e 648.3 (M++1, 100).
Analysis for C32H41N3O9S1Cl1P1:
Calcd: C, 53.37; H, 7.14; N, 5.83.
Found: C, 53.44; H, 6.76; N, 5.84. Example 81
3-(Acetyl)hydroxy-2-methylbenzoic acid
Figure imgf000243_0001
To a heterogeneous solution of 3.06 g (30 mmol) of acetic anhydride and 1.53 g (10 mmol) of 3-hydroxy-2-methylbenzoic acid was added one drop of concentrated sulfuric acid. The mixture was heated with a heat gun for 2 min. and then poured into 14 mL of cold water. The resulting precipitate was collected by vacuum filtration, washed twice with water and dried overnight in a vacuum oven. Recrystallization from 20% ethyl acetate/ hexane (7 mL) gave 595 mg of a white solid, which is 3-(Acetyl)hydroxy-2-methyl benzoic acid.
Yield: 31%
IR (CHCl3): 3700-2300 (br), 1765, 1698, 1460, 1404, 1372, 1299, 1273, 1172, 1081, 1041, 1012, 933, 913, 865, 823 cm-1.
MS (FD): m/e 194 (M+, 100). Example 82
[3S-(3R*, 4aR*, 8aR*, 2'S*, 3'R*)]-2-[2'-Hydroxy- 3'-phenylmethyl-4'-aza-5'-oxa-5'-(2"-methyl- 3''-(acetyl)hydroxyphenyl)pentyl]decahydroisoquinoline- 3-N-t-butyl carboxamide
Figure imgf000244_0001
To a cooled (-10°C) stirred solution of 34 mg (0.174 mmol) of the subtitled compound of Example 81, 3-(Acetyl)hydroxy-2-methyl benzoic acid, 70 mg (0.174 mmol) of [3S-( 3R*, 4aR*, 8aR*, 2 ' S*,3 'R*) ] -2 -[3'-Amino-2'-hydroxy-4'-phenyl]butyl
decahydroisoquinoline-3-N-t-butyl carboxamide and 24 mg (0.174 mmol) of HOBt in 3 mL of anhydrous THF was added 36 mg (0.174 mmol) of DCC in one portion. After stirring for 2 days at room temperature, the reaction mixture was diluted with ethyl acetate and filtered through a plug of cotton. The resulting filtrate was extracted once with saturated sodium carbonate, once with brine, and dried over sodium sulfate. Purification of the crude product by radial chromatography (1 mm plate; gradient eluent of 0%-5% methanol/ methylene chloride) gave 65 mg of a white foam, which is [3S-( 3R*, 4aR*, 8aR*, 2 'S*, 3 'R*)]-2-[2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''-(acetyl)hydroxyphenyl)
pentyl]-decahydroisoquinoline-3-N-t-butyl carboxamide.
Yield: 65% 1H NMR (CDCl3): d 1.15 (s, 9H), 1.16-2.37 (m, 21H), 2.50-2.70 (m, 2H), 2.93-3.05 (m, 2H), 3.39-3.50 (m, 1H), 3.99-4.10 (m, 1H), 4.53-4.64 (m, 1H), 3.99-4.10 (m, 1H), 4.53-4.64 (m, 1H), 5.69 (s, 1H), 6.64 (d, J = 8.45 Hz, 1H), 6.91 (d, J = 7.47 Hz, 1H), 7.00 (d, J = 7.57 Hz, 1H), 7.11 (t, J = 7.75 Hz, 1H), 7.19-7.40 (m, 5H).
IR (CDCl3): 3700-3100 (br), 3008, 2929, 2865, 1762, 1671, 1604,
1514, 1455, 1394, 1368, 1303, 1277, 1175, 1121, 1082, 1047, 910
-1
cm
MS (FD): m/e 578 (M+, 100). EXAMPLE 83
Figure imgf000245_0001
To a cold (0°C) solution of 35 mg (0.061 mmol) of the
subtitled compound of Example 82, [3S- ( 3R*, 4aR*, 8aR*, 2 'S*,3 'R*)]-2-[2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''-(acetyl)hydroxyphenyDpentyl]-decahydroisoquinoline-3-N-t-butyl carboxamide in 2 mL of anhydrous methylene chloride, was added dropwise 128 microliters (0.064 mmol) of a 0.5 M solution of methanesulfonic acid in methylene chloride. The resulting reaction was reduced to dryness under reduced pressure (0.2-0.1 Torr) to provide 40.5 mg (crude) of a light yellow foam, which is [3S-( 3R* , 4aR* , 8aR* , 2 ' S* , 3 'R*)]-2-[2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''- (acetyl)hydroxyphenyl)pentyl]-decahydroisoquinoline-3-N-t-butyl carboxamide methanesulfonic acid salt.
Yield: 98%
Exaraple 84
Figure imgf000246_0001
N-Boc-4-thio-L-proline (available from Sigma) (1.5 g) was dissolved in 3 ml of methanol and cooled to 0°C in an ice bath. In a separate flask, 5.8 g of "OXONE" was dissolved in 5 ml of H2O and added dropwise to the reaction mixture. After 30 minutes, the reaction mixture was allowed to warm to room temperature and stirred overnight, followed by dilution with CHCl3/H2O,
separation, and extraction with CHCD (3 × 100 ml). The organic layers were combined, dried over Na2SO4, and concentrated in vacuo to afford the compound of the formula shown above (700 mg, 41' yield) as a white solid.
Example 85
Figure imgf000247_0001
The compound of the formula shown in Example 84 and (3S-(3R*,4aR*, 8aR*, 2'S*, 3'S*)]-2-[3'-amino-2'-hydroxy-4'(phenyl)thio]butyl decahydroisoquinoline-3-N-t-butyl
carboxamide were coupled together by a procedure similar to that shown in Example 79 above. The crude material was purified by flash chromatography (3% MeOH/CH2Cl2) to afford 40 mg (51% yield) of a compound of the formula shown above.
Examppe 86
Figure imgf000247_0002
The compound of the formula shown in Example 85 (20 mg) was dissolved in 1 ml of CH2Cl2 and treated with 1 ml of
trifluoroacetic acid. After 30 minutes at room temperature, the reaction product was concentrated in vacuo to give the compound of the formula shown above, which is [3S-{3R*, 4aR*, 8aR*, 2'S*,3'S*, 4"S)]-2-[2'-Hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(thiazolino-4''-yl-1'',1''-dioxide)pentyl]-decahydroisoquinoline-3-N-t-butyl carboxamide.
Pandex IC50 = 244 ng/ml
Example 87
Figure imgf000248_0001
3-Carboxylic acid thiophene (available from Aldrich) and
[3S-(3R*, 4aR*, 8aR*, 2'S*, 3'R*)]-2-[3'-Amino-2'-hydroxy-4'-phenyl]butyl decahydroisoquinoline-3-N-t-butyl carboxamide were coupled together by a procedure similar to Example 77 above. The crude material was purified by flash chromatography (2% MeOH/CH2CI2) to afford 70 mg (63% yield) of the compound of the formula shown above, which is [3S-(3R*, 4aR*, 8aR*, 2'S*, 3'R*)]-2-[2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(thieno- 3''-yl)pentyl]-decahydroisoquinoline-3-N-t-butyl carboxamidi e.
Pandex IC50 = 25% at 1,000 ng/ml
Example 88
Figure imgf000249_0001
3-Carboxylic acid tetrahydrothiophene-1,1-dioxide and [3S- (3R*, 4aR*, 8aR*, 2'S*, 3'R*)]-2-[3'-Amino-2'-hydroxy-4'-phenyl]butyl decahydroisoquinoline-3-N-t-butyl carboxamide
were coupled together by a procedure similar to that described in Example 77 above. The crude material was purified by flash chromatography (3% MeOH/CH2Cl2) to afford 50 mg (42% yield) of the compound of the formula shown above, [3S-(3R*, 4aR*, 8aR*, 2'S*,3'R*)]-2-[2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'- (tetrahydrothieno-3''-yl-1'',1''-dioxide)pentyl]-decahydroisoquinoline-3-N-t-butyl carboxamide, as a mixture of diastereoisomers.
Pandex IC50 = 28% at 20 ng/ml. Example 89
Figure imgf000250_0001
3-Carboxylic acid tetrahydrothiophene-1,1-dioxide and [6S-(6R*, 3aS*, 7aR*, 2'S*, 3'S*)]-5-[2-Hydroxy-4-phenylthio-3-(benzoxycarbonyl)-aminobutyl]-octahydrothieno[3,2-c]pyridine-6-N-t-butyl carboxamide were coupled together by a procedure similar to that of Examples 74 G and H above. The crude material was purified by flash chromatography (3-4% MeOH/CH2Cl2) to afford 30 mg (57% yield) of [6S-(6R*, 3aS*, 7aR*, 2'S*, 3'S*)]-2-[2'-Hydroxy-3'- phenylthiomethyl-4'-aza-5'-oxo-5'-(tetrahydrothieno-3''-yl- 1'',1''-dioxide)pentyl]-octahydrothieno[3,2-c]pyridine-6-N-t- butyl carboxamide, as a mixture of diastereoisomers.
CEM IC95 = 98 nM
Pandex IC50 = 0.5 ng/ml (0.9) Example 90
Figure imgf000251_0002
3-Methyl-2-carboxylic acid thiophene and (3S-(3R*, 4aR*,8aR*, 2'S*, 3'S*)]-2-[3'-amino-2'-hydroxy-4'(phenyl)thio]butyl , decahydroisoquinoline-3-N-t-butyl carboxamide were coupled
together by a procedure similar to that of Example 79 above, which afforded 39 mg (76% yield) of a compound of the above formula, which is [3S-(3R*, 4aR*, 8aR*, 2'S*, 3'S*)]-2-[2'-Hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(3''-methyl-thieno-2''-yl)pentyl]-decahydroisoquinoline-3-N-t-butyl carboxamide.
Examppe 91
Figure imgf000251_0001
[6S-(6R*, 3aS*, 7aR*, 2'S*, 3'R*)]-2-[2'-Hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''-hydroxyphenyl)pentyl]-octahydrothieno[3,2-c]pyridine-6-N-t-butyl carboxamide (see for example Example 74 L) (30.5 mg) was dissolved in 2 ml of MeOH. In another flask, "OXONE" (51 mg) was dissolved in 1 ml of water and added to the first flask. After 6 hours of stirring, another portion of "OXONE" (17 mg) was added, and the reaction mixture was stirred for 42 hours. The reaction mixture was diluted with CH2Cl2 and washed with water. The organic layer was dried with Na2SO4, filtered and concentrated. The crude residue was purified by radial chromatography (1000 micron plate; 3-9% MeOH/CH2Cl2) to afford 5 mg of [6S-(6R*, 3aS*, 7aR*, 2'S*,3'R*)]-2- [2'-Hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''-hydroxyphenyl)pentyl]-octahydrothieno[3,2-c]pyridine-1,1-dioxide-6-N-t-butyl carboxamide.
Example 92
Figure imgf000252_0001
The compound shown above, [3S-(3R*, 4aR*, 8aR*, 2'S*,
3'R*)]-2-[2'-Hydroxy-3'-(4'''-fluoro)phenylthiomethyl-4'-aza-5'oxo-5'-(2''-methyl-3''-hydroxyphenyl)pentyl]- decahydroisoquinoline-3-N-t-butyl carboxamide was prepared using analogous procedures as set forth in Example 23, with the
exception that thiophenol was replaced by 4-fluorothiophenol in Preparation 8A.
The resulting product is used in an analogous manner as the product of Preparation 8A in the subsequent preparation protocol of Example 23.
Example 93
Figure imgf000253_0001
The compound shown above, [3S-( 3R* , 4aR* , 8aR* , 2 ' S* ,
3 'R*) ]-2-[2'-Hydroxy-3'-(4'''-fluoro)phenylthiomethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''-hydroxyphenyl)pentyl]-decahydroisoquinoline-3-N-t-butyl carboxamide methanesulfonic acid salt was prepared by a method analogous to Example 75 (step 2) above.
As noted above, the compounds of the present invention are useful for inhibiting HIV protease, which is an enzyme associated with viral component production and assembly. An embodiment of the present invention is a method of treating HIV infection comprising administering to a host or patient, such as a primate, an effective amount of a compound of formula (1) or a pharmaceutically acceptable salt thereof. Another embodiment of the present invention is a method of treating AIDS comprising administering to a host or patient an effective amount of a compound of formula (1) or a pharmaceutically acceptable salt thereof. A further embodiment of the present invention is a method of inhibiting HIV protease comprising administering to an HIV infected cell or a host or patient, such as a primate, infected with HIV, an effective amount of a compound of formula (1) or a pharmaceutically acceptable salt thereof.
The term "effective amount" means an amount of a compound of formula (1) or its pharmaceutically acceptable salt that is effective to inhibit the HIV protease mediated viral component production and assembly. The specific dose of compound
administered according to this invention to obtain therapeutic or inhibitory effects will, of course, be determined by the
particular circumstances surrounding the case, including, for example, the compound administered, the route of administration, the condition being treated and the individual host or patient being treated. An exemplary daily dose (administered in single or divided doses) contains a dosage level of from about 0.01 mg/kg to about 50 mg/kg of body weight of a compound of this invention. Preferred daily doses generally are from about 0.05 mg/kg to about 20 mg/kg and, more preferably, from about 0.1 mg/kg to about 10 mg/kg.
The compounds of the invention may be administered by a variety of routes, including oral, rectal, transdermal,
subcutaneous, intravenous, intramuscular and intranasal routes. The compounds of the present invention are preferably formulated prior to administration. Therefore, another embodiment of the present invention is a pharmaceutical composition or formulation comprising an effective amount of a compound of formula (1) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, such as a diluent or excipient therefor.
The active ingredient preferably comprises from 0.1% to 99.9% by weight of the formulation. By "pharmaceutically acceptable" it is meant that the carrier, such as the diluent or excipient, is compatible with the other ingredients of the formulation and not deleterious to the host or patient.
Pharmaceutical formulations may be prepared from the
compounds of the invention by known procedures using known and readily available ingredients. In making the compositions of the present invention, the active ingredient will usually be admixed with a carrier, or diluted by a carrier, or enclosed within a carrier, which may be in the form of a capsule, sachet, paper or other suitable container. When the carrier serves as a diluent, it may be a solid, semi-solid or liquid material which acts as a vehicle, excipient or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments (containing, for example, up to 10% by weight of the active compound), soft and hard gelatin capsules, suppositories, sterile injectable solutions, sterile packaged powders and the like. The following formulation examples are illustrative only and are not intended to limit the scope of the invention. The term "active ingredient" represents a compound of formula (1) or a pharmaceutically acceptable salt thereof.
Formulation 1
Hard gelatin capsules are prepared using the following ingredients:
Quantity
(mg/capsule)
Active ingredient 250
Starch, dried 200
Magnesium stearate 10
Total 460 mg
Formulation 2
A tablet is prepared using the ingredients below:
Quantity
(mg/capsule)
Active ingredient 250
Cellulose, microcrystalline 400
Silicon dioxide, fumed 10
Stearic acid 5
Total 665 mg
The components are blended and compressed to form tablets each weighing 665 mg.
Formulation 3
An aerosol solution is prepared containing the following components: Weight
Active ingredient 0, .25
Methanol 25.75
Propellant 22
(Chlorodifluoromethane) 74 .00
Total 100.00
The active compound is mixed with ethanol and the mixture added to a portion of the propellant 22, cooled to -30°C and
transferred to a filling device. The required amount is then fed to a stainless steel container and diluted with the remainder of the propellant. The valve units are then fitted to the
container.
Formulation 4
Tablets, each containing 60 mg of active ingredient, are made as follows:
Quantity
(mg/tablet)
Active ingredient 60
Starch 45
Microcrystalline cellulose 35
Polyvinylpyrrolidone
(as 10% solution in water) 4
Sodium carboxymethyl starch 4.5
Magnesium stearate 0.5
Talc 1
Total 150
The active ingredient, starch and cellulose are passed through a No. 45 mesh U.S. sieve and mixed thoroughly. The aqueous solution containing polyvinylpyrrolidone is mixed with the resultant powder, and the mixture then is passed through a No. 14 mesh U.S. sieve. The granules so produced are dried at 50°C and passed through a No. 18 mesh U.S. sieve. The sodium carboxymethyl starch, magnesium stearate and talc, previously passed through a No. 60 mesh U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 150 mg.
Formulation 5
Capsules, each containing 80 mg of active ingredient, are made as follows:
Quantity
(mg/capsule)
Active ingredient 80 mg
Starch 59 mg
Microcrystalline cellulose 59 mg
Magnesium stearate 2 mg
Total 200 mg
The active ingredient, cellulose, starch and magnesium stearate are blended, passed through a No. 45 mesh U.S. sieve, and filled into hard gelatin capsules in 200 mg quantities.
Formulation 6
Suppositories, each containing 225 mg of active ingredient, are made as follows:
Active ingredient 225 mg
Saturated fatty acid glycerides 2,000 mg
Total 2,225 mg
The active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum heat necessary. The mixture is then poured into a suppository mold of nominal 2 g capacity and allowed to cool. Formulation 7
Suspensions, each containing 50 mg of active ingredient per 5 ml dose, are made as follows:
Active ingredient 50 mg
Sodium carboxymethyl cellulose 50 mg
Syrup 1.25 ml
Benzoic acid solution 0.10 ml
Flavor q.v.
Color q.v.
Purified water to total 5 ml
The active ingredient is passed through a No. 45 mesh U.S. sieve and mixed with the sodium carboxymethylcellulose and syrup to form a smooth paste. The benzoic acid solution, flavor and color are diluted with a portion of the water and added, with stirring.
Sufficient water is then added to produce the required volume.
Formulation 8
An intravenous formulation is prepared as follows:
Active ingredient 100 mg
Isotonic saline 1,000 mL
The solution of the above ingredients generally is administered intravenously to a subject at a rate of 1 ml per minute.
ACTIVITY SCREENING
A number of tests were used to test the biological activity of HIV protease inhibitory compounds. For example, tests were used to analyze proteolytic inhibition rates and antiviral effects on HIV-infected cell lines. The procedures for these experiments are described below. The results from these assays are summarized in Table 1 below or are summarized in the examples above. I. Primary Drug Screening of Anti-HIV Compounds at Southern
Research Institute (SRI) (Results recorded in Table 1 are designated "SRI CEM (ng/ml)" or "SRI MT2 (ng/ml)")
A. Principle of MTT Assay:
SRI has an established program for the primary antiviral analysis of compounds in microtiter assays which measures the ability of a selected compound to inhibit HIV-induced cell killing. This assay involves the conversion of the tetrazolium dye MTT to a colored formazan product by mitochondrial enzymes in metabolically active cells. This assay system is used at SRI to screen over 30,000 compounds per year. Briefly, the assay
involves the infection of CEM or MT2 cells in round bottom 96-well plates. The compound of interest is added just prior to
infection. Following 6 days of incubation at 37°C the plates are stained with MTT. The results of the assay are quantitated spectrophotometrically on a Molecular Devices Vmax plate reader. The data are analyzed by linear regression utilizing an in-house software program to calculate antiviral activity (IC25, IC50, IC95) and toxicity (TC25, TC50, TC95) as well as other values.
Primary antiviral assays are routinely performed in CEM or MT-2 cells. SRI has found that all active compounds have been identified in CEM cells, while experiments performed in the MT-2 cell line miss a small proportion of the active compounds.
B. Standard Screening Assays in CEM and MT-2 Cells
1. Compound dilution and delivery to the plates
Drugs are solubilized in the appropriate vehicle such as distilled water or DMSO if necessary. Latex gloves, lab coats and masks are used during all phases of the handling process to prevent exposure to potentially harmful agents. The drug is prepared at the appropriate concentration and stored at -20°C until used by the screening laboratory. The first dilution of each compound is made in a dilution tube with medium to yield a concentration two-fold that of the highest test concentration. Sterile titer tubes are then used to make serial one half-log dilutions of each compound. Following drug dilution, the diluted compound is added to the appropriate well of a 96-well microtiter plate. Up to 12 dilutions can be assayed conveniently in
triplicate on a single plate with all appropriate controls
including cell control, virus control, toxicity control, drug color control, medium control and plastic (background) control. When testing includes only six dilutions, two drugs can be assayed on a single microtiter plate. The drugs are added to the plate in a final volume of 100 microliters.
2. Cells and virus
During the time the drug dilutions are prepared, cells are washed and counted. Viability is monitored by trypan blue dye exclusion and assays are not performed if the viability falls below 90%. Cells are maintained in an exponential growth phase and are split 1:2 on the day prior to assay to assure exponential growth rate .
For the primary screen, the cell lines utilized are CEM and MT-2. Unless otherwise indicated, the medium used is RPMI 1640 with 10% heat-inactivated fetal calf serum (FBS), glutamine and antibiotics. Cells are propagated at 37°C in an atmosphere of 5% CO2 in air. The virus employed for this work is HIV-1 isolates IIIB and/ or RF, which are prepared by an acute infection process.
Briefly, virus-infected cells are pelleted on a daily basis beginning at three days post-infection until the virus has killed all of the cells in the culture. Reverse transcriptase activity and p24 ELISA are used to identify pools with the greatest amount of virus .
These 24 -hour harvests are pooled, filtered and frozen at -90°C. Prior to use in the assay, the infectious pool of virus is titered on all available cell lines in order to determine the amount of virus required in the antiviral assay.
In general, pools produced by the acute infection method require the addition of one microliter of infectious virus per well resulting in the screening of drugs at a multiplicity of infection of 0.01. In this manner, enough virus is prepared and frozen to complete over one thousand microtiter plates, allowing the testing of up to two thousand compounds from a single stock of infectious virus. The use of a single stock of virus for a long period of testing has very favorable effects on the repeatability of the assay systems.
Virus infection of the CEM and MT-2 cells for the antiviral assay is carried out in a bulk infection process. The appropriate number of cells required to complete the assay is mixed with infectious virus in a conical centrifuge tube in a small total volume of 1-2 milliliters. Following a 4-hour incubation the infected cells are brought to the appropriate final concentration of 5 × 104 cells per milliliter with fresh tissue culture medium and 100 microliters are added to the appropriate experimental and virus control wells.
Uninfected cells at the same concentration are plated for the toxicity controls and for the cell controls. Assays can also be performed using an in-well infection method. In this case, drug, cells and virus are added to the well individually. In each case the MOI is adjusted to give complete cell killing in the virus control wells by Day 6.
3. Evaluation of CPE-inhibition
Following the addition of cells and drugs to the microtiter plate, the plate is incubated for 6 days at 37°C. Experience has determined that incubation for longer periods of time (7-8 days) or the use of higher input cell numbers (1 × 104) results in significant decreases in cell control viability and a narrowing in the differential in optical density between cell and virus
controls upon staining with MTT.
The method of evaluating the antiviral assay involves the addition of 20 microliters of the tetrazolium salt MTT at 5mg/ml to each well of the plate for 4-8 hours. After this incubation period, the cells are disrupted by the addition of 50 microliters of 20% SDS in 0.01N HCl.
The metabolic activity of the viable cells in the culture result in a colored reaction product which is measured
spectropotometrically in a Molecular Devices Vmax plate reader at 570nm. The optical density (O.D.) value is a function of the amount of formazan product which is proportional to the number of viable cells.
The plate reader is on-line to the screening laboratory microcomputer which evaluates the plate data and calculates plate data. The plate report provides a rundown of all pertinent information including the raw O.D. values, the calculated mean O.D.'s and the percent reduction in viral CPE as well as
calculations including TC50, IC50 and antiviral and specificity indices. Finally, the results include a plot which visually depicts the effect of the compound on uninfected cells (toxicity) and the protective or nonprotective effect of the compound on the infected cells.
II. Whole Cell Screening of Anti-HIV Compounds at
Eli Lilly (Results Recorded in Table 1 Are Designated
"Whole Cell IC50 nM" or "Whole Cell IC90 nM"
A. Purpose and Materials
Purpose: To determine IC50 and CC50 for compounds:
Reagents and Materials
Media A
Media A[1% DMSO] (100 microliters DMSO + 9.9 ml media A)
SN 123 used to infect cells (15 ml for 6 plates) (10 ml for 4
plates)
CEM cells @ [1 × 104] cells/ml (4 plate=40 ml) (6 plate=60 ml) DMSO (need 5 ml)
35B at [10 mM] (need 70 microliters of each)
A-D at [10 mM] in 100% DMSO
4 or 6 u-bottom 96-well plates
4 flat bottom 96-well plates for dilutions
8-10 boxes of sterile costar tips
Approximately 10 reagent trays
Costar 12-pette Relevant information:
1000 cells/well = 1 × 104 cells/ml = 1000 cells/100 microliters
200 microliters = total volume in a well
Final concentration of DMSO = 0.25%
Final dilution of Snl23 = 1:64
Serially diluted compounds 35B, A-D, 1:3
B . Procedure
1. Cell Preparation and Plating of Cells, Media A
and Media A (1% DMSO)
a. Number a 96-well tissue culture plate for each compound tested, one for a control plate, and one for the control compound.
Plate # Description
1 Controls Neg. and Pos .
2 35B
3 A
4 B
5 C
6 D
b. Count cells on hemacytoraeter and resuspend them in 40 ml or 80 ml of Media A at a concentration of [1 × 104] cells/ml.
Counting Cells on a Hemacytomer:
Label two 1.8 ml nunc tubes 1 and 2.
Put 0.5 ml of well mixed CEM cells (in growth phase) in tube
1.
Put 50 micoliters PBS and 40 microliters of trypan blue into tube 2.
Mix up the cells in tube 1 then remove 10 microliters of
cells and put them into tube 2.
Mix well in tube 2, then remove 10 microliters of the
stained cells and put them on the hemacytometer . Count the number of cells in the center square of the
hemacytometer with the microscope set on 10X.
The concentration of the stock CEM's in cells/ml is as
follows:
Cells counted × 1 × 105 = Conentration of CEM' s in
[cells/ml] . c. Add 200 microliters Media A to:
Al of plates 2-6.
These are Blanks.
A4-H4 of plate 1.
These are Blanks.
d. Add 5 microliters Media A to all wells of Rows A-D of plates 2-6 except Al (the top half of each plate).
e. Add 50 microliters of Media A to wells A1-D3 of
Plate 1 (the top half of the plate).
f . Add 50 microliters Media A[l% DMSO] to all
wells of Columns 1-3 of plate 1.
g. Add 100 microliters of [1 × 104] cells/ml to all wells of Columns 1- 3 of plate 1 and to all wells
(except Al which is the blank) of the other plates. This puts 1000 cells/well.
h. Put plates in an incubator while doing drug
dilutions.
2. Preparation Control and Test Drugs
(a) Preparation of (35B, A-D) 1:3 serial dilutions in plate with 100% DMSO.
(1) Put 60 microliters of DMSO into all wells of
Columns 2-12, Rows A-E.
(2) Put 70 microliters of 35B [10 mM] at 100% DMSO
into well Al.
(3) Put 70 microliters of A [10 mM] at 100% DMSO into well Bl.
(4) Put 70 microliters of B [10 mM] at 100% DMSO into well Cl.
(5) Put 70 microliters of C [10 mM] at 100% DMSO into well DI.
(6) Put 70 microliters of D [10 mM] at 100% DMSO into well El.
(7) Serially dilute (35B, A-D) 1:3 down through Column 12 by transfering 30 microliters from Column 1 to Column 2, then from Column 2 to Column 3, etc., down through Column 12. Change tips before each dilution. (b) Preparation of 1:10 Dilution plate in Media A:
(1) In rows A-E of another plate make a row for the first 1:10 dilution to correspond to each compound's 100 % DMSO row.
35B into Row A for the first 1:10
dilution.
A into Row B for the first 1:10 dilution.
B into Row C for the first 1:10 dilution.
C into Row D for the first 1:10 dilution.
D into Row E for the first 1:10 dilution.
(2) Put 180 microliters of media A into all wells of rows A-E corresponding to the 100% DMSO rows. 2.5 ml needed per row.
(3) Remove 20 microliters from all wells of each row of the 100% DMSO rows and transfer it to the corresponding 1:10 row.
C. Preparation of 1:100 Dilution plate in Media A:
(1) Make a plate for every 3 compounds to be tested.
(2) Put 225 microliters of media A into all wells of rows A, B, D, E, G, and H, leaving rows C and F empty. Use 20 ml of media A per plate.
(3) Transfer 25 microliters of each compound from the row in the 1:10 dilution to the corresponding two rows on the 1:100 dilution plate changing tips before each transfer.
Drug Drug
Column No. Conc. [nM] Cone. [microliters]
1 25000 25.00000
2 8333 8.33333
3 2778 2.77778
4 926 0.92593
5 309 0.30864
6 103 0.10288
7 34 0.03429
8 11 0.01143
9 3.81 0.00381
10 1.27 0.00127
11 0.42 0.00042
12 0.14 0.00014 3. Addition of Viral SN123 to Plates
a. Thaw Snl23 in 37°C water bath for approximately 10
minutes.
b. Dilute Snl23 1:16 by adding 1 ml of Snl23 to 15 ml of media A.
c. Add 50 microliters of Snl23 [1:16] to wells E1-H12 of plates 2-6 and to wells E1-H3 of plate 1.
4. Addition of Drugs to Plates
a. Add 50 microliters of the control and test drugs from the rows in the 1:100 dilution plates to the appropriate rows in the final plates (changing tips before each transfer). One row in the 1:100 plate will do 4 rows in the final plate. Leave Al blank.
b. Incubate all plates 7 days at 37°C 5% CO2.
c. Do Xtt protocol on day 7 as follows: d. Preparation of Xtt/PMS Solution: (4 plate = 20 ml)
(6 plate = 30 ml)
(1) Recipe for 2 mM PMS :
15.3 mg PMS + 0.5 ml PBS = PMS at [100 mM]
100 microliters [100 mM] PMS + 4.9 ml PBS =
PMS at [2 mM]
(2) Heat 500 ml of H2O in microwave for 5 minutes
on high.
(3) Put 20 or 30 ml of phenol red RPMI in a 50 ml
centrifuge tube.
(4) Put the RPMI in the beaker of hot water.
(5) Add 20 or 30 mg of XTT to the warmed up RPMI.
Final concentration of XTT = [1 mg/ml] .
(6) Wait for XTT to dissolve, then add 200 microlitert of [2 mM] PMS per 10 ml of XTT solution. e. Addition of Xtt/PMS to Plate:
(1) Add 50 microliters of XTT/PMS solution to all
wells of all plates.
(2) Cover plates and incubate 4 hours at 37°C at 5% CO2.
(3) Remove plates from incubator and replace covers with plastic plate sealers.
(4) Mix contents of plates.
(5) Read plates at test wavelength 450 nM and reference wavelength 650 nM.
III. Fluorescence HIV-1 Protease Inhibitor Assay To Screen For
Inhibition of HIV Protease (Results Recorded in Table 1 Are Designated "Pandex (ng/ml)")
As used herein, the abbreviations are defined as follows:
BSA - bovine serum albumin
BOC - t-butoxycarbonyl
BrZ - 2-bromobenzyloxycarbonyl
2-ClZ - 2-chlorobenzyloxycarbonyl
DCC - dicyclohexylcarbodiiraide
DIEA - diisopropylethylaraine
DTT - dithiothreitol
EDTA - ethylenediaminetetraacetic acid
FITC - fluorescein isothiocarbamyl
HEPES - 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
MES - 4 morpholineethanesulfonic acid
PAM - phenylacetimidomethyl
TAPS - 3-[tris(hydroxymethyl)methyl]amino- 1-sulfonic acid
TRIS - tris(hydroxymethyl)aminomethane
TOS - p-toluenesulfonyl (tosyl) A. Preparation of Protease and Gag Fractions
1. Culture of E. coli K12 L507/pHP10D
Lyophils of E. coli K12 L507/pHP10D were obtained from the Northern Regional Research Laboratory, Peoria, Illinois 61604, under the accession number NRRL B-18560 (deposited November 14, 1989). The lyophils were decanted into tubes containing 10 ml LB medium (10 g Bacto-tryptone, 5 g Bacto-yeast extract, and 10 g aqueous sodium chloride per liter; the pH was adjusted to 7.5 and incubated at 32 °C overnight).
A small portion of the overnight culture was placed on LB-agar (LB medium with 15 g/L Bacto-agar) plates containing 12.5 micrograms/ml tetracycline in a manner so as to obtain a single colony isolate of E. coli K12 L507/pHP10D. The single colony obtained was inoculated into 10 ml of LB medium containing 12.5 micrograms/ml tetracycline and incubated overnight at 32 °C with vigorous shaking. The 10 ml overnight culture was inoculated into LB medium containing 12.5 micrograms/ml tetracycline and incubated at 32°C with vigorous shaking until the culture reached mid-log phase.
2. Culture of E. coli K12 L507/pHGAG
Lyophils of E. coli K12 L507/pHGAG were obtained from the NRRL under the accession number NRRL B-18561 (deposited November 14, 1989). A purified colony of E. coli K 12 L507/pHGAG was isolated, and used as an inoculum for a culture which was grown to mid-log phase in substantial accordance with the teaching of Step A, above, for E. Coli K12 L507/pHP10D. 3. Preparation of Protease Fraction
A culture of E. coli K12 L507/pHP10D was grown to mid-log phase at 32 °C in LB media containing 12.5 micrograms/ml
tetracycline. The cultivation temperature was quickly elevated to 40°C to induce gene expression, and the cells were allowed to grow for 2.5 hours at this temperature before the culture was quickly chilled on ice. The cells were centrifuged and the cell pellet was resuspended in 20 ml of 50 mmol MES buffer (pH 6.0) containing 1 mmol EDTA, 1 mmol DTT, 1 mmol PMSF and 10% glycerol ("Buffer A"). Cells were lysed by sonication using a Fischer Model 300 Dismembrator and a microtip probe. Following centrifugation at 27,000xg, the supernatant was diluted to a total volume of 60 ml with Buffer A and loaded onto a 2.0×19 cm QAE-Sepharose column (1 ml/rain, 4°C), that had been equilibrated in Buffer A. The column was washed isocratically for 180 min and then eluted with a gradient eluent of 0-l.OM aqueous sodium chloride in Buffer A over 120 min. Enzymatic activity was measured by HPLC using the synthetic peptide Ser-Gln-Asn-Tyr-Pro-Ile-Val as described in Margolin et al., Biochem. Biophvs. Res. Coraraun.. 167. 554-560 (1990); the production of the pl peptide (Ser-Gln-Asn-Tyr) was measured.
The active fractions were combined, adjusted to pH 1.2M in ammonium sulfate, and applied to a 2.0x18 cm hexyl agarose column that had been equilibrated in Buffer A containing 1.2M ammonium sulfate. The sample was loaded at a flow rate of 1 ml/min at 4°C, washed with the equilibration buffer for 240 rain (1 ml/min) and then eluted using a reverse linear gradient of 1.2-0M ammonium sulfate in Buffer A for 120 min at the same flow rate. The column was then washed isocratically in Buffer A for 120 min.
The active fractions were combined, concentrated to 10 ml using an Amicon stirred cell with a YM-10 membrane and then applied to a MonoS cation exchange column (1.0x10 cm) that had been equilibrated in Buffer A. The sample was loaded at a flow rate of 1 ml/rain at 25°C. After washing isocratically for 30 min, the protease was eluted using a linear gradient of 0-0.45M aqueous sodium chloride in Buffer A over 40 min. The column was washed isocratically in Buffer A containing 0.45M aqueous sodium chloride for 30 minutes.
The active fractions were combined and concentrated to 200 microliters using an Amicon stirred cell and a YM-10 membrane and then the protease was applied to a Superose 6 size exclusion column equilibrated in Buffer A containing 0.1M aqueous sodium chloride. The column was washed isocratically in this buffer at a flow rate of 0.5 ml/min, following which the HIV protease was eluted as a single peak.
QAE-Sepharose and hexyl agarose were purchased from Sigma Chemical Company. Superose 6 and MonoS were were purchased from Pharmacia. Buffers and reagents were obtained from Sigma.
4. Preparation of Gag Fraction
In an analogous manner, a culture of E. coli K12 507/pHGAG was grown to mid-log phase at 32°C then shifted to 40°C for about 4 to 5 hours. The culture was chilled on ice and centrifuged, then the pellet was resuspended in 8 ml lysis buffer containing 5 mg/ml lysozyme. Lysis buffer was comprised of 50 mM Tris-HCl (pH 7.8), 5 mM EDTA, 1 mM DTT, 100 mM NaCl, 1 microgram/ml E64 and 2 micrograms/ml aprotinin. The culture was incubated about 30 to 60 minutes at 4°C, then briefly sonicated in a Branson® Cell
Disrupter at 60% power for three 20 second bursts with chilling between each burst. The culture was then centrifuged at 15,000 x g. The supernatant, which contains the unprocessed gag protein, was partially purified by size exclusion chromatography on a
Sephadex G-50 column and stored at -20°C in 50% glycerol and lysis buffer.
B. Preparation of Substrate: Na-Biotin-Gly-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gly-Lys(Ne-FITC)-OH
(a = Alpha, e = Epsilon)
1. Preparation of the amino-terminal biotinylated peptide
The protected peptide-resin Na-Boc-Gly-Ser-Gln-Asn-Tyr(BrZ)- Pro-Ile-Val-Gly-Lys(2-ClZ)-OCH2-PAM-resin was synthesized on an
Advanced Chemtech Model 200 peptide synthesizer at 1.5 mmol scale using the standard double-couple protocol. The amino terminal t- Boc group was removed with 50% trifluoroacetic acid in methylene chloride and the resulting resin neutralized with 5%
diisopropylethylamine (DIEA) in methylene chloride. Then, 1.1 g
(4.5 mmol) of biotin in 20 ml of dimethylsulfoxide was added to the peptide resin, followed by 4.5 mmol of
dicyclohexylcarbodiimide (DCC) in 9 ml of methylene chloride. The resulting reaction mixture was diluted to 40 ml total volume using
11 ml of methylene chloride, and then allowed to react for
approximately 5 hours. The reaction solution was concentrated, the resin washed sequentially with dimethylsulfoxide,
dimethylformamide and methylene chloride and then neutralized with 5% DIEA in methylene chloride. This reaction was repeated twice, with the reaction time being extended to 12 hours per reaction. Ninhydrin analysis of the resin indicated complete reaction of the biotin with the glycine amine group. The final peptide resin was washed extensively with dimethylformamide and methylene chloride and dried to provide 4.3 g (98%) yield.
2. Deprotection
The peptide was deprotected and cleaved from the resin using 50 ml of a hydrofluoric acid/m-cresol solution, 0°C, 1 hour.
After removal of the hydrofluoric acid by vacuum distillation, the m-cresol was extracted from the reaction mixture using 100 ml of diethylether. The peptide was then solubilized in 50% aqueous acetic acid, frozen and lyophilized to provide 2.14 g.
3. Purification
The crude peptide, biotinylated at the amino terminal, was dissolved in 200 ml of a 5% acetonitrile in water solution
containing 0.1% trifluoroacetic acid and then filtered through a 0.22 micron filter. The resulting solution was applied to a
2.2x25 cm reverse phase column of octadecyl-silica (Vydac C-18) which had been equilibrated with the same buffer. The peptide was eluted using an 855 minute linear gradient of 7.5-25%
acetonitrile, at 2 ml/minute, with collection of fractions. These fractions were analyzed using Analytical HPLC was performed on a 4.6x250 mm Vydac C-18 column using similar buffer conditions. The fractions containing the desired material were combined, frozen and lyophilized to provide 1.206 g (62% yield). Amino acid analysis of the isolated biotinylated peptide gave the following ratios in agreement with theoretical: Asn 1.1; Ser 0.96; Gln 1.1; Pro 1.1; Gly 2.1; Val 0.80; He 0.78; Tyr 1.1; Lys 1.1. Fast-atom bombardment mass spectrometry gave a molecular ion mass peak of 1288, in agreement with theoretical.
4. Labeling
The purified biotinylated peptide was then labeled with a fluorescent marker at the C-terminal end for use in the Pandex assay. First, the biotinylate peptide (1.206 g, 0.936 mmol) was dissolved in 100 ml of 0. IM sodium borate, pH 9.5. Then, a solution of 3 g (7.7 mmol) of fluorescein isothiocyanate in 15 ml of dimethylsulfoxide was added to the reaction mixture in 10 equal portions over two hours. The resulting mixture was allowed to react for one hour after the final addition. The solution was adjusted to pH 3 using 5N hydrochloric acid, resulting in the formation of a precipitate which was removed by centrifugation.
The peptide solution was then adjusted to pH 7.8 using 5N sodium hydroxide and then diluted to 200 ml by the addition of 0.1M ammonium acetate, pH 7.5. The resulting solution was then filtered through a 0.22 micron filter and loaded onto a 2.2×25 cm column of Vydac C-18 which had been equilibrated with of 5% acetonitrile in 0. IM ammonium acetate (pH 7.5). The peptide was eluted from the column using an 855 minute linear gradient of 5-25% acetonitrile, at 2 ml/minute, with collection of fractions. Analytical HPLC was used to analyze the fractions. The fractions containing the desired product were then combined, frozen and lyophilized to provide 190.2 mg (12%). Amino acid analysis of the purified peptide gave the following in agreement with theory: Asn 1.1; Ser 1.0; Gln 1.1: Pro 1.1; Gly 2.1; Val 0.8; He 0.8; Tyr 1.1; Lys 1.0. Fast-atom bombardment mass spectrometry gave a molecular ion mass peak of 1678, in agreement with theory.
5. Fluorescence HIV-1 Protease Inhibitor Assay
The following buffers and solutions are used in the
Fluorescence HIV-1 Protease Inhibitor Assay:
MES-ALB Buffer: 0.05M 4-morpholine ethane
sulfonic acid, pH 5.5
0.02M NaCl
0.002M EDTA
0.001M DTT
1.0 mg/ml BSA
TBSA Buffer: 0.02M TRIS
0.15M NaCl
1.0 mg/ml BSA
Avidin Coated
Beads Solution: 0.1% solution of Fluoricon
Avidin Assay Particles
(Avidin conjugated to solid polystyrene beads, 0.6-0.8 microns in diameter in TBSA Buffer
Enzyme Solution:
27 IU/ml of purified HIV-1 protease in MES-ALB buffer (1 IU equals the amount of
enzyme required to hydrolyze 1 micromole of substrate per minute at 37°C) To each well of a round bottom, 96-well plate is added 20 microliters of the Enzyme Solution followed by 10 microliters of the compound to be evaluated in a 20% aqueous dimethylsulfoxide solution. Purified HIV-1 protease was obtained as described above. The resulting solution is incubated for one hour at room temperature and then 20 microliters of a solution containing the substrate, prepared above, in MES-ALB buffer (1.5 microliters/ml) is added to each well. The solutions are then incubated for 16 hours at room temperature and then each well is diluted with 150 microliters of MES-ALB buffer.
To each well of a second round bottom, 96-well Pandex plate is added 25 microliters of the Avidin Coated Beads Solution.
Then, to each well is added 25 microliters of the diluted
incubation solutions, prepared above. The solutions are mixed thoroughly and the plates are loaded into a Pandex® machine, washed, evacuated and read. Sample detection was performed by excitation at 485 nm, reading the resulting epifluorescence at 535 nm.
The IC,_n results obtained in the Fluorescence Assay for the compounds of the present invention are set forth below in Tables 1, 2, and 3. All values have been normalized to a positive control which is [1S- (1R* , 4R*, 5S*) ] -N-(1-(2-amino-2-oxoethyl)-2-oxo-3-aza-4-phenylmethyl-5-hydroxy-6-(2-(1-t-butylamino-1-oxomethyl)phenyl)hexyl)-2-quinolinyl carboxamide.
Activity data for exemplary compounds emcompassed by the present invention is provided in Tables 1, 2, and 3 below and in the preceeding Examples. Results in Parentheses are for Example 1 of Published European Patent Application 0 526 009 Al = 35B in same assay.
Figure imgf000279_0001
Figure imgf000280_0001
Figure imgf000281_0001
Figure imgf000282_0001
Figure imgf000283_0001
Figure imgf000284_0001
Figure imgf000285_0001
Figure imgf000286_0001
Figure imgf000287_0001
Table 2 Example 74 I
IC50 = 0.3 nM (Pandex)
IC50 = 4.06 nM (Whole Cell)
IC90 = 9.74 nM (Whole Cell)
Example 75
IC50 = 14.5 nM (Whole Cell)
IC90 = 56.1 nM (Whole Cell)
Table 3
Inhibitory Activity
Fluorescence
Assay IC50
Example No. in μg/ml
Control 1.0
1 962
2 1083
3 24.2
4 1425*
5 2631
6 513*
7 255*
8 16.4
9 17
10 N.T.
11 5.1
12 8.3*
13 346
14 101
15 377
16 329
17 269*
18 67.2*
19 0.32
20 6.5
21 9.4
22 0.73
23 0.25
24 5.8
25 3.2
26 3.1
27 N.T. 28 N.T. 29 1.7 30 4.2 31 1.2 32 0.52 33 1.7 34 4.5 35 31.7 36 62 37 27.5 38 15.2 39 5.3 40 0.010 41 0.006 43 0.106 44 0.540 45 0.07 46 0.133 47 0.063 48 0.091 49 0.177 50 0.086 51 0.12 52 0.50 53 0.281 54 0.055 55 0.077 56 0.112 57 0.094 58 0.8 59 0.18 60 0.350 61 0.4 62 1.6 63 0.198 64 0.250 65 0.113
66 0.39
67 0.274
68 0.54310
69 30
70 IC35(15)**0.105 71 0.18
72 0.63
73 1.94
N.T. not tested.
* a calculated average
** The concentration of the inhibitor was not increased above 15 μg/mL
Exemplary structures of compounds encompassed by the present invention are shown in Table 4 below.
Figure imgf000293_0001
Figure imgf000294_0001
Figure imgf000295_0001
Figure imgf000296_0001
Figure imgf000297_0001
Figure imgf000298_0001
Figure imgf000299_0001
Figure imgf000300_0001
Figure imgf000301_0001
Figure imgf000302_0001
Figure imgf000303_0001
Figure imgf000304_0001
Figure imgf000305_0001
Figure imgf000306_0001
Figure imgf000307_0001
Figure imgf000308_0001
Figure imgf000309_0001
Figure imgf000310_0001

Claims

WE CLAIM :
1. A compound of the formula (1)
Figure imgf000311_0001
wherein:
Q1 and Q2 are independently selected from hydrogen and substituted and unsubstituted alkyl and aryl, and Q1 and Q2 may form a ring with G;
Q3 is selected from mercapto and substituted and
unsubstituted alkoxyl, aryloxyl, thioether, amino, alkyl, cycloalkyl, saturated and partially saturated heterocycle, and aryl;
Q4-Q8 are independently selected from hydrogen, hydroxyl, mercapto, nitro, halogen, -O-J, wherein J is a substituted or unsubstituted hydrolyzable group, and substituted and
unsubstituted alkoxyl, aryloxyl, thioether, sulfinyl, sulfonyl, amino, alkyl, cycloalkyl, saturated and partially saturated heterocycle, aryl, and L6C(O)L4, wherein L6 is a single bond, -O or -N, and further wherein L. is preferably alkyl, hydroxyl, alkoxyl or hydrogen; and further wherein any one or more of Q4-Q8 may be a member of a spiro ring and any two of Q4-Q8 may together be members of a ring;
Y and G are independently selected from oxygen, - N-H,
-N-alkyl, sulfur, selenium, and two hydrogen atoms;
D is carbon or nitrogen, and wherein D is singly bonded to each of the adjacent ring atoms;
E is carbon or nitrogen;
Q9 is selected from hydrogen, halogen, hydroxyl, mercapto, and substituted and unsubstituted alkoxyl, aryloxyl, thioether, amino, alkyl, and aryl, wherein Q may form part of a ring;
A is a carbocycle or heterocycle, which is optionally further substituted; and
B is a carbocycle or heterocycle, which is optionally further substituted;
or a pharmaceutically acceptable salt thereof.
2. A compound or pharmaceutically acceptable salt according to claim 1, wherein Q3 is selected from substituted and
unsubstituted alkoxyl, aryloxyl, thioether, alkyl, cycloalkyl, saturated and partially saturated heterocycle, and aryl.
3. A compound or pharmaceutically acceptable salt according to claim 1, wherein Q3 is selected from substituted and
unsubstituted aryloxyl, thioether, and aryl.
4. A compound or pharmaceutically acceptable salt according to claim 1, wherein Q3 is selected from substituted and
unsubstituted aryl and thioaryl.
5. A compound or pharmaceutically acceptable salt according to claim 1, wherein Q3 is selected from substituted and
unsubstituted phenyl, thiophenyl, naphthyl, and thionaphthyl.
6. A compound or pharmaceutically acceptable salt according to claim 1, wherein Q3 is selected from substituted and
unsubstituted phenyl and thiophenyl.
7. A compound or pharmaceutically acceptable salt according to claim 1, wherein Q3 is selected from substituted and
unsubstituted phenyl.
z A . A compound or pharmaceutically acceptable salt according to claim 1, wherein Q3 is selected from substituted and
unsubstituted thiophenyl.
9. A compound or pharmaceutically acceptable salt according to claim 1, wherein:
at least one of Q1 and Q2 is substituted or unsubstituted alkyl;
Q 4-Q8 are independently selected from hydrogen, hydroxyl, halogen, -O-J, wherein J is a substituted or unsubstituted
hydrolyzable group, and substituted and unsubstituted alkoxyl, amino, alkyl, and L6C(O)L4, wherein L6 is a single bond, -O or -N, and further wherein L is preferably alkyl, hydroxyl, alkoxyl or hydrogen; and further wherein any one or more of Q4-Q8 may form part of a ring;
Y and G are each oxygen;
D is nitrogen;
Q9 is hydrogen; A is a carbocycle or heterocycle that is an aromatic or partially saturated, 5-7 membered monocyclic ring, which is optionally further substituted; and
B is a heterocycle that is a saturated or partially
saturated, 8-12 membered polycyclic ring, which is optionally further substituted.
10. A compound or pharmaceutically acceptable salt according to claim 9, wherein Q3 is selected from substituted and
unsubstituted alkoxyl, aryloxyl, thioether, alkyl, cycloalkyl, saturated and partially saturated heterocycle, and aryl.
11. A compound or pharmaceutically acceptable salt according to claim 9, wherein Q3 is selected from substituted and
unsubstituted aryloxyl, thioether, and aryl.
12. A compound or pharmaceutically acceptable salt according to claim 9, wherein Q3 is selected from substituted and
unsubstituted aryl and thioaryl.
13. A compound or pharmaceutically acceptable salt according to claim 9, wherein Q3 is selected from substituted and
unsubstituted phenyl, thiophenyl, naphthyl, and thionaphthyl.
14. A compound or pharmaceutically acceptable salt according to claim 9, wherein Q3 is selected from substituted and
unsubstituted phenyl and thiophenyl.
15. A compound or pharmaceutically acceptable salt according to claim 9, wherein Q3 is selected from substituted and
unsubstituted phenyl.
16. A compound or pharmaceutically acceptable salt according to claim 9, wherein Q3 is selected from substituted and
unsubstituted thiophenyl.
17. A compound or pharmaceutically acceptable salt according to claim 9, wherein:
one of Q1 and Q2 is substituted or unsubstituted alkyl and the other is hydrogen;
Q4 is alkyl;
Q5 is hydroxyl or -O-J, wherein J is a hydrolyzable group, or substituted or unsubstituted alkoxyl or amino;
E is carbon;
A is a carbocycle that is an aromatic, 5-6 membered
monocyclic ring, which is optionally further substituted; and
B is a heterocycle that is a saturated or partially
saturated, 8-10 membered polycyclic ring, which is optionally further substituted.
18. A compound or pharmaceutically acceptable salt according to claim 17, wherein Q3 is selected from substituted and
unsubstituted alkoxyl, aryloxyl, thioether, alkyl, cycloalkyl, saturated and partially saturated heterocycle, and aryl.
19. A compound or pharmaceutically acceptable salt according to claim 17, wherein Q3 is selected from substituted and
unsubstituted aryloxyl, thioether, and aryl.
20. A compound or pharmaceutically acceptable salt according to claim 17, wherein Q3 is selected from substituted and
unsubstituted aryl and thioaryl.
21. A compound or pharmaceutically acceptable salt according to claim 17, wherein Q3 is selected from substituted and
unsubstituted phenyl, thiophenyl, naphthyl, and thionaphthyl.
22. A compound or pharmaceutically acceptable salt according to claim 17, wherein Q3 is selected from substituted and
unsubstituted phenyl and thiophenyl.
23. A compound or pharmaceutically acceptable salt according to claim 17, wherein Q3 is selected from substituted and
unsubstituted phenyl.
24. A compound or pharmaceutically acceptable salt according to claim 17, wherein Q3 is selected from substituted and
unsubstituted thiophenyl.
25. A compound or pharmaceutically acceptable salt according to claim 17, wherein:
one of Q1 and Q2 is tertiary alkyl and the other is hydrogen;
Q4 is methyl;
Q5 is hydroxyl, amino, or -O-J, wherein J is a substituted or unsubstituted hydrolyzable group;
A is phenyl; and
B is a heterocycle that is a saturated, 9-10 membered
bicyclic ring, which is optionally further substituted.
26. A compound or pharmaceutically acceptable salt according to claim 25, wherein Q3 is selected from substituted and
unsubstituted alkoxyl, aryloxyl, thioether, alkyl, cycloalkyl, saturated and partially saturated heterocycle, and aryl.
27. A compound or pharmaceutically acceptable salt according to claim 25, wherein Q3 is selected from substituted and
unsubstituted aryloxyl, thioether, and aryl.
28. A compound or pharmaceutically acceptable salt according to claim 25, wherein Q3 is selected from substituted and
unsubstituted aryl and thioaryl.
29. A compound or pharmaceutically acceptable salt according to claim 25, wherein Q3 is selected from substituted and
unsubstituted phenyl, thiophenyl, naphthyl, and thionaphthyl.
30. A compound or pharmaceutically acceptable salt according to claim 25, wherein Q3 is selected from substituted and
unsubstituted phenyl and thiophenyl.
31. A compound or pharmaceutically acceptable salt according to claim 25, wherein Q3 is selected from substituted and
unsubstituted phenyl.
32. A compound or pharmaceutically acceptable salt according to claim 25, wherein Q3 is selected from substituted and
unsubstituted thiophenyl.
33. A compound or pharmaceutically acceptable salt according to claim 25, wherein:
B is decahydroisoquinolinyl or octahydrothieno[3,2-c]pyridinyl.
34. A compound or pharmaceutically acceptable salt according to claim 1, wherein:
one of Q1 and Q2 is substituted or unsubstituted alkyl and the other is hydrogen; Q3 is selected from thioether and aryl;
Q4-Q8 are independently selected from hydrogen, hydroxyl, halogen, -O-J, wherein J is a substituted or unsubstituted
hydrolyzable group, and substituted and unsubstituted alkoxyl, amino, alkyl, and L6C(O)L4, wherein L6 is a single bond, -O or -N, and further wherein L4 is preferably alkyl, hydroxyl, alkoxyl or hydrogen; and further wherein any one or more of Q4-Q8 may form part of a ring;
A is a carbocycle or heterocycle that is an aromatic or partially saturated, 5-7 membered monocyclic ring, which is optionally further substituted; and
B is a heterocycle that is a saturated or partially
saturated, 8-10 membered polycyclic ring, which is optionally further substituted.
35. A compound or pharmaceutically acceptable salt according to claim 34, wherein:
B is a heterocycle that is a saturated, 9-10 membered
bicyclic ring, which is optionally further substituted.
36. A compound or pharmaceutically acceptable salt according to claim 35, wherein:
B is
Figure imgf000318_0001
wherein M1 and M2 are independently selected from hydrogen, mercapto, hydroxyl, and substituted and unsubstituted thioether, alkyl, alkoxyl, aryloxyl, amino, five membered heterocycle and carbocycle, sulfinyl, sulfonyl, and acyl, and M1 and M2 may form part of a ring having up to 10 members.
37. A compound of the formula
Figure imgf000319_0001
or a prodrug thereof or a pharmaceutically acceptable salt thereof.
38. A stereoisomer of the compound according to claim 37, which has the formula
Figure imgf000319_0002
or a prodrug thereof or pharmaceutically acceptable salt thereof.
39. The essentially pure stereoisomer, prodrug or salt according to claim 38.
40. The essentially pure stereoisomer according to claim 39.
41. A compound of the formula
Figure imgf000320_0001
42. A stereoisomer of the compound according to claim 41, which has the formula
Figure imgf000321_0001
43. The essentially pure stereoisomer according to claim 42.
44. A compound of the formula
Figure imgf000321_0002
45. A stereoisomer of the compound according to claim 41, which has the formula
Figure imgf000322_0001
46. A compound of the formula
Figure imgf000322_0002
47. A stereoisomer of the compound according to claim 46, which has the formula
Figure imgf000323_0001
48. The essentially pure stereoisomer according to claim 47.
49. A compound of the formula
Figure imgf000323_0002
or a prodrug thereof or a pharmaceutically acceptable salt
thereof.
50. A stereoisomer of the compound according to claim 49, which has the formula
Figure imgf000324_0001
or a prodrug thereof or pharmaceutically acceptable salt thereof.
51. The essentially pure stereoisomer, prodrug or salt according to claim 50.
52. The essentially pure stereoisomer according to claim 51.
53. A compound or pharmaceutically acceptable salt according to claim 4, wherein:
one of Q1 and Q2 is t-butyl;
Q3 is thiophenyl or phenyl; and
Q5 is hydroxyl or -O-J.
54. A compound or pharmaceutically acceptable salt according to claim 1, wherein:
one of Q1 and Q2 is t-butyl and the other is hydrogen;
Q3 is thiophenyl or phenyl;
Q4 is methyl;
Q5 is hydroxyl or -O-J;
Q6, Q7, and Q8 are hydrogen;
Y and G are both oxygen;
D is nitrogen;
E is carbon;
Q9 is hydrogen; A is phenyl; and
B is
Figure imgf000325_0001
wherein M1 and M2 are independently selected from hydrogen, mercapto, hydroxyl, and substituted and unsubstituted thioether, alkyl, alkoxyl, aryloxyl, amino, five membered heterocycle and carbocycle, sulfinyl, sulfonyl, and acyl, and M1 and M2 may form part of a ring having up to 10 members.
55. A compound or pharmaceutically acceptable salt according to claim 54, wherein M1 and M2 independently have from zero to eight non-hydrogen atoms.
56. A compound or pharmaceutically acceptable salt according to claim 1, wherein:
one of Q1 and Q2 is t-butyl and the other is hydrogen;
Q3 is selected from mercapto and substituted and
unsubstituted alkoxyl, aryloxyl, thioether, amino, alkyl,
cycloalkyl, saturated and partially saturated heterocycle, and aryl;
Q4 is methyl;
Q5 is hydroxyl or -O-J; Q6, Q7, and Q8 are hydrogen;
Y and G are both oxygen;
D is nitrogen;
E is carbon;
Q9 is hydrogen;
A is phenyl; and
B is decahydroisoquinolinyl or octahydro-thieno
[3,2-c] pyridinyl.
57. A compound or pharmaceutically acceptable salt according to claim 56, wherein:
Q3 is thioether.
58. A compound or pharmaceutically acceptable salt according to claim 1, wherein:
one of Q1 and Q2 is t-butyl and the other is hydrogen;
Q3 is thioaryl;
Y and G are both oxygen;
D is nitrogen;
E is carbon;
Q9 is hydrogen;
A is carbocycle or heterocycle, which is optionally further substituted; and
B is decahydroisoquinolinyl or octahydro-thieno
[3,2-c]pyridinyl.
59. A compound or pharmaceutically acceptable salt according to claim 58, wherein: A is carbocycle;
Q4 is hydroxyl, or substituted or unsubstituted alkoxyl, thioether, or alkyl; and
Q5 is hydroxyl, -O-J or substituted or unsubstituted alkoxyl.
5
60. A compound or pharmaceutically acceptable salt according to claim 59, wherein:
A is phenyl;
Q4 is alkyl; and
Q5 is hydroxyl or -OPO(OH)2.
61. The essentially pure stereoisomer of claim 45.
62. A compound or pharmaceutically acceptable salt according to claim 58, wherein:
Q3 is thiophenyl.
63. A pharmaceutical composition comprising:
(a) an effective amount of compound of the formula (1)
Figure imgf000327_0001
wherein: Q1 and Q2 are independently selected from hydrogen and substituted and unsubstituted alkyl and aryl, and Q1 and Q2 may form a ring with G;
Q3 is selected from mercapto and substituted and
unsubstituted alkoxyl, aryloxyl, thioether, amino, alkyl,
cycloalkyl, saturated and partially saturated heterocycle, and aryl;
Q4-Q8 are independently selected from hydrogen, hydroxyl, mercapto, nitro, halogen, -O-J, wherein J is a substituted or unsubstituted hydrolyzable group, and substituted and
unsubstituted alkoxyl, aryloxyl, thioether, sulfinyl, sulfonyl, -amino, alkyl, cycloalkyl, L6C(O)L4, wherein L6 is a single bond, -O or -N, and further wherein L4 is preferably alkyl, hydroxyl, alkoxyl or hydrogen, saturated and partially saturated heterocycle and aryl, and further wherein any one or more of Q 4-Q8 may be a member of a spiro ring and any two of Q4-Q8 may together be members of a ring;
Y and G are independently selected from oxygen, - N-H,
-N-alkyl, sulfur, selenium, and two hydrogen atoms;
D is carbon or nitrogen, and wherein D is singly bonded to each of the adjacent ring atoms;
E is carbon or nitrogen;
Q9 is selected from hydrogen, halogen, hydroxyl, mercapto, and substituted and unsubstituted alkoxyl, aryloxyl, thioether, amino, alkyl, and aryl, wherein Q9 may form part of a ring;
A is a carbocycle or heterocycle, which is optionally further substituted; and B is a carbocycle or heterocycle, which is optionally further substituted;
or a pharmaceutically acceptable salt thereof; and
(b) a pharmaceutically acceptable carrier therefor.
64. A method of inhibiting HIV protease, comprising
administering to a host an effective amount of compound of the formula (1)
Figure imgf000329_0001
wherein:
Q1 and Q2 are independently selected from hydrogen and substituted and unsubstituted alkyl and aryl, and Q1 and Q2 may form a ring with G;
Q3 is selected from mercapto and substituted and
unsubstituted alkoxyl, aryloxyl, thioether, amino, alkyl,
cycloalkyl, saturated and partially saturated heterocycle, and aryl;
Q4-Q8 are independently selected from hydrogen, hydroxyl, mercapto, nitro, halogen, -O-J, wherein J is a substituted or unsubstituted hydrolyzable group, and substituted and unsubstituted alkoxyl, aryloxyl, thioether, sulfinyl, sulfonyl, amino, alkyl, cycloalkyl, L6C(O)L4, wherein L6 is a single bond, -O or -N, and further wherein L4 is preferably alkyl, hydroxyl, alkoxyl or hydrogen, saturated and partially saturated heterocycle and aryl, and further wherein any one or more of Q4-Q8 may be a member of a spiro ring and any two of Q4-Q8 may together be members of a ring;
Y and G are independently selected from oxygen, - N-H,
-N-alkyl, sulfur, selenium, and two hydrogen atoms;
D is carbon or nitrogen, and wherein D is singly bonded to each of the adjacent ring atoms;
E is carbon or nitrogen;
Q9 is selected from hydrogen, halogen, hydroxyl, mercapto, and substituted and unsubstituted alkoxyl, aryloxyl, thioether, amino, alkyl, and aryl, wherein Q9 may form part of a ring;
A is a carbocycle or heterocycle, which is optionally further substituted; and
B is a carbocycle or heterocycle, which is optionally further substituted;
or a pharmaceutically acceptable salt thereof.
65. A compound of formula 1(A)
Figure imgf000330_0001
wherein: Z is a group having the structure:
Figure imgf000331_0001
where :
a is 1, 2, 3, 4, or 5;
b is 1, or 2;
c is 1, or 2;
d is 1, 2, 3, 4;
each R2 is independently hydrogen, hydroxy, thiol, halo, amino, C1-C4 alkylamino, di(C1-C4)alkylamino, nitro, carboxy, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, halo(C1-C4)alkyl, hydroxy(C1-C4)alkyl, C1-C6 alkylthio(C1-C6)alkyl, C1-C4
alkoxycarbonyl, carbamoyl, N-(C1-C4)alkylcarbamoyl, C1-C4 alkylsulfonyl, N,N-di(C1-C4)alkylcarbamoyl, or C1-C4 alkylsulfonylamino;
A1 and A2 are independently -CH_- or -N(R8)-; A 3 and A4 are independently -CH- or -N-;
A 5 and A6 are independently -CH2~ or -N(R9)-; A 7 and A8 are independently -CH- or -N- ;
R8 is hydrogen or C1-C4 alkyl;
R9 is hydrogen or C1-C4 alkyl;
R1 is aryl, or -S-aryl;
X is a group having the structure:
Figure imgf000332_0001
where :
R is hydrogen, C1-C4 alkyl, or -CH2-pyridyl; R3 is a group having the structure:
1) -C(O)-NR4R4, 2) ,
Figure imgf000332_0002
3)
;
Figure imgf000332_0003
p is 4 or 5;
R4 at each occurrence is independently hydrogen, C1-C6 alkyl or hydroxy(C1-C4)alkyl; and
R5 and R6 are independently selected from hydrogen, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, or hydroxy(C1-C4)alkyl; with the provisos that:
(1) one of A1 and A2 must be -N(R8)-;
(2) A1 and A2 cannot both be -N(R8)-;
3 4
(3) A and A cannot both be -N-;
(4) one of A5 and A6 must be -N(R9)-;
(5) A5 and A6 cannot both be -N(R9)-;
(6) A7 and A8 cannot both be -N-;
or a pharmaceutically acceptable salt thereof.
66. A compound according to claim 65 wherein:
Z is a group having the structure:
Figure imgf000333_0001
R2 is hydrogen, hydroxy, C1-C4 alkyl, halo, amino, nitro, or trifluoromethyl;
a is 1, 2, or 3;
c is 1; and
R3 is -C(O)NR4R4;
or a pharmaceutically acceptable salt thereof.
67. A compound according to claim 66 wherein: Z is ;
Figure imgf000334_0001
R2 is hydrogen, methyl, ethyl, propyl, chloro, fluoro, hydroxy, or amino;
X is
Figure imgf000334_0003
, or ;
Figure imgf000334_0002
R is -CH2-pyridyl;
R1 is phenyl or -S-phenyl; and
R3 is -C(O)NH(R4);
or a pharmaceutically acceptable salt thereof.
68. A compound according to claim 67 wherein:
Z is
;
Figure imgf000334_0004
R 2a is methyl, ethyl, or propyl;
R2b is hydrogen, hydroxy, or amino; R2c is hydrogen, hydroxy, or ammo;
R3 is -C(O)NH(t-butyl);
or a pharmaceutically acceptable salt thereof.
69. A compound according to claim 68 which is
[3S- (3R* , 4aR* , 8aR* , 2 ' S* , 3 ' R*)]-2-[2'-hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2''-propyl-3''-hydroxyphenyl)pentyl]
decahydroisoquinoline-3-N-t-butylcarboxamide; or a
pharmaceutically acceptable salt thereof.
70. A compound according to claim 68 which is
[3S-(3R*,4aR*,8aR*,2'S*,3'S*)]-2-[2'-hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''-hydroxyphenyl)pentyl]
decahydroisoquinoline-3-N-t-butylcarboxamide; or a
pharmaceutically acceptable salt thereof.
71. A compound according to claim 67 which is
[2S-(2R*,2'S*,3'S*)]-1-[2'-hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(3''-hydroxy-2''-methylphenyl)pentyl]-4-pyrid-3''-ylmethylpiperazine-2-N-t-butylcarboxamide; or a pharmaceutically
acceptable salt thereof.
72. A compound according to claim 66 which is
[3S-(3R*,4aR*,8aR*,2'S*,3'S*)]-2-[2'-hydroxy-3'-phenylthiomethyl-4'-aza-5'-oxo-5'-(1'',2'',3'',4''-tetrahydroquinolin-5''-yl)pentyl] decahydroisoquinoline-3-N-t-butylcarboxamide; or a pharmaceutically acceptable salt thereof.
73. A compound according to claim 67 which is
[3S-(3R*,4aR*,8aR*,2'S*,3'R*)]-2-[2'-hydroxy-3'-phenylmethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''-hydroxyphenyl)pentyl] decahydroisoquinoline-3-N-t-butylcarboxamide; or a pharmaceutically acceptable salt thereof.
74. A compound according to claim 67 which is
[3S-(3R* , 4aR*, 8aR*, 2 'S*, 3 'R*) ]-2-[2'-hydroxy-3'-phenylmethyl-4aza-5'-oxo-5'-(2''-ethyl-3''-hydroxyphenyl)pentyl]
decahydroisoquinoline-3-N-t-butylcarboxamide; or a
pharmaceutically acceptable salt thereof .
75. A compound of formula 1(B)
Figure imgf000336_0001
wherein:
R1 is aryl, or -S-aryl;
X1 is a group having the formula:
Figure imgf000336_0002
T2 is hydrogen, halo, or C1-C4 alkyl,
R3 is a group having the structure: 1 ) -C (O) -NR4R4 2 ) , or
Figure imgf000337_0002
3)
;
Figure imgf000337_0003
p is 4 or 5 ;
R4 at each occurrence is independently hydrogen,
C1-C6 alkyl or hydroxy(C1-C4)alkyl; and
R5 and R6 are independently selected from hydrogen, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, or hydroxy(C1-C4)alkyl;
Z1 is a group having the structure:
Figure imgf000337_0001
where:
a is 1, 2, 3, 4, or 5;
b is 1, or 2;
c is 1, or 2;
d is 1, 2, 3, or 4;
each R7 is independently hydrogen, hydroxy, thiol, halo, amino, C1-C4 alkylamino, di(C1-C4)alkylamino, nitro, carboxy, C1-
C6 alkyl, C1-C6 alkoxy, C1-C4 alkylthio, halo(C1-C4)alkyl, hydroxy(C1-C4)alkyl, C1-C4 alkylthio(C1-C4)alkyl, C1-C4
alkoxycarbonyl, carbamoyl, N-(C1-C4)alkylcarbamoyl, C1CC4
alkylsulfonyl, N,N-di(C1-C4)alkylcarbamoyl, or C1-C4
alkylsulfonylamino;
A 1 and A2 are independently -CH2- or -N(R8)-;
A 3 and A4 are independently -CH- or -N-;
A 5 and A6 are independently -CH2- or -N(R9)-;
A 7 and A8 are independently -CH- or -N-;
R8 is hydrogen or C1-C4 alkyl;
R9 is hydrogen or C1-C4 alkyl;
T2 is hydrogen, or C1-C4 alkyl; with the provisos that:
(1) one of A1 and A2 must be -N(R8)-;
(2) A1 and A2 cannot both be -N(R8)-;
(3) A3 and A4 cannot both be -N-;
(4) one of A5 and A6 must be -N(R9)-; (5) A5 and A6 cannot both be -N(R9)-;
(6) A 7 and A8 cannot both be -N-;
or a pharmaceutically acceptable salt thereof,
76. A compound according to claim 75 wherein:
X1 is ;
Figure imgf000339_0001
T2 is hydrogen or methyl;
Z1 is a group having the structure:
Figure imgf000339_0002
R7 is hydrogen, C1-C4 alkyl, halo, nitro, amino, hydroxy; a is 1, 2, or 3;
c is 1;
or a pharmaceutically acceptable salt thereof.
77. A compound according to claim 76 wherein:
Z1 is ;
Figure imgf000339_0003
R7 is hydrogen, methyl, ethyl, hydroxy, amino, chloro;
R1 is -S-phenyl, or -S-naphth-2-yl; and
R3 is -C(O)NR4R4;
or a pharmcaceutically acceptable salt thereof.
78. A compound according to claim 77 wherein:
Z1 is ;
Figure imgf000340_0001
R 7a is hydrogen, methyl, ethyl, chloro, bromo or fluoro;
R7b is hydrogen, hydroxy, chloro or amino;
R7c is hydrogen, hydroxy, or ammo;
R3 is -C(O)NH(t-butyl); or a pharmaceutically acceptable salt thereof.
79. The compound according to claim 77 which is
[2'R-(2 'R*, 3 'S*) ]-N-t-butyl-2-[2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(1'',2'',3'',4''-tetrahydroquinolin-5''-yl)pentyl] benzamide; or a pharmcaceutically acceptable salt thereof.
80. The compound according to claim 79 which is [2'R- (2 'R*, 3 'S*) ]-N-t-butyl-2-[2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''-hydroxyphenyl)pentyl] benzamide; or a pharmaceutically acceptable salt thereof.
81. The compound according to claim 79 which is [2'R-(2 'R*, 3 'S*) ]-N-t-butyl-2-[2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(2''-methyl-3'',5''-diaminophenyl)pentyl] benzamide; or a pharmaceutically acceptable salt thereof.
82. The compound according to claim 79 which is [2'R- (2 'R*, 3 'S*) ]-N-t-butyl-2-[2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(2''-methyl-3''-hydroxyphenyl)pentyl]-1-naphthylamide; or a pharmaceutically acceptable salt thereof.
83. The compound according to claim 79 which is [2'R- (2 'R*, 3 'S*) ]-N-t-butyl-2-[2'-hydroxy-3'-naphth-2-ylthiomethyl-4'-aza-5'-oxo-5'-(2''-chloro-3''-aminophenyl)pentyl]-1-naphthylamide; or a pharmaceutically acceptable salt thereof.
PCT/US1994/011307 1993-10-07 1994-10-07 Hiv protease inhibitors WO1995009843A1 (en)

Priority Applications (27)

Application Number Priority Date Filing Date Title
UA96041689A UA56984C2 (en) 1993-10-07 1994-07-10 HIV protease inhibitors, a pharmaceutical composition and a method for inhibition of HIV protease
EP94930609A EP0722439B1 (en) 1993-10-07 1994-10-07 Hiv protease inhibitors
HU9600908A HU226814B1 (en) 1993-10-07 1994-10-07 Hiv protease inhibitors based on decahydroisoquinoline-carboxamide derivatives and use thereof
AT94930609T ATE222240T1 (en) 1993-10-07 1994-10-07 HIV - PROTEASE INHIBITORS
TJ96000281A TJ339B (en) 1993-10-07 1994-10-07 A compound pharmaceutical composition and method for hiv protease inhibitors
APAP/P/1996/000844A AP600A (en) 1993-10-07 1994-10-07 HIV Protease inhibitors.
AU79674/94A AU694746B2 (en) 1993-10-07 1994-10-07 HIV protease inhibitors
BR9407782A BR9407782A (en) 1993-10-07 1994-10-07 HIV protease inhibitors
JP7511006A JP2951724B2 (en) 1993-10-07 1994-10-07 HIV protease inhibitor
MD96-0141A MD1507G2 (en) 1993-10-07 1994-10-07 Inhibitors, pharmaceutical composition on base thereof and process for HIV protease inhibition
DK94930609T DK0722439T3 (en) 1993-10-07 1994-10-07 HIV protease inhibitors
HU0900219A HU227885B1 (en) 1993-10-07 1994-10-07 Hiv protease inhibitor carboxamide-derivatives with hiv protease inhibitor effect
SK439-96A SK284115B6 (en) 1993-10-07 1994-10-07 HIV protease inhibitors
RU96109378A RU2139280C1 (en) 1993-10-07 1994-10-07 Compound, pharmaceutical composition and method of inhibition of hiv-protease activity
CA002173328A CA2173328C (en) 1993-10-07 1994-10-07 Hiv protease inhibitors
DE69431193T DE69431193T2 (en) 1993-10-07 1994-10-07 HIV PROTEASE INHIBITORS
RO96-00738A RO119363B1 (en) 1993-10-07 1994-10-07 Decahydroisoquinoline derivative, pharmaceutical composition and use thereof
NZ275633A NZ275633A (en) 1993-10-07 1994-10-07 N-(3-hetero)cyclyl-2-hydroxy propyl)-(hetero)cyclyl carboxamide derivatives and analogues
PL94313871A PL185647B1 (en) 1993-10-07 1994-10-07 Inhibitors of hiv protease
SI9430421T SI0722439T1 (en) 1993-10-07 1994-10-07 Hiv protease inhibitors
EE9600091A EE05399B1 (en) 1993-10-07 1994-10-07 HIV protease inhibitors
SK493-2002A SK284116B6 (en) 1993-10-07 1994-10-07 Carboaxamide compounds, pharmaceutical composition containing thereof and use thereof
KR1019960700897A KR100190517B1 (en) 1993-10-07 1996-02-23 Hiv protease inhibitors
BG100455A BG62567B1 (en) 1993-10-07 1996-03-27 Hiv-protease inhibitors
FI961449A FI114794B (en) 1993-10-07 1996-03-29 HIV protease inhibitors
NO961382A NO307050B1 (en) 1993-10-07 1996-04-03 HIV protease inhibitors
HK98114956A HK1013650A1 (en) 1993-10-07 1998-12-23 Hiv protease inhibitors

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US13354393A 1993-10-07 1993-10-07
US13369693A 1993-10-07 1993-10-07
US08/190,764 US5484926A (en) 1993-10-07 1994-02-02 HIV protease inhibitors
US08/190,764 1994-02-02
US08/133,543 1994-02-02
US08/133,696 1994-02-02

Publications (1)

Publication Number Publication Date
WO1995009843A1 true WO1995009843A1 (en) 1995-04-13

Family

ID=27384442

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/011307 WO1995009843A1 (en) 1993-10-07 1994-10-07 Hiv protease inhibitors

Country Status (36)

Country Link
US (14) US5484926A (en)
EP (3) EP1340744B1 (en)
JP (2) JP2951724B2 (en)
KR (1) KR100190517B1 (en)
CN (2) CN1195737C (en)
AP (1) AP600A (en)
AT (3) ATE286025T1 (en)
AU (1) AU694746B2 (en)
BG (1) BG62567B1 (en)
BR (1) BR9407782A (en)
CA (2) CA2268709C (en)
CZ (1) CZ290417B6 (en)
DE (3) DE69434977T2 (en)
DK (2) DK0722439T3 (en)
EE (1) EE05399B1 (en)
ES (3) ES2287387T3 (en)
FI (1) FI114794B (en)
GE (2) GEP20002209B (en)
HK (3) HK1013650A1 (en)
HU (2) HU227885B1 (en)
MD (1) MD1507G2 (en)
MY (1) MY138860A (en)
NO (1) NO307050B1 (en)
NZ (2) NZ329626A (en)
OA (1) OA10718A (en)
PL (1) PL185647B1 (en)
PT (2) PT722439E (en)
RO (1) RO119363B1 (en)
RU (1) RU2139280C1 (en)
SI (2) SI0722439T1 (en)
SK (2) SK284116B6 (en)
TJ (1) TJ339B (en)
TW (1) TW432049B (en)
UA (1) UA56984C2 (en)
UY (1) UY23840A1 (en)
WO (1) WO1995009843A1 (en)

Cited By (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0741719A1 (en) * 1994-02-02 1996-11-13 Eli Lilly And Company Intermediate and process for making
EP0744948A1 (en) * 1994-02-02 1996-12-04 Eli Lilly And Company Protease inhibitors
EP0746320A1 (en) * 1994-02-02 1996-12-11 Eli Lilly And Company Hiv protease inhibitors and intermediates
WO1997011938A1 (en) * 1995-09-26 1997-04-03 Japan Tobacco Inc. Process for producing amide derivatives and intermediate compounds
WO1997011937A1 (en) * 1995-09-26 1997-04-03 Japan Tobacco Inc. Process for producing amide derivatives and intermediates
WO1998040357A2 (en) * 1997-03-13 1998-09-17 Agouron Pharmaceuticals, Inc. Hiv protease inhibitors
DE19730602A1 (en) * 1997-07-17 1999-01-21 Clariant Gmbh 3-Acetoxy-2-methylbenzoic acid chloride and a process for its preparation
US5962725A (en) * 1996-09-05 1999-10-05 Agouron Pharmaceuticals, Inc. Intermediate compounds useful for making HIV protease inhibitors such as nelfinavir
WO1999054297A1 (en) * 1998-04-16 1999-10-28 Nagase & Company, Ltd. Process for preparing chloro alcohol derivatives and intermediates
US6001851A (en) * 1997-03-13 1999-12-14 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US6084107A (en) * 1997-09-05 2000-07-04 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
US6107511A (en) * 1998-07-29 2000-08-22 Kaneka Corporation Process for the purification or isolation of (2S,3R)-1-halo-2-hydroxy-3-(protected amino)4-phenylthiobutanes or optical antipodes thereof
US6117999A (en) * 1996-09-05 2000-09-12 Agouron Phramaceuticals, Inc. Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors
US6197966B1 (en) 1998-01-16 2001-03-06 Japan Tobacco Inc. Production method of optically active amino alcohols
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
US6319946B1 (en) 1999-02-12 2001-11-20 Vertex Pharmaceuticals Incorporated Inhibitors of aspartyl protease
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
WO2002064553A1 (en) * 2001-02-14 2002-08-22 Kureha Chemical Industry Company, Limited Process for preparation of halogenoalcohol derivatives
US6613743B2 (en) 1998-06-19 2003-09-02 Vertex Pharmaceuticals Incorporated Sulfonamide inhibitors of aspartyl protease
US6703403B2 (en) 1995-06-29 2004-03-09 Abbott Laboratories Method for improving pharmacokinetics
US6846813B2 (en) * 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
BG64457B1 (en) * 1996-03-22 2005-03-31 Glaxo Group Limited Hiv protease inhibitor-containing pharmaceutical form for oral administration
US6878728B1 (en) 1999-06-11 2005-04-12 Vertex Pharmaceutical Incorporated Inhibitors of aspartyl protease
US6953858B2 (en) 2001-06-11 2005-10-11 Agouron Pharmaceuticals, Inc. HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
WO2006127133A2 (en) 2005-04-01 2006-11-30 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
WO2007087504A2 (en) 2006-01-25 2007-08-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
WO2007087505A2 (en) 2006-01-25 2007-08-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
WO2007092729A2 (en) 2006-02-02 2007-08-16 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
EP1917958A2 (en) 2000-01-19 2008-05-07 Abbott Laboratories Improved HIV protease inhibitors pharmaceutical formulations
WO2009151695A1 (en) 2008-03-13 2009-12-17 Wellstat Therapeutics Corporation Compounds and method for reducing uric acid
WO2010144869A2 (en) 2009-06-12 2010-12-16 Nektar Therapeutics Protease inhibitors
EP2266946A2 (en) 2003-02-13 2010-12-29 Wellstat Therapeutics Corporation Compound For The Treatment Of Metabolic Disorders
USRE42889E1 (en) 1992-08-25 2011-11-01 G.D. Searle Llc α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US8076514B2 (en) 2005-07-20 2011-12-13 Eli Lilly And Company Phenyl compounds and their use in the treatment of Type II diabetes
US8106090B2 (en) 2005-07-20 2012-01-31 Eli Lilly And Company 1-amino linked compounds
US8114901B2 (en) 2002-07-12 2012-02-14 Eli Lilly And Company Crystalline 2,5-dione-3-(1-methyl-1H-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl]-1H-pyrrole mono-hydrochloride
USRE43596E1 (en) 1992-08-25 2012-08-21 G.D. Searle Llc α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
EP2522367A1 (en) 2007-03-12 2012-11-14 Nektar Therapeutics Oligomer-protease inhibitor conjugates
US8455497B2 (en) 1999-06-11 2013-06-04 Vertex Pharmaceuticals Incorporated Inhibitors of aspartyl protease
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
US8716263B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Synthesis of purine nucleosides
US8716262B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8779144B2 (en) 2006-03-16 2014-07-15 Evotec (Us) Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
US8859756B2 (en) 2010-03-31 2014-10-14 Gilead Pharmasset Llc Stereoselective synthesis of phosphorus containing actives
US9095620B2 (en) 2008-03-12 2015-08-04 Nektar Therapeutics Reagents
US9227990B2 (en) 2012-10-29 2016-01-05 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
US10640457B2 (en) 2009-12-10 2020-05-05 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
WO2021176369A1 (en) 2020-03-06 2021-09-10 Pfizer Inc. Methods of inhibiting sars-cov-2 replication and treating coronavirus disease 2019
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
US11426412B2 (en) 2017-10-18 2022-08-30 Jubilant Epipad LLC Imidazo-pyridine compounds as PAD inhibitors
US11459338B2 (en) 2017-11-24 2022-10-04 Jubilant Episcribe Llc Heterocyclic compounds as PRMT5 inhibitors
US11529341B2 (en) 2018-03-13 2022-12-20 Jubilant Prodel LLC Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
US11833156B2 (en) 2017-09-22 2023-12-05 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USH1649H (en) * 1987-07-31 1997-05-06 Barrish; Joel C. HIV protease inhibitor combinations
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5514801A (en) * 1992-12-29 1996-05-07 Monsanto Company Cyclic sulfone containing retroviral protease inhibitors
IL110255A (en) * 1993-07-16 1998-12-06 Merck & Co Inc Formation and resolution of 2-tert-butylcarboxamido-piperazine
US20030207813A1 (en) * 1996-12-09 2003-11-06 G.D. Searle Retroviral protease inhibitor combinations
UA49803C2 (en) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Method for treatment of retrovirus infections
US5831117A (en) * 1995-01-20 1998-11-03 G. D. Searle & Co. Method of preparing retroviral protease inhibitor intermediates
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
DE69731715T2 (en) * 1996-06-05 2005-11-03 Sega Enterprises, Ltd. IMAGE PROCESSOR, IMAGE PROCESSING, GAME COMPUTER AND RECORD MEDIUM
UA67727C2 (en) * 1996-09-05 2004-07-15 Агурон Фармасевтікелс, Інк. Intermediate compounds for preparation of hiv-protease inhibitors and methods for the preparation of hiv-protease inhibitors
US5705647A (en) * 1996-09-05 1998-01-06 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
DE19704885C1 (en) * 1997-02-11 1998-06-10 Clariant Gmbh Preparation of 3-acetoxy-2-methyl-benzoic acid
EP0975601B1 (en) * 1997-04-10 2003-03-12 F. Hoffmann-La Roche Ag Process for making a butylthio-isoquinoline and intermediates therefor
US6130348A (en) 1997-04-10 2000-10-10 Hoffmann-La Roche Inc. Process for a phenylthiobutyl-isoquinoline and intermediates therefor
US6123694A (en) * 1997-05-09 2000-09-26 Paragon Trade Brands Disposable absorbent article with unitary leg gathers
US6124500A (en) * 1998-03-09 2000-09-26 Rohm And Haas Company Process for synthesizing benzoic acids
FR2776292B1 (en) 1998-03-20 2004-09-10 Oncopharm CEPHALOTAXANES SUPPORTING THE SIDE CHAIN AND THEIR SYNTHESIS PROCESS
US6538006B1 (en) 1998-07-08 2003-03-25 Pharmacia Corporation Retroviral protease inhibitors
US7115584B2 (en) * 1999-01-22 2006-10-03 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US7635690B2 (en) * 1999-01-22 2009-12-22 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
AU3910700A (en) 1999-03-22 2000-10-09 Immugen Pharmaceuticals, Inc. Treatment of immune diseases
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
US6589962B1 (en) 1999-07-20 2003-07-08 Merck & Co., Inc. Alpha-hydroxy-gamma-[[(carbocyclic-or heterocyclic-substituted)amino]carbonyl]alkanamide derivatives and uses thereof
EP1202626A4 (en) * 1999-07-20 2002-10-30 Merck & Co Inc Alpha-hydroxy-gamma-[[(carbocyclic-or heterocyclic-substituted)amino]carbonyl]alkanamide derivatives and uses thereof
KR100339831B1 (en) 1999-08-18 2002-06-07 김태성 New ethyl arizidine derivatives and their preparation methods
US6403799B1 (en) 1999-10-21 2002-06-11 Agouron Pharmaceuticals, Inc. Methods for the preparation of intermediates in the synthesis of HIV-protease inhibitors
ATE377011T1 (en) 1999-11-24 2007-11-15 Merck & Co Inc GAMMA-HYDROXY-2-(FLUORALKYLAMINOCARBONYL)-1-PIPERAZINE PENTANAMIDE AS AN HIV PROTEASE INHIBITOR
US6992081B2 (en) 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
CA2401749A1 (en) * 2000-03-23 2001-09-27 Elan Pharmaceuticals, Inc. Compounds and methods to treat alzheimer's disease
AU2001259817A1 (en) 2000-05-04 2001-11-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The National Institutes Of Health Methods of and compounds for inhibiting calpains
US20020198207A1 (en) * 2000-05-18 2002-12-26 Kath John Charles Novel Hexanoic acid derivatives
WO2002002505A2 (en) 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
EP1666452A2 (en) 2000-06-30 2006-06-07 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
PE20020276A1 (en) 2000-06-30 2002-04-06 Elan Pharm Inc SUBSTITUTE AMINE COMPOUNDS AS ß-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER
US20030096864A1 (en) * 2000-06-30 2003-05-22 Fang Lawrence Y. Compounds to treat alzheimer's disease
US7425537B2 (en) * 2000-08-22 2008-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services SH2 domain binding inhibitors
WO2002026224A2 (en) * 2000-09-28 2002-04-04 Immugen Pharmaceuticals, Inc. Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation
AU2002213429A1 (en) * 2000-09-28 2002-04-08 Immugen Pharmaceuticals, Inc. Antiviral methods and compounds
IT1318986B1 (en) * 2000-10-09 2003-09-19 Archimica S P A Ora Clariant L PROCEDURE FOR THE PREPARATION OF (S) -N-TERBUTYL-1,2,3,4-TETRAIDROISOCHINOLIN-3-CARBOXYAMIDE.
WO2002066952A2 (en) * 2000-10-19 2002-08-29 Target Discovery, Inc Mass defect labeling for the determination of oligomer sequences
MXPA04000140A (en) * 2001-06-27 2004-06-03 Elan Pharm Inc Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease.
US20070213407A1 (en) * 2001-06-29 2007-09-13 Elan Pharmaceuticals And Pharmacia & Upjohn Company Llc Compounds to treat Alzheimer's disease
US20030191121A1 (en) * 2001-08-09 2003-10-09 Miller Ross A. Piperazine carboxamide intermediates of HIV protease inhibitors and processes for their preparation
US20030068655A1 (en) * 2001-09-12 2003-04-10 Protiveris, Inc. Microcantilever apparatus and methods for detection of enzymes
US6696494B2 (en) 2001-10-22 2004-02-24 Enanta Pharmaceuticals, Inc. α-hydroxyarylbutanamine inhibitors of aspartyl protease
EP1490090A4 (en) 2002-02-22 2006-09-20 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
US20040067216A1 (en) * 2002-02-22 2004-04-08 Karki Shyam B. Hiv protease inhibitors supported on cation exchange resins for oral administration
US7157489B2 (en) * 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
US20030232101A1 (en) * 2002-03-18 2003-12-18 Immugen Pharmaceuticals, Inc. Topical formulations of resorcinols and cannibinoids and methods of use
DE10212885A1 (en) * 2002-03-22 2003-10-02 Bayer Ag Process for the preparation of 3-hydroxy-2-methylbenzoic acid
EP1371626A3 (en) * 2002-06-13 2004-07-21 Bayer Chemicals AG Process for the preparation of 3-Alkoxy-2-methylbenzoic acids
DE10226219A1 (en) * 2002-06-13 2004-01-08 Bayer Ag Process for the preparation of 3-acyloxy-2-methylbenzoic acids
DE50302717D1 (en) * 2002-08-21 2006-05-11 Lanxess Deutschland Gmbh Chiral diphosphorus compounds and their transition metal complexes
JP2006525307A (en) * 2003-05-08 2006-11-09 ファイザー インコーポレイテッド Intermediates useful for the synthesis of HIV-protease inhibitors and methods for their preparation
WO2005004868A1 (en) * 2003-07-15 2005-01-20 Arigen, Inc. Anti-coronavirus drug
US7211588B2 (en) * 2003-07-25 2007-05-01 Zentaris Gmbh N-substituted indolyl-3-glyoxylamides, their use as medicaments and process for their preparation
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
RS51799B (en) 2004-07-27 2011-12-31 Gilead Sciences Inc. Nucleoside phosphonate conjugates as anti hiv agents
US8367832B2 (en) * 2004-08-23 2013-02-05 Mylan Laboratories Limited Crystalline forms of Nelfinavir mesylate
JP4788958B2 (en) * 2006-02-28 2011-10-05 東亞合成株式会社 Antiviral peptides and uses thereof
JP4831410B2 (en) * 2006-02-28 2011-12-07 東亞合成株式会社 Antiviral peptides and antiviral agents
US20080161324A1 (en) * 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
WO2008041087A1 (en) * 2006-10-06 2008-04-10 Aurobindo Pharma Limited An improved process for preparation of amorphous nelfinavir mesylate
US20110009411A1 (en) * 2007-06-29 2011-01-13 Gilead Sciences ,Inc. Therapeutic compositions and the use thereof
AP2965A (en) * 2007-06-29 2014-09-30 Gilead Sciences Inc Therapeutic compositions and the use thereof
US20110105477A1 (en) * 2007-09-14 2011-05-05 The Regents Of The University Of Michigan Compositions and methods relating to hiv protease inhibition
JP2010540517A (en) * 2007-09-25 2010-12-24 メルク・シャープ・エンド・ドーム・コーポレイション HIV protease inhibitor
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
AR074506A1 (en) 2008-12-09 2011-01-19 Gilead Sciences Inc TOLL TYPE RECEIVERS MODULATORS
SG171308A1 (en) * 2008-12-11 2011-07-28 Shionogi & Co Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
CA2762582A1 (en) 2009-05-27 2010-12-02 Merck Sharp & Dohme Corp. Hiv protease inhibitors
ES2907862T3 (en) * 2009-12-10 2022-04-26 Univ Columbia Histone acetyltransferase activators and uses thereof
DE102010004957A1 (en) 2010-01-14 2011-07-21 Universitätsklinikum Jena, 07743 Biologically active molecules for influencing virus, bacterial, parasite-infected cells and / or tumor cells and methods for their use
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
TWI577377B (en) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 Pharmaceutical compositions
US9079834B2 (en) 2010-10-28 2015-07-14 Merck Canada Inc. HIV protease inhibitors
EP2771332B1 (en) 2011-10-26 2016-06-29 Merck Canada Inc. Thiophen and thiazol sulfonamid derivatives as HIV protease inhibitors for the treatment of AIDS
BR112015005347A2 (en) 2012-09-11 2017-08-08 Merck Sharp & Dohme Corp E Merck Canada Inc compound, pharmaceutical composition, and method for treatment or prophylaxis of HIV infection or for treatment, prophylaxis, or delay in the onset of AIDS
RU2505286C1 (en) 2012-12-29 2014-01-27 Открытое Акционерное Общество "Фармасинтез" Pharmaceutical composition for treating hiv infection, method for preparing it, and method of treating
WO2015013835A1 (en) 2013-07-31 2015-02-05 Merck Sharp & Dohme Corp. Piperazine derivatives as hiv protease inhibitors
RU2543322C1 (en) * 2013-09-19 2015-02-27 Открытое Акционерное Общество "Фармасинтез" Pharmaceutical composition for treating hiv-infection, method for preparing and method of using
US9737545B2 (en) 2013-12-19 2017-08-22 Merck Sharp & Dohme Corp. HIV protease inhibitors
EP3082822B1 (en) 2013-12-19 2020-01-15 Merck Sharp & Dohme Corp. Hiv protease inhibitors
WO2015134366A1 (en) 2014-03-06 2015-09-11 Merck Sharp & Dohme Corp. Hiv protease inhibitors
US10138255B2 (en) 2014-03-10 2018-11-27 Merck Sharp & Dohme Corp. Piperazine derivatives as HIV protease inhibitors
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
ES2930667T3 (en) 2014-07-11 2022-12-21 Gilead Sciences Inc Toll-like receptor modulators for the treatment of HIV
EP3212196A4 (en) 2014-10-29 2018-07-11 Wisconsin Alumni Research Foundation Boronic acid inhibitors of hiv protease
US20180263985A1 (en) 2015-09-15 2018-09-20 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
US10539397B2 (en) 2017-04-12 2020-01-21 Wilcox Industries Corp. Modular underwater torpedo system

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0346847A2 (en) * 1988-06-13 1989-12-20 F. Hoffmann-La Roche Ag Amino acid derivatives
EP0539192A1 (en) * 1991-10-23 1993-04-28 Merck & Co. Inc. HIV Protease inhibitors
EP0560268A1 (en) * 1992-03-13 1993-09-15 Bio-Mega/Boehringer Ingelheim Research Inc. Substituted pipecolinic acid derivatives as HIV protease inhibitors

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2448392A1 (en) * 1979-02-12 1980-09-05 Vilbiss Toussaint De AUTOMATIC DEVICE FOR PROJECTING COATING PRODUCTS
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
IL89900A0 (en) * 1988-04-12 1989-12-15 Merck & Co Inc Hiv protease inhibitors useful for the treatment of aids and pharmaceutical compositions containing them
IL91307A0 (en) * 1988-08-24 1990-03-19 Merck & Co Inc Hiv protease inhibitors and pharmaceutical compositions for the treatment of aids containing them
EP0361341A3 (en) * 1988-09-28 1991-07-03 Miles Inc. Therapeutics for aids based on inhibitors of hiv protease
US5063208A (en) * 1989-07-26 1991-11-05 Abbott Laboratories Peptidyl aminodiol renin inhibitors
WO1991008221A1 (en) * 1989-12-04 1991-06-13 Wisconsin Alumni Research Foundation Peptide inhibitors of hiv protease
GB8927915D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Novel alcohols
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
CA2032259A1 (en) * 1989-12-18 1991-06-19 Wayne J. Thompson Hiv protease inhibitors useful for the treatment of aids
CA2056911C (en) * 1990-12-11 1998-09-22 Yuuichi Nagano Hiv protease inhibitors
CA2060844A1 (en) * 1991-02-08 1992-08-09 Yabe Yuichiro Beta-amino-alpha-hydroxycarboxylic acids and their use
US5235039A (en) * 1991-06-10 1993-08-10 Eli Lilly And Company Substrates for hiv protease
US5508407A (en) * 1991-07-10 1996-04-16 Eli Lilly And Company Retroviral protease inhibitors
CN1071930A (en) * 1991-07-10 1993-05-12 伊莱利利公司 Inhibitor as the human immunodeficiency virus protease who treats acquired immune deficiency syndrome (AIDS)
US5220796A (en) 1991-07-15 1993-06-22 The Boc Group, Inc. Adsorption condensation solvent recovery system
DE4126482A1 (en) * 1991-08-10 1993-02-11 Bayer Ag (ALPHA) -TRIFLUORMETHYL-SUBSTITUTED, SATURATED-BICYCLIC AMINES AND METHOD FOR THE PRODUCTION THEREOF
US5516784A (en) * 1991-08-13 1996-05-14 Schering Corporation Anti-HIV (AIDS) agents
EP0534511A1 (en) * 1991-08-16 1993-03-31 Merck & Co. Inc. HIV protease inhibitors useful for the treatment of aids
US5256783A (en) * 1991-09-18 1993-10-26 Hoffmann-La Roche Inc. Method for producing 2-isoquinoline compounds
WO1993013066A1 (en) * 1991-12-20 1993-07-08 Syntex (U.S.A.) Inc. Cyclic amides of 3-amino-2-hydroxy-carboxylic acids as hiv-protease inhibitors
EP1148050A1 (en) * 1992-05-21 2001-10-24 Monsanto Company Retroviral protease inhibitors
ATE172717T1 (en) * 1992-08-25 1998-11-15 Searle & Co HYDROXYETHYLAMINOSULFONAMIDES USABLE AS INHIBITORS OF RETROVIRAL PROTEASES
IS2334B (en) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl protease inhibitor of a new class of sulfonamides
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
EP0604182B1 (en) 1992-12-22 2000-10-11 Eli Lilly And Company Inhibitors of HIV protease useful for the treatment of Aids
US5554653A (en) * 1992-12-22 1996-09-10 Eli Lilly And Company Inhibitors of HIV protease useful for the treatment of AIDS
US5475136A (en) * 1992-12-22 1995-12-12 Eli Lilly And Company Inhibitors of HIV protease useful for the treatment of AIDS
US5846993A (en) * 1992-12-22 1998-12-08 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5733906A (en) * 1993-10-12 1998-03-31 Eli Lilly And Company Inhibitors of HIV Protease useful for the treatment of Aids
MX9308016A (en) 1992-12-22 1994-08-31 Lilly Co Eli HUMAN IMMUNODEFICIENCY VIRUS PROTEASE INHIBITING COMPOUNDS, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL FORMULATION CONTAINING THEM.
MX9308025A (en) * 1992-12-22 1994-08-31 Lilly Co Eli HUMAN IMMUNODEFICIENCY VIRUS PROTEASE INHIBITING COMPOUNDS, PROCEDURE FOR SUPREPARATION AND PHARMACEUTICAL FORMULATION CONTAINING THEM.
US5434265A (en) * 1992-12-22 1995-07-18 Eli Lilly And Company Inhibitors of HIV protease
US5491166A (en) * 1992-12-22 1996-02-13 Eli Lilly And Company Inhibitors of HIV protease useful for the treatment of AIDS
US5480887A (en) * 1994-02-02 1996-01-02 Eli Lilly And Company Protease inhibitors
US5527829A (en) * 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0346847A2 (en) * 1988-06-13 1989-12-20 F. Hoffmann-La Roche Ag Amino acid derivatives
EP0539192A1 (en) * 1991-10-23 1993-04-28 Merck & Co. Inc. HIV Protease inhibitors
EP0560268A1 (en) * 1992-03-13 1993-09-15 Bio-Mega/Boehringer Ingelheim Research Inc. Substituted pipecolinic acid derivatives as HIV protease inhibitors

Cited By (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE43596E1 (en) 1992-08-25 2012-08-21 G.D. Searle Llc α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
USRE42889E1 (en) 1992-08-25 2011-11-01 G.D. Searle Llc α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
EP0741719A1 (en) * 1994-02-02 1996-11-13 Eli Lilly And Company Intermediate and process for making
EP0744948A1 (en) * 1994-02-02 1996-12-04 Eli Lilly And Company Protease inhibitors
EP0746320A1 (en) * 1994-02-02 1996-12-11 Eli Lilly And Company Hiv protease inhibitors and intermediates
EP0741719A4 (en) * 1994-02-02 1997-04-02 Lilly Co Eli Intermediate and process for making
EP0744948A4 (en) * 1994-02-02 1997-06-11 Lilly Co Eli Protease inhibitors
EP0746320A4 (en) * 1994-02-02 1997-06-11 Lilly Co Eli Hiv protease inhibitors and intermediates
US6703403B2 (en) 1995-06-29 2004-03-09 Abbott Laboratories Method for improving pharmacokinetics
EP2295052A1 (en) 1995-06-29 2011-03-16 Abbott Laboratories Use of ritonavir for improving the pharmacokinetics of drugs metabolized by cytochrome P450
EP2130534A1 (en) 1995-06-29 2009-12-09 Abbott Laboratories Use of ritonavir for improving the pharmacokinetics of drugs metabolized by cytochrome P450
US6476232B2 (en) 1995-09-26 2002-11-05 Japan Tobacco Inc. 4-(2-amino-1-hydroxyethyl)oxazoline derivative and method for producing same
WO1997011937A1 (en) * 1995-09-26 1997-04-03 Japan Tobacco Inc. Process for producing amide derivatives and intermediates
EP0983999A1 (en) * 1995-09-26 2000-03-08 Japan Tobacco Inc. Process for producing amide derivatives and intermediates
US6252085B1 (en) 1995-09-26 2001-06-26 Japan Tobacco Inc. Production of amide derivatives and intermediates therefor
WO1997011938A1 (en) * 1995-09-26 1997-04-03 Japan Tobacco Inc. Process for producing amide derivatives and intermediate compounds
US6596903B2 (en) 1995-09-26 2003-07-22 Japan Tobacco Inc. Methods for producing amide derivative
EP0983999A4 (en) * 1995-09-26 2002-09-11 Japan Tobacco Inc Process for producing amide derivatives and intermediates
US6121468A (en) * 1995-09-26 2000-09-19 Japan Tobacco Inc. Process for producing amide derivatives and intermediate compounds
US6133461A (en) * 1995-09-26 2000-10-17 Japan Tobacco Inc. Process for producing amide derivatives and intermediates therefor
US6333416B2 (en) 1995-09-26 2001-12-25 Japan Tobacco Inc. (Oxazolin-4-yl) oxirane derivative
BG64457B1 (en) * 1996-03-22 2005-03-31 Glaxo Group Limited Hiv protease inhibitor-containing pharmaceutical form for oral administration
US6605721B2 (en) 1996-09-05 2003-08-12 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors and methods for making HIV-protease inhibitors
US6303786B1 (en) 1996-09-05 2001-10-16 Agouron Pharmaceuticals, Inc. Processes for making nelfinavir mesylate
US6316625B1 (en) 1996-09-05 2001-11-13 Agouron Pharmaceuticals, Inc. Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors
US6512135B2 (en) 1996-09-05 2003-01-28 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors and methods for making HIV-protease inhibitors
US6117999A (en) * 1996-09-05 2000-09-12 Agouron Phramaceuticals, Inc. Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors
US6392067B1 (en) 1996-09-05 2002-05-21 Agouron Pharmaceuticals, Inc. Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors
US6407285B1 (en) 1996-09-05 2002-06-18 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors and methods for making HIV-protease inhibitors
US6465661B1 (en) 1996-09-05 2002-10-15 Agouron Pharmaceuticals, Inc. Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors
US5962725A (en) * 1996-09-05 1999-10-05 Agouron Pharmaceuticals, Inc. Intermediate compounds useful for making HIV protease inhibitors such as nelfinavir
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
US6521651B1 (en) 1996-11-21 2003-02-18 Abbott Laboratories Pharmaceutical composition
US6458818B1 (en) 1996-11-21 2002-10-01 Abbott Laboratories Pharmaceutical composition
US6001851A (en) * 1997-03-13 1999-12-14 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
KR100511089B1 (en) * 1997-03-13 2005-08-31 아구론 파마슈티컬스, 인크. HIV protease inhibitors
EA002378B1 (en) * 1997-03-13 2002-04-25 Агурон Фармасьютикалз, Инк. Hiv protease inhibitors
WO1998040357A2 (en) * 1997-03-13 1998-09-17 Agouron Pharmaceuticals, Inc. Hiv protease inhibitors
WO1998040357A3 (en) * 1997-03-13 1998-11-26 Agouron Pharma Hiv protease inhibitors
AP1358A (en) * 1997-03-13 2004-12-03 Agouron Pharma 1-Aryl-2-Hydroxy-3-Isoquinoline Carboxamide HIV Protease Inhibitors, Their Preparation and Use.
DE19730602A1 (en) * 1997-07-17 1999-01-21 Clariant Gmbh 3-Acetoxy-2-methylbenzoic acid chloride and a process for its preparation
US6051732A (en) * 1997-07-17 2000-04-18 Clariant Gmbh Process for the preparation of 3-acetoxy-2-methylbenzoyl chloride
US6084107A (en) * 1997-09-05 2000-07-04 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
US7592368B2 (en) 1997-12-24 2009-09-22 Vertex Pharmaceuticals Incorporated Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6559137B1 (en) 1997-12-24 2003-05-06 Vertex Pharmaceuticals Incorporated Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors
US6838474B2 (en) 1997-12-24 2005-01-04 Vertex Pharmaceuticals, Incorporated Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors
US6197966B1 (en) 1998-01-16 2001-03-06 Japan Tobacco Inc. Production method of optically active amino alcohols
WO1999054297A1 (en) * 1998-04-16 1999-10-28 Nagase & Company, Ltd. Process for preparing chloro alcohol derivatives and intermediates
US7419967B2 (en) 1998-06-19 2008-09-02 Vertex Pharmaceuticals Incorporated Sulfonamide inhibitors of aspartyl protease
US6613743B2 (en) 1998-06-19 2003-09-02 Vertex Pharmaceuticals Incorporated Sulfonamide inhibitors of aspartyl protease
US6107511A (en) * 1998-07-29 2000-08-22 Kaneka Corporation Process for the purification or isolation of (2S,3R)-1-halo-2-hydroxy-3-(protected amino)4-phenylthiobutanes or optical antipodes thereof
US6617350B2 (en) 1999-02-12 2003-09-09 Vertex Pharmaceuticals Incorporated Inhibitors of aspartyl protease
US7919523B2 (en) 1999-02-12 2011-04-05 Vertex Pharmaceuticals, Inc. Inhibitors of aspartyl protease
US6319946B1 (en) 1999-02-12 2001-11-20 Vertex Pharmaceuticals Incorporated Inhibitors of aspartyl protease
US7442718B2 (en) 1999-02-12 2008-10-28 Vertex Pharmaceuticals Incorporated Inhibitors of aspartyl protease
US6878728B1 (en) 1999-06-11 2005-04-12 Vertex Pharmaceutical Incorporated Inhibitors of aspartyl protease
US8455497B2 (en) 1999-06-11 2013-06-04 Vertex Pharmaceuticals Incorporated Inhibitors of aspartyl protease
EP2269591A2 (en) 2000-01-19 2011-01-05 Abbott Laboratories Improved pharmaceutical formulations
EP1917958A2 (en) 2000-01-19 2008-05-07 Abbott Laboratories Improved HIV protease inhibitors pharmaceutical formulations
US6846813B2 (en) * 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
WO2002064553A1 (en) * 2001-02-14 2002-08-22 Kureha Chemical Industry Company, Limited Process for preparation of halogenoalcohol derivatives
US6953858B2 (en) 2001-06-11 2005-10-11 Agouron Pharmaceuticals, Inc. HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
US7179918B2 (en) 2001-06-11 2007-02-20 Agouron Pharmaceuticals, Inc. HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
US8114901B2 (en) 2002-07-12 2012-02-14 Eli Lilly And Company Crystalline 2,5-dione-3-(1-methyl-1H-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl]-1H-pyrrole mono-hydrochloride
EP2266946A2 (en) 2003-02-13 2010-12-29 Wellstat Therapeutics Corporation Compound For The Treatment Of Metabolic Disorders
WO2006127133A2 (en) 2005-04-01 2006-11-30 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
US8076514B2 (en) 2005-07-20 2011-12-13 Eli Lilly And Company Phenyl compounds and their use in the treatment of Type II diabetes
US8106090B2 (en) 2005-07-20 2012-01-31 Eli Lilly And Company 1-amino linked compounds
WO2007087504A2 (en) 2006-01-25 2007-08-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
WO2007087505A2 (en) 2006-01-25 2007-08-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
WO2007092729A2 (en) 2006-02-02 2007-08-16 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
US8779144B2 (en) 2006-03-16 2014-07-15 Evotec (Us) Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
US8598364B2 (en) 2007-03-12 2013-12-03 Nektar Therapeutics Oligomer-protease inhibitor conjugates
US9107956B2 (en) 2007-03-12 2015-08-18 Nektar Therapeutics Oligomer-protease inhibitor conjugates
EP2522367A1 (en) 2007-03-12 2012-11-14 Nektar Therapeutics Oligomer-protease inhibitor conjugates
US9095620B2 (en) 2008-03-12 2015-08-04 Nektar Therapeutics Reagents
WO2009151695A1 (en) 2008-03-13 2009-12-17 Wellstat Therapeutics Corporation Compounds and method for reducing uric acid
US8716263B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Synthesis of purine nucleosides
US8716262B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8957045B2 (en) 2008-12-23 2015-02-17 Gilead Pharmasset Llc Nucleoside phosphoramidates
US9045520B2 (en) 2008-12-23 2015-06-02 Gilead Pharmasset Llc Synthesis of purine nucleosides
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
WO2010144869A2 (en) 2009-06-12 2010-12-16 Nektar Therapeutics Protease inhibitors
US11034647B2 (en) 2009-12-10 2021-06-15 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
US10640457B2 (en) 2009-12-10 2020-05-05 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
USRE46757E1 (en) 2010-03-19 2018-03-20 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US9365552B2 (en) 2010-03-19 2016-06-14 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US10117858B2 (en) 2010-03-19 2018-11-06 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US8476269B2 (en) 2010-03-19 2013-07-02 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US11911371B2 (en) 2010-03-19 2024-02-27 Novartis Ag Pyridine and pyrazine derivative for the treatment of chronic bronchitis
US8859756B2 (en) 2010-03-31 2014-10-14 Gilead Pharmasset Llc Stereoselective synthesis of phosphorus containing actives
US9227990B2 (en) 2012-10-29 2016-01-05 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
US11833156B2 (en) 2017-09-22 2023-12-05 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
US11426412B2 (en) 2017-10-18 2022-08-30 Jubilant Epipad LLC Imidazo-pyridine compounds as PAD inhibitors
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
US11459338B2 (en) 2017-11-24 2022-10-04 Jubilant Episcribe Llc Heterocyclic compounds as PRMT5 inhibitors
US11529341B2 (en) 2018-03-13 2022-12-20 Jubilant Prodel LLC Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation
WO2021176369A1 (en) 2020-03-06 2021-09-10 Pfizer Inc. Methods of inhibiting sars-cov-2 replication and treating coronavirus disease 2019
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Also Published As

Publication number Publication date
AP9600844A0 (en) 1996-07-31
BR9407782A (en) 1997-03-18
BG100455A (en) 1997-09-30
CA2268709C (en) 2008-03-25
SI0722439T1 (en) 2002-10-31
ES2236849T3 (en) 2005-07-16
NZ329626A (en) 1999-08-30
CZ100496A3 (en) 1996-09-11
SK284115B6 (en) 2004-09-08
US6271235B1 (en) 2001-08-07
SI0889036T1 (en) 2005-04-30
EP0722439B1 (en) 2002-08-14
DE69434214T2 (en) 2005-06-02
SK43996A3 (en) 1997-01-08
US5837710A (en) 1998-11-17
EP1340744B1 (en) 2007-05-23
DK0722439T3 (en) 2002-12-16
RO119363B1 (en) 2004-08-30
KR100190517B1 (en) 1999-06-01
US5859002A (en) 1999-01-12
AU694746B2 (en) 1998-07-30
US6525215B2 (en) 2003-02-25
ES2181725T3 (en) 2003-03-01
DE69431193D1 (en) 2002-09-19
CA2268709A1 (en) 1995-04-13
ATE362918T1 (en) 2007-06-15
NO307050B1 (en) 2000-01-31
TJ339B (en) 2002-07-01
AU7967494A (en) 1995-05-01
US5827891A (en) 1998-10-27
UA56984C2 (en) 2003-06-16
FI961449A0 (en) 1996-03-29
ATE222240T1 (en) 2002-08-15
US6162812A (en) 2000-12-19
PL313871A1 (en) 1996-07-22
TW432049B (en) 2001-05-01
CA2173328C (en) 1999-08-31
FI114794B (en) 2004-12-31
ATE286025T1 (en) 2005-01-15
EP1340744A3 (en) 2003-12-03
PL185647B1 (en) 2003-06-30
PT722439E (en) 2002-12-31
NO961382D0 (en) 1996-04-03
JP2951724B2 (en) 1999-09-20
MD1507F2 (en) 2000-07-31
BG62567B1 (en) 2000-02-29
US5834467A (en) 1998-11-10
HU9600908D0 (en) 1996-05-28
US5852043A (en) 1998-12-22
DE69434977D1 (en) 2007-07-05
ES2287387T3 (en) 2007-12-16
HU226814B1 (en) 2009-11-30
CN1195737C (en) 2005-04-06
PT889036E (en) 2005-05-31
JPH11310573A (en) 1999-11-09
MY138860A (en) 2009-08-28
EP0722439A1 (en) 1996-07-24
UY23840A1 (en) 1994-10-21
NO961382L (en) 1996-04-09
CA2173328A1 (en) 1995-04-13
US5827858A (en) 1998-10-27
EP1340744A2 (en) 2003-09-03
EP0889036B1 (en) 2004-12-29
US6693199B2 (en) 2004-02-17
DE69434977T2 (en) 2008-03-13
CN1262272A (en) 2000-08-09
GEP20084497B (en) 2008-09-25
NZ275633A (en) 1998-03-25
DK0889036T3 (en) 2005-02-28
JP3703647B2 (en) 2005-10-05
DE69434214D1 (en) 2005-02-03
HU0900219D0 (en) 2009-06-29
HK1014950A1 (en) 1999-10-08
US5484926A (en) 1996-01-16
CN1131942A (en) 1996-09-25
EE05399B1 (en) 2011-04-15
HK1013650A1 (en) 1999-09-03
MD1507G2 (en) 2001-04-30
EE9600091A (en) 1996-12-16
CN1046269C (en) 1999-11-10
GEP20002209B (en) 2000-08-25
US20020077338A1 (en) 2002-06-20
FI961449A (en) 1996-05-29
HUT75652A (en) 1997-05-28
HU227885B1 (en) 2012-05-29
AP600A (en) 1997-07-23
HK1056172A1 (en) 2004-02-06
SK284116B6 (en) 2004-09-08
CZ290417B6 (en) 2002-07-17
EP0889036A1 (en) 1999-01-07
OA10718A (en) 2001-11-02
US5827859A (en) 1998-10-27
JPH09501443A (en) 1997-02-10
RU2139280C1 (en) 1999-10-10
US20030216569A1 (en) 2003-11-20
US5952343A (en) 1999-09-14
US5824688A (en) 1998-10-20
DE69431193T2 (en) 2002-12-12

Similar Documents

Publication Publication Date Title
AU694746B2 (en) HIV protease inhibitors
US5554653A (en) Inhibitors of HIV protease useful for the treatment of AIDS
US5461154A (en) Intermediate and process for making
JPH06256277A (en) Hiv-protease inhibitor being useful for treatment of aids
US5846993A (en) HIV protease inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 94193534.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 275633

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1994930609

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 96-0141

Country of ref document: MD

WWE Wipo information: entry into national phase

Ref document number: 961449

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: 2173328

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 43996

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: PV1996-1004

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 96-00738

Country of ref document: RO

EX32 Extension under rule 32 effected after completion of technical preparation for international publication
LE32 Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b)
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1994930609

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1996-1004

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 4932002

Country of ref document: SK

WWG Wipo information: grant in national office

Ref document number: PV1996-1004

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 1994930609

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 961449

Country of ref document: FI